Clinical Annotation Id	Location	Gene	Level of Evidence	Clinical Annotation Types	Genotype-Phenotype IDs	Annotation Text	Variant Annotations IDs	Variant Annotations	PMIDs	Evidence Count	Related Drugs	Related Diseases	Race
981204774	rs1799971	OPRM1 (PA31945)	3	Efficacy	981204775; 981204776; 981204777	AA:Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AG and GG genotype. However, contradictory findings have been reported, with the AA genotype may be associated with a decreased likelihood of smoking cessation compared to AG and GG genotype. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.; AG:Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the AG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.; GG:Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the GG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.	655385584; 655386750; 655386751	Genotype AA is associated with increased likelihood of smoking cessation when treated with Drugs used in nicotine dependence and nicotine as compared to genotypes GG + AG.; Genotype AG is associated with increased likelihood of smoking cessation when treated with as compared to genotype AA.; Genotype GG is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotype AA.	17224915; 15007373; 15007373	3	Drugs used in nicotine dependence;nicotine	Tobacco Use Disorder	White	
981419532	rs4693075	COQ2 (PA142672084)	2B	Toxicity/ADR	981419535; 981419534; 981419533	CC:Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patient's risk of toxicity.; CG:Patients with the CG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.; GG:Patients with the GG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.	981419513; 827776736	Allele G is associated with increased risk of statin intolerance, defined primarily through muscle symptomatology when treated with hmg coa reductase inhibitors as compared to allele C.; Allele G is associated with increased risk of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Hyperlipoproteinemia Type II as compared to allele C.	17376224; 20347093	2	atorvastatin;hmg coa reductase inhibitors;rosuvastatin	Muscular Diseases	White	
981204874	rs16969968	CHRNA3 (PA113),CHRNA5 (PA26491)	3	Efficacy	981204875; 981204876; 981204877	AA:Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the GG genotype. However, contradictory findings have been reported, with the AA genotype may be associated with a decreased likelihood of smoking cessation compared to GG genotype. Finding are based on haplotype analysis of rs16969968 and rs680244. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.; AG:Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the AG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Finding are based on haplotype analysis of rs16969968 and rs680244. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.; GG:Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the GG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Finding are based on haplotype analysis of rs16969968 and rs680244. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.	827921971; 827921996	Allele A is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.; Allele G is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.	22648373; 22648373	2	Drugs used in nicotine dependence	Tobacco Use Disorder		
981204995	rs1799793	ERCC2 (PA27848)	3	Efficacy;Toxicity/ADR	981204996; 981204997; 981204998	CC:Patients with the CC genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of overall survival as compared to patients with the CT genotype. This has been contradicted in another studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide.; CT:Patients with the CT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of overall survival as compared to patients with the CC genotype. Genotype CT is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide. Both findings have been contradicted in another studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide.; TT:Genotype TT is not associated with increased risk of Drug Toxicity or decreased progression-free or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	655386620; 827827919; 827827949; 827828246	Genotype CT is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms.; Genotypes CT + TT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Genotypes CT + TT are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Genotype CT is associated with increased likelihood of overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	19786980; 22188361; 22188361; 22188361	4	cisplatin;cyclophosphamide	Ovarian Neoplasms		
981239568	rs104894542	VKORC1 (PA133787052)	4	Dosage	981239569; 981239570; 981239571	AA:Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence warfarin dose.; AC:Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.; CC:Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.	981239489; 981239497	Allele C is associated with increased dose of warfarin as compared to allele A.; Allele C is associated with increased dose of warfarin as compared to allele A.	14765194; 18234403	2	warfarin			
981237878	rs1105879	UGT1A6 (PA37181)	3	Dosage	981237879; 981237880; 981237881	AA:Patients with the AA genotype and Epilepsy who are treated with valproic acid may require a decreased dose as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.; AC:Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.; CC:Patients with the CC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.	769164793; 827812640; 827812695	Allele C is associated with increased glucuronidation of valproic acid.; Genotype CC is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AC.; Genotype AC is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype AA.	15761113; 21806385; 21806385	3	valproic acid	Epilepsy	Asian	
981238234	rs1360780	FKBP5 (PA28162)	3	Toxicity/ADR	981238235; 981238236; 981238237	CC:Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.; CT:Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased, but not absent, risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.; TT:Patients with the TT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased, but not absent, risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.	827793233; 827793245	Allele T is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.; Allele T is associated with increased risk of suicidal ideation when treated with paroxetine in people with Depression as compared to allele C.	21449676; 21449676	2	clomipramine;nefazodone;paroxetine;venlafaxine	Depression		
981238562	rs1051266	SLC19A1 (PA327)	3	Efficacy;Toxicity/ADR	981238563; 981238564; 981238565	CC:Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) increased likelihood of Toxic liver disease 2) decreased, but not absent, risk of Drug Toxicity 3) decreased likelihood of treatment interruptions as compared to patients with the CT and TT genotype. Further, patients with the CC genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patient's response to leucovorin, mercaptopurine and methotrexate.; CT:Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) decreased, but not absent, risk of Toxic liver disease 2) increased risk of Drug Toxicity 3) increased likelihood of treatment interruptions as compared to patients with the CC genotype. Further, patients with the CT genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patient's response to leucovorin, mercaptopurine and methotrexate.; TT:Patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) decreased, but not absent, risk of Toxic liver disease 2) increased risk of Drug Toxicity 3) increased likelihood of treatment interruptions as compared to patients with the CC genotype. Further, patients with the TT genotype may have 4) increased likelihood of Myelosuppression and 5) increased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the CT and CC genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patient's response to leucovorin, mercaptopurine and methotrexate.	769171135; 769171002; 769171125; 769171132; 769170677; 769171074; 978639812	Genotype CC is associated with increased likelihood of Toxic liver disease when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes TT + CT.; Allele T is not associated with Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotype TT is associated with increased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; Genotype TT is associated with increased likelihood of Myelosuppression when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; Genotypes TT + CT are associated with increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.; Genotypes TT + CT are associated with increased likelihood of Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.; Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	20335220; 17323057; 20335220; 20335220; 18458567; 17264302; 22838948	7	leucovorin;mercaptopurine;methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma		
981237670	rs1799853	CYP2C9 (PA126)	3	Efficacy;Toxicity/ADR	981237671; 981237672; 981237673	CC:Patients with the CC genotype and Epilepsy who are treated with phenytoin may have an increased metabolism of phenytoin, decreased plasma free phenytoin concentration, and a decreased, but not absent, risk of drug toxicity as compared to patients with the CT and TT genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.; CT:Patients with the CT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.; TT:Patients with the TT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.	769250028; 613978599; 769248925; 769248937; 769250082; 769259087; 769250046	Genotype CT is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype CC.; Allele T is not associated with increased dose of phenytoin in people with Epilepsy as compared to allele C.; Allele T is associated with increased plasma free phenytoin concentration when treated with phenytoin in people with Epilepsy as compared to genotype CC.; Allele T is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to allele C.; Allele T is not associated with decreased metabolism of phenytoin.; Allele T is not associated with likelihood of adverse reaction when treated with phenytoin in people with Epilepsy as compared to allele C.; Genotype TT is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to genotype CC.	16815679; 15805193; 21068649; 21068649; 10901705; 21537551; 19617466	7	phenytoin	Epilepsy		
981238437	rs1057910	CYP2C9 (PA126)	2A	Toxicity/ADR	981238438; 981238439; 981238440	AA:Patients with the AA genotype who are treated with non-steroid antiinflammatory agents, celecoxib or diclofenac may have a decreased, but not absent, risk of gastrointestinal bleeding as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.; AC:Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.; CC:Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.	827826832; 827826844	Allele C is associated with increased risk of acute  gastrointestinal bleeding when treated with Antiinflammatory agents, non-steroids, celecoxib or diclofenac as compared to allele A.; Allele C is associated with increased risk of gastrointestinal bleeding when treated with Antiinflammatory agents, non-steroids, celecoxib, diclofenac, ibuprofen, naproxen or piroxicam as compared to allele A.	14707031; 17681167	2	Antiinflammatory agents, non-steroids;celecoxib;diclofenac			
655387753	rs11188072	CYP2C19 (PA124)	3	Dosage	655387754; 655387755; 655387756	CC:Patients with the CC genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; CT:Patients with the CT genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; TT:Patients with the TT genotype who are treated with escitalopram may require an increased dose as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.	655387725	Genotype TT is associated with decreased serum concentration of escitalopram in people with Mental Disorders as compared to genotype CC.	17625515	1	escitalopram	Mental Disorders	White	
981204941	rs1801019	UMPS (PA363)	2B	Toxicity/ADR	981204942; 981204943; 981204944	CC:Patients with CC genotype and cancer may have an increased risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and leucovorin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.; CG:Patients with CG genotype and cancer may have a decreased, but not absent, risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and leucovorin as compared to patients with the CC genotype. However, contradictory findings have been reported that show the CG genotype may be associated with increased risk for grade 3 to 4 diarrhea when treated with fluorouracil and leucovorin compared to the GG genotype.Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.; GG:Patients with GG genotype and cancer may have a decreased, but not absent, risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and leucovorin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.	769169649; 769245624; 769245627; 769169655	Genotype CC is associated with increased likelihood of experiencing severe toxicity when treated with fluorouracil and leucovorin in people with Adenocarcinoma as compared to genotypes GG + CG.; Genotype CC is associated with increased severity of Diarrhea when treated with leucovorin and tegafur in people with Colorectal Neoplasms as compared to genotypes GG + CG.; Genotype CC is associated with increased likelihood of any grade 3 adverse event when treated with leucovorin and tegafur in people with Colorectal Neoplasms as compared to genotypes GG + CG.; Genotypes CC + CG are associated with grade 3 to 4 diarrhea when treated with fluorouracil and leucovorin in people with Adenocarcinoma as compared to genotype GG.	16818689; 20647221; 20647221; 16818689	4	fluorouracil;leucovorin;tegafur	Drug Toxicity	Asian	
981204641	rs1799971	OPRM1 (PA31945)	2B	Toxicity/ADR	981204642; 981204643; 981204644	AA:Patients with the AA genotype may have a decreased , but not absent, severity of intoxication and a decreased response when exposed to ethanol as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's ethanol response.; AG:Patients with the AG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's ethanol response.; GG:Patients with the GG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's ethanol response.	769171518; 827806034	Allele G is associated with increased subjective feelings of intoxication, stimulation, sedation, and happiness when exposed to ethanol as compared to allele A.; Genotypes AG + GG are associated with increased severity of intoxication when exposed to ethanol and naltrexone in healthy individuals as compared to genotype AA.	15608594; 21900886	2	ethanol			
981237959	rs13181	ERCC2 (PA27848)	3	Efficacy;Toxicity/ADR	981237960; 981237961; 981237962	GG:Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.; GT:Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.; TT:Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) a decreased, but not absent, risk of Drug Toxicity 2) a decreased, but not absent, risk of early relapse and 3) increased progression free survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.	769261451; 655388448; 769166392	Allele G is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT.; Genotypes GG + GT are associated with increased risk of early relapse when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype TT.; Genotypes TT + GT are associated with increased progression free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.	20385995; 18267032; 20078613	3	fluorouracil;leucovorin;oxaliplatin	Colorectal Neoplasms		
981478131	rs10919035	NOS1AP (PA142671259)	3	Toxicity/ADR	981478134; 981478133; 981478132	CC:Patients with the CC genotype may have decreased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.; CT:Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.; TT:Patients with the TT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.	981478047; 981478059	Allele T is associated with amiodarone-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to allele C.; Allele T is associated with amiodarone-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to allele C.	22682551; 22682551	2	amiodarone	Long QT Syndrome	White	
981239773	rs8099917	IL28B (PA134952671)	1B	Efficacy	981239774; 981239775; 981239776	GG:Patients with the GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.; GT:Patients with the GT genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.; TT:Patients with the TT genotype may have increased response (higher SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.	981240106; 769248378; 827814618; 827814630; 827815352	Genotype GG is associated with lack of treatment response when treated with peginterferon alfa-2a and ribavirin in people with HCVGT1/4 (PPV 0.86 and NPV 0.48 P = 0.05) and HCVGT2/3 patients [PPV 0.50 and NPV 0.86 P < 0.05]. as compared to genotypes GT + TT.; Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele G.; Genotype TT is associated with increased likelihood of sustained virological response (SVR) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis as compared to genotypes GG + GT.; Genotype TT is associated with increased baseline viral load in people with Hepatitis as compared to genotypes GG + GT.; Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	22863269; 19749757; 21628662; 21628662; 21745312	5	peginterferon alfa-2a;peginterferon alfa-2b;ribavirin	Hepatitis C, Chronic		
981238570	rs1050828	G6PD (PA28469)	3	Toxicity/ADR	981238571; 981238572; 981238573	CC:Pediatric patients with the CC genotype may have decreased, but not absent, risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.; CT:Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.; TT:Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.	827793071; 827793083	Genotype TT is associated with increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine in children as compared to genotype CC.; Genotype CT is associated with increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine in children as compared to genotype CC.	20194698; 20194698	2	artesunate;primaquine;pyrimethamine;sulfadoxine		Black or African American	
981204210	rs17602729	AMPD1 (PA24776)	3	Efficacy;Toxicity/ADR	981204211; 981204212; 981204213	AA:Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.; AG:Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of CNS adverse events as compared to patients with the GG genotype. Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of CNS adverse events.; GG:Patients with the GG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a decreased response to methotrexate as compared to patients with the AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.	769173649; 769171345; 827863316	Allele A is associated with increased response to folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to allele G.; Genotype AG is associated with increased likelihood of CNS adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.; Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	16947783; 20386493; 22450926	3	methotrexate	Arthritis, Rheumatoid		
981238550	rs1051740	EPHX1 (PA27829)	2B	Dosage	981238551; 981238552; 981238553	CC:Patients with the CC genotype and Epilepsy who are treated with carbamazepine may have an increased dose of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.; CT:Patients with the CT genotype and Epilepsy who are treated with carbamazepine may have an increased dose of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.; TT:Patients with the TT genotype and Epilepsy who are treated with carbamazepine may have a decreased dose of carbamazepine as compared to patients with the CT and CC genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.	827815311; 827824027; 827824037	Allele C is associated with increased dose of carbamazepine in people with Epilepsy as compared to allele T.; Genotype CC is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.; Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype TT.	19620853; 22188362; 22188362	3	carbamazepine	Epilepsy		
981238332	rs1695	GSTP1 (PA29028)	3	Efficacy	981238333; 981238334; 981238335	AA:Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased progression free survival as compared to patients with the AG and GG genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide.; AG:Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide.; GG:Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide.	655386344; 827824994	Genotype AA is associated with increased progression free survival when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes GG + AG.; Genotype AA is not associated with increased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes AG + GG.	19786980; 22188361	2	cisplatin;cyclophosphamide	Ovarian Neoplasms		
981204851	rs1800497	ANKK1 (PA134872551)	3	Efficacy	981204852; 981204853; 981204854	AA:Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.; AG:Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.; GG:Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the AG and AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.	769172985; 655386707; 655387313; 655386706; 655387311	Allele A is not associated with response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.; Genotype AA is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotype GG.; Genotype AA is associated with increased likelihood of smoking cessation when treated with nicotine in people with female gender as compared to genotype GG.; Genotype AG is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotype GG.; Genotype AG is associated with increased likelihood of smoking cessation when treated with nicotine in people with female gender as compared to genotype GG.	19273465; 15077009; 15033882; 15077009; 15033882	5	Drugs used in nicotine dependence;nicotine	Tobacco Use Disorder	White	
981237871	rs11045585	SLCO1B3 (PA35844)	3	Toxicity/ADR	981237872; 981237873; 981237874	AA:Patients with the AA genotype and Neoplasms who are treated with docetaxel may have 1) a decreased, but not absent, risk of leukopenia, 2) an increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.; AG:Patients with the AG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.; GG:Patients with the GG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.	769180246; 827784589; 827784616	Allele G is associated with increased risk of leukopenia when treated with docetaxel as compared to allele A.; Allele G is associated with increased AUC of docetaxel in people with Nasopharyngeal Neoplasms.; Allele G is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.	18294295; 21995462; 21995462	3	docetaxel	Neoplasms	Asian	
981204549	rs1799752	ACE (PA139)	3	Efficacy	981204550; 981204551; 981204552	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype and essential hypertension who are treated with hydrochlorothiazide may have a decreased reduction in blood pressure as compared to patients with the del/del genotype. The opposite association is found for females in some studies where female patients carrying the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have an increased reduction in blood pressure as compared to female patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.; ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype and essential hypertension who are treated with hydrochlorothiazide may have a decreased reduction in blood pressure as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.; del/del:Patients with the del/del genotype and essential hypertension who are treated with hydrochlorothiazide may have an increased reduction in blood pressure as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype. The opposite association is found for females in some studies where female patients carrying the del/del genotype may have a decreased reduction in blood pressure as compared to female patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.	827921297; 827921327; 827922461	Genotype DEL/DEL is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in men with Essential hypertension as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.; Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in women with Essential hypertension as compared to genotype DEL/DEL.; Genotype DEL/DEL is associated with increased reduction in systolic blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/DEL.	12371972; 12371972; 21269061	3	hydrochlorothiazide	Essential hypertension		
981237930	rs11615	ERCC1 (PA155)	3	Toxicity/ADR	981237931; 981237932; 981237933	AA:Genotype AA is not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide as compared to genotypes AG and GG. Please note, patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.No result; AG:Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.; GG:Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.	655386332; 827826160	Genotype AG is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotype GG.; Genotypes AG + GG are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype AA.	19786980; 22188361	2	cisplatin;cyclophosphamide	Ovarian Neoplasms		
981238415	rs1127354	ITPA (PA29973)	3	Efficacy;Toxicity/ADR	981238418; 981238417; 981238416	AA:Patients with the AA genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AA genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Other genetic and clinical factors may also influence a patient's response to methotrexate.; AC:Patients with the AC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AC genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Other genetic and clinical factors may also influence a patient's response to methotrexate.; CC:Patients with the CC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) a decreased, but not absent, risk for gastrointestinal toxicities 2) an increased response to folic acid and methotrexate as compared to patients with the AA and AC genotype. However, this association is contradicted in other studies that show the CC genotype may have decreased response to methotrexate as compared to patients with the AC and AA genotype or show no association of the allele with response to methotrexate. Other genetic and clinical factors may also influence a patient's response to methotrexate.	827813059; 827813071; 827863280; 769173671; 769173660	Allele A is associated with response to methotrexate when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.; Allele A is associated with gastrointestinal toxicities when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.; Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.; Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.; Genotype CC is associated with increased response to folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.	19858780; 19858780; 22450926; 19193698; 16947783	5	methotrexate	Arthritis, Rheumatoid		
981239556	rs104894541	VKORC1 (PA133787052)	4	Dosage	981239557; 981239558; 981239559	CC:Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose.; CT:Patients with the CT genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose.; TT:Patients with the TT genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence warfarin dose.	981239471; 981239505	Allele C is associated with increased dose of warfarin as compared to allele T.; Allele C is associated with increased dose of warfarin as compared to allele T.	14765194; 18234403	2	warfarin			
981239532	rs104894539	VKORC1 (PA133787052)	4	Dosage	981239533; 981239534; 981239535	AA:Patients with the AA genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose.; AC:Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose.; CC:Patients with the CC genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence warfarin dose.	981239462; 981239523	Allele A is associated with increased dose of warfarin as compared to allele C.; Allele A is associated with increased dose of warfarin as compared to allele C.	14765194; 18234403	2	warfarin			
981238501	rs1057910	CYP2C9 (PA126)	3	Toxicity/ADR	981238502; 981238503; 981238504	AA:Patients with the AA genotype and with Epilepsy who are treated with phenytoin may have an increased metabolism, decreased plasma free phenytoin concentration, and decreased, but not absent, risk of Drug Toxicity as compared to patients with the AC and CC genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.; AC:Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.; CC:Patients with the CC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.	769250031; 769250049; 613978582; 769248929; 769248932; 769250083; 769259088	Genotype AC is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype AA.; Genotype AC is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to genotype AA.; Allele C is associated with increased dose of phenytoin in people with Epilepsy as compared to allele A.; Allele C is associated with increased plasma free phenytoin concentration when treated with phenytoin in people with Epilepsy as compared to allele A.; Allele C is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to allele A.; Allele C is associated with decreased metabolism of phenytoin.; Allele C is not associated with likelihood of adverse reaction when treated with phenytoin in people with Epilepsy as compared to allele A.	16815679; 19617466; 15805193; 21068649; 21068649; 10901705; 21537551	7	phenytoin	Epilepsy		
981204902	rs16969968	CHRNA5 (PA26491)	3	Toxicity/ADR	981204903; 981204904; 981204905	AA:Patients with AA genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patient's risk for nicotine dependency.; AG:Patients with AG genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype. Findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patient's risk for nicotine dependency.; GG:Patients with GG genotype may have a decreased, but not absent, risk for nicotine dependence when exposed to nicotine as compared to patients with the AG and AA genotype. Findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence a patient's risk for nicotine dependency.	769178836; 827921955	Allele A is associated with increased risk of Tobacco Use Disorder.; Allele A is associated with decreased likelihood of abstinence of nicotine in people with Tobacco Use Disorder.	18618000; 22648373	2	nicotine	Tobacco Use Disorder		
981419257	HLA-B *57:01:01	HLA-B (PA35056)	1A	Toxicity/ADR	981419393	*57:01:01:Patients with one or two copies of the HLA-B*57:01:01 allele have an increased risk of hypersensitivity to abacavir as compared to patients with no HLA-B*57:01:01 alleles or negative for the HLA-B*57:01:01 test.	981349371; 981349377	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.; HLA-B *57:01:01 is associated with increased likelihood of Drug Hypersensitivity when treated with abacavir in people with HIV.	18256392; 15247625	2	abacavir	Drug Hypersensitivity		
981419260	HLA-B *58:01:01	HLA-B (PA35056)	1A	Toxicity/ADR	981419395	*58:01:01:Patients with one or two copies of the HLA-B*58:01:01 allele have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with allopurinol as compared to patients with no HLA-B*58:01:01 alleles or negative for the HLA-B*58:01:01 test.	827919454; 981345627; 981345632; 981345637; 981345642; 981345647; 981345654	HLA-B *58:01:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.; HLA-B *58:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol in people with Kidney Failure, Chronic.; HLA-B *58:01:01 is associated with increased risk of SCAR when treated with allopurinol.; HLA-B *58:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.; HLA-B *58:01:01 is not associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.; HLA-B *58:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.; HLA-B *58:01:01 is associated with increased risk of SCAR when treated with allopurinol.	21545408; 21393610; 21301380; 19696695; 19018717; 18192896; 15743917	7	allopurinol	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome		
981419263	HLA-B *15:02:01	HLA-B (PA35056)	1A	Toxicity/ADR	981419407	*15:02:01:Patients with one or two copies of the HLA-B*15:02:01 allele have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with carbamazepine as compared to patients with no HLA-B*15:02:01 alleles or negative for the HLA-B*15:02:01 test.	981349387; 981349397; 981349402; 981349408; 981349415	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.; HLA-B *15:02:01 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine or phenytoin in people with Epilepsy.; HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.; HLA-B *15:02:01 is not associated with Stevens-Johnson Syndrome when treated with carbamazepine.; HLA-B *15:02:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine.	18637831; 18637831; 15057820; 16415921; 16538176	5	carbamazepine	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome	Asian	
981419487	rs118192172	RYR1 (PA34896)	3	Toxicity/ADR	981419490; 981419489; 981419488	CC:Patients with CC genotype may have decreased risk to statin-related myopathy as compared patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to statins.; CT:Patients with CT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to statins. The RYR1 cysteine for arginine 614 mutation is potentially causative of human malignant hyperthermia. ; TT:Patients with TT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to statins. The RYR1 cysteine for arginine 614 mutation is potentially causative of human malignant hyperthermia. 	981419430; 981419447	Allele T is associated with severe statin myopathy and unknown myopathy when exposed to hmg coa reductase inhibitors in people with drug-induced muscle diseases as compared to allele C.; Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	21795085; 1774074	2	hmg coa reductase inhibitors	Malignant Hyperthermia;Muscular Diseases		
981419550	rs2819742	RYR2 (PA300)	3	Toxicity/ADR	981419551; 981419552; 981419553	AA:Patients with the AA genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity. ; AG:Patients with the AG genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity. ; GG:Patients with the GG genotype may have an increased risk of cerivastatin-associated rhabdomyolysis as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity. 	769180491	Genotype AA is associated with smaller risk of rhabdomyolysis when treated with cerivastatin as compared to genotype GG.	21386754	1	cerivastatin	Rhabdomyolysis		
655387745	rs11188072	CYP2C19 (PA124)	3	Dosage	655387746; 655387747; 655387748	CC:Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; CT:Patients with the CT genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; TT:Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.	655387714	Genotype TT is associated with increased metabolism of mephenytoin in people with no disease as compared to genotype CC.	16413245	1	mephenytoin		Black or African American	
981478113	rs10800397	NOS1AP (PA142671259)	3	Toxicity/ADR	981478116; 981478115; 981478114	CC:Patients with the CC genotype may have decreased risk of drug-induced ventricular arrhythmia and QT prolongation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.; CT:Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.; TT:Patients with the TT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.	981478023; 981478039	Allele T is associated with drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone, diuretics or sotalol as compared to allele C.; Allele T is associated with amiodarone-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to allele C.	22682551; 22682551	2	amiodarone	Long QT Syndrome	White	
655385379	rs2276307	HTR3B (PA29556)	3	Toxicity/ADR	655385381; 655385382; 655385383	AA:Patients with the AA genotype and Hypercholesterolemia may have a decreased, but not absent, risk of statin-related myalgia as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.; AG:Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.; GG:Patients with the GG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.	655387802	Allele G is associated with increased risk of Myalgia unspecified when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele A.	17600820	1	atorvastatin;pravastatin;simvastatin	Myalgia unspecified		
655385384	rs5443	GNB3 (PA176)	4	Efficacy	655385385; 655385386; 655385387	CC:Patients with the CC genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a smaller reduction in risk of myocardial infarction compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.; CT:Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.; TT:Patients with the TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.	655388002	Genotypes CT + TT are associated with decreased risk of Myocardial Infarction when treated with hmg coa reductase inhibitors in people with Hypercholesterolemia as compared to genotype CC.	18551043	1	atorvastatin;fluvastatin;hmg coa reductase inhibitors;lovastatin;pravastatin;rosuvastatin;simvastatin	Hypercholesterolemia;Myocardial Infarction		
655385388	rs762551	CYP1A2 (PA27093)	3	Toxicity/ADR	655385389; 655385390; 655385391	AA:Patients with the AA genotype may have a decreased, but not absent, risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.; AC:Patients with the AC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.; CC:Patients with the CC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.	655387864; 655387870	Genotype AA is not associated with increased risk of Myocardial Infarction in people with increased coffee intake.; Genotypes CC + AC are associated with increased risk of Myocardial Infarction in people with increased coffee intake.	16522833; 16522833	2	caffeine	Myocardial Infarction	Hispanic or Latino	
655385392	rs9934438	VKORC1 (PA133787052)	1B	Dosage	655385393; 655385394; 655385395	AA:Patients with the AA genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin or acenocoumarol.; AG:Patients with the AG genotype who are treated with warfarin or acenocoumarol may require a lower dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin or acenocoumarol.; GG:Patients with the GG genotype who are treated with warfarin or acenocoumarol may require higher dose as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin or acenocoumarol.	637879816; 655388076; 769277894; 655388351; 827567313; 827642001; 827642014; 827647045; 827654491; 827661232; 827845768	Allele A is associated with decreased dose of warfarin as compared to allele G.; Allele A is associated with decreased dose of warfarin.; Allele A is associated with decreased dose of warfarin as compared to allele G.; Genotype AA is associated with decreased dose requirement of acenocoumarol as compared to genotypes GG + AG.; Allele A is associated with decreased dose of warfarin as compared to allele G.; Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.; Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.; Allele A is associated with decreased dose of warfarin as compared to allele G.; Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.; Allele A is associated with decreased dose of warfarin as compared to allele G.; Genotypes AG + GG are associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to genotype AA.	20203262; 16676068; 15358623; 19270263; 15883587; 17329985; 17329985; 16611750; 17111199; 16432637; 22248286	11	acenocoumarol;warfarin	Arteriosclerosis;Heart Diseases;Hemorrhage;Intracranial Hemorrhages;Myocardial Infarction;Peripheral Vascular Diseases;Pulmonary Embolism;Stroke;Thromboembolism;venous thromboembolism;Venous Thrombosis		
655385400	rs2108622	CYP4F2 (PA27121)	1B	Dosage	981478009; 981478010; 981478011	CC:Patients with the CC genotype who are taking an oral anticoagulant may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's required dose.; CT:Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required dose.; TT:Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's required dose.	981477999; 608431751; 827864558; 655388274; 655388281; 655388324; 699638607; 769246303; 655388287; 769182565; 827641885; 827807881; 827813045; 827925134; 978614465	Genotypes CT + TT are associated with 8.3% higher mean daily coumarin dose to reach a stable international normalized ratio (INR) when treated with acenocoumarol, phenprocoumon or warfarin as compared to genotype CC.; Allele C is associated with dose of warfarin.; Allele C is not associated with decreased dose of warfarin as compared to allele T.; Genotype CC is associated with decreased dosage requirement when treated with acenocoumarol in people with Atrial Fibrillation as compared to genotypes TT + CT.; Genotype CC is associated with decreased levels of vitamin K-dependent proteins when treated with acenocoumarol in people with Atrial Fibrillation as compared to genotypes TT + CT.; Genotype CC is not associated with decreased required dose of warfarin as compared to genotypes TT + CT.; Genotype CC is associated with decreased dose of warfarin as compared to genotypes TT + CT.; Genotype CC is associated with decreased dose of warfarin as compared to genotype CT.; Genotype CT is associated with decreased levels of vitamin K-dependent proteins when treated with in people with Atrial Fibrillation as compared to genotype TT.; Genotypes TT + CT are associated with increased dose of warfarin in people with a stable therapeutic international normalized ratio between two and three as compared to genotype CC.; Allele T is associated with increased dose of warfarin as compared to allele C.; Allele T is associated with increased dose of phenprocoumon maintenance dosage by 1.5 mg/week as compared to allele C.; Allele C is not associated with stable warfarin dose univariately when treated with warfarin as compared to allele T.; Genotypes CT + TT are associated with increased dose of warfarin in people with Thromboembolism as compared to genotype CC.; Allele T is associated with dose of warfarin.	23132553; 19794411; 21228733; 19270263; 19270263; 20182420; 18250228; 20442691; 19270263; 21383771; 19300499; 21063236; 19741565; 22528326; 22676192	15	acenocoumarol;phenprocoumon;warfarin	Arteriosclerosis;Heart Diseases;Hemorrhage;Intracranial Hemorrhages;Myocardial Infarction;Peripheral Vascular Diseases;Pulmonary Embolism;Stroke;Thromboembolism;venous thromboembolism;Venous Thrombosis		
655385404	rs688	LDLR (PA227)	3	Efficacy	655385406; 655385407; 655385408	CC:Patients with the CC genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.; CT:Patients with the CT genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.; TT:Patients with the TT genotype may have less effective lowering of systolic blood pressure with atenolol as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's likelihood of response.	655387083; 655387086	Genotype CC is associated with response to atenolol in people with Hypertension.; Genotype CT is associated with response to atenolol in people with Hypertension.	15453913; 15453913	2	atenolol	Hypertension	White	
655385409	rs1801252	ADRB1 (PA38)	3	Efficacy	655385410; 655385411; 655385412	AA:Patients with the AA genotype may 1) experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253).; AG:Patients with the AG genotype may 1) experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253).; GG:People with the GG genotype may 1) not experience more benefit from beta blocking agents (such as atenolol) than verapamil 2) not require additional heart failure medications (such as diuretics) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253).	613979010; 655387640; 655387645; 655387637; 655387953; 655387960; 827604540; 827816346	Allele A is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to allele G.; Allele A is not associated with response to atenolol in people with Hypertension.; Allele A is associated with increased response to atenolol in people with Hypertension.; Genotype AA is not associated with increased response to bisoprolol in people with Hypertension.; Genotypes AA + AG are associated with increased risk of Death when treated with verapamil in people with Coronary Artery Disease as compared to genotype GG.; Genotypes AA + AG are not associated with increased risk of Death when treated with atenolol in people with Coronary Artery Disease as compared to genotype GG.; Genotype AA is associated with increased likelihood of requiring more heart failure medication when treated with metoprolol in people with Heart Failure as compared to genotypes GG + AG.; Genotypes AG + GG are not associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype AA.	15861037; 20235788; 18794726; 20300048; 18615004; 18615004; 15735607; 22192668	8	Antihypertensives;atenolol;Beta Blocking Agents;bisoprolol;metoprolol;verapamil	Coronary Artery Disease;Death;Heart Failure		
655385418	rs165599	ARVCF (PA25018),COMT (PA117)	3	Efficacy	981419379; 981419380; 981419381	AA:Patients with the AA genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.; AG:Patients with the AG genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AG genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.; GG:Patients with the GG genotype may have a decreased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.	981419300	Genotypes AA + AG are associated with increased response to bupropion in smokers as compared to genotype GG.	16876132	1	bupropion	Tobacco Use Disorder	White	
655385422	rs1800497	ANKK1 (PA134872551)	1B	Efficacy	655385423; 655385424; 655385425	AA:Patients with the AA genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.; AG:Patients with the AG genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.; GG:Patients with the GG genotype who are treated with bupropion may be more likely to quit smoking as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.	655386715; 655386722; 655386727	Genotype GG is associated with increased likelihood of smoking cessation when treated with bupropion in people with female gender as compared to genotypes AA + AG.; Genotype GG is associated with increased likelihood of smoking cessation as compared to genotypes AA + AG.; Genotype GG is associated with increased likelihood of smoking cessation when treated with bupropion as compared to genotypes AA + AG.	15492764; 17654295; 18058343	3	bupropion	Tobacco Use Disorder	White	
655385426	rs1935349	HTR7 (PA29561)	3	Toxicity/ADR	655385428; 655385429; 655385430	CC:Patients with the CC genotype may have decreased but not non-existent, risk for statin-related myalgia as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.; CT:Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.; TT:Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.	655387788	Allele T is associated with increased risk of Myalgia unspecified when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele C.	17600820	1	atorvastatin;hmg coa reductase inhibitors;pravastatin;simvastatin	Myalgia unspecified		
655385462	rs1045642	ABCB1 (PA267)	4	Efficacy;Toxicity/ADR	655385463; 655385464; 655385465	AA:Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) as compared to patients with the GG genotype. The GA genotype is associated with the risk of poor response to treatment, however no results are provided for the AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse drug events and responsiveness when treated with methotrexate.; AG:Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have an increased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have an increased risk of not responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse drug events and responsiveness when treated with methotrexate.; GG:Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have a decreased risk of adverse drug events (please note this association was not significant after correcting for multiple variables) 2) may have increased likelihood of responding to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse drug events and responsiveness when treated with methotrexate.	769173251; 619523386	Allele A is associated with increased risk of adverse drug event when treated with folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to allele G.; Genotype GA is associated with increased risk of nonresponse when treated with methotrexate in people with Arthritis, Rheumatoid.	20136356; 19093297	2	methotrexate	Arthritis, Rheumatoid		
655385466	rs7992226	NALCN (PA162396840)	3	Other	655385467; 655385468; 655385469	AA:Patients with the AA genotype and childhood acute lymphoblastic leukemia (ALL) may have reduced exposure to methotrexate and higher likelihood of minimal residual disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.; AG:Patients with the AG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.; GG:Patients with the GG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.	622888380	Allele A is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	19176441	1	methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma		
655385471	rs10821936	ARID5B (PA134943193)	3	Other	655385472; 655385473; 655385474	CC:Pediatric patients with the CC genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.; CT:Pediatric patients with the CT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.; TT:Pediatric patients with the TT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have lower methotrexate polyglutamate accumulation as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.	637879601	Allele C is associated with greater methotrexate polyglutamate accumulation in people with B-hyperdiploid subtype of Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	19684603	1	methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma	White	
655385475	rs4846051	MTHFR (PA245)	3	Toxicity/ADR	655385476; 655385477; 655385478	AA:Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.; AG:Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a higher drug toxicity score as compared to patients with the AA genotype or may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.; GG:Patients with the GG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a higher drug toxicity score as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.	637879608	Allele G is associated with higher mean toxicity score when treated with methotrexate in people with Arthritis, Rheumatoid.	16439441	1	methotrexate	Arthritis, Rheumatoid;Drug Toxicity	Black or African American	
655385479	rs1800909	GGH (PA432)	3	Efficacy	655385480; 655385481; 655385482	AA:Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may have less improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.; AG:Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.; GG:Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.	637879621	Allele G is associated with decreased in the disease activity score when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.	17286537	1	methotrexate	Arthritis, Rheumatoid		
655385483	rs1079598	DRD2 (PA27478)	3	Toxicity/ADR	655385484; 655385485; 655385486	AA:Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.; AG:Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.; GG:Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.	637879900	Allele G is associated with increased likelihood of weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to allele A.	20714340	1	antipsychotics;clozapine;olanzapine	Schizophrenia	White	
655385491	rs6277	DRD2 (PA27478)	3	Toxicity/ADR	655385492; 655385493; 655385494	AA:Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.; AG:Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.; GG:Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.	637879906	Allele G is associated with increased likelihood of weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to allele A.	20714340	1	antipsychotics;clozapine;olanzapine	Schizophrenia	White	
655385495	rs1800497	ANKK1 (PA134872551)	2B	Toxicity/ADR	655385496; 655385497; 655385498	AA:Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.; AG:Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.; GG:Patients with the GG genotype may have decreased but not non-existent risk of side effects including hyperprolactinemia and weight gain during treatment with antipsychotic drugs as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.	637879896; 637879909; 699638580; 655387666	Allele A is associated with increased likelihood of weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to allele G.; Allele A is associated with higher prolactin level when treated with antipsychotics in people with Schizophrenia as compared to allele G.; Allele A is associated with increased likelihood of side effects when exposed to antipsychotics as compared to allele G.; Genotypes AA + AG are associated with increased risk of Hyperprolactinemia when treated with risperidone as compared to genotype GG.	20714340; 15286066; 18086475; 19339912	4	antipsychotics;clozapine;olanzapine;risperidone	Hyperprolactinemia;Weight gain		
655385579	rs2070744	NOS3 (PA254)	3	Efficacy	655385580; 655385581; 655385582	CC:Patients with the CC genotype who are treated with antihypertensive drugs may have an increased risk for resistance as compared to patients with the CT or TT genotype.; CT:Patients with the CT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance.; TT:Patients with the TT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance.	769164961; 699638662	Allele C is associated with increased likelihood of response when treated with Antihypertensives in people with Pre-Eclampsia as compared to allele T.; Genotype CC is associated with increased risk of resistant hypertension when treated with Antihypertensives and diuretics in people with Hypertension as compared to genotypes TT + CT.	19704415; 19650939	2	Antihypertensives And Diuretics In Combination		White	
655385586	rs1800497	ANKK1 (PA134872551)	1B	Toxicity/ADR	655385587; 655385588; 655385589	AA:Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk for tardive dyskinesia as compared to patients with the GA and GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia when taking antipsychotics.; AG:Patients with the AG genotype and schizophrenia who are treated with antipsychotics may have an increased risk for tardive dyskinesia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia when taking antipsychotics.; GG:Patients with the GG genotype and schizophrenia who are treated with antipsychotics may have an increased risk for tardive dyskinesia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia when taking antipsychotics.	699638580; 699638552; 699638564	Allele A is associated with increased likelihood of side effects when exposed to antipsychotics as compared to allele G.; Allele G is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele A.; Allele G is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele A.	18086475; 17767146; 18180754	3	antipsychotics	Schizophrenia;tardive dyskinesia		
655385604	rs762551	CYP1A2 (PA27093)	3	Efficacy	655385605; 655385606; 655385607	AA:Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have decreased response to olanzapine based on decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.; AC:Patients with the AC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.; CC:Patients with the CC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.	655385601	Genotype AA is associated with decreased mean dose-/body weight-normalized serum concentrations when treated with olanzapine in people with psychiatric disorders as compared to allele C.	19636338	1	olanzapine		White	
655385613	rs7997012	HTR2A (PA193)	3	Toxicity/ADR	655385614; 655385615; 655385616	AA:Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have an increased risk for more side effects as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.; AG:Patients with the AG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.; GG:Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.	655385610	Genotype AA is associated with increased risk of side effects when treated with olanzapine in people with psychiatric disorders as compared to allele G.	19636338	1	olanzapine		White	
655385674	rs1414334	HTR2C (PA194)	1B	Toxicity/ADR	655385675; 655385676; 655385677	CC:Patients with the CC genotype who are treated with antipsychotics may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.; CG:Patients with the CG genotype who are treated with antipsychotics may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.; GG:Patients with the GG genotype who are treated with antipsychotics may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.	655388451; 655388454	Allele C is associated with increased likelihood of Metabolic Syndrome X when treated with antipsychotics as compared to allele G.; Allele C is associated with increased risk of Metabolic Syndrome X when treated with clozapine and risperidone in people with Schizophrenia as compared to allele G.	20680028; 19142101	2	antipsychotics;clozapine;risperidone	Metabolic Syndrome X;Schizophrenia	White	
655385701	rs1045642	ABCB1 (PA267)	3	Efficacy;Toxicity/ADR	655385702; 655385703; 655385704	AA:Patients with the AA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have increased CD4-cell count as compared to patients with the GA and GG genotype 2) May have increased virologic response as compared to patients with the GA and GG genotype 3) May have an increased risk for toxicity-related failure as compared to patients with the GA and GG genotype 4) May have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the GA and GG genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.; AG:Patients with the GA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.; GG:Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.	655387331; 769169899; 655385690; 655385693; 655385696; 769163065; 827695457	Allele A is not associated with decreased response to efavirenz in people with Acquired Immunodeficiency Syndrome.; Allele A is associated with decreased risk of hepatotoxicity during antiretroviral therapy when treated with efavirenz and nevirapine in people with HIV as compared to allele G.; Genotype AA is associated with increased rise in CD4-cell count when treated with nelfinavir in people with HIV as compared to genotypes GG + GA.; Genotype AA is associated with increased CD4 T cell count when treated with efavirenz in people with HIV Infections as compared to genotype GG.; Genotype AA is associated with increased likelihood of favorable virologic responses when treated with efavirenz in people with HIV as compared to genotypes GG + GT.; Genotypes AA + AG are not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; Allele A is associated with increased likelihood of toxicity-related treatment failure when treated with efavirenz in people with HIV Infections as compared to allele G.	20662624; 16912956; 11809184; 16267764; 16267764; 20860463; 16267764	7	efavirenz;nelfinavir	HIV		
655385705	rs61888800	BDNF (PA31891)	3	Efficacy	655385706; 655385707; 655385708	GG:Patients with the GG genotype with major depressive disorder may experience a greater response when treated with desipramine or fluoxetine compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to antidepressants.; GT:Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.; TT:Patients with the TT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.	655387194	Genotype GG is associated with increased response to antidepressants, desipramine and fluoxetine in people with Depressive Disorder, Major.	19414708	1	antidepressants;desipramine;fluoxetine	Depression;Depressive Disorder, Major	Hispanic or Latino	
655385717	rs1057910	CYP2C9 (PA126)	3	Efficacy	655385718; 655385719; 655385720	AA:Patients with the AA genotype who are treated with sulfonylurea: 1) May be less likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be more likely to have failure of therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylurea therapy.; AC:Results from patients with the AC genotype were not statistically significant.; CC:Patients with the CC genotype who are treated with sulfonylurea: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the AA genotype 2) May be less likely to have failure of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylurea therapy.	655385712	Genotype CC is associated with increased response to sulfonamides, urea derivatives.	19794412	1	sulfonamides, urea derivatives	Diabetes Mellitus, Type 2		
655385721	rs1799853	CYP2C9 (PA126)	3	Efficacy	655385722; 655385723; 655385724	CC:Patients with the CC genotype and type II diabetes who are treated with sulfonylureas: 1) May be less likely to achieve a HbA1c level of <7% as compared to patients with the TT genotype 2) May be more likely to experience treatment failure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylureas.; CT:Results from patients with the CT genotype were not statistically significant.; TT:Patients with the TT genotype and type II diabetes who are treated with sulfonylureas: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be less likely to experience treatment failure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylureas.	655385709	Genotype TT is associated with increased response to sulfonamides, urea derivatives.	19794412	1	sulfonamides, urea derivatives	Diabetes Mellitus, Type 2		
655385749	rs12721627	CYP3A (PA27114),CYP3A4 (PA130)	4	Other	655385750; 655385751; 655385752	CC:The expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells.; CG:While the expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells, it is not clear what the influence of one G allele with the C allele is.; GG:The expression of a construct caring the G variant is not associated with decreased clearance of midazolam in transfected cells.	655385744	Allele C is associated with decreased clearance of midazolam.	19255940	1	midazolam			
655385763	rs290487	TCF7L2 (PA36394)	3	Efficacy	655385764; 655385765; 655385766	CC:Patients with the CC genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse.; CT:Patients with the CT genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse.; TT:Patients with the TT genotype may have better response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's repsonse.	655385762	Genotype TT is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.	20054294	1	repaglinide	Diabetes Mellitus, Type 2	Asian	
655385814	rs2273697	ABCC2 (PA116)	3	Toxicity/ADR	655385815; 655385816; 655385817	AA:Patients with the AA genotype and epilepsy who are treated with carbamazepine 1) may have an increased risk for neurological adverse events 2) may have increased likelihood of response to antiepileptic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; AG:Patients with the AG genotype and epilepsy who are treated with carbamazepine 1) may have an increased risk for neurological adverse events 2) may have increased likelihood of response to antiepileptic drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; GG:Patients with the GG genotype and epilepsy who are treated with carbamazepine 1) may have a decreased, but not absent, risk for neurological adverse events 2) may have a lesser response to antiepileptic drugs as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.	699639378; 827705076; 827824194; 827824458; 827824539; 827844971; 827921760	Genotypes AA + AG are associated with increased risk of neurological ADR when treated with carbamazepine in people with Epilepsy as compared to genotype GG.; Allele A is associated with increased probability of antiepileptic drug response when treated with antiepileptics in children with Epilepsy as compared to allele G.; Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.; Genotypes AA + AG are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.; Allele A is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele G.; Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.; Allele G is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele A.	20216337; 21799461; 22188362; 22256867; 22256867; 21449672; 22630058	7	antiepileptics;carbamazepine	Epilepsy		
655385818	rs1800629	LST1 (PA37856),LTA (PA30474),TNF (PA435)	3	Toxicity/ADR	655385819; 655385820; 655385821	AA:Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.; AG:There were too few patients with the AG genotype in this one small study for a conclusion to be drawn.; GG:Patients with the GG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.	655388335	Allele A is associated with increased likelihood of serious hypersensitivity when treated with carbamazepine as compared to allele G.	11294926	1	carbamazepine	Hypersensitivity	White	
655385856	rs2032582	ABCB1 (PA267)	3	Efficacy	655385857; 655385858; 655385859	AA:Patients with the AA genotype may have 1) decreased, but not absent, risk for resistance 2) increased response to taxanes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to taxanes.; AT:Patients with the AA genotype may have 1) decreased, but not absent, risk for resistance 2) increased response to taxanes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to taxanes.; TT:Patients with the TT genotype may have decreased, but not absent, risk for resistance to taxanes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to taxanes.	655387959; 699638624	Genotype AA is associated with increased chance of positive response to paclitaxel when treated with paclitaxel in people with Ovarian Neoplasms as compared to genotype CC.; Genotype CC is associated with increased risk of resistance when treated with paclitaxel in people with Breast Neoplasms as compared to genotype AC.	16467099; 18836089	2	paclitaxel;taxanes	Breast Neoplasms		
655385860	rs2032582	ABCB1 (PA267)	3	Efficacy	655385861; 655385862; 655385863	AA:Patients with the AA genotype and cancer who are treated with anthracyclines: 1) may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype 2) may have increased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines.; AC:Patients with the CA genotype and cancer who are treated with anthracyclines: 1) may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype 2) may have increased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines.; CC:Patients with the CC, CT or TT genotype and cancer who are treated with anthracyclines 1) may have an increased risk of resistance as compared to patients with the AC and AA genotype 2) may have decreased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines.	769152976; 769250973; 769169476; 655388061; 655388064; 699638627; 769152967; 827811288	Genotype AA is associated with increased sensitivity in vitro when treated with mitoxantrone as compared to genotypes CC + AC.; Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype CC.; Genotypes AA + AC are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma.; Genotype CC is associated with increased likelihood of complete remission in people with Leukemia, Myeloid, Acute.; Genotype CC is associated with increased likelihood of 3 year event free survival in people with Leukemia, Myeloid, Acute.; Genotype CC is associated with increased risk of resistance when treated with anthracyclines and related substances in people with Breast Neoplasms as compared to genotype AC.; Genotype CC is associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AC.; Genotypes CT + TT are associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes AC + CC.	20938465; 18377430; 18408561; 16331627; 16331627; 18836089; 20938465; 20179710	8	anthracyclines and related substances	Breast Neoplasms;Leukemia, Myeloid, Acute;Multiple Myeloma		
655385917	rs1051266	SLC19A1 (PA327)	3	Toxicity/ADR	655385918; 655385919; 655385920	CC:Patients with the CC genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hepatoxicity.; CT:Patients with the TC genotype and psoriasis who are treated with methotrexate may have an increased risk of hepatotoxicity as compared to patients with the CC genotype or may have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hepatoxicity.; TT:Patients with the TT genotype and psoriasis who are treated with methotrexate may have an increased risk of hepatotoxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hepatoxicity.	655385902	Allele T is associated with increased hepatotoxicity when treated with methotrexate in people with Psoriasis as compared to allele C.	17410198	1	methotrexate	Drug Toxicity;Psoriasis		
655385969	rs13058338	RAC2 (PA34163)	3	Toxicity/ADR	655385970; 655385971; 655385972	AA:Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the TT genotype. Please note, the risk allele reported in the study has been complemented to the positive chromosomal strand here. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; AT:Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the AA genotype or may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the TT genotype. Please note, the risk allele reported in the study has been complemented to the positive chromosomal strand here. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; TT:Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the AA genotype. Please note, the risk allele reported in the study has been complemented to the positive chromosomal strand here. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.	655385959	Allele T is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele A.	16330681	1	doxorubicin	Arrhythmias, Cardiac;Drug Toxicity;Lymphoma, Non-Hodgkin	White	
655385973	rs17222723	ABCC2 (PA116)	3	Toxicity/ADR	655385974; 655385975; 655385976	AA:Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; AT:Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; TT:Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.	655385891	Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele T.	16330681	1	doxorubicin	Arrhythmias, Cardiac;Drug Toxicity;Lymphoma, Non-Hodgkin	White	
655385977	rs1883112	NCF4 (PA31465)	3	Toxicity/ADR	655385978; 655385979; 655385980	AA:Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; AG:Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; GG:Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubcin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.	655385953	Genotype AA is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to genotypes GG + AG.	16330681	1	doxorubicin	Arrhythmias, Cardiac;Drug Toxicity;Lymphoma, Non-Hodgkin	White	
655385981	rs45511401	ABCC1 (PA244)	3	Toxicity/ADR	655385982; 655385983; 655385984	GG:Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; GT:Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; TT:Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.	655385947	Allele T is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.	16330681	1	doxorubicin	Arrhythmias, Cardiac;Drug Toxicity;Lymphoma, Non-Hodgkin	White	
655385985	rs4673	CYBA (PA27075)	3	Toxicity/ADR	655385986; 655385987; 655385988	AA:Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; AG:Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; GG:Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.	655385965	Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.	16330681	1	doxorubicin	Arrhythmias, Cardiac;Drug Toxicity;Lymphoma, Non-Hodgkin	White	
655385989	rs1051740	EPHX1 (PA27829)	3	Toxicity/ADR	655385990; 655385991; 655385992	CC:Patients with the CC genotype who use phenytoin during the first trimester of pregnancy may be less likely to have a child with a craniofacial abnormality as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of having a child with a craniofacial abnormality.; CT:Patients with the CT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.; TT:Patients with the TT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.	655387520	Allele T is associated with increased risk of Craniofacial Abnormalities when exposed to phenytoin in people with first trimester pregnancy as compared to allele C.	19952982	1	phenytoin	Congenital Abnormalities;Craniofacial Abnormalities		
655385993	rs2234922	EPHX1 (PA27829)	3	Toxicity/ADR	655385994; 655385995; 655385996	AA:Patients with the AA genotype who are exposed to phenytoin during the first trimester of pregnancy may have a decreased, but not absent, risk for having a child with a craniofacial abnormality as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a person's risk for having a child with a craniofacial abnormality after phenytoin exposure.; AG:Patients with the AG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	655387523	Allele G is associated with increased risk of Craniofacial Abnormalities when exposed to phenytoin in people with first trimester pregnancy as compared to allele A.	19952982	1	phenytoin	Congenital Abnormalities;Craniofacial Abnormalities		
655385997	rs2784917	SLIT1 (PA35938)	4	Toxicity/ADR	655385998; 655385999; 655386000	AA:Patients with the AA genotype may have increased risk of toxicity with etoposide compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AG:Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	769143881	Genotype AA is associated with increased gene expression of WNT5 and etoposide toxicity  based upon IC50 values in cell lines from 30 parent-child trios.	17537913	1	etoposide		Black or African American	
655386002	rs6539870		4	Toxicity/ADR	655386003; 655386004; 655386005	AA:Patients with the AA genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AG:Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype may have increased risk of toxicity with etoposide compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	748448812	Genotype GG is associated with increased gene expression of IL1B and etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios.	17537913	1	etoposide		White	
655386028	rs1045642	ABCB1 (PA267)	3	Dosage	655386029; 655386030; 655386031	AA:Healthy individuals with the AA genotype who are treated with fexofenadine may have lower plasma drug levels as compared to healthy individuals with the AG or GG genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.; AG:Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.; GG:Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.	655386010; 655386021	Genotype AA is not associated with plasma concentration of fexofenadine in people with no disease (healthy volunteers) as compared to genotype GG.; Genotype AA is associated with decreased plasma concentration of fexofenadine in people with no disease (healthy volunteers) as compared to genotypes GG + AG.	11994059; 11503014	2	fexofenadine		White	
655386070	rs9024	CBR1 (PA26121)	4	Dosage	655386071; 655386072; 655386073	AA:In patients with the AA genotype, the levels of clearance and exposure to doxorubicin may be similar to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.; AG:Patients with the AG genotype 1) may have decreased clearance of doxorubicin 2) increased exposure to doxorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.; GG:Patients with the GG genotype 1) may have increased clearance of doxorubicin 2) decreased exposure to doxorubicin compared to patients with the AG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.	655386059; 655386064; 655386067; 769173407; 769173442	Genotype GG is associated with increased clearance of doxorubicin in people with Breast Neoplasms as compared to genotype AG.; Genotype GG is associated with decreased exposure when treated with doxorubicin in people with Breast Neoplasms as compared to genotype AG.; Genotype GG is associated with decreased plasma concentration of doxorubicinol in people with Breast Neoplasms as compared to genotype AG.; Genotype GG is associated with increased catalytic activity of CBR1 of doxorubicin.; Genotype GG is associated with increased catalytic activity of CBR1 of doxorubicin.	19016765; 19016765; 19016765; 19022938; 19022938	5	doxorubicin	Breast Neoplasms		
655386075	rs1045642	ABCB1 (PA267)	3	Efficacy	655386076; 655386077; 655386078	AA:Patients with the AA genotype may have 1) increased exposure to doxorubicin metabolites and 2) increased response to anthracycline regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.; AG:Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.; GG:Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.	655386281; 769250961; 655385849; 769152970; 769169480; 827817217	Genotype AA is associated with increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to genotypes GG + AG.; Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype GG.; Genotype GG is associated with increased time to progression when treated with anthracyclines and related substances, doxorubicin and epirubicin in people with Breast Neoplasms as compared to genotypes AA + AG.; Genotype GG is not associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype AA.; Genotype GG is associated with decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype AA.; Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.	12684679; 18377430; 19752884; 20938465; 18408561; 22026922	6	anthracyclines and related substances;cytarabine;doxorubicin;epirubicin;idarubicin	Breast Neoplasms;Leukemia, Myeloid, Acute;Multiple Myeloma		
655386079	rs8187710	ABCC2 (PA116)	3	Toxicity/ADR	655386080; 655386081; 655386082	AA:Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.; AG:Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.; GG:Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.	655385943	Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.	16330681	1	doxorubicin	Lymphoma, Non-Hodgkin	White	
655386083	rs714368	SLC22A16 (PA134911502)	4	Other	655386084; 655386085; 655386086	CC:Patients with the CC genotype may have increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CT or TT. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.; CT:Patients with the CT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.; TT:Patients with the TT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.	699642282; 699642283	Genotype CC is associated with increased doxorubicin AUC when treated with doxorubicin in people with Breast Neoplasms as compared to genotypes TT + CT.; Genotype CC is associated with increased doxorubicinol AUC when treated with doxorubicin in people with Breast Neoplasms as compared to genotypes TT + CT.	17559346; 17559346	2	doxorubicin;doxorubicinol	Breast Neoplasms	Asian	
655386088	rs20572	CBR1 (PA26121)	4	Dosage	655386089; 655386090; 655386091	CC:Patients with the CC genotype may have 1) increased clearance of doxorubicin 2) decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.; CT:Patients with the CT genotype may have 1) decreased clearance of doxorubicin 2) increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with CC genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.; TT:Patients with the TT genotype 1) may have similar levels of clearance of doxorubicin 2) may have similar exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.	655386045; 655386047; 655386048	Genotype CC is associated with increased clearance of doxorubicin in people with Breast Neoplasms as compared to genotype CT.; Genotype CC is associated with decreased exposure when treated with doxorubicin in people with Breast Neoplasms as compared to genotype CT.; Genotype CC is associated with decreased plasma concentration of doxorubicinol in people with Breast Neoplasms as compared to genotype CT.	19016765; 19016765; 19016765	3	doxorubicin;doxorubicinol	Breast Neoplasms	Asian	
655386093	rs7769719	PPARD (PA33557)	3	Efficacy	655386094; 655386095; 655386096	AA:Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.	655388209	Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386099	rs730720	CHST3 (PA26503)	3	Efficacy	655386100; 655386101; 655386102	CC:Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.	699638963	Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386104	rs6922548	PPARD (PA33557)	3	Efficacy	655386105; 655386106; 655386107	AA:Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.	655388206	Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386109	rs4646487	CYP4B1 (PA27119)	3	Toxicity/ADR	655386110; 655386111; 655386112	CC:Patients with the CC genotype may have a decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.	655388200	Allele T is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386114	rs4148950	CHST3 (PA26503)	3	Efficacy;Toxicity/ADR	655386115; 655386116; 655386117	AA:Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.	699638968; 699638971	Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.; Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	20038957; 20038957	2	docetaxel;thalidomide	Prostatic Neoplasms		
655386120	rs4148947	CHST3 (PA26503)	3	Efficacy	655386121; 655386122; 655386123	CC:Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.	699638975	Allele T is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386126	rs4148945	CHST3 (PA26503)	3	Efficacy;Toxicity/ADR	655386127; 655386128; 655386129	CC:Patients with the CC genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.	655388257; 655388260	Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.; Allele C is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	20038957; 20038957	2	docetaxel;thalidomide	Prostatic Neoplasms		
655386131	rs4148943	CHST3 (PA26503)	3	Efficacy	655386132; 655386133; 655386134	CC:Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.	655388254	Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386136	rs3734254	PPARD (PA33557)	3	Efficacy	655386137; 655386138; 655386139	CC:Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.	655388251	Allele T is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386141	rs2301159	SLC10A2 (PA318)	3	Toxicity/ADR	655386142; 655386143; 655386144	AA:Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.	655388248	Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386146	rs2292954	SPG7 (PA36067)	3	Toxicity/ADR	655386147; 655386148; 655386149	AA:Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.	655388245	Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386151	rs2238472	ABCC6 (PA58)	3	Toxicity/ADR	655386152; 655386153; 655386154	CC:Patients with the CC genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.	655388242	Allele C is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386156	rs2227291	ATP7A (PA72)	3	Toxicity/ADR	655386157; 655386158; 655386159	CC:Patients with the CC genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.; CG:Patients with the CG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.	655388239	Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386161	rs2016520	PPARD (PA33557)	3	Efficacy	655386162; 655386163; 655386164	CC:Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.	655388236	Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386166	rs1883322	PPARD (PA33557)	3	Efficacy	655386167; 655386168; 655386169	CC:Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.	655388213	Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386171	rs1871450	CHST3 (PA26503)	3	Efficacy;Toxicity/ADR	655386172; 655386173; 655386174	AA:Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.	655388228; 655388232	Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.; Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	20038957; 20038957	2	docetaxel;thalidomide	Prostatic Neoplasms		
655386176	rs1799931	NAT2 (PA18)	3	Toxicity/ADR	655386177; 655386178; 655386179	AA:Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.	655388223	Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386181	rs1402467	SULT1C4 (PA162405070)	3	Efficacy	655386182; 655386183; 655386184	CC:Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.; CG:Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.	655388203	Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386186	rs12960	RPL13 (PA34670),SNORD68 (PA145007789),SPG7 (PA36067)	3	Toxicity/ADR	655386187; 655386188; 655386189	AA:Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.	655388219	Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386191	rs12418	CHST3 (PA26503)	3	Efficacy	655386192; 655386193; 655386194	AA:Patients with the AA genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.	655388216	Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	20038957	1	docetaxel;thalidomide	Prostatic Neoplasms		
655386212	rs2070995	KCNJ6 (PA30049)	3	Efficacy	655386213; 655386214; 655386215	CC:Patients with the CC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic.; CT:Patients with the TC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic.; TT:Patients with the TT genotype and post-operative pain may be more likely to require rescue analgesic administration as compared to patients with the TC or CC genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic.	655386202	Genotype TT is associated with increased frequency of rescue analgesic administration in people with Pain as compared to genotypes CC + CT.	19756153	1	Analgesics	Pain	Asian	
655386244	rs1045642	ABCB1 (PA267)	2A	Toxicity/ADR	655386245; 655386246; 655386247	AA:Patients with the AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hepatotoxicity with nevirapine treatment.; AG:While patients with the AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype, it is not clear what the influence of one A allele with the G allele is. Other genetic and clinical factors may also influence a patient's risk for hepatotoxicity with nevirapine treatment.; GG:Patients with the GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for hepatotoxicity with nevirapine treatment.	655386223; 769169877; 769169899	Allele A is associated with decreased risk of hepatotoxicity when treated with nevirapine in people with HIV.; Allele A is associated with decreased risk of nevirapine hepatotoxicity when treated with nevirapine in people with HIV as compared to allele G.; Allele A is associated with decreased risk of hepatotoxicity during antiretroviral therapy when treated with efavirenz and nevirapine in people with HIV as compared to allele G.	20017669; 16912957; 16912956	3	nevirapine	HIV Infections		
655386310	rs870995	PIK3CA (PA33308)	4	Dosage	655386311; 655386312; 655386313	AA:Patients with the AA genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.; AC:Patients with the CA genotype may have increased clearance of docetaxel compared to patients with the AA genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.; CC:Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.	699638956	Allele C is associated with increased clearance of docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	20157331	1	docetaxel	Carcinoma, Non-Small-Cell Lung	White	
655386315	rs518329	PRDX4 (PA33725)	4	Dosage	655386316; 655386317; 655386318	CC:Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.; CT:Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.; TT:Patients with the TT genotype may have decreased clearance of docetaxel compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.	699638960	Genotype TT is associated with decreased clearance of docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.	20157331	1	docetaxel	Carcinoma, Non-Small-Cell Lung	White	
655386320	rs2234922	EPHX1 (PA27829)	4	Dosage	655386321; 655386322; 655386323	AA:Patients with the AA genotype may have increased clearance of docetaxel compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence docetaxel clearance.; AG:Patients with the AG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.; GG:Patients with the GG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.	655388313	Genotype AA is associated with increased clearance of docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GG + AG.	20157331	1	docetaxel	Carcinoma, Non-Small-Cell Lung	White	
655386324	rs1382368	XRCC4 (PA37423)	4	Dosage	655386325; 655386326; 655386327	CC:Patients with the CC genotype may have decreased clearance of docetaxel compared to patients with TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.; CT:Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the CC genotype, or decreased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.; TT:Patients with the TT genotype may have increased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.	655388312	Allele T is associated with increased clearance of docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	20157331	1	docetaxel	Carcinoma, Non-Small-Cell Lung	White	
655386421	rs1051266	SLC19A1 (PA327)	3	Efficacy	655386422; 655386423; 655386424	CC:Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have less symptom improvement as compared to patients with the TT genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.; CT:Patients with the TC genotype and Rheumatoid Arthritis who are treated with methotrexate may have less symptom improvement as compared to patients with the TT genotype or may have more symptom improvement as compared to patients with the CC genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.; TT:Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have more symptom improvement as compared to patients with the CC genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.	769171199; 769171231; 655386407; 655387659; 769170794; 769171198; 769171200; 827863341	Allele T is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.; Allele T is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele C.; Genotype TT is associated with lower disease activity as assessed by the physician, less patient-assessed difficulty with physical tasks, and fewer swollen joints when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.; Genotype TT is associated with increased methotrexate polyglutamate (MTXPG3-5) levels when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.; Genotype TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.; Genotype TT is associated with increased likelihood of remission when treated with methotrexate and prednisone in people with Arthritis, Rheumatoid as compared to genotype CC.; Genotype TT is associated with increased aminotransferase activity when treated with methotrexate and prednisone in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.; Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	17325736; 18322994; 15457444; 15564880; 19827168; 17325736; 17325736; 22450926	8	methotrexate	Arthritis, Rheumatoid		
655386436	rs1801131	MTHFR (PA245)	3	Toxicity/ADR	655386437; 655386438; 655386439	GG:Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.; GT:Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype or may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.; TT:Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.	655386428; 769170689; 769170681; 827813090; 827774243	Allele G is associated with increased risk of overall Adverse drug events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.; Allele G is associated with increased likelihood of elevated transaminases when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.; Allele T is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.; Allele G is associated with increased likelihood of central nervous system toxicities when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.; Allele G is not associated with Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	16572443; 20514079; 16439441; 19858780; 21931346	5	methotrexate	Arthritis, Rheumatoid		
655386447	rs11042725	ADM (PA24580)	3	Efficacy	655386448; 655386449; 655386450	AA:Patients with the AA genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.; AC:Patients with the AC genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.; CC:Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a decreased response as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.	655386443	Genotype CC is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotypes AA + AC.	19636336	1	paroxetine	Depressive Disorder, Major		
655386550	rs1801133	CLCN6 (PA26551),MTHFR (PA245)	3	Toxicity/ADR	655386551; 655386552; 655386553	AA:Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; AG:Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; GG:Has average risk for metabolic syndrome when treated with antipsychotics. Patients with the GG genotype treated with antipsychotics may have decreased risk for metabolic syndrome as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking antipsychotics based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.	655386547	Allele A is associated with increased likelihood of metabolic syndrome when treated with antipsychotics in people with Schizophrenia.	17976958	1	antipsychotics	Schizophrenia		
655386585	rs1142345	TPMT (PA356)	3	Toxicity/ADR	981478429; 981478430; 981478431	CC:Patients with the CC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; CT:Patients with the TC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; TT:Patients with the TT genotype who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to patients with the TC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.	655386562	Allele C is associated with increased risk of Deafness when treated with cisplatin in people with Neoplasms as compared to allele T.	19898482	1	cisplatin	Neoplasms		
655386589	rs4646316	COMT (PA117)	1B	Toxicity/ADR	655386590; 655386591; 655386592	CC:Patients with the CC genotype and cancer who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; CT:Patients with the CT genotype and cancer who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; TT:Patients with the TT genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk of hearing loss as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.	655386573	Allele C is associated with increased risk of Deafness when treated with cisplatin in people with Neoplasms as compared to allele T.	19898482	1	cisplatin	Neoplasms		
655386593	rs12201199	TPMT (PA356)	3	Toxicity/ADR	655386594; 655386595; 655386596	AA:Patients with the AA genotype may have decreased risk for hearing loss with cisplatin treatment compared to patients with the TT or AT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AT:Patients with the AT genotype may have increased risk for hearing loss with cisplatin treatment compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype may have increased risk for hearing loss with cisplatin treatment compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	655386554	Allele T is associated with increased risk of Deafness when treated with in people with Neoplasms as compared to allele A.	19898482	1	cisplatin	Neoplasms		
655386597	rs1800460	TPMT (PA356)	3	Toxicity/ADR	981478420; 981478421; 981478422	CC:Patients with the CC genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to patients with the TC or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; CT:Patients with the TC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; TT:Patients with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.	655386568	Allele T is associated with increased risk of Deafness when treated with cisplatin in people with Neoplasms as compared to allele C.	19898482	1	cisplatin	Neoplasms		
655386601	rs9332377	COMT (PA117)	1B	Toxicity/ADR	981478457; 981478458; 981478459	CC:Patients with the CC genotype who are treated with cisplatin may have a decreased, but not absent, risk of hearing loss as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; CT:Patients with the CT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; TT:Patients with the TT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.	655386579	Allele T is associated with increased risk of Deafness when treated with cisplatin in people with Neoplasms as compared to allele C.	19898482	1	cisplatin	Neoplasms		
655386612	rs2228001	XPC (PA37413)	1B	Toxicity/ADR	981478446; 981478447; 981478448	GG:Patients with the GG genotype may have an increased risk for toxicity with cisplatin treatment, including hearing loss and neutropenia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GT:Patients with the GT genotype may have an increased risk for toxicity with cisplatin treatment, including hearing loss and neutropenia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	655386605; 769165283; 827695853; 827695864; 827695873	Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in people with Osteosarcoma as compared to allele T.; Genotypes GG + GT are associated with increased risk of Neutropenia when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT.; Genotype GG is associated with increased risk of Neutropenia when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT.; Genotypes GG + GT are associated with increased risk of Drug Toxicity when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT.; Genotype GG is associated with increased risk of Drug Toxicity when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT.	19434073; 21047201; 21047201; 21047201; 21047201	5	cisplatin	Neoplasms;Osteosarcoma;Urinary Bladder Neoplasms		
655386616	rs13181	ERCC2 (PA27848),KLC3 (PA142671588)	3	Efficacy	655386617; 655386618; 655386619	GG:Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.; GT:Patients with the GT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.; TT:Patients with the TT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.	827813109; 827816865; 827816886; 655386609; 637880131; 769166392; 827704200; 827793330; 827827967	Allele G is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele T.; Genotype GG is associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.; Genotype GG is associated with decreased progression-free survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.; Allele G is associated with decreased event free survival when treated with cisplatin in people with Osteosarcoma as compared to genotype TT.; Genotype GG is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype TT.; Genotypes TT + GT are associated with increased progression free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.; Genotype GG is associated with increased event free survival when treated with cisplatin, doxorubicin, ifosfamide and methotrexate in people with Osteosarcoma as compared to genotype TT.; Genotype GT is associated with increased progression-free survival when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GG + TT.; Genotypes GG + GT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	19620936; 22026922; 22026922; 19434073; 15213713; 20078613; 21826087; 21449681; 22188361	9	cisplatin;oxaliplatin;platinum;Platinum compounds	Colorectal Neoplasms;Esophageal Neoplasms;Osteosarcoma;Ovarian Neoplasms;Pancreatic Neoplasms		
655386635	rs1042522	TP53 (PA36679)	2B	Efficacy;Toxicity/ADR	981478468; 981478469; 981478470	CC:Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.; CG:Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.; GG:Patients with the GG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.	827810841; 827810856; 827828096; 827828127; 769245653; 637879888; 655386329	Genotypes CG + GG are associated with decreased response to cisplatin and paclitaxel in people with Stomach Neoplasms as compared to genotype CC.; Genotypes CG + GG are associated with decreased one year progression free survival when treated with cisplatin and paclitaxel in people with Stomach Neoplasms as compared to genotype GG.; Genotype GG is not associated with increased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes CC + CG.; Genotypes CG + GG are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Allele G is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele C.; Genotype GG is associated with decreased survival time when treated with fluorouracil in people with Stomach Neoplasms as compared to genotypes CC + GC.; Genotype GG is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CC + CG.	19052714; 19052714; 22188361; 22188361; 20638924; 18357466; 19786980	7	antineoplastic agents;cisplatin;cyclophosphamide;fluorouracil;paclitaxel	Breast Neoplasms;Neoplasms;Neutropenia;Ovarian Neoplasms;Stomach Neoplasms		
655386639	rs11615	ERCC1 (PA155)	2B	Efficacy;Toxicity/ADR	655386640; 655386641; 655386642	AA:Patients with the AA genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.; AG:Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.; GG:Patients with the GG genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.	637880127; 655386332; 769172563; 827699103; 827784148; 827784157; 827816143; 827816972; 827817004; 827817015; 827826160; 827826170; 827832057; 827922697; 827922717; 827922728	Genotype AA is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype AG is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotype GG.; Genotypes GG + AG are associated with increased likelihood of response to platinum-based chemotherapy treatment in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.; Allele A is not associated with response to carboplatin and pemetrexed in people with Mesothelioma as compared to allele G.; Genotype GG is associated with increased overall survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.; Genotype GG is associated with increased progression-free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.; Genotype GG is associated with decreased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AA + AG.; Genotypes AG + GG are associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with decreased progression-free survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with increased likelihood of toxicity when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype AA.; Allele G is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele A.; Genotype AA is associated with decreased response to Platinum compounds in women with Ovarian Neoplasms as compared to genotype GG.; Genotype AA is associated with increased risk of recurrence of disease when treated with Platinum compounds in women Ovarian Neoplasms as compared to genotype GG.; Genotype AA is associated with increased risk of death when treated with Platinum compounds in women Ovarian Neoplasms as compared to genotype GG.	15213713; 19786980; 19362955; 21262916; 21057378; 21057378; 21902499; 22026922; 22026922; 22026922; 22188361; 22188361; 19620936; 22329723; 22329723; 22329723	16	carboplatin;cisplatin;oxaliplatin;platinum;Platinum compounds	Carcinoma, Non-Small-Cell Lung;Colorectal Neoplasms;Esophageal Neoplasms;Mesothelioma;Neoplasms;Ovarian Neoplasms;Pancreatic Neoplasms		
655386649	rs1799735	GSTM3 (PA29024)	3	Toxicity/ADR	655386650; 655386651; 655386652	CCT/CCT:Patients with the CCT/CCT genotype may have decreased but not non-existent risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the del/del or del/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.; CCT/del:Patients with the CCT/del genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the CCT/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.; del/del:Patients with the del/del genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the CCT/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.	655386478; 655386482; 655386485; 827824953	Genotype CCT/CCT is associated with decreased risk of Thrombocytopenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CCT/DEL + DEL/DEL.; Genotype CCT/CCT is associated with decreased risk of Anemia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CCT/DEL + DEL/DEL.; Genotype CCT/CCT is associated with decreased risk of Peripheral Nervous System Diseases when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CCT/DEL + DEL/DEL.; Genotype CCT/CCT is not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes CCT/DEL + DEL/DEL.	19786980; 19786980; 19786980; 22188361	4	cisplatin;cyclophosphamide	Ovarian Neoplasms	White	
655386653	rs1799793	ERCC2 (PA27848)	3	Efficacy;Toxicity/ADR	655386654; 655386655; 655386656	CC:Patients with the CC genotype may have decreased survival with cisplatin regimens as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to cisplatin regimens.; CT:Patients with the CT genotype may have 1) increased survival and 2) increased risk for hematological toxicity with cisplatin regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to cisplatin regimens.; TT:Patients with the TT genotype may have increased survival with cisplatin regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to cisplatin regimens.	655386620; 827704209; 827813099; 827817088; 827817099; 827817107; 827827919; 827827949; 827828246	Genotype CT is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms.; Genotypes CT + TT are associated with increased event free survival when treated with cisplatin, doxorubicin, ifosfamide and methotrexate in people with Osteosarcoma as compared to genotype CC.; Allele T is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele C.; Genotype CC is associated with increased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.; Genotype CC is not associated with increased progression-free survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.; Genotype CC is not associated with increased likelihood of toxicity when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.; Genotypes CT + TT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Genotypes CT + TT are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Genotype CT is associated with increased likelihood of overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	19786980; 21826087; 19620936; 22026922; 22026922; 22026922; 22188361; 22188361; 22188361	9	cisplatin	Esophageal Neoplasms;Osteosarcoma;Ovarian Neoplasms;Pancreatic Neoplasms		
655386657	rs25487	XRCC1 (PA369)	2B	Efficacy;Toxicity/ADR	655386658; 655386659; 655386660	CC:Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.; CT:Patients with the CT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.; TT:Patients with the TT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.	655386624; 769172568; 827641636; 827784173; 827784178; 827817158; 827817180; 827828058; 827828072; 827828226	Genotype CC is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes TT + CT.; Genotype TT is associated with worse overall survival outcome when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.; Allele T is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele C.; Genotype CC is associated with increased overall survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.; Genotype CC is associated with increased progression-free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.; Genotypes CT + TT are associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.; Genotypes CT + TT are not associated with decreased toxicity when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.; Genotypes CC + CT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.; Genotypes CT + TT are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Genotypes CT + TT are associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	19786980; 19362955; 16875718; 21057378; 21057378; 22026922; 22026922; 22188361; 22188361; 22188361	10	carboplatin;cisplatin;oxaliplatin;platinum;Platinum compounds	Carcinoma, Non-Small-Cell Lung;Colorectal Neoplasms;Neoplasms;Ovarian Neoplasms;Pancreatic Neoplasms;Uterine Cervical Neoplasms		
655386661	rs3212986	ERCC1 (PA155)	2B	Toxicity/ADR	655386662; 655386663; 655386664	AA:Patients with the AA genotype may have decreased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.; AC:Patients with the AC genotype may have increased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.; CC:Patients with the CC genotype may have increased risk for nephrotoxicity with platinum-based regimens as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.	827816070; 827826211; 655386628	Genotype AA is associated with decreased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AC + CC.; Genotypes AA + AC are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Genotype AC is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms.	21902499; 22188361; 19786980	3	cisplatin;platinum;Platinum compounds	Neoplasms;Ovarian Neoplasms	White	
655386665	rs3212986	CD3EAP (PA142672156),ERCC1 (PA155),PPP1R13L (PA34195)	3	Efficacy	655386666; 655386667; 655386668	AA:Patients with the AA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.; AC:Patients with the CA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.; CC:Patients with the CC genotype and ovarian cancer who are treated with platinum compounds may have increased survival as compared to patients with the CA or AA genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.	613979640	Genotype CC is associated with increased survival when treated with Platinum compounds in people with Ovarian Neoplasms as compared to genotypes AA + CA.	19203783	1	Platinum compounds	Ovarian Neoplasms	Asian	
655386801	rs3957357	GSTA1 (PA29016),GSTA6P (PA29020)	3	Toxicity/ADR	655386802; 655386803; 655386804	AA:Patients with the AA genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.; AG:Patients with the AG genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.; GG:Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.	655386631; 827824914; 827824940	Genotype AA is associated with increased overall survival when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes GG + AG.; Genotypes AA + AG are associated with increased likelihood of Anemia when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype GG.; Genotypes AA + AG are not associated with increased likelihood of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype GG.	19786980; 22188361; 22188361	3	cisplatin;cyclophosphamide	Anemia;Ovarian Neoplasms		
655386830	rs60369023	CDA (PA98)	3	Toxicity/ADR	655386831; 655386832; 655386833	AA:Patients with the AA genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.; AG:Patients with the AG genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity Neutropenia as compared to patients with the GG genotype, or 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.; GG:Patients with the GG genotype and cancer who are treated with gemcitabine 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.	655386824; 655386827; 655386814	Allele A is associated with decreased metabolism of gemcitabine in people with Neoplasms as compared to allele G.; Allele A is associated with increased severity of Neutropenia when treated with gemcitabine in people with Neoplasms as compared to allele G.; Genotype AA is associated with increased severity of Drug Toxicity when treated with cisplatin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype GG.	17194903; 17194903; 15814642	3	gemcitabine	Neoplasms;Neutropenia	Asian	
655386852	rs1799889	SERPINE1 (PA261)	3	Efficacy	655386853; 655386854; 655386855	AA:Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs2227631. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.; AG:Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.; GG:Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.	655386848	Allele G is associated with decreased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to genotype A.	18794724	1	antidepressants;citalopram;fluoxetine	Depressive Disorder, Major	Asian	
655386856	rs2227631	SERPINE1 (PA261)	3	Efficacy	655386857; 655386858; 655386859	AA:Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs1799889. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.; AG:Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.; GG:Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.	655386834	Allele G is associated with decreased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.	18794724	1	antidepressants;citalopram;fluoxetine	Depressive Disorder, Major	Asian	
655386869	rs1544410	VDR (PA37301)	3	Efficacy	655386870; 655386871; 655386872	CC:Patients with the CC genotype who are treated with bisphosphonates may have greater improvement in bone mineral density as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bisphosphonates.; CT:The response of patients with the CT genotype who are treated with bisphosphonates is not clear compared to that of patients with the CC or the TT genotype.; TT:Patients with the TT genotype who are treated with bisphosphonates may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bisphosphonates.	655386860; 769143853; 769164322; 769164327; 769164354; 699638952; 827695820; 827822903	Allele C is associated with increased likelihood of resistance when treated with clodronate in people with Osteitis Deformans.; Genotype CC is associated with increased greater improvement in bone mineral density when treated with alendronate and raloxifene in people with Osteoporosis, Postmenopausal as compared to genotype TT.; Genotype CC is associated with increased Bone Mineral Density when treated with alendronate in people with Osteoporosis as compared to genotype TT.; Genotype CC is associated with decreased urinary DPD/Cr levels when treated with alendronate in people with Osteoporosis as compared to genotype TT.; Genotype CC is associated with decreased Bone Mineral Density in people with as compared to genotype TT.; Genotype TT is associated with increased Mean spinal bone mineral density changes when treated with calcium and etidronic acid in people with Osteoporosis, Postmenopausal as compared to genotype CC.; Genotype CC is associated with decreased serum osteocalcin when treated with alendronate in people with Osteoporosis as compared to genotype TT.; Allele T is not associated with response to zoledronate in people with beta-Thalassemia.	19020788; 15739035; 12608943; 12608943; 12162507; 10692979; 12608943; 18443790	8	alendronate;Bisphosphonates;Calcium;clodronate;etidronic acid;raloxifene	Osteitis Deformans;Osteoporosis	White	
655386873	rs731236	VDR (PA37301)	3	Efficacy	655386874; 655386875; 655386876	AA:Patients with the AA genotype and Osteitis Deformans may have increased likelihood of resistance when treated with clodronate compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clodronate.; AG:Patients with the AG genotype and Osteitis Deformans may have increased likelihood of resistance when treated with clodronate compared to patients with genotype GG, or may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate.; GG:Patients with the GG genotype may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate.	655386864	Allele A is associated with increased likelihood of resistance when treated with clodronate in people with Osteitis Deformans as compared to allele G.	19020788	1	clodronate	Osteitis Deformans	White	
655386888	rs16944	IL1B (PA29808)	3	Efficacy	655386889; 655386890; 655386891	AA:Patients with the AA genotype and Paget's disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.; AG:Patients with the AG genotype and Paget's disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.; GG:Patients with the GG genotype and Paget's disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.	655386877	Genotype GG is associated with increased likelihood of resistance when treated with Bisphosphonates in people with Osteitis Deformans as compared to genotypes AA + AG.	16257277	1	Bisphosphonates;clodronate;etidronic acid;risedronate;tiludronate	Osteitis Deformans	White	
655386913	rs12248560	CYP2C19 (PA124)	1A	Dosage;Efficacy;Toxicity/ADR	655386916; 655386915; 655386914	CC:Patients with the CC genotype (*1/*1): 1) may have decreased activation of clopidogrel 2) may have a decreased, but not absent, risk for bleeding with clopidogrel as compared to patients with the CT or TT genotype 3) may have an increased risk for adverse cardiovascular events as compared to patients with a CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding and adverse cardiovascular events.; CT:Patients with the CT (*1/*17) genotype: 1) may have increased activation of clopidogrel 2) may have an increased risk of bleeding with clopidogrel as compared to patients with the CC genotype 3) may have a decreased, but not absent, risk for adverse cardiovascular events as compared to patients with a CC genotype. Current CPIC guidelines recommend no change in clopidogrel dosing based on *1/*17 genotype as yet. Other genetic and clinical factors may also influence a patient's risk for bleeding and adverse cardiovascular events.; TT:Patients with the TT (*17/*17) genotype: 1) may have increased activation of clopidogrel 2) may have an increased risk of bleeding with clopidogrel as compared to patients with a CC genotype 3) may have a decreased, but not absent, risk for adverse cardiovascular events as compared to patients with a CC genotype. Current CPIC guidelines recommend no change in clopidogrel dosing based on *17/*17 genotype as yet. Other genetic and clinical factors may also influence a patient's risk for bleeding and adverse cardiovascular events.	604843186; 655387717; 655387724; 699638703; 699638709; 769146047; 769146312; 769245459; 769245468; 827815445; 827815453; 827919816	Allele T is associated with decreased rates of target lesion revascularization and major adverse cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.; Allele T is associated with CYP2C19*17.; Allele T is associated with increased transcription of CYP2C19.; Allele T is associated with decreased ADP-induced platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.; Allele T is associated with increased risk of bleeding when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.; Allele T is associated with higher rate of events of major bleeding when treated with clopidogrel in people with Acute coronary syndrome as compared to allele C.; Allele T is associated with a more pronounced reduction in cardiovascular events with clopidogrel treatment as compared with placebo in people with Acute coronary syndrome as compared to allele C.; Allele T is not associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease.; Allele T is associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele C.; Genotypes CT + TT are associated with decreased magnitude of platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.; Genotypes CT + TT are associated with increased risk of occurrence of major bleedings when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.; Genotype CT is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	20826260; 16413245; 16413245; 20083681; 20083681; 20801498; 20979470; 21392617; 21392617; 22228204; 22228204; 22462746	12	clopidogrel	Acute coronary syndrome;Coronary Artery Disease;Myocardial Infarction		
655386945	rs7793837	CRHR2 (PA26875)	2B	Efficacy	655386946; 655386947; 655386948	AA:Patients with the AA genotype and asthma who are treated with short-acting beta2-antagonists may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.; AT:Patients with the AT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype, or may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.; TT:Patients with the TT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.	655386935; 655386940	Allele T is associated with decreased response to salbutamol and selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele A.; Allele T is associated with decreased response to salbutamol and selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele A.	18408560; 18408560	2	salbutamol;selective beta-2-adrenoreceptor agonists	Asthma	White	
655386961	rs2298383	ADORA2A (PA24584)	3	Toxicity/ADR	655386962; 655386963; 655386964	CC:Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.; CT:Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.; TT:Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.	655386955	Allele T is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	18539621	1	methotrexate	Arthritis, Rheumatoid	White	
655386969	rs3761422	ADORA2A (PA24584)	3	Toxicity/ADR	655386970; 655386971; 655386972	CC:Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.; CT:Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.; TT:Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.	655386965	Allele T is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	18539621	1	methotrexate	Arthritis, Rheumatoid	White	
655386981	rs2267076	ADORA2A (PA24584)	3	Toxicity/ADR	655386982; 655386983; 655386984	CC:Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.; CT:Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.; TT:Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.	655386973	Allele T is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	18539621	1	methotrexate	Arthritis, Rheumatoid	White	
655386985	rs2236624	ADORA2A (PA24584)	3	Toxicity/ADR	655386986; 655386987; 655386988	CC:Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for an adverse event as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for an adverse event.; CT:Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for an adverse event as compared to patients with the CC genotype or may have a decreased, but not absent, risk for an adverse event as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for an adverse event.; TT:Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for an adverse event as compared to patients with the CC genotype.	655386977	Allele T is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	18539621	1	methotrexate	Arthritis, Rheumatoid	White	
655386990	rs2279343	CYP2B6 (PA123)	3	Toxicity/ADR	655386991; 655386992; 655386993	AA:Patients with the AA genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have a decreased, but not absent, risk for oral mucositis as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.; AG:Patients with the AG genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.; GG:Patients with the GG genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.	699642255	Genotypes GG + AG are associated with increased risk of oral mucositis when treated with cyclophosphamide in people with recipients of HLA-identical hematopoietic stem cell transplantation as compared to genotype AA.	19005482	1	cyclophosphamide	Transplantation		
655386995	rs2740574	CYP3A4 (PA130)	3	Toxicity/ADR	655386996; 655386997; 655386998	CC:Premenopausal patients with the CC genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.; CT:Premenopausal patients with the CT genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.; TT:Premenopausal patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have a shorter period of time before chemotherapy-induced ovarian failure compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.	699642279	Allele C is associated with increased time to chemotherapy-related ovarian failure when treated with cyclophosphamide in people with Breast Neoplasms as compared to genotype TT.	19376514	1	cyclophosphamide	Breast Neoplasms		
655386999	rs8192709	CYP2B6 (PA123)	3	Toxicity/ADR	655387000; 655387001; 655387002	CC:Recipients of HLA-identical hematopoietic stem cell transplantation with the CC genotype and leukemia may have a decreased, but not absent, risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.; CT:Recipients of HLA-identical hematopoietic stem cell transplantation with the CT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.; TT:Recipients of HLA-identical hematopoietic stem cell transplantation with the TT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.	699642248	Genotypes TT + CT are associated with increased risk of hemorrhagic cystitis when treated with cyclophosphamide in people with recipients of HLA-identical hematopoietic stem cell transplantation as compared to genotype CC.	19005482	1	cyclophosphamide	Cystitis;Transplantation		
655387004	rs9561778	ABCC4 (PA397)	3	Toxicity/ADR	655387005; 655387006; 655387007	GG:Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.; GT:Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.; TT:Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.	655387574; 655387577; 655387580	Allele T is associated with increased risk of gastrointestinal toxicity when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele G.; Allele T is associated with increased severity of Neutropenia when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele G.; Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.	19696793; 19696793; 19696793	3	cyclophosphamide	Breast Neoplasms;Drug Toxicity	Asian	
655387009	rs1799983	NOS3 (PA254)	3	Efficacy	655387010; 655387011; 655387012	GG:Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.; GT:Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.; TT:Patients with the TT genotype 1) may have shorter disease-free survival when treated with cyclophosphamide-based regimens 2) may have longer disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence disease-free survival.	699638540; 699638544	Genotypes GG + GT are associated with increased disease free survival when treated with cyclophosphamide, doxorubicin, fluorouracil and methotrexate in people with Breast Neoplasms as compared to genotype TT.; Genotype TT is associated with increased disease free survival in people with Breast Neoplasms as compared to genotypes GG + GT.	19671875; 19671875	2	cyclophosphamide;doxorubicin;fluorouracil;methotrexate	Breast Neoplasms		
655387014	rs2070744	NOS3 (PA254)	3	Efficacy	655387015; 655387016; 655387017	CC:Patients with the CC genotype and breast cancer who are not treated with adjuvant cyclophophamide-based regimens may have longer disease-free survival as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence disease-free survival.; CT:Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.; TT:Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.	699638537	Genotype CC is associated with increased disease free survival in people with Breast Neoplasms as compared to genotypes TT + CT.	19671875	1	cyclophosphamide;doxorubicin;fluorouracil;methotrexate	Breast Neoplasms		
655387018	rs4795541	SLC6A4 (PA312)	3	Efficacy;Toxicity/ADR	655387020; 655387021; 655387019	AGATGCTGGGGGGGCTGCAGGGGGGATGCTGGGGGTGCAGGGG/AGATGCTGGGGGGGCTGCAGGGGGGATGCTGGGGGTGCAGGGG:Patients with the insert/insert (Long/ Long) genotype who are treated with treated with escitalopram: 1) who have experienced one or more Stressful Life Event in the 6 months pretreatment may have increased response when treated with escitalopram compared to patients with the del/del genotype. Patients who have not experienced one or more Stressful Life Event in the 6 months pretreatment may have a similar response compared to patients with the del/del genotype. 2) may have a decreased risk of side effects, including headache, compared to patients with the insert/del or del/del genotype. Other genetic and clinical factors may also influence response to escitalopram and side effects induced by escitalopram.; AGATGCTGGGGGGGCTGCAGGGGGGATGCTGGGGGTGCAGGGG/del:Patients with the insert/del (Long/ Short) genotype who are treated with escitalopram: 1) who have experienced one or more Stressful Life Event in the 6 months pretreatment may have increased response compared to patients with the del/del genotype. Patients who have not experienced one or more Stressful Life Event in the 6 months pretreatment may have a similar response compared to patients with the del/del genotype. 2) may have an increased risk of side effects, including headache, compared to patients with the insert/insert genotype. Other genetic and clinical factors may also influence response to escitalopram and side effects induced by escitalopram.; del/del:Patients with the del/del (Short/ Short) genotype who are treated with escitalopram: 1) who have experienced one or more Stressful Life Event in the 6 months pretreatment, may have reduced response compared to patients with the insert/del or insert/insert genotype. Patients who have not experienced one or more Stressful Life Event in the 6 months pretreatment, may have similar response compared to patients with the insert/del or insert/insert genotype. 2) may have increased risk of side effects, including headache, compared to patients with the insert/insert genotype. Other genetic and clinical factors may also influence response to escitalopram and side effects induced by escitalopram.	655388088; 769170877; 769143808; 769169349; 769169352; 769169355; 827820324; 827832038	Genotype AGATGCTGGGGGGGCTGCAGGGGGGATGCTGGGGGTGCAGGGGAGATGCTGGGGGGGCTGCAGGGGGGATGCTGGGGGTGCAGGGG is associated with the presence of sexual dysfunction when treated with Selective serotonin reuptake inhibitors as compared to genotype DELDEL.; Genotype DEL is not associated with response rate or mean change of depressive symptoms when treated with escitalopram in people with Depressive Disorder, Major as compared to genotype AGATGCTGGGGGGGCTGCAGGGGGGATGCTGGGGGTGCAGGGG.; Genotype DELDEL is associated with attenuated response to escitalopram among patients with major depression, who reported a stressful life event when treated with escitalopram.; Genotype DELDEL is associated with increased likelihood of remission after second treatment switch when treated with antidepressants in people with depression.; Genotype DELDEL is associated with improved second treatment switch response when treated with antidepressants in people with depression.; Genotype DELDEL is associated with increased likelihood of response when treated with antidepressants in people with depression.; Genotype AGATGCTGGGGGGGCTGCAGGGGGGATGCTGGGGGTGCAGGGG is not associated with increased sexual dysfunction when treated with escitalopram or nortriptyline in people with Depressive Disorder, Major as compared to genotype DEL.; Genotype DEL is associated with increased risk of side effects when treated with escitalopram in people with Depressive Disorder, Major as compared to genotype AGATGCTGGGGGGGCTGCAGGGGGGATGCTGGGGGTGCAGGGG.	19204908; 19272758; 20212518; 18253134; 18253134; 18253134; 21388237; 19272758	8	escitalopram	Depression;Depressive Disorder	White	
655387023	rs2072671	CDA (PA98)	3	Toxicity/ADR	655387024; 655387025; 655387026	AA:Patients with the AA genotype who are treated with cytarabine may have a decreased, but not absent, risk of toxicity as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; AC:Patients with the AC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; CC:Patients with the CC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.	699639373; 827803684; 827829894; 827922313	Genotype AA is associated with decreased risk of grade III/IV liver toxicity when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes CC + AC.; Genotypes AC + CC are associated with increased toxicity when treated with cytarabine as compared to genotype AA.; Genotype CC is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotype AA.; Genotype CC is associated with increased risk of Drug Toxicity when treated with cytarabine in children with Lymphoma, T-Cell.	19458626; 21521023; 22304580; 22379997	4	cytarabine	Leukemia, Myeloid, Acute	White	
655387027	rs532545	CDA (PA98)	3	Efficacy	655387028; 655387029; 655387030	CC:Patients with the genotype CC and Myeloid Leukemia who are treated with cytarabine 1) may have an increased survival time 2) may have a decreased risk for death, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.; CT:Patients with the genotype CT and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk for death as compared to patients with the CC genotype, or may have an increased survival time and a decreased risk for death as compared to patients with the TT genotype, though this may not be statistically significant. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.; TT:Patients with the genotype TT and Myeloid Leukemia who are treated with cytarabine 1) may have a decreased survival time 2) may have an increased risk for death, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.	699639367; 699639370	Genotype TT is associated with decreased 5 year survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.; Genotype TT is associated with increased risk of Death when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.	19458626; 19458626	2	cytarabine	Leukemia, Myeloid, Acute	White	
655387053	rs776746	CYP3A5 (PA131)	3	Dosage	655387054; 655387055; 655387056	CC:Patients with the CC genotype may require a decreased dose of cyclosporine to reach target blood concentration as compared to patients with the TC or TT genotype, although some studies find no association with dosage. Other genetic and clinical factors may also influence dose of cyclosporine.; CT:Patients with the TC genotype may require an increased dose of cyclosporine to reach target blood concentration as compared to patients with the CC genotype, although some studies find no association with dosage. Other genetic and clinical factors may also influence dose of cyclosporine.; TT:Patients with the TT genotype may require an increased dose of cyclosporine to reach target blood concentration as compared to patients with the CC genotype, although some studies find no association with dosage. Other genetic and clinical factors may also influence dose of cyclosporine.	827813960; 827830124; 655388265	Allele C is not associated with dose of cyclosporine in people with Kidney Transplantation as compared to allele T.; Genotypes CT + TT are not associated with increased dose of cyclosporine in people with Kidney Transplantation as compared to genotype CC.; Genotype CC is associated with decreased dose of cyclosporine as compared to genotypes TT + CT.	21806386; 12966368; 20368718	3	cyclosporine	Organ Transplantation;Transplantation		
655387058	rs2740574	CYP3A (PA27114),CYP3A4 (PA130)	2A	Dosage	655387059; 655387060; 655387061	CC:Patients with the CC genotype may require an increased dose of tacrolimus or sirolimus as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's dose requirements.; CT:Patients with the CT genotype may require an increased dose of tacrolimus or sirolimus as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's dose requirements.; TT:Patients with the TT genotype may require a decreased dose of tacrolimus or sirolimus as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's dose requirements.	827813847; 827815626; 827830204; 769250131; 769179630	Allele C is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele T.; Allele T is associated with tacrolimus concentration to dose ratio (C/D ratio) when treated with tacrolimus as compared to allele C.; Genotypes CC + CT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype TT.; Genotypes CC + CT are associated with increased dose of sirolimus in people with Transplantation as compared to genotype TT.; Allele T is associated with increased dose-corrected exposure of tacrolimus in people with Kidney Transplantation as compared to allele C.	21770725; 22108237; 12966368; 15707415; 17495880	5	sirolimus;tacrolimus	Organ Transplantation;Transplantation		
655387221	rs6280	DRD3 (PA27479)	3	Efficacy	655387222; 655387223; 655387224	CC:Patients with the CC genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response.; CT:Patients with the CT genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype may have smaller reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating poorer response to risperidone in Children with Autism, than TT homozygotes compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.	655387218	Allele C is associated with increased response to risperidone in people with Autistic Disorder as compared to genotype TT.	19997080	1	risperidone	Autistic Disorder		
655387229	rs1128503	ABCB1 (PA267)	3	Efficacy	655387230; 655387231; 655387232	AA:Patients with the AA genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response.; AG:Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response.; GG:Patients with the GG genotype may have poorer response to risperidone in Children with Autism, than patients with AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.	655387327	Genotypes AA + AG are associated with increased response to risperidone in people with Autistic Disorder as compared to genotype GG.	19997080	1	risperidone	Autistic Disorder		
655387237	rs6311	HTR2A (PA193)	3	Efficacy	655387238; 655387239; 655387240	CC:Patients with the CC genotype may have poorer response to risperidone in children with autism as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.; CT:Patients with the CT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.	655387233	Allele T is associated with increased response to risperidone in people with Autistic Disorder as compared to genotype CC.	19997080	1	risperidone	Autistic Disorder		
655387245	rs3813928	HTR2C (PA194)	3	Efficacy	655387246; 655387247; 655387248	AA:Patients with the AA genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.; AG:Patients with the AG genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.; GG:Patients with the GG genotype may have better response to risperidone as compared to patients with the AA or AG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.	655387241	Allele A is associated with decreased response to risperidone in people with Autistic Disorder as compared to genotype GG.	19997080	1	risperidone	Autistic Disorder		
655387257	rs7799039	LEP (PA228)	3	Toxicity/ADR	655387258; 655387259; 655387260	AA:Patients with the AA genotype may have excessive risperidone-associated weight gain in youths as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AG:Patients with the AG genotype may have excessive risperidone-associated weight gain in youths as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype may less likely to be overweight/obese in risperidone treated youth as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	655387253	Allele A is associated with increased likelihood of wight gain when treated with risperidone as compared to genotype GG.	19873684	1	risperidone			
655387652	rs1799978	DRD2 (PA27478)	2A	Efficacy	655387653; 655387654; 655387655	CC:Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.; CT:Patients with the TC genotype and schizophrenia who are treated with risperidone may be more likely to have improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.; TT:Patients with the TT genotype and schizophrenia who are treated with risperidone may be more likely to have improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.	655387624; 655387634	Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.; Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	17105675; 18855532	2	risperidone	Schizophrenia	Asian	
655387672	rs1799978	DRD2 (PA27478)	3	Toxicity/ADR	655387673; 655387674; 655387675	CC:Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; CT:Patients with the CT genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype may have decreased but not absent, risk of Hyperprolactinemia when treated with risperidone as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	655387669	Allele C is associated with increased risk of Hyperprolactinemia when treated with risperidone as compared to allele T.	19339912	1	risperidone		White	
655387688	rs1800497	ANKK1 (PA134872551)	3	Toxicity/ADR	655387689; 655387690; 655387691	AA:Female patients with the AA genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.; AG:Female patients with the AG genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.; GG:Female patients with the GG genotype and schizophrenia treated with nemonapride may have a decreased, but not absent, prolactin response to nemonapride compared to female patients with the AG and AA genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.	655387683	Allele A is associated with increased prolactin response in females when exposed to nemonapride in people with schizophrenia as compared to allele G.	10823405	1	nemonapride	Schizophrenia	Asian	
655387763	rs12248560	CYP2C19 (PA124)	3	Dosage	655387764; 655387765; 655387766	CC:Patients with the CC genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; CT:Patients with the CT genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; TT:Patients with the TT genotype who are treated with escitalopram may require an increased dose as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.	655387729	Genotype TT is associated with decreased serum concentration of escitalopram in people with Mental Disorders as compared to genotype CC.	17625515	1	escitalopram	Mental Disorders	White	
655387767	rs12248560	CYP2C19 (PA124)	3	Dosage	655387768; 655387769; 655387770	CC:Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; CT:Patients with the CT genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; TT:Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.	655387719	Genotype TT is associated with increased metabolism of mephenytoin in people with no disease as compared to genotype CC.	16413245	1	mephenytoin		Black or African American	
655387798	rs1902023	UGT2B15 (PA37188)	2B	Other	655387799; 655387800; 655387801	AA:Subjects with the AA genotype who are treated with oxazepam may have a decreased oxazepam oral clearance as compared to subjects with the CC genotype which the study reports resulted in no differences in pharmacodynamic measures. Other genetic and clinical factors may also influence the oral clearance of oxazepam.; AC:Subjects with the AC genotype who are treated with oxazepam may have a decreased oxazepam oral clearance as compared to subjects with the CC genotype which the study reports resulted in no differences in pharmacodynamic measures. Other genetic and clinical factors may also influence the oral clearance of oxazepam.; CC:Subjects with the CC genotype who are treated with oxazepam may have an increased oxazepam oral clearance as compared to subjects with the AA and AC genotype which the study reports resulted in no differences in pharmacodynamic measures. Other genetic and clinical factors may also influence the oral clearance of oxazepam.	655387783; 655387790	Genotype AA is associated with decreased S-oxazepam glucuronidation in human liver microsomes when exposed to oxazepam as compared to genotype CC.; Genotype AA is associated with decreased oxazepam oral clearance when exposed to oxazepam as compared to genotype CC.	15044558; 19916996	2	oxazepam			
655387821	rs2853539	TYMS (PA359)	3	Efficacy	655387822; 655387823; 655387824	AA:Patients with the AA genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have improvement in disease activity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; AG:Patients with the AG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; GG:Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.	655387811	Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	19902562	1	methotrexate	Arthritis, Rheumatoid	Asian	
655387825	rs1544105	FPGS (PA167)	3	Efficacy	655387826; 655387827; 655387828	CC:Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to respond to methotrexate as compared to patients with the TC and TT genotype. Patients with the CC genotype may still be at risk for non-response to methotrexate based on their genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; CT:Patients with the TC genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; TT:Patients with the TT genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.	655387805	Genotypes TT + CT are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	19902562	1	methotrexate	Arthritis, Rheumatoid	Asian	
655387835	rs1801133	MTHFR (PA245)	3	Toxicity/ADR	655387836; 655387837; 655387838	AA:Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.; AG:Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.; GG:Patients with the GG genotype who undergo elective surgery with nitrous oxide anesthesia may have lower plasma total homocysteine concentrations as compared to patients with the GA of AA genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.	655387832	Genotype AA is associated with higher plasma total homocysteine concentrations after nitrous oxide anesthesia when exposed to nitrous oxide in people with surgery as compared to genotype GG.	18580170	1	nitrous oxide			
655387839	rs1801131	MTHFR (PA245)	3	Toxicity/ADR	655387840; 655387841; 655387842	GG:Patients with the GG genotype may have higher homocysteine levels after nitrous oxide anesthesia as compared to patients with the TG and TT genotype.Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.; GT:Patients with the TG genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.; TT:Patients with the TT genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.	655387829	Genotype GG is associated with higher plasma total homocysteine concentrations after nitrous oxide anesthesia when exposed to nitrous oxide in people with surgery as compared to genotype TT.	18580170	1	nitrous oxide			
655387876	rs167771	DRD3 (PA27479)	3	Toxicity/ADR	655387877; 655387878; 655387879	AA:Patients with the AA genotype may have decreased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AG or GG genotype. Patients with the AA genotype may still be at risk for toxicity when taking risperidone. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AG:Patients with the AG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	655387845	Allele G is associated with increased risk of extrapyramidal symptoms when treated with risperidone in people with Schizophrenia as compared to allele A.	19506579	1	risperidone	Bipolar Disorder;Schizophrenia	White	
655387895	rs70991108	DHFR (PA143)	3	Toxicity/ADR	655387896; 655387897; 655387898	TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT:Pediatric patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased risk for Thrombocytopenia as compared to pediatric patients with the TGGCGCGTCCCGCCCAGGT/del or del/del genotype. Adult patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased, but not absent, risk for hepatic toxicity as compared to adult patients with the TGGCGCGTCCCGCCCAGGT/del or del/del genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.; TGGCGCGTCCCGCCCAGGT/del:Adult patients with the TGGCGCGTCCCGCCCAGGT/del genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased risk for hepatic toxicity as compared to patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT or del/del genotype. Pediatric patients with the TGGCGCGTCCCGCCCAGGT/del genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased, but not absent, risk for Thrombocytopenia as compared to pediatric patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT or del/del genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.; del/del:Adult patients with the del/del genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased risk for hepatic toxicity as compared to patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT or TGGCGCGTCCCGCCCAGGT/del genotype. Pediatric patients with the del/del genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased, but not absent, risk for Thrombocytopenia as compared to pediatric patients with the TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT or TGGCGCGTCCCGCCCAGGT/del genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.	655387888; 827698251	Genotype DEL is associated with increased risk of hepatic toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotype TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT is associated with increased risk of Thrombocytopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes TGGCGCGTCCCGCCCAGGT/DEL + DEL/DEL.	19648163; 21747412	2	methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma		
655387938	rs4149081	SLCO1B1 (PA134865839)	3	Toxicity/ADR	655387939; 655387940; 655387941	AA:Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the AG or GG genotype 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.; AG:Patients with the AG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the AA genotype 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.; GG:Patients with the GG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the AA genotype 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.	655387918; 655387922; 655387925	Allele G is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Allele G is associated with increased risk of GI toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.; Allele G is associated with clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	19901119; 19901119; 19901119	3	methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma		
655387942	rs11045879	SLCO1B1 (PA134865839)	3	Toxicity/ADR	655387943; 655387944; 655387945	CC:Patients with the CC genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the CT or TT genotype 2) may have a decreased, but not absent, risk for GI toxicity (mucositis) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity when treated with methotrexate.; CT:Patients with the CT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the CC genotype 2) may have an increased risk for GI toxicity (mucositis) when treated with methotrexate as compared to patients with the CC genotype.; TT:Patients with the TT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the CC genotype 2) may have an increased risk for GI toxicity (mucositis) when treated with methotrexate as compared to patients with the CC genotype.	655387928; 655387932; 655387935	Allele T is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.; Allele T is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.; Allele T is associated with increased risk of gastrointestinal toxicity (mucositis) when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	19901119; 19901119; 19901119	3	methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma		
655387949	rs4149056	SLCO1B1 (PA134865839)	3	Other	655387950; 655387951; 655387952	CC:Patients with the CC genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the TT genotype 2) may not require additional monitoring as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; CT:Patients with the CT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the TT genotype 2) may not require additional monitoring as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; TT:Patients with the TT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the CT or CC genotype 2) may require additional monitoring as compared to patients with the CT or CC genotype.	655387946	Allele C is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	19901119	1	methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma		
655387972	rs2032582	ABCB1 (PA267)	3	Efficacy	655387973; 655387975; 655387974	AC:Patients with the AC genotype may have decreased, but not absent, risk for resistance to taxanes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to taxanes.; CC:Patients with the CC genotype may have 1) increased risk for resistance 2) decreased response to taxanes as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence a patient's response to taxanes.; CT:Patients with the CT genotype may have decreased, but not absent, risk for resistance to taxanes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to taxanes.	655387959; 699638624	Genotype AA is associated with increased chance of positive response to paclitaxel when treated with paclitaxel in people with Ovarian Neoplasms as compared to genotype CC.; Genotype CC is associated with increased risk of resistance when treated with paclitaxel in people with Breast Neoplasms as compared to genotype AC.	16467099; 18836089	2	paclitaxel;taxanes	Breast Neoplasms;Neoplasms;Ovarian Neoplasms		
655388022	rs1045642	ABCB1 (PA267)	3	Other	655388023; 655388024; 655388025	AA:Pediatric patients with the AA genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.; AG:Pediatric patients with the AG genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.; GG:Pediatric patients with the GG genotype who are treated with prednisone and tacrolimus may have an increased risk of remaining on steroids 1 year after heart transplantation compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.	655388018	Genotype GG is associated with increased risk of remaining on steroids at 1 year after transplantation when treated with prednisone and tacrolimus in people with heart transplantation as compared to genotypes AA + AG.	12175731	1	prednisone;tacrolimus	Organ Transplantation;Transplantation		
655388510	rs1799732	DRD2 (PA27478)	3	Efficacy	655388511; 655388512; 655388513	G/del:Patients with the G/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.; GG:Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.; del/del:Patients with the del/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.	637879832; 637879842; 655387630; 655388500; 769168983; 655386544; 655386540; 769171560; 769172782; 769250907	Genotype DEL is not associated with increased response to clozapine in people with Schizophrenia as compared to allele G.; Genotype DEL is not associated with increased response to clozapine in people with Schizophrenia as compared to allele G.; Genotype DEL is not associated with response to risperidone in people with Schizophrenia.; Genotype DEL is associated with longer time to respond when treated with olanzapine and risperidone in people with Schizophrenia as compared to genotype GG.; Genotype DEL is associated with decreased response to antipsychotics in people with Schizophrenia as compared to genotype GG.; Allele G is not associated with response to antipsychotics in people with Schizophrenia as compared to genotype DEL.; Genotype GG is associated with increased likelihood of Schizophrenia as compared to genotypes DELDEL + GDEL.; Genotype GG is associated with increased improvement in Anxiety-Depression symptoms when treated with Bromperidol and nemonapride in people with Schizophrenia as compared to genotypes DELDEL + GDEL.; Genotype GG is associated with increased response to chlorpromazine in people with Schizophrenia as compared to genotypes DELDEL + GDEL.; Genotype GG is not associated with increased response to aripiprazole in people with Schizophrenia as compared to genotype G/DEL.	9918131; 15830237; 17105675; 16513877; 20194480; 9858029; 9858029; 11505224; 15694263; 18926547	10	antipsychotics;aripiprazole;Bromperidol;chlorpromazine;clozapine;nemonapride;olanzapine;risperidone	Schizophrenia		
699639249	rs776746	CYP3A (PA27114),CYP3A5 (PA131)	3	Toxicity/ADR	699639250; 699639251; 699639252	CC:Patients with the CC genotype may have decreased but not absent risk of neurotoxicity when treated with paclitaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.; CT:Patients with the CT genotype may have decreased but not absent risk of neurotoxicity when treated with paclitaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.; TT:Patients with the TT genotype may have an increased risk of neurotoxicity when treated with paclitaxel as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.	655387903	Allele C is associated with decreased risk of neurotoxicity when treated with paclitaxel in people with Neoplasms as compared to allele T.	20212519	1	paclitaxel			
699639328	rs1113129	CYP2C8 (PA125)	3	Toxicity/ADR	699639329; 699639330; 699639331	CC:Patients with the CC genotype may have increased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; CG:Patients with the CG genotype may have decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype may have decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	655388360	Allele G is associated with decreased risk of neurotoxicity when treated with paclitaxel in people with Neoplasms as compared to allele C.	20212519	1	paclitaxel			
699639332	rs1801131	MTHFR (PA245)	3	Toxicity/ADR	699639333; 699639334; 699639335	GG:Patients with the GG genotype and non-Hodgkin lymphoma who are treated with methotrexate may have an increased risk of mucositis as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for mucositis when treated with methotrexate.; GT:Patients with the GT genotype and non-Hodgkin lymphoma who are treated with methotrexate may have a decreased, but not absent, risk of mucositis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for mucositis when treated with methotrexate.; TT:Patients with the TT genotype and non-Hodgkin lymphoma who are treated with methotrexate may have a decreased, but not absent, risk of mucositis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for mucositis when treated with methotrexate.	637879731	Genotype GG is associated with increased risk of mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes TT + TG.	17488658	1	methotrexate	Lymphoma, Non-Hodgkin	White	
699639336	rs1801131	MTHFR (PA245)	3	Efficacy	699639337; 699639338; 699639339	GG:Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of clinical response but may have a decreased response base on Disease Activity Score in 44 joints improvement at 6 months as compared to patients with the TT genotype. This association has been contradicted in other studies including a larger meta-analysis that found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; GT:Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of clinical response but may have a decreased response base on Disease Activity Score in 44 joints improvement at 6 months as compared to patients with the TT genotype. This association has been contradicted in other studies including a larger meta-analysis that found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; TT:Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an decreased likelihood of clinical response but may have an increased response base on Disease Activity Score in 44 joints improvement at 6 months as compared to patients with the GG and GT genotype. This association has been contradicted in other studies including a larger meta-analysis that found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.	608431521; 769170664; 769171245; 769170786; 655386425; 827774232	Allele G is associated with increased likelihood of clinical response when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.; Allele G is not associated with response to methotrexate in people with Arthritis, Juvenile Rheumatoid.; Allele G is not associated with response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid.; Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.; Genotype TT is associated with increased response base on Disease Activity Score in 44 joints improvement at 6 months of treatment when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + GT.; Allele G is not associated with efficacy when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	20863444; 20595278; 18322994; 19827168; 16572443; 21931346	6	methotrexate	Arthritis, Rheumatoid		
699639343	rs2016848	MME (PA30864)	3	Toxicity/ADR	699639344; 699639345; 699639346	AA:Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment.; AG:Patients with the AG genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment. Patients with this genotype were not studied directly.; GG:Patients with the GG genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment.	699639186	Allele A is associated with increased incidence of cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele G.	21052031	1	Ace Inhibitors, Plain	Cough;Hypertension		
699639347	rs11209716	PTGER3 (PA288)	3	Toxicity/ADR	699639348; 699639349; 699639350	CC:Patients with the CC genotype and hypertension who are treated with ACE inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with ACE inhibitors.; CT:Patients with the genotype have not been studied.; TT:Patients with the TT genotype and hypertension who are treated with ACE inhibitors may have an increased risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with ACE inhibitors.	699639147	Allele C is associated with decreased incidence of cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele T.	21052031	1	Ace Inhibitors, Plain	Cough;Hypertension		
699639351	rs8012552	BDKRB2 (PA80)	3	Toxicity/ADR	699639352; 699639353; 699639354	CC:Patients with the CC genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.; CT:Patients with the CT genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. (please note that patients with this genotype were not studied directly). Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.; TT:Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.	699639202	Allele C is associated with increased incidence of cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele T.	21052031	1	Ace Inhibitors, Plain	Cough;Hypertension		
699642190	rs10879346	TPH2 (PA128747823)	3	Efficacy	699642191; 699642192; 699642193	CC:Patients with the CC genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.; CT:Patients with the CT genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.; TT:Patients with the TT genotype who are treated with antidepressants may have less improvement in symptoms as compared to patients with the CT and CC genotype.	699642186	Allele C is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype TT.	18496129	1	antidepressants;mirtazapine;venlafaxine	Depressive Disorder, Major	White	
769143802	rs4343	ACE (PA139)	3	Efficacy	769143803; 769143804; 769143805	AA:Patients with the AA genotype is associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.; AG:Patients with the AG genotype is associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.; GG:Patients with the GG genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response.	699638681	Genotypes AA + AG are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume when treated with spironolactone in people with chronic heart failure as compared to genotype GG.	15121491	1	spironolactone			
769171387	rs1695	GSTP1 (PA29028)	3	Toxicity/ADR	769171388; 769171389; 769171390	AA:Patients with the AA genotype and cancer who are treated with fluorouracil may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.; AG:Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.; GG:Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to flourouracil.	769171384	Genotype GG is associated with decreased risk of haematological toxicity when exposed to fluorouracil in people with Rectal Neoplasms as compared to genotype AA.	18540691	1	fluorouracil	Rectal Neoplasms	White	
769171582	rs334558	GSK3B (PA29009)	3	Efficacy	769171583; 769171584; 769171585	AA:Patients with the AA genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.; AG:Patients with the AG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.; GG:Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.	769171579	Genotype GG is associated with increased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.	18195729	1	citalopram;fluoxetine	Depressive Disorder, Major	Asian	
769181841	rs1057910	CYP2C9 (PA126)	2A	Dosage;Toxicity/ADR	769181842; 769181843; 769181844	AA:Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.; AC:Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.; CC:Patients with the CC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.	769169804; 655388486; 827814749; 827814788	Genotype AC is associated with response to acenocoumarol in people with no disease as compared to genotype AA.; Genotype CC is associated with increased risk of overanticoagulation when treated with acenocoumarol.; Allele C is associated with decreased dose of acenocoumarol as compared to allele A.; Allele C is not associated with bleeding events when treated with acenocoumarol or warfarin.	15116053; 11692083; 21148049; 21148049	4	acenocoumarol			
613976757	rs2234922	EPHX1 (PA27829)	2B	Dosage	613976758; 613976759; 613976760	AA:Patients with the AA genotype may require a decreased dose of carbamazepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence dose of carbamazepine.; AG:Patients with the AG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of carbamazepine.; GG:Patients with the GG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of carbamazepine.	613976745; 827815322; 827824071	Allele G is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to allele A.; Allele G is associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A.; Allele G is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A.	15692831; 19620853; 22188362	3	carbamazepine	Epilepsy		
613976848	rs750332	BAT2 (PA25263),BAT3 (PA25264)	3	Toxicity/ADR	613976849; 613976850; 613976851	CC:Patients with the CC genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.; CT:Patients with the CT genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.; TT:Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.	613976809	Allele C is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to allele T.	16538176	1	carbamazepine		Asian	
613977037	rs2227956	HSPA1A (PA29498),HSPA1L (PA29500),LSM2 (PA25929)	3	Toxicity/ADR	613977038; 613977039; 613977040	AA:Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.; AG:Patients with the AG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.; GG:Patients with the GG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.	613977005	Allele G is associated with decreased risk of severe hypersensitivity when treated with carbamazepine as compared to allele A.	16538175	1	carbamazepine	Epilepsy	White	
613977064	rs2236196	CHRNA4 (PA26490)	3	Other	613977065; 613977066; 613977067	AA:Patients with the AA genotype may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.; AG:Patients with the AG genotype may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.; GG:Patients with the GG genotype may have a decreased, but not absent, risk for nicotine dependence as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.	605833570	Allele A is associated with increased likelihood of nicotine dependence when exposed to nicotine as compared to allele G.	15790597	1	nicotine	Tobacco Use Disorder	Black or African American	
613978931	rs3812718	SCN1A (PA301)	2B	Dosage	613978932; 613978933; 613978934	CC:Patients with the CC genotype who are treated with carbamazepine may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of carbamazepine.; CT:Patients with the CT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.; TT:Patients with the TT genotype who are treated with carbamazepine may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.	769258364; 613978592; 827823984; 827823998	Allele C is associated with increased expression of SCN1A.; Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.; Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.; Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	21453355; 15805193; 22188362; 22188362	4	carbamazepine	Epilepsy		
613978937	rs3812718	SCN1A (PA301)	2B	Dosage	613978938; 613978939; 613978940	CC:Patients with the CC genotype who are treated with phenytoin may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of phenytoin.; CT:Patients with the CT genotype who are treated with phenytoin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.; TT:Patients with the TT genotype who are treated with phenytoin may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.	613978601; 769248943	Allele T is associated with increased dose of phenytoin in people with Epilepsy as compared to allele C.; Genotypes TT + CT are associated with increased dose of phenytoin in people with Epilepsy as compared to genotype CC.	15805193; 17001291	2	phenytoin	Epilepsy		
613979021	rs1042714	ADRB2 (PA39)	3	Efficacy	613979022; 613979023; 613979024	CC:Patients with the CC genotype and heart failure may be less likely to have improved left ventricular ejection fraction after carvedilol treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.; CG:Patients with the CG genotype and heart failure may be more likely to have improved left ventricular ejection fraction after carvedilol treatment as compared to patients with the CC genotype. Patients with the CG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.; GG:Patients with the GG genotype and heart failure may be more likely to have improved left ventricular ejection fraction after carvedilol treatment as compared to patients with the CC genotype. Patients with the GG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.	613978953; 613978984; 827807199; 827808203	Genotype CC is associated with decreased likelihood of improved left ventricular ejection fraction when treated with carvedilol in people with Heart Failure as compared to genotypes GG + CG.; Allele G is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to allele C.; Allele C is associated with increased reduction in resting blood pressure when treated with carvedilol in healthy individuals as compared to allele G.; Allele G is not associated with the reduction in systolic blood pressure, diastolic blood pressure, pulse pressure, mean arterial pressure, or heart rate, or treatment differences between losartan and atenolol on these endpoints or risk of the primary composite endpoint or its components stroke, myocardial infarction, and cardiovascular death, or treatment differences between losartan and atenolol on these endpoints when treated with atenolol and losartan as compared to allele C.	12835612; 15861037; 21599570; 20065889	4	carvedilol	Heart Failure	White	
613979403	rs5443	GNB3 (PA176)	3	Efficacy	613979404; 613979405; 613979406	CC:Patients with the CC genotype and cluster headache who are treated with triptans may be less likely to have reduced pain or attack frequency as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to sumatriptan.; CT:Patients with the CT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sumatriptan.; TT:Patients with the TT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. However, patients with this genotype were not studied directly. Other genetic and clinical factors may also influence a patient's response to sumatriptan.	655385715	Genotype CT is associated with increased response to sumatriptan in people with Cluster Headache as compared to genotype CC.	17361120	1	sumatriptan	Cluster Headache	White	
613979643	rs730012	LTC4S (PA235),MGAT4B (PA30783)	3	Toxicity/ADR	613979644; 613979645; 613979646	AA:Patients with the AA genotype who are treated with aspirin may have a decreased, but not absent, risk of urticaria as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.; AC:Patients with the AC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.; CC:Patients with the CC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.	655385753	Allele C is associated with increased risk of Urticaria when treated with aspirin.	19862937	1	aspirin	Urticaria		
618376538	rs2236196	CHRNA4 (PA26490)	3	Other	618376550; 618376560; 618376569	AA:Patients with the AA genotype may have a decreased, but not absent, risk for nicotine dependence as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.; AG:Patients with the AG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.; GG:Patients with the GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.	613977087	Allele G is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A.	19290018	1	nicotine	Tobacco Use Disorder	White	
619523389	rs12720441	KCNH2 (PA212)	4	Toxicity/ADR	619523390; 619523391; 619523392	AA:Patients with the AA genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; AG:Patients with the AG genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; GG:Patients with the GG genotype may have decreased risk for Torsades de Point when treated with amiodarone as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking amiodarone based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.	655385772	Allele A is associated with increased risk of Torsades de Pointes when treated with amiodarone as compared to allele G.	11997281	1	amiodarone	Torsades de Pointes		
619523395	rs2297480	FDPS (PA28075)	2B	Efficacy	981478438; 981478439; 981478440	GG:Patients with the GG genotype may have an decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's chance of response.; GT:Patients with the GT genotype may have an increased chance of response to bisphosphonate treatment as compared to patients with the GG genotype. Patients with the GT genotype may still be at risk for non-response to bisphosphonate treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.; TT:Patients with the TT genotype may have an increased chance of response to bisphosphonate treatment as compared to patients with the GG genotype. Patients with the TT genotype may still be at risk for non-response to bisphosphonate treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.	655385769; 769154675	Genotype GG is associated with decreased response to Bisphosphonates in people with Osteoporosis, Postmenopausal as compared to genotypes TT + TG.; Allele T is associated with increased hip bone mineral density change when treated with Bisphosphonates in people with Osteoporosis as compared to allele G.	18687167; 21151198	2	alendronate;Bisphosphonates;risedronate	Osteoporosis;Osteoporosis, Postmenopausal	White	
619523400	rs9937	RRM1 (PA298)	4	Toxicity/ADR	619523401; 619523402; 619523403	AA:Patients with the AA genotype with advanced breast cancer who are treated with gemcitabine 1) may be more likely to experience toxicity such as neutropenia as compared to a patient with genotype GG or GA and the A allele at rs1042858 2) may have a tendency, though not a statistically significant one, towards better progression-free survival as compared to patients with the GG genotype and the A allele at rs1042858. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.; AG:Patients with the AG genotype and the A allele of rs1042858 with advanced breast cancer who are treated with gemcitabine 1) may be less likely to experience toxicity such as neutropenia 2) may have a tendency, though not a statistically significant one, towards poorer progression-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.; GG:Patients with the GG genotype and the A allele of rs1042858 with advanced breast cancer who are treated with gemcitabine 1) may be less likely to experience toxicity such as neutropenia 2) may have a tendency, though not a statistically significant one, towards poorer progression-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.	655388028; 655388027	Genotype AA is associated with increased likelihood of progression-free survival when treated with gemcitabine in women with Breast Neoplasms as compared to allele G.; Allele G is associated with decreased risk of Neutropenia when treated with gemcitabine in women with Breast Neoplasms as compared to allele A.	17602053; 17602053	2	gemcitabine	Breast Neoplasms	Asian	
619523414	rs2032583	ABCB1 (PA267)	3	Efficacy	619523415; 619523416; 619523417	AA:Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.; AG:Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance for remission.; GG:Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance for remission.	655385916	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.	18215618	1	antidepressants;Other antidepressants	Depression;Depressive Disorder;Depressive Disorder, Major	White	
619523422	rs2235015	ABCB1 (PA267)	3	Efficacy	619523423; 619523424; 619523425	AA:Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance for remission.; AC:Patients with the AC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance for remission.; CC:Patients with the CC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's chance for remission.	655386253	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.	18215618	1	antidepressants;Other antidepressants	Depression;Depressive Disorder;Depressive Disorder, Major	White	
637879590	rs11572080	CYP2C8 (PA125)	4	Toxicity/ADR	637879591; 637879592; 637879593	CC:Patients with the CC genotype may have decreased risk of side effects with amodiaquine as compared to patients with the CT or TT genotype. Patients with the CC genotype may still be at risk for adverse events when taking amodiaquine based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; CT:Patients with the CT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; TT:Patients with the TT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.	655386098	Genotype CC is associated with decreased risk of side effects when treated with amodiaquine as compared to genotypes TT + CT.	18855526	1	amodiaquine			
637879595	rs10509681	CYP2C8 (PA125)	4	Toxicity/ADR	637879596; 637879597; 637879598	CC:Patients with the CC genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.; CT:Patients with the CT genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.; TT:Patients with the TT genotype may have decreased but not non-existent risk of side effects to amodiaquine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.	655386119	Genotype TT is associated with decreased risk of side effects when treated with amodiaquine as compared to genotypes CC + CT.	18855526	1	amodiaquine			
637879631	rs25531	SLC6A4 (PA312)	4	Efficacy	637879632; 637879633; 637879634	CC:Patients with the CC genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response.; CT:Patients with the CT genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype and Major Depressive Disorder who are treated with fluoxetine may be more likely to respond compared to patients with genotype CC or CT . Other genetic and clinical factors may also influence a patient's response.	655386196	Genotypes CC + CT are associated with increased risk of reduced response when treated with fluoxetine in people with Depressive Disorder, Major as compared to genotype TT.	15993855	1	fluoxetine	Depressive Disorder, Major		
637879637	rs1127354	DDRGK1 (PA164718734),ITPA (PA29973)	3	Efficacy	637879638; 637879639; 637879640	AA:Patients with the AA genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AA genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.; AC:Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.; CC:Patients with the CC genotype may experience less response to azathiopurine treatment for SLE as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's likelihood of response.	655386256; 655386259; 827784888	Genotype AA is associated with increased response when treated with azathioprine in people with Lupus Erythematosus, Systemic.; Genotype AC is associated with increased response when treated with azathioprine in people with Lupus Erythematosus, Systemic.; Genotype AC is associated with increased likelihood of non-response when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype CC.	19129747; 19129747; 21961091	3	azathioprine	Lupus Erythematosus, Systemic	Asian	
637879781	rs1799853	CYP2C9 (PA126)	1A	Dosage	637879782; 637879783; 637879784	CC:Patients with the CC genotype who are treated with warfarin may require a higher dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.; CT:Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.; TT:Patients with the TT genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.	608431758; 655387565; 827864546; 827602050; 827641894; 827657784; 827823816	Allele T is associated with decreased dose of warfarin.; Allele T is associated with decreased dose of warfarin.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.; Allele T is associated with decreased dose of warfarin as compared to allele C.	19794411; 19228618; 21228733; 18305455; 19300499; 17111199; 21110192	7	warfarin		White	
637879785	rs2292566	EPHX1 (PA27829)	3	Dosage	637879786; 637879787; 637879788	AA:Patients with the AA genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.; AG:Patients with the AG genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.; GG:Patients with the GG genotype may require a higher dose of warfarin than patients with the AA or AG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.	608431768; 827690618	Allele A is associated with decreased dose of warfarin.; Allele A is not associated with dose of warfarin.	19794411; 21593757	2	warfarin		White	
637879789	rs28371685	CYP2C9 (PA126)	3	Dosage	637879790; 637879791; 637879792	CC:Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.; CT:Patients with the CT genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.; TT:Patients with the TT genotype who are treated with warfarin may require the lowest does as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.	608431789	Allele T is associated with decreased dose of warfarin.	20072124	1	warfarin	Atrial Fibrillation;Pulmonary Embolism;Stroke;Venous Thrombosis	Black or African American	
637879793	rs28371686	CYP2C9 (PA126)	2A	Dosage	637879794; 637879795; 637879796	CC:Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.; CG:Patients with the CG genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.; GG:Patients with the GG genotype who are treated with warfarin may require the lowest does as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.	608431793; 827864554	Allele G is associated with decreased dose of warfarin.; Allele G is associated with decreased dose of warfarin as compared to allele C.	20072124; 21228733	2	warfarin	Atrial Fibrillation;Pulmonary Embolism;Stroke;Venous Thrombosis	Black or African American	
637879801	rs7900194	CYP2C9 (PA126)	3	Dosage;Toxicity/ADR	637879802; 637879803; 637879804	AA:Patients with the AA genotype who are treated with warfarin may require the lowest maintenance dose as compared to patients with the AG or GG genotype.; AG:Patients with the AG genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the GG genotype.; GG:Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AG or GG genotype.	608431781	Allele A is associated with decreased dose of warfarin.	20072124	1	warfarin	Atrial Fibrillation;Pulmonary Embolism;Stroke;Venous Thrombosis	Black or African American	
637879807	rs9332131	CYP2C9 (PA126)	3	Dosage	637879808; 637879809; 637879810	A/del:Patients with A/del genotype may require a lower daily warfarin maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.; AA:Patients with the AA genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the del/A or del/del genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.; del/del:Patients with del/del genotype may require significantly lower daily warfarin maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.	608431785	Genotype DEL is associated with decreased dose of warfarin.	20072124	1	warfarin	Atrial Fibrillation;Pulmonary Embolism;Stroke;Venous Thrombosis	Black or African American	
637879864	rs5760410	ADORA2A (PA24584),CYTSA (PA164718673)	3	Toxicity/ADR	637879865; 637879866; 637879867	AA:Patients with the AA genotype who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.; AG:Patients with the AG genotype who are treated with methotrexate may have an increased risk of gastrointestinal adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.; GG:Patients with the GG genotype who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.	637879861	Allele G is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	18539621	1	methotrexate	Arthritis, Rheumatoid		
637879869	rs11545078	GGH (PA432)	3	Toxicity/ADR	637879870; 637879871; 637879872	AA:Patients with the AA genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.; AG:Patients with the AG genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.; GG:Patients with the GG genotype who are treated with methotrexate: 1) may have reduced accumulation of active methotrexate metabolites 2) may have a decreased risk for thrombocytopenia as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.	637879857; 769173745	Allele A is associated with decreased clearance of methotrexate.; Allele A is associated with increased likelihood of Thrombocytopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	15284538; 16999998	2	methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma		
637879879	rs339097	CALU (PA26047)	2B	Dosage	637879880; 637879881; 637879882	AA:Patients with the AA genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.; AG:Patients with the AG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.; GG:Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.	608431797; 637879873; 637879876; 827864550	Allele G is associated with increased dose of warfarin.; Allele G is associated with increased dose of warfarin.; Allele G is associated with increased dose of warfarin.; Genotypes GG + AG are associated with increased dose of warfarin as compared to genotype AA.	20200517; 20200517; 20200517; 21228733	4	warfarin		Black or African American	
637879932	rs2814707	MOBKL2B (PA134886513)	3	Efficacy	637879933; 637879934; 637879935	CC:Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.; CT:Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.; TT:Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.	655386216	Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637879937	rs3849942	C9orf72 (PA134908144)	4	Efficacy	637879938; 637879939; 637879940	CC:Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.; CT:Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.; TT:Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.	655386219	Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637879942	rs437943		4	Efficacy	637879943; 637879944; 637879945	CC:Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.; CT:Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.; TT:Rheumatoid Arthritis patients with the TT genotype may be more likely to respond to TNF inhibitors compared to a patient with genotype CC or CT .	655386250	Allele C is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637879947	rs6138150		3	Efficacy	637879948; 637879949; 637879950	CC:Rheumatoid Arthritis patients with the genotype CC may be more likely to respond to TNF inhibitors compared with patients with genotypes TT or CT . Other genetic and clinical factors may also influence a patient's response.; CT:Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC . Other genetic and clinical factors may also influence a patient's response.; TT:Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response.	655386347	Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637879952	rs7046653	MOBKL2B (PA134886513)	3	Efficacy	637879953; 637879954; 637879955	AA:Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.; AG:Rheumatoid Arthritis patients with the AG genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.; GG:Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.	655386350	Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637879957	rs854555	PON1 (PA33529),PPP1R9A (PA33661)	3	Efficacy	637879958; 637879959; 637879960	AA:Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response.; AC:Rheumatoid Arthritis patients with the AC genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response.; CC:Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AC. Other genetic and clinical factors may also influence a patient's response.	655386353	Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637879962	rs854548	PON1 (PA33529),PPP1R9A (PA33661)	4	Efficacy	637879963; 637879964; 637879965	AA:Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.; AG:Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.; GG:Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.	655386356	Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637879967	rs854547	PON1 (PA33529),PPP1R9A (PA33661)	4	Efficacy	637879968; 637879969; 637879970	AA:Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.; AG:Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.; GG:Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.	655386360	Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637879972	rs6028945		3	Efficacy	637879973; 637879974; 637879975	GG:Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared with patients with the genotypes GT or TT. Other genetic and clinical factors may also influence a patient's response.; GT:Rheumatoid Arthritis patients with the genotype GT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.; TT:Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.	655386363	Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637879977	rs6071980		3	Efficacy	637879978; 637879979; 637879980	CC:Rheumatoid Arthritis patients with the genotype CC may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patient's response.; CT:Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patient's response.; TT:Rheumatoid Arthritis patients with the genotype TT may be more likely to respond to TNF inhibitors compared with patients with genotypes CC or CT . Other genetic and clinical factors may also influence a patient's response.	655386373	Allele C is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637879982	rs983332		3	Efficacy	637879983; 637879984; 637879985	GG:Rheumatoid Arthritis patients with genotype GG may be more likely to respond to TNF inhibitors as compared with patients with GT or TT genotypes . Other genetic and clinical factors may also influence a patient's response.; GT:Rheumatoid Arthritis patients with genotype GT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.; TT:Rheumatoid Arthritis patients with genotype TT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.	655386377	Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637879987	rs774359	C9orf72 (PA134908144)	3	Efficacy	637879988; 637879989; 637879990	CC:Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.; CT:Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.; TT:Rheumatoid Arthritis patients with the TT genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CC or CT. Other genetic and clinical factors may also influence a patient's response.	655386381	Allele C is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637879992	rs868856	MOBKL2B (PA134886513)	3	Efficacy	637879993; 637879994; 637879995	AA:Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.; AG:Rheumatoid Arthritis patients with the AG genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.; GG:Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AG. Other genetic and clinical factors may also influence a patient's response.	655386386	Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637879997	rs928655	GBP6 (PA134964409)	4	Efficacy	637879998; 637879999; 637880000	AA:Rheumatoid Arthritis patients with genotype AA may be less likely to respond to TNF inhibitors compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.; AG:Rheumatoid Arthritis patients with genotype AG may be less likely to respond to TNF inhibitors compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.; GG:Rheumatoid Arthritis patients with genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patient's response.	655386391	Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	18615156	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Arthritis, Rheumatoid	White	
637880014	rs2032582	ABCB1 (PA267)	3	Toxicity/ADR	637880016; 637880015; 637880017	AC:Patients with the AC genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.; CC:Patients with the CC genotype may have decreased but not non-existent risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CA, CT, AA or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.; CT:Patients with the CT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.	613979632	Genotype CC is associated with decreased risk of grade 3 or 4 gastrointestinal toxicity when treated with platinum and taxanes in people with Ovarian Neoplasms.	19203783	1	Platinum compounds;taxanes	Ovarian Neoplasms	Asian	
637880078	rs2075252	LRP2 (PA30452)	3	Toxicity/ADR	637880079; 637880080; 637880081	CC:Patients with the CC genotype treated with cisplatin may have a reduced but not non-existent risk for hearing loss as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's chance of adverse events.; CT:Patients with the CT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of adverse events.; TT:Patients with the TT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of adverse events.	637880063	Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to allele C.	17457342	1	cisplatin	Neoplasms		
637880087	rs316019	SLC22A2 (PA331)	3	Toxicity/ADR	637880088; 637880089; 637880090	AA:Patients with the AA genotype may have reduced but not non-existent risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AC:Patients with the AC genotype may have reduced but not non-existent risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; CC:Patients with the CC genotype may have increased risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	637880083; 827816530	Genotype CA is associated with decreased risk of nephrotoxicity when treated with cisplatin in people with neoplasms as compared to genotype CC.; Genotype CC is not associated with increased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AA + AC.	19625999; 21902499	2	cisplatin	Neoplasms	White	
637880217	rs1695	GSTP1 (PA29028)	3	Toxicity/ADR	637880218; 637880219; 637880220	AA:Patients with the AA genotype and cancer who are treated with oxaliplatin or platinum compounds may have an increased risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AG or GG genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AA might have a decreased, but not absent, risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.; AG:Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.; GG:Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.	613979636; 637880188; 637880206; 637880210; 637880145; 637880175	Genotype AA is associated with increased risk of hematological toxicity when treated with Platinum compounds and taxanes in people with Ovarian Neoplasms as compared to genotypes GG + AG.; Genotype AA is associated with increased severity of Peripheral Nervous System Diseases when treated with oxaliplatin in people with Gastrointestinal Neoplasms as compared to genotypes GG + AG.; Genotype AA is associated with increased severity of Neurotoxicity Syndromes when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GG + AG.; Genotype AA is associated with increased likelihood of discontinuation of oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GG + AG.; Allele G is associated with decreased risk of Neutropenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.; Genotype GG is associated with increased severity of Neurotoxicity Syndromes when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	19203783; 16707601; 20530282; 20530282; 17409936; 17401013	6	oxaliplatin;Platinum compounds	Carcinoma, Non-Small-Cell Lung;Colorectal Neoplasms;Gastrointestinal Neoplasms;Ovarian Neoplasms		
637880221	rs1695	GSTP1 (PA29028)	2A	Toxicity/ADR	637880222; 637880223; 637880224	AA:Patients with the AA genotype and cancer who are treated with platinum-based drugs may have the highest risk of toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AG:Patients with the AG genotype and cancer who are treated with platinum-based drugs may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype and cancer who are treated with platinum-based drugs may have a decreased, but not absent, risk of toxicity as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	613979636; 637880107; 637880121; 637880210; 637880145	Genotype AA is associated with increased risk of hematological toxicity when treated with Platinum compounds and taxanes in people with Ovarian Neoplasms as compared to genotypes GG + AG.; Genotype AA is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype AA is associated with increased risk of disease progression when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype AA is associated with increased likelihood of discontinuation of oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GG + AG.; Allele G is associated with decreased risk of Neutropenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	19203783; 15213713; 15213713; 20530282; 17409936	5	Platinum compounds	Neoplasms		
637880226	rs1695	GSTP1 (PA29028)	3	Efficacy	637880227; 637880228; 637880229	AA:Patients with the AA genotype may have increased risk for progression and decreased survival with platinum-based treatments with colorectal cancer but studies of ovarian cancer found increased survival and studies of non-small cell lung cancer found no association with survival. Other genetic and clinical factors may also influence a patient's response.; AG:Patients with the AG genotype may have average risk for progression and survival with platinum-based treatments. Other genetic and clinical factors may also influence a patient's response.; GG:Patients with the AA genotype may have average risk for progression and survival with platinum-based treatments. Other genetic and clinical factors may also influence a patient's response.	637880107; 637880121; 655386344; 637880148	Genotype AA is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype AA is associated with increased risk of disease progression when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype AA is associated with increased progression free survival when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes GG + AG.; Allele G is not associated with survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	15213713; 15213713; 19786980; 17409936	4	Platinum compounds	Neoplasms		
637880243	rs712829	EGFR (PA7360)	4	Efficacy	637880244; 637880245; 637880246	GG:Patients with the GG genotype may be less sensitive to treatment with erlotinib compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence drug sensitivity.; GT:Patients with the GT genotype may be more sensitive to treatment with erlotinib compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.; TT:Patients with the TT genotype may be more sensitive to treatment with erlotinib compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.	655386396	Genotypes TT + GT are associated with increased sensitivity when exposed to erlotinib as compared to genotype GG.	18652519	1	erlotinib	Neoplasms		
637880250	rs712829	EGFR (PA7360)	4	Efficacy	637880251; 637880252; 637880253	GG:Cancer patients with genotype GG may be more likely to respond to topoisomerase I inhibitors compared to patients with genotypes GT or TT (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.; GT:Cancer patients with genotype GT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.; TT:Cancer patients with genotype TT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.	655386400	Genotypes TT + GT are associated with decreased sensitivity when treated with topoisomerase I inhibitors as compared to genotype GG.	18652519	1	topoisomerase I inhibitors	Neoplasms		
637880258	rs712829	EGFR (PA7360)	4	Efficacy	637880259; 637880260; 637880261	GG:Patients with the genotype GG who are treated with geldanamycin may be more likely to respond as compared to patients with genotype GT or TT (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.; GT:Patients with the genotype GT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the genotype TT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.	655386399	Genotypes TT + GT are associated with decreased sensitivity when exposed to geldanamycin as compared to genotype GG.	18652519	1	geldanamycin	Neoplasms		
637880263	rs712829	EGFR (PA7360)	4	Efficacy	637880264; 637880265; 637880266	GG:Cancer cells with the GG genotype may be more sensitive to Alkylating agents than are cells with genotype GT or TT. Other genetic and clinical factors may also influence tumor response to Alkylating agents.; GT:Cancer cells with the GT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.; TT:Cancer cells with the TT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.	655386403	Genotypes TT + GT are associated with decreased sensitivity when exposed to Alkylating Agents as compared to genotype GG.	18652519	1	Alkylating Agents	Neoplasms		
637880267	rs712829	EGFR (PA7360)	3	Efficacy	637880268; 637880269; 637880270	GG:Patients with the GG genotype who are treated with gefitinib may be less likely to respond compared to a patient with one or more T alleles. Other genetic and clinical factors may also influence a patient's response.; GT:Patients with the GT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.	655386406	Genotypes GT + TT are associated with increased progression-free survival (PFS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype GG.	17375033	1	gefitinib	Neoplasms		
637880303	rs1954787	GRIK4 (PA28976)	1B	Efficacy	637880304; 637880305; 637880306	CC:Patients with the CC genotype may have an increased chance of response to citalopram treatment as compared to patients with the TT genotype. Patients with the CC genotype may still be at risk for non-response to citalopram treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.; CT:Patients with the CT genotype may have an increased chance of response to citalopram treatment as compared to patients with the TT genotype. Patients with the CT genotype may still be at risk for non-response to citalopram treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.; TT:Patients with the TT genotype may have a decreased chance of response to citalopram treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's chance of response.	637880231; 637880307	Allele C is associated with decreased likelihood of non-response when treated with citalopram in people with Depression as compared to allele T.; Genotype CC is associated with increased likelihood of remission when treated with antidepressants in people with Depressive Disorder.	17671280; 19924111	2	citalopram	Depression		
637880425	rs7997012	HTR2A (PA193)	2B	Efficacy	637880426; 637880427; 637880428	AA:Patients with the AA genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.; AG:Patients with the AG genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.; GG:Patients with the GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.	637880298; 637880382; 637880402; 637880422; 637880371; 637880323; 827778142; 827778150	Allele A is associated with increased likelihood of response when treated with citalopram in people with Depression as compared to allele G.; Allele A is associated with increased likelihood of response when treated with citalopram in people with Depression as compared to allele G.; Allele A is not associated with increased likelihood of response when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele G.; Allele A is associated with increased resistance when treated with antidepressants in people with Depressive Disorder, Major as compared to allele G.; Genotype AA is associated with increased likelihood of response when treated with citalopram in people with Depression as compared to genotype GG.; Allele G is associated with increased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to allele A.; Genotypes AG + GG are associated with increased significantly better response (Hamilton Anxiety Scale (HAM-A)) at 6 months of treatment when treated with venlafaxine in people with Anxiety Disorders as compared to genotype AA.; Genotypes AG + GG are associated with significantly better improvement (Clinical Global Impression of Improvement (CGI-I) score) at 6 months of treatment when treated with venlafaxine in people with Anxiety Disorders as compared to genotype AA.	17671280; 19077664; 19937159; 20453658; 16642436; 19924111; 22006095; 22006095	8	antidepressants;citalopram;Selective serotonin reuptake inhibitors	Depression;Depressive Disorder		
637880446	rs2229109	ABCB1 (PA267)	4	Other	637880447; 637880448; 637880449	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.	655386731; 655386911	Genotype TT is not associated with decreased clearance of bisantrene.; Genotype TT is not associated with decreased expression of ABCB1.	12065748; 12065748	2	bisantrene			
637880451	rs2229109	ABCB1 (PA267)	4	Other	637880452; 637880453; 637880454	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.	655386741; 655386911	Genotype TT is not associated with decreased clearance of calcein.; Genotype TT is not associated with decreased expression of ABCB1.	12065748; 12065748	2	calcein			
637880455	rs2229109	ABCB1 (PA267)	4	Other	637880456; 637880457; 637880458	CC:Cells with the C allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.; CT:Cells with this genotype would show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other genotypes (inferred).; TT:Cells with the T allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.	655386742; 655386911	Genotype TT is not associated with decreased clearance of forskolin.; Genotype TT is not associated with decreased expression of ABCB1.	12065748; 12065748	2	forskolin			
637880459	rs2229109	ABCB1 (PA267)	4	Other	637880460; 637880461; 637880462	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.	655386743; 655386911	Genotype TT is not associated with decreased clearance of prazosin.; Genotype TT is not associated with decreased expression of ABCB1.	12065748; 12065748	2	prazosin			
637880463	rs2229109	ABCB1 (PA267)	4	Other	637880464; 637880465; 637880466	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.	655386744; 655386911	Genotype TT is not associated with decreased clearance of verapamil.; Genotype TT is not associated with decreased expression of ABCB1.	12065748; 12065748	2	verapamil			
637880467	rs2229109	ABCB1 (PA267)	4	Other	637880468; 637880469; 637880470	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.	655386745; 655386911	Genotype TT is not associated with decreased clearance of vinblastine.; Genotype TT is not associated with decreased expression of ABCB1.	12065748; 12065748	2	vinblastine			
637880471	rs2229109	ABCB1 (PA267)	4	Other	637880472; 637880473; 637880474	CC:Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.; CT:Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.; TT:Cells with the TT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.	655386746; 655386747	Genotype CT is associated with decreased clearance of paclitaxel.; Genotype TT is associated with decreased clearance of paclitaxel.	12065748; 12065748	2	paclitaxel			
637880505	rs9282564	ABCB1 (PA267)	4	Other	637880506; 637880507; 637880508	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.	655386748; 655386912	Genotype CC is not associated with decreased clearance of bisantrene.; Genotype CC is not associated with decreased expression of ABCB1.	12065748; 12065748	2	bisantrene			
637880510	rs9282564	ABCB1 (PA267)	4	Other	637880511; 637880512; 637880513	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.	655386756; 655386912	Genotype CC is not associated with decreased clearance of calcein.; Genotype CC is not associated with decreased expression of ABCB1.	12065748; 12065748	2	calcein			
637880518	rs9282564	ABCB1 (PA267)	4	Other	637880519; 637880520; 637880521	CC:Cells with the C allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.; CT:Cells with the CT genotype would show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other genotypes(inferred).; TT:Cells with the T allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.	655386764; 655386912	Genotype CC is not associated with decreased clearance of forskolin.; Genotype CC is not associated with decreased expression of ABCB1.	12065748; 12065748	2	forskolin			
637880522	rs9282564	ABCB1 (PA267)	4	Other	637880523; 637880524; 637880525	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.	655386903; 655386912	Genotype CC is not associated with decreased clearance of prazosin.; Genotype CC is not associated with decreased expression of ABCB1.	12065748; 12065748	2	prazosin			
637880526	rs9282564	ABCB1 (PA267)	4	Other	637880527; 637880528; 637880529	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.	655386906; 655386912	Genotype CC is not associated with decreased clearance of verapamil.; Genotype CC is not associated with decreased expression of ABCB1.	12065748; 12065748	2	verapamil			
637880530	rs9282564	ABCB1 (PA267)	4	Other	637880531; 637880532; 637880533	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastinel compared to cells with other genotypes.	655386907; 655386912	Genotype CC is not associated with decreased clearance of vinblastine.; Genotype CC is not associated with decreased expression of ABCB1.	12065748; 12065748	2	vinblastine			
637880534	rs9282564	ABCB1 (PA267)	4	Other	637880535; 637880536; 637880537	CC:Cells with the CC genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.; CT:Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.; TT:Cells with the TT genotype have normal ability to efflux fluorescently labelled paclitaxel.	655386908; 655386909	Genotype CC is associated with decreased clearance of paclitaxel.; Genotype CT is associated with decreased clearance of paclitaxel.	12065748; 12065748	2	paclitaxel			
637880538	rs72552784	ABCB1 (PA267)	4	Other	637880539; 637880540; 637880541	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.	655386917; 655386918	Genotype TT is not associated with decreased expression of ABCB1.; Genotype TT is not associated with decreased clearance of bisantrene.	12065748; 12065748	2	bisantrene			
637880543	rs72552784	ABCB1 (PA267)	4	Other	637880544; 637880545; 637880546	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.	655386917; 655386919	Genotype TT is not associated with decreased expression of ABCB1.; Genotype TT is not associated with decreased clearance of calcein.	12065748; 12065748	2	calcein			
637880547	rs72552784	ABCB1 (PA267)	4	Other	637880548; 637880549; 637880550	CC:Cells with the C allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.; CT:Cells with this genotype would show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other genotypes.; TT:Cells with the T allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.	655386917; 655386920	Genotype TT is not associated with decreased expression of ABCB1.; Genotype TT is not associated with decreased clearance of forskolin.	12065748; 12065748	2	forskolin			
637880551	rs72552784	ABCB1 (PA267)	4	Other	637880552; 637880553; 637880554	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.	655386917; 655386921	Genotype TT is not associated with decreased expression of ABCB1.; Genotype TT is not associated with decreased clearance of prazosin.	12065748; 12065748	2	prazosin			
637880555	rs72552784	ABCB1 (PA267)	4	Other	637880556; 637880557; 637880558	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.	655386917; 655386922	Genotype TT is not associated with decreased expression of ABCB1.; Genotype TT is not associated with decreased clearance of verapamil.	12065748; 12065748	2	verapamil			
637880559	rs72552784	ABCB1 (PA267)	4	Other	637880560; 637880561; 637880562	CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.	655386917; 655386924	Genotype TT is not associated with decreased expression of ABCB1.; Genotype TT is not associated with decreased clearance of vinblastine.	12065748; 12065748	2	vinblastine			
637880563	rs72552784	ABCB1 (PA267)	4	Other	637880564; 637880565; 637880566	CC:Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.; CT:Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.; TT:Cells with the TT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.	655386926; 655386925	Genotype CT is associated with decreased clearance of paclitaxel.; Genotype TT is associated with decreased clearance of paclitaxel.	12065748; 12065748	2	paclitaxel			
637880569	rs1800584	TPMT (PA356)	1A	Toxicity/ADR	637880570; 637880571; 637880572	CC:Patients with the CC genotype who are treated with standard doses of mercaptopurine may not be at increased risk for life-threatening myelosuppression. Other genetic and clinical factors may also influence a patient's risk for adverse events.; CT:Patients with the CT genotype who are treated with standard doses of mercaptopurine may be at increased risk for life-threatening myelosuppression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; TT:Patients with the TT genotype who are treated with standard doses of mercaptopurine may be at increased risk for life-threatening myelosuppression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.	655386679	Genotype CC is not associated with increased risk of myelosuppresion when treated with mercaptopurine as compared to genotypes TT + CT.	9486974	1	mercaptopurine		White	
652472012	rs12050217	BDKRB1 (PA79)	3	Efficacy	652472013; 652472014; 652472015	AA:Patients with the AA genotype who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.; AG:Patients with the AG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.; GG:Patients with the GG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.	652351416	Genotype AA is associated with decreased risk of cardiac events when treated with perindopril in people with Coronary Artery Disease as compared to genotypes GG + AG.	20712529	1	perindopril	Coronary Artery Disease	White	
652509715	rs275651	AGTR1 (PA43),RPL38P1 (PA34742)	3	Efficacy	652509718; 652509720; 652509722	AA:Patients with the AA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.; AT:Patients with the TA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.; TT:Patients with the TT genotype and coronary artery disease who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the TA or AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.	652252614	Genotype TT is associated with decreased risk of cardiac events when treated with perindopril in people with Coronary Artery Disease as compared to genotypes AA + TA.	20712529	1	perindopril	Coronary Artery Disease	White	
652519736	rs5182	AGTR1 (PA43)	4	Efficacy	652519737; 652519738; 652519739	CC:Patients with the CC genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.; CT:Patients with the CT genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype may have reduced risk for cardiac events when treated with perindopril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.	652326097	Genotype TT is associated with decreased risk of cardiac events when treated with perindopril in people with Coronary Artery Disease as compared to genotypes CC + CT.	20712529	1	perindopril	Coronary Artery Disease	White	
652595205	rs10836235	CAT (PA26099)	3	Toxicity/ADR	652595206; 652595207; 652595209	CC:Patients with the CC genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; CT:Patients with the CT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the CT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; TT:Patients with the TT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the TT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.	655387557	Genotype CC is associated with increased risk of cardiac damage when treated with anthracyclines and related substances in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes TT + CT.	19863340	1	anthracyclines and related substances	Precursor Cell Lymphoblastic Leukemia-Lymphoma	White	
652779372	rs1056892	CBR3 (PA26122)	2B	Toxicity/ADR	652779373; 652779374; 652779375	AA:Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; AG:Patients with the AG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; GG:Patients with the GG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.	655387546; 827807593; 827807601	Allele G is associated with increased risk of Heart Failure when treated with anthracyclines and related substances as compared to allele A.; Genotype GG is associated with increased risk of Cardiomyopathies when treated with anthracyclines and related substances in people with Neoplasms as compared to genotypes AA + AG.; Genotypes AA + AG are not associated with increased risk of Cardiomyopathies when treated with anthracyclines and related substances in people with Neoplasms.	18457324; 22124095; 22124095	3	anthracyclines and related substances	Heart Failure;Neoplasms		
652882846	rs8133052	CBR3 (PA26122)	3	Efficacy;Toxicity/ADR	652882847; 652882848; 652882849	AA:Patients with the AA genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.; AG:Patients with the AG genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype, or 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.; GG:Patients with the GG genotype and breast cancer who are treated with doxorubicin: 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.	699642239; 699639388; 699642230; 699642233	Allele A is associated with decreased expression of CBR3 in breast tissue.; Allele G is associated with increased doxorubicinol AUC when treated with doxorubicin in people with Breast Neoplasms as compared to allele A.; Allele G is associated with decreased severity of Neutropenia when treated with doxorubicin in people with Breast Neoplasms as compared to allele A.; Allele G is associated with decreased tumor response when treated with doxorubicin in people with Breast Neoplasms as compared to genotype AA.	18551042; 18551042; 18551042; 18551042	4	doxorubicin	Breast Neoplasms;Neutropenia	Asian	
655384011	rs4149056	SLCO1B1 (PA134865839)	1A	Toxicity/ADR	655384012; 655384013; 655384014	CC:Patients with the CC genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; CT:Patients with the CT genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype may have a lower risk of simvastatin-related myopathy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	769162953; 769169405; 655386684; 655386692; 769164512; 655386696; 827811024	Allele C is associated with general intolerance to statins in a logistic regression model accounting for age, both the genotypes, statin adherence, study duration, maximum dose, and concomitant prescriptions for other lipid-regulating drugs and CYP3A4 inhibiting drugs when treated with hmg coa reductase inhibitors in people with Diabetes Mellitus, Type 2 as compared to allele T.; Allele C is associated with increased risk of composite adverse events when treated with atorvastatin, hmg coa reductase inhibitors and simvastatin in people with Hypercholesterolemia as compared to allele T.; Genotype CC is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Myocardial Infarction as compared to genotype TT.; Genotype CC is associated with increased risk of Muscular Diseases when treated with simvastatin as compared to genotype CT.; Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin in people with Hyperlipidemias as compared to genotype TT.; Genotype CT is associated with increased risk of Muscular Diseases when treated with simvastatin as compared to genotype TT.; Genotype CC is associated with increased plasma concentrations of simvastatin when exposed to simvastatin in healthy individuals as compared to genotypes CT + TT.	21178985; 19833260; 18650507; 18650507; 21243006; 18650507; 17108811	7	simvastatin	Muscular Diseases;Myopathy, Central Core		
655384022	rs1142345	TPMT (PA356)	1A	Toxicity/ADR	655384023; 655384024; 655384025	CC:Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; CT:Patients with the CT genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype 1) may have increased inactivation of thiopurines 2) a decreased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CT or CC genotype. Patients with the TT genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based on their genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	827924549; 699638938; 769173727; 655386931; 655387032; 827551852; 827641965; 827641975; 827823905	Genotypes CC + CT are associated with increased severity of hematopoietic toxicity when treated with azathioprine, mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Allele C is associated with decreased catalytic activity of TPMT in human liver samples.; Allele C is associated with increased risk of toxicity when treated with thiopurines as compared to allele T.; Genotype CT is associated with decreased metabolism of purine analogues as compared to genotype TT.; Genotype CT is associated with decreased metabolism of purine analogues as compared to genotype TT.; Allele C is associated with decreased enzyme activity of TPMT when exposed to mercaptopurine and s-adenosylmethionine.; Allele C is associated with decreased half-life of TPMT.; Allele C is associated with decreased steady-state level of TPMT.; Allele C is not associated with dose of azathioprine as compared to allele T.	8644731; 8561894; 15228163; 9103127; 9246020; 16220112; 10591545; 10591545; 21819368	9	azathioprine;mercaptopurine;purine analogues;thioguanine			
655384474	rs2032582	ABCB1 (PA267)	3	Toxicity/ADR	655384478; 655384480; 655384476	AA:Patients with the AA genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.; AT:Patients with the AT genotype and cancer who are treated with taxanes and platinum therapy may have a decreased, but not absent, risk for gastrointestinal toxicity as compared to patients with the CA and AA genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxanes and platinum therapy.; TT:Patients with the TT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.	613979632	Genotype CC is associated with decreased risk of grade 3 or 4 gastrointestinal toxicity when treated with platinum and taxanes in people with Ovarian Neoplasms.	19203783	1	Platinum compounds;taxanes	Ovarian Neoplasms	Asian	
655384485	rs9344	CCND1 (PA75)	3	Efficacy	655384489; 655384488; 655384487	AA:Patients with the AA genotype may have increased survival when treated with cetuximab as compared to patients with the AG or GG genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.; AG:Patients with the AG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.; GG:Patients with the GG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.	827843529; 827843536; 827843546	Allele A is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele G.; Genotype AA is associated with decreased survival when treated with cetuximab in people with Colorectal Neoplasms.; Allele G is associated with decreased overall survival and progression-free survival when treated with cetuximab in people with Colorectal Neoplasms as compared to allele A.	18349392; 16788380; 22117530	3	cetuximab	Colorectal Neoplasms		
655384510	rs7569963	CREB1 (PA26864),FAM119A (PA145008433)	3	Efficacy;Toxicity/ADR	655384512; 655384513; 655384514	AA:Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.; AG:Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.; GG:Patients with the GG genotype may have increased likelihood of remission on anti-depressants as compared to patients with the AA or AG genotype. Male patients with the GG genotype and depression who are treated with citalopram may have an increased risk of suicidal ideation as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.	699642404; 699642415	Allele A is associated with decreased likelihood of treatment-emergent suicidality when treated with in people with Depressive Disorder, Major as compared to allele G.; Genotype GG is associated with increased likelihood of remission when treated with antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG.	17548750; 20643483	2	antidepressants;citalopram	Depression		
655384520	rs4244285	CYP2C19 (PA124)	1A	Efficacy	655384522; 655384523; 655384524	AA:Patients with the AA genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel.; AG:Patients with the AG genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel.; GG:Patients with the GG genotype: 1) may have sufficient metabolism of clopidogrel and increased formation of active drug metabolite 2) may have a decreased risk for secondary cardiovascular events with clopidogrel as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for secondary cardiovascular events when taking clopidogrel based on their genotype. Other genetic and clinical factors may also influence a patient's risk for secondary cardiovascular events and response to clopidogrel.	655386898; 655388276; 769146008; 769146034; 769146043; 769146308; 769173983; 769173984; 769245456; 769245465; 769255152; 769258868; 827784087; 827784103; 827787114; 827814610; 827815433; 827815461; 827823391; 827919768	Allele A is associated with increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.; Allele A is associated with increased risk of cardiovascular event when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.; Allele A is associated with increased risk of of death from cardiovascular causes, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.; Allele A is associated with increased risk of cardiovascular ischemic event or death during 1 year of follow-up when treated with clopidogrel in people with percutaneous coronary intervention as compared to allele G.; Allele A is associated with increased risk of a higher rate of ischaemic events during the first 30 days of treatment when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.; Allele A is not associated with a difference in reducing the rate of the primary efficacy outcome when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.; Allele A is associated with increased risk of major adverse cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.; Allele A is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.; Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.; Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.; Genotype AA is associated with decreased response to clopidogrel.; Genotype AA is associated with increased risk of stent thrombosis when treated with in people with Coronary Artery Disease as compared to genotype GG.; Allele A is associated with increased ADP-stimulated platelet aggregation when treated with clopidogrel as compared to allele G.; Allele A is associated with High Platelet Reactivity (HPR) as compared to allele G.; Genotype AG is associated with increased risk of significantly higher on-treatment platelet reactivity with a maintenance dose of 75 mg daily when treated with clopidogrel in people with Cardiovascular Diseases as compared to genotype GG.; Allele A is associated with higher composite har outcome (cardiac death, non fatal myocardial infarction and stent thrombosis) up to 12 months'  follow up when treated with aspirin and clopidogrel in people with drug-eluting stents as compared to allele G.; Genotypes AA + AG are associated with increased risk of on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.; Genotypes AA + AG are not associated with altered risk on major bleedings when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.; Allele A is associated with increased risk of High Platelet Reactivity when treated with clopidogrel in people with coronary artery disease undergoing stent implantation as compared to allele G.; Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.	20801494; 19106083; 19106084; 19706858; 20801498; 20979470; 20351750; 20351750; 21392617; 21392617; 21178986; 21527445; 21881565; 21881565; 22088980; 21700758; 22228204; 22228204; 21628721; 22462746	20	clopidogrel	Cardiovascular Diseases;Death;Myocardial Infarction;Stroke;Thrombosis		
655384529	rs742105	DTNBP1 (PA27512)	3	Efficacy	655384533; 655384532; 655384531	CC:Patients with the CC genotype and Schizophrenia may have a decreased response to clozapine compared to patients with a CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.; CT:Patients with the CT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.; TT:Patients with the TT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.	699642395	Genotypes TT + CT are associated with increased response to clozapine in people with Schizophrenia as compared to genotype CC.	19369910	1	clozapine	Schizophrenia	Black or African American	
655384534	rs4880	SOD2 (PA36017)	2B	Efficacy	655384538; 655384537; 655384536	AA:Patients with the AA genotype and breast cancer who are treated with cyclophosphamide may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.; AG:Patients with the AG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype or may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.; GG:Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.	699642290	Allele G is associated with decreased survival when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele A.	19509150	1	cyclophosphamide	Breast Neoplasms		
655384539	rs2032582	ABCB1 (PA267)	3	Efficacy	655384544; 655384543; 655384545	AA:Patients with the AA genotype may have an increased risk of resistance to cyclosporine compared to patients with the CC and CA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.; AC:Patients with the AC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.; CC:Patients with the CC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.	699638648	Genotype AA is associated with increased risk of resistance when treated with cyclosporine in people with Colitis, Ulcerative as compared to genotypes CC + AC.	17206635	1	cyclosporine	Colitis, Ulcerative	White	
655384546	rs1128503	ABCB1 (PA267)	3	Dosage	655384548; 655384549; 655384550	AA:Patients with the AA genotype and Myasthenia Gravis may have reduced clearance of cyclosporine and therefore may require a decreased dose of cyclosporine, compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.; AG:Patients with the AG genotype and Myasthenia Gravis may have altered clearance of cyclosporine, compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.; GG:Patients with the GG genotype and Myasthenia Gravis may have increased clearance of cyclosporine and therefore may require an increased dose of cyclosporine, compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.	655388180; 827814000	Genotype AA is associated with increased trough blood concentration of cyclosporine in people with Myasthenia Gravis as compared to genotype GG.; Allele A is not associated with dose of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.	18717915; 21806386	2	cyclosporine	Myasthenia Gravis	Asian	
655384558	rs10932125	NRP2 (PA31784)	4	Other	655384560; 655384561; 655384562	CC:Patients with the CC genotype may have reduced response to daunorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment.; CG:Patients with the CG genotype may have reduced response to daunorubicin compared to patients with the GG genotype or may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.; GG:Patients with the GG genotype may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.	655387597; 655387598	Allele C is associated with increased expression of CYP1B1 in CEU and YRI cell lines.; Allele C is associated with increased IC50 of daunorubicin as compared to allele G.	18451141; 18451141	2	daunorubicin	Drug Toxicity		
655384563	rs3800373	FKBP5 (PA28162)	2B	Efficacy	655384565; 655384566; 655384567	AA:Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.; AC:Patients with the AC genotype and depression who are treated with antidepressants may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.; CC:Patients with the CC genotype and depression who are treated with antidepressants may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.	655388432; 655388405; 827828566	Genotype CC is associated with increased response to antidepressants in people with Depressive Disorder as compared to genotypes AA + AC.; Genotypes CC + AC are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.; Allele A is not associated with clinical outcomes when treated with mirtazapine or paroxetine in people with Depression.	15565110; 18597649; 19676097	3	antidepressants	Depression	White	
655384568	rs1360780	FKBP5 (PA28162)	3	Efficacy	655384570; 655384571; 655384572	CC:Patients with the CC genotype may 1) have decreased response to antidepressants 2) have decreased suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.; CT:Patients with the CT genotype may 1) have increased response to antidepressants 2) have increased suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.; TT:Patients with the TT genotype may 1) have increased response to antidepressants 2) have increased suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.	655388437; 655388402; 827793233; 827793245; 827828556	Genotype TT is associated with increased response to antidepressants in people with Depressive Disorder as compared to genotypes CC + CT.; Genotypes TT + CT are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype CC.; Allele T is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.; Allele T is associated with increased risk of suicidal ideation when treated with paroxetine in people with Depression as compared to allele C.; Allele C is not associated with clinical outcomes when treated with mirtazapine or paroxetine in people with Depression as compared to allele T.	15565110; 18597649; 21449676; 21449676; 19676097	5	antidepressants	Depression		
655384573	rs1056836	CYP1B1 (PA27094),FAM82A1 (PA162387925)	3	Efficacy	655384575; 655384576; 655384577	CC:Patients with the CC genotype who are treated with taxanes may have shorter disease-free progression as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.; CG:Patients with the CG genotype who are treated with taxanes may have shorter disease-free progression as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.; GG:Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.	655387529; 655387526; 827817238; 827922834	Allele G is associated with decreased progression free survival when treated with paclitaxel in people with Breast Neoplasms as compared to allele C.; Genotype GG is associated with decreased survival when treated with docetaxel in people with Prostatic Neoplasms as compared to genotypes CC + CG.; Genotypes CG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.; Genotypes CC + CG are not associated with increased response to paclitaxel in women with Breast Neoplasms as compared to genotype GG.	17224914; 18187806; 22026922; 22527101	4	docetaxel;paclitaxel;taxanes	Breast Neoplasms;Prostatic Neoplasms		
655384578	rs2740574	CYP3A (PA27114),CYP3A4 (PA130)	3	Dosage	655384579; 655384580; 655384581	CC:Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of docetaxel.; CT:Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the TT genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of docetaxel.; TT:Patients with the TT genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of docetaxel.	699642219; 699642223	Allele C is associated with increased clearance of docetaxel in people with Neoplasms as compared to allele T.; Allele C is associated with expression of CYP3A5.	18509327; 18509327	2	docetaxel	Neoplasms	White	
655384582	rs11045819	SLCO1B1 (PA134865839)	3	Efficacy	655384586; 655384585; 655384584	AA:Patients with the AA genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's response to fluvastatin.; AC:Patients with the AC genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin.; CC:Patients with the CC genotype who are treated with fluvastatin may have a lesser reduction in LDL-C as compared to patients with the AC and AA genotype.	655387623	Genotype CC is associated with decreased LDL-C reduction when treated with fluvastatin in people with Hypercholesterolemia as compared to genotypes AA + AC.	18781850	1	fluvastatin	Hypercholesterolemia	White	
655384587	rs11572103	CYP2C8 (PA125)	4	Dosage	655384589; 655384590; 655384591	AA:Patients with the AA genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.; AT:Patients with the AT genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.; TT:Patients with the TT genotype may have increased clearance of paclitaxel as compared to patients with the AA or AT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.	655387869; 655388183	Allele A is associated with decreased clearance of paclitaxel.; Allele T is not associated with metabolism of paclitaxel in people with Neoplasms as compared to allele A.	11668219; 16299241	2	paclitaxel		White	
655384592	rs12721627	CYP3A (PA27114),CYP3A4 (PA130)	3	Dosage	655384594; 655384595; 655384596	CC:Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.; CG:Patients with the CG genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.; GG:Patients with the GG genotype may have increased metabolism of paclitaxel as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence paclitaxel metabolism.	655387863	Allele C is associated with decreased metabolism of paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	16890579	1	paclitaxel	Carcinoma, Non-Small-Cell Lung;Neoplasms	Asian	
655384597	rs1934951	CYP2C8 (PA125)	3	Toxicity/ADR	655384601; 655384600; 655384599	CC:Patients with the CC genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.; CT:Patients with the CT genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.; TT:Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.	699638940; 827863672	Genotype TT is associated with increased risk of Osteonecrosis of the jaw when treated with Bisphosphonates in people with Multiple Myeloma as compared to genotypes CC + CT.; Genotypes CT + TT are not associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates in men with Prostatic Neoplasms as compared to genotype CC.	18594024; 21151627	2	Bisphosphonates;pamidronate;zoledronate	Multiple Myeloma;Osteonecrosis	White	
655384602	rs951439	RGS4 (PA34375)	3	Efficacy	655384604; 655384605; 655384606	CC:Patients with the CC genotype may have decreased chance of response to risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of response to risperidone.; CT:Patients with the CT genotype may have decreased chance of response to risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of response to risperidone.; TT:Patients with the TT genotype may have increased chance of response to risperidone as compared to patients with CC or CT genotypes. Other genetic and clinical factors may also influence a patients chance of response to risperidone.	655387128	Genotype TT is associated with increased likelihood of response when treated with risperidone in people with Schizophrenia as compared to genotypes CC + CT.	17588543	1	risperidone	Schizophrenia	White	
655384607	rs951439	RGS4 (PA34375)	3	Efficacy	655384608; 655384609; 655384610	CC:Patients with the CC genotype and schizophrenia: 1) may have increased treatment response with perphanzine and olanzapine treatment 2) may have decreased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.; CT:Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.; TT:Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.	655387127; 655387131; 655387138	Genotype CC is associated with increased likelihood of positive response when treated with olanzapine and perphenazine in people with Schizophrenia as compared to genotypes TT + CT.; Genotype CT is associated with increased likelihood of response when treated with olanzapine in people with Schizophrenia.; Genotype TT is associated with increased response to quetiapine and ziprasidone in people with Schizophrenia as compared to genotype CC.	17588543; 17588543; 17588543	3	antipsychotics;olanzapine;perphenazine;quetiapine;ziprasidone	Schizophrenia	Black or African American	
655384611	rs17244841	HMGCR (PA189)	2A	Efficacy	655384615; 655384614; 655384613	AA:Patients with the AA genotype who are treated with statins may be more likely to respond as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.; AT:Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.; TT:Patients with the TT genotype are too infrequent to have been assessed for this response.	699638701; 699638684; 699638675; 827925947	Allele A is not associated with response to fluvastatin in people with renal transplantation as compared to allele T.; Genotype AA is associated with increased reduction of LDL cholesterol when treated with simvastatin.; Genotype AT is associated with decreased reduction in LDL when treated with pravastatin as compared to genotype AA.; Genotype AT is associated with decreased reduction in total cholesterol when treated with pravastatin as compared to genotype AA.	17563401; 18332269; 15199031; 15199031	4	fluvastatin;hmg coa reductase inhibitors;pravastatin;simvastatin			
655384616	rs17238540	HMGCR (PA189)	3	Efficacy	655384620; 655384619; 655384618	GG:Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.; GT:Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.; TT:Patients with the TT genotype who are treated with statins may be more likely to reach target LDL levels as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.	699639067; 769152897; 699638678; 699638985; 699639070; 699638688; 827925965	Allele G is not associated with response to pravastatin as compared to genotype TT.; Allele G is not associated with response to pravastatin in people with Vascular Diseases as compared to allele T.; Genotype GT is associated with decreased reduction in LDL when exposed to pravastatin as compared to genotype TT.; Genotype GT is associated with decreased likelihood of reaching target cholesterol levels when treated with atorvastatin, cerivastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin in people with Diabetes Mellitus as compared to genotype TT.; Allele T is not associated with response to fluvastatin in people with renal tranplantation as compared to allele G.; Genotype TT is associated with increased reduction of LDL cholesterol when treated with simvastatin as compared to genotypes GG + GT.; Genotype GT is associated with decreased reduction in total cholesterol when treated with pravastatin as compared to genotype TT.	16103896; 18261733; 15199031; 18815589; 17563401; 18332269; 15199031	7	atorvastatin;fluvastatin;hmg coa reductase inhibitors;lovastatin;pravastatin;simvastatin			
655384621	rs20455	KIF6 (PA134920075)	2B	Efficacy	655384625; 655384624; 655384623	AA:Patients with the AA genotype may have a decreased, but not absent, risk for adverse cardiovascular events as compare to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events.; AG:Patients with the AG genotype may have an increased risk for adverse cardiovascular events (myocardial infarction and coronary heart diseases) as compared to patients with the AA genotype. Pravastatin treatment substantially reduced that risk. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events.; GG:Patients with the GG genotype may have an increased risk for adverse cardiovascular events (myocardial infarction and coronary heart diseases) as compared to patients with the AA genotype. Pravastatin treatment substantially reduced that risk. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events.	769146472; 769146457; 769146465; 769146469	Genotype AA is associated with decreased risk of Myocardial Infarction when treated with pravastatin.; Genotypes GG + AG are associated with increased risk of Myocardial Infarction as compared to genotype AA.; Genotypes GG + AG are associated with increased risk of Coronary Disease as compared to genotype AA.; Genotypes GG + AG are associated with decreased risk of Myocardial Infarction when treated with pravastatin.	18222353; 18222353; 18222353; 18222353	4	pravastatin	Myocardial Infarction	White	
655384626	rs4149015	SLCO1B1 (PA134865839)	2A	Efficacy	655384628; 655384629; 655384630	AA:Patients carrying the AA genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. This variant is part of the SLCO1B1*17 haplotype. Other genetic and clinical factors may also influence a patient's response.; AG:Patients carrying the AG genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. Other genetic and clinical factors may also influence a patient's response.; GG:Patients carrying the GG genotype may have increased chance of response to pravastatin compared to patients carrying the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.	769146231; 769146445	Genotype AG is associated with decreased response to pravastatin as compared to genotype GG.; Genotype AG is associated with increased AUC0-12 when exposed to pravastatin as compared to genotype GG.	15864131; 15226675	2	pravastatin		White	
655384635	rs58597806	UGT1A9 (PA419)	4	Toxicity/ADR	655384637; 655384638; 655384639	AA:Patients with the AA genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.; AG:Patients with the AG genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.; GG:Patients with the GG genotype may have decreased but not non-existent risk of adverse effects when treated with propofol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to propofol.	748897582	Allele A is associated with lower UGT1A9 activity for propofol as compared to allele G.	18816295	1	propofol			
655384640	rs1800460	TPMT (PA356)	1A	Toxicity/ADR	655384644; 655384643; 655384642	CC:Patients with the CC genotype may have a decreased, but not absent, risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CT or TT genotype. Patients with the CC genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based on their genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; CT:Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	699638934; 699638939; 769173741; 827551878; 827924562	Allele T is associated with increased risk of Drug Toxicity when treated with mercaptopurine and purine analogues as compared to genotype CC.; Allele T is associated with decreased catalytic activity of TPMT in human liver samples.; Allele T is associated with increased risk of toxicity when treated with thiopurines.; Allele T is associated with decreased enzyme activity of TPMT when treated with mercaptopurine and s-adenosylmethionine.; Genotypes CT + TT are associated with increased severity of hematopoietic toxicity when treated with azathioprine, mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	8561894; 8561894; 15228163; 16220112; 8644731	5	azathioprine;mercaptopurine;purine analogues;thioguanine			
655384645	rs4149056	SLCO1B1 (PA134865839)	3	Efficacy	655384646; 655384647; 655384648	CC:Patients with the CC genotype may have increased mean plasma AUC of repaglinide and greater blood glucose-lowering effect in response to repaglinide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.; CT:Patients with the CT genotype may have decreased mean plasma AUC of repaglinide and lower blood glucose-lowering effect in response to repaglinide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype may have decreased mean plasma AUC of repaglinide and lower blood glucose-lowering effect in response to repaglinide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.	747790540	Genotype CC is associated with increased mean plasma AUC of repaglinide as compared to genotypes CT + TT.	18187595	1	repaglinide		White	
655384653	rs10509681	CYP2C8 (PA125)	3	Dosage	655384654; 655384655; 655384656	CC:Patients with the CC genotype (CYP2C8*3/*3) may have increased metabolism of rosiglitazone compared to patients with the TT genotype (CYP2C8*1/*1), but this is not associated with differences in blood glucose lowering efficacy compared to patients with the TT genotype. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of rosiglitazone and blood glucose levels.; CT:Patients with the CT (CYP2C8*3/*1) genotype may have increased metabolism of rosiglitazone compared to patients with the TT genotype (CYP2C8*1/*1), or may have decreased metabolism of rosiglitazone compared to patients with the CC genotype (CYP2C8*3/*3). This is not associated with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of rosiglitazone and blood glucose levels.; TT:Patients with the TT (CYP2C8*1/*1) genotype may have decreased metabolism of rosiglitazone compared to patients with the CC genotype (CYP2C8*3/*3), but this is not associated with differences in blood glucose lowering efficacy compared to patients with the CC genotype. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of rosiglitazone and blood glucose levels.	655387147; 655387153	Allele C is associated with increased metabolism of rosiglitazone in people with no disease as compared to allele T.; Allele C is not associated with glucose lowering when treated with rosiglitazone in people with no disease as compared to allele T.	17178266; 17178266	2	rosiglitazone		White	
655384666	rs429358	APOC1 (PA51),APOE (PA55),TOMM40 (PA38274)	3	Toxicity/ADR	655384667; 655384668; 655384669	CC:Patients with the CC genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.; CT:Patients with the CT genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.; TT:Patients with the TT genotype who are treated with antiretrovirals for HIV such as ritonavir may have a decreased but not non-existent risk for elevated plasma lipids as compared to patients with the CC or CT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.	827843584	Genotypes CC + CT are associated with increased non-HDL cholesterol when treated with Antivirals for treatment of HIV infections, combinations and ritonavir in people with HIV as compared to allele C.	15809899	1	Antivirals for treatment of HIV infections, combinations;ritonavir	HIV;HIV Infections;Hyperlipidemias		
655384670	rs7412	APOC1 (PA51),APOE (PA55)	3	Toxicity/ADR	655384673; 655384672; 655384671	CC:Patients with the CC genotype may have decreased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the TT or CT genotype. Patients with the CC genotype may still be at risk for toxicity when taking ritonavir. Other genetic and clinical factors may also influence a patient's risk for toxicity.; CT:Patients with the CT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	699642389; 699642392	Allele T is associated with increased triglycerides when treated with Antivirals for treatment of HIV infections, combinations and ritonavir in people with HIV as compared to allele C.; Allele T is associated with increased triglycerides when treated with Antivirals for treatment of HIV infections, combinations in people with HIV as compared to allele C.	15809899; 17700364	2	ritonavir	HIV;HIV Infections;Hyperlipidemias;Hypertriglyceridemia		
655384674	rs396991	FCGR3A (PA28065)	2B	Efficacy	655384678; 655384677; 655384676	AA:Lymphoma patients with the AA genotype who are treated with rituximab may be less likely to have tumor shrinkage as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.; AC:Lymphoma patients with the AC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.; CC:Lymphoma patients with the CC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.	769143864; 769143868; 769143871	Genotype AA is associated with decreased levels of IgG when treated with rituximab in people with non-Hodgkin's lymphoma and stem cell transplantation as compared to genotypes CC + AC.; Allele C is associated with increased complete response rate when treated with rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to allele A.; Genotype CC is associated with response rate when treated with rituximab in people with Lymphoma, Non-Hodgkin as compared to genotypes AA + AC.	19018870; 16609067; 12975461	3	rituximab	Lymphoma, B-Cell;Lymphoma, Follicular;Lymphoma, Large-Cell, Diffuse;Lymphoma, Non-Hodgkin		
655384679	rs20417	PTGS2 (PA293)	3	Efficacy	655384681; 655384682; 655384683	CC:Patients with the CC genotype may have better pain relief response to rofecoxib as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.; CG:Patients with the CG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.; GG:Patients with the GG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.	699638652	Genotype CC is associated with increased pain relief when treated with rofecoxib as compared to genotypes GG + CG.	16678543	1	rofecoxib		White	
655384684	rs2231142	ABCG2 (PA390)	2B	Efficacy	655384688; 655384687; 655384686	GG:Patients with the GG genotype who are treated with rosuvastatin may be less likely to reach target LDL levels as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.; GT:Patients with the GT genotype who are treated with rosuvastatin may be more likely to reach target LDL levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.; TT:Patients with the TT genotype may have increased response to rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.	655388369; 655388082; 655388379; 655388373	Genotype GG is associated with decreased AUC of rosuvastatin in people with no disease as compared to genotypes TT + GT.; Allele T is associated with increased reduction in low-density lipoprotein cholesterol (LDL-C) level, in a gene-dose-dependent manner, when treated with rosuvastatin in people with Hypercholesterolemia as compared to allele G.; Allele T is associated with increased likelihood of achievement of target LDL when treated with rosuvastatin in people with Myocardial Infarction as compared to allele G.; Genotype TT is associated with increased AUC of rosuvastatin in people with no disease as compared to genotypes GG + GT.	16784736; 20130569; 20207952; 19474787	4	rosuvastatin			
655384694	rs4343	ACE (PA139)	3	Efficacy	655384697; 655384696; 655384695	AA:Patients with the AA genotype and erectile dysfunction who are treated with sildenafil may have an increased chance of positive erectile response as compared to patient's with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.; AG:Patients with the AG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.; GG:Patients with the GG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.	769145994	Genotypes GG + AG are associated with decreased chance of response when treated with sildenafil in people with Erectile Dysfunction (male patients) as compared to genotype AA.	12837457	1	sildenafil	Erectile Dysfunction	White	
655384698	rs3892097	CYP2D6 (PA128)	2A	Efficacy;Toxicity/ADR	655384702; 655384701; 655384700	CC:Patients with the CC genotype who are treated with tamoxifen: 1) may have a decreased, but not absent, risk of relapse as compared to patients with the TT genotype 2) may have an increased severity in hot flashes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of relapse.; CT:Patients with the CT genotype who are treated with tamoxifen: 1) may have a decreased, but not absent, risk of relapse as compared to patients with the TT genotype 2) may have an increased severity in hot flashes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of relapse.; TT:Patients with the TT genotype who are treated with tamoxifen: 1) may have an increased risk of relapse as compared to patients with the CT or CC genotype 2) may have a decreased severity in hot flashes as compared to patients with the CT or CC genotype.	769169314; 769146128; 769146138; 769146179; 769146129; 769146130; 769146131; 769146144; 769146163	Allele C is associated with increased risk of recurrance when treated with tamoxifen in people with Breast Neoplasms as compared to allele T.; Allele T is associated with CYP2D6*4.; Allele T is not associated with decreased overall survival when treated with tamoxifen in people with Breast Neoplasms as compared to allele C.; Allele T is associated with decreased event-free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotype CC.; Genotype TT is associated with decreased relapse free time when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.; Genotype TT is associated with decreased disease free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.; Genotype TT is associated with decreased severity of hot flashes when treated with in people with Breast Neoplasms as compared to genotypes CC + CT.; Genotype TT is associated with increased disease free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.; Genotype TT is associated with decreased progression free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.	18024866; 16361630; 16361630; 19809024; 16361630; 16361630; 16361630; 17244352; 20849243	9	tamoxifen	Breast Neoplasms		
655384703	rs10811661		3	Efficacy	655384705; 655384706; 655384707	CC:Patients with the CC genotype and at high-risk for type II diabetes who are treated with troglitazone may have increased beta cell function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.; CT:Patients with the CT genotype and at high risk for type II diabetes who are treated with troglitazone may have increased beta call function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to troglitazone.; TT:Patients with the TT genotype and at high risk for type II diabetes who are treated with troglitazone may have decreased beta cell function as compared to patients with the CT and CC genotype.	655387539	Allele C is associated with increased beta cell function when treated with troglitazone in people with high risk for type 2 diabetes as compared to allele T.	18544707	1	troglitazone	Diabetes Mellitus, Type 2		
655384708	rs5030655	CYP2D6 (PA128)	3	Toxicity/ADR	655384712; 655384711; 655384710	A/del:Patients with the A/del genotype who are treated with venlafaxine may have an increased risk of adverse effects (check other variants for PM phenotype) as compared to patients with the A/A genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.; AA:Patients with the A/A genotype who are treated with venlafaxine may have average risk of adverse effects (check other variants for PM phenotype) as compared to patients with the del/del or A/del genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.; del/del:Patients with the del/del genotype who are treated with venlafaxine may have an increased risk of adverse effects (check other variants for PM phenotype) as compared to patients with the A/A genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.	750192626	Genotype DEL is associated with impaired metabolic activity and more side effects when treated with venlafaxine in people with Depressive Disorder, Major as compared to allele A.	16958828	1	venlafaxine	Depression;Depressive Disorder;Depressive Disorder, Major;Diarrhea;Drug Toxicity;Nausea;Vomiting	White	
655384713	rs3892097	CYP2D6 (PA128)	3	Toxicity/ADR	655384719; 655384716; 655384718	CC:Patients with the CC genotype who are treated with venlafaxine may have average risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.; CT:Patients with the CT genotype who are treated with venlafaxine may have an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.; TT:Patients with the TT genotype who are treated with venlafaxine may have an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.	769143878	Allele T is associated with impaired metabolic activity and more side effects when treated with venlafaxine in people with Depressive Disorder, Major as compared to allele C.	16958828	1	venlafaxine	Depression;Depressive Disorder;Depressive Disorder, Major;Diarrhea;Drug Toxicity;Nausea;Vomiting	White	
655384720	rs1057910	CYP2C9 (PA126)	1A	Dosage;Toxicity/ADR	655384723; 655384722; 655384721	AA:Patients with the AA genotype: 1) may require an increased dose of warfarin as compared to patients with the AC or CC genotype 2) may have a decreased risk for adverse events as compared to patients with the AC or CC genotype. Patients with the AA genotype may still be at risk for adverse events when taking warfarin based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; AC:Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.; CC:Patients with the CC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.	608431732; 655387562; 655388494; 655388497; 655388486	Allele C is associated with decreased dose of warfarin.; Allele C is associated with decreased dose of warfarin.; Allele C is associated with decreased dose of warfarin as compared to allele A.; Allele C is associated with increased risk of bleeding when treated with warfarin as compared to allele A.; Genotype CC is associated with increased risk of overanticoagulation when treated with acenocoumarol.	19794411; 19228618; 11127854; 11127854; 11692083	5	warfarin			
655384724	rs4086116	CYP2C9 (PA126)	3	Dosage	655384728; 655384727; 655384726	CC:Patients with the CC genotype may require an increased dose of acenocoumarol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence acenocoumarol dose.; CT:Patients with the CT genotype may require a lower dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.; TT:Patients with the TT genotype may require the lowest dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.	769146304	Allele T is associated with decreased dose of acenocoumarol as compared to allele C.	19578179	1	acenocoumarol		White	
655384733	rs7294	VKORC1 (PA133787052)	1B	Dosage	655384737; 655384736; 655384735	CC:Patients with the CC genotype who are treated with warfarin may require a lower dose as compared to patients with the TC or TT genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.; CT:Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.; TT:Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.	769277912; 655388073; 769277903; 827567329; 827649690	Genotype CT is associated with increased dose of warfarin as compared to genotype CC.; Allele T is associated with increased dose of warfarin.; Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.; Allele C is associated with decreased dose of warfarin as compared to allele T.; Allele T is associated with increased dose of warfarin as compared to allele C.	17049586; 16676068; 15358623; 15883587; 16611750	5	warfarin			
655384738	rs17708472	VKORC1 (PA133787052)	3	Dosage	655384740; 655384741; 655384742	AA:Patients with the AA genotype: 1) may require a higher dose of warfarin as compared to patients with the GG genotype 2) may have an increased risk of warfarin resistance as compared to patients with the GG genotype.; AG:Patients with the AG genotype: 1) may require a higher dose of warfarin as compared to patients with the GG genotype 2) may have an increased risk of warfarin resistance as compared to patients with the GG genotype.; GG:Patients with the GG genotype: 1) may require a lower dose of warfarin as compared to patients with the AG and AA genotype 2) may have a decreased risk of warfarin resistance as compared to patients with the AA genotype. Patients with the GG genotype may still be at risk for warfarin resistance based on their genotype. Other genetic and clinical factors may also influence a patient's response to warfarin.	769146206	Genotype AA is associated with increased dose of warfarin.	18781852	1	warfarin			
655384763	rs1801253	ADRB1 (PA38)	3	Efficacy	655384764; 655384765; 655384766	CC:Patients with the CC genotype and Atrial Fibrillation may have a decreased response to verapamil treatment compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.; CG:Patients with the CG genotype and Atrial Fibrillation may have an increased response to verapamil treatment compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.; GG:Patients with the GG genotype and Atrial Fibrillation may have an increased response to verapamil treatment compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.	827816261	Genotypes CG + GG are associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype CC.	22192668	1	verapamil	Atrial Fibrillation	White	
655384767	rs5065	NPPA (PA256)	4	Efficacy	655384769; 655384770; 655384771	AA:Patients with Hypertension and the AA genotype 1) may have an increased chance of positive treatment response to amlodipine as compared to patients with the AG or GG genotype 2) may have lower chance of positive treatment response to chlorthalidone as compared to patients with the AG or GG genotype 3) may have an increased chance of positive treatment response to amlodipine compared to treatment with chlorthalidone. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.; AG:Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.; GG:Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.	699642298; 699642297; 699642296	Genotype AA is associated with decreased cardiovascular events when treated with amlodipine in people with Hypertension as compared to allele G.; Allele G is associated with decreased cardiovascular events when treated with chlorthalidone in people with Hypertension as compared to genotype AA.; Genotype GG is associated with increased reduction in systolic bood pressure when treated with chlorthalidone in people with Hypertension.	18212314; 18212314; 18212314	3	amlodipine;chlorthalidone	Cardiovascular Diseases;Coronary Disease;Stroke		
655384772	rs6295	HTR1A (PA192)	3	Efficacy	655384773; 655384774; 655384775	CC:Patients with the CC genotype may have a decreased likelihood of response to antidepressants as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence response to antidepressants.; CG:Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.; GG:Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.	655386291; 655386295; 608178498; 655386298	Genotype CC is associated with increased likelihood of nonresponse when treated with paroxetine and sertraline in people with Panic Disorder as compared to genotypes GG + CG.; Allele G is associated with increased likelihood of response when treated with antidepressants.; Genotype GG is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CG.; Genotype GG is associated with decreased treatment response when treated with antidepressants in people with Depressive Disorder, Major as compared to genotypes CC + CG.	19800133; 18047755; 18484082; 18387740	4	antidepressants;fluvoxamine;paroxetine;Selective serotonin reuptake inhibitors	Depressive Disorder;Depressive Disorder, Major		
655384776	rs1800462	TPMT (PA356)	1A	Toxicity/ADR	981420075; 981420076; 981420077	CC:Patients with the CC genotype (e.g. TPMT*1/*1): 1) may have increased deactivation of thiopurines 2) may have a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2). Other genetic and clinical factors may also influence a patient's risk for toxicity.; CG:Patients with the CG genotype (e.g. TPMT*1/*2): may have increased deactivation of thiopurines and a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2) or may have decreased deactivation of thiopurines and an increased risk for toxicity with thiopurine drugs as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patient's risk for toxicity.	769146082; 769146083; 769146102; 769173715; 769146079; 827551865; 827641912; 827641920; 827663302; 827663582	Allele G is associated with decreased catalytic activity of TPMT in yeast.; Allele G is associated with TPMT*2.; Allele G is associated with decreased TPMT activity when treated with purine analogues as compared to allele C.; Allele G is associated with increased risk of hematopoietic toxicity when treated with thiopurines.; Genotype GG is associated with increased severity of Drug Toxicity when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Allele G is associated with decreased enzyme activity of TPMT when exposed to mercaptopurine and s-adenosylmethionine.; Allele G is associated with decreased steady-state level of TPMT.; Allele G is associated with decreased half-life of TPMT.; Allele G is associated with decreased steady-state level of TPMT.; Allele G is associated with decreased half-life of TPMT.	7862671; 11304783; 9831928; 15228163; 7862671; 16220112; 10591545; 10591545; 9177237; 9177237	10	azathioprine;mercaptopurine;purine analogues;thioguanine			
655384781	rs4253778	PPARA (PA280)	3	Efficacy	655384785; 655384784; 655384783	CC:Patients with the CC genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.; CG:Patients with the CG genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.; GG:Patients with the GG genotype and acute coronary artery syndrome who are treated with beta blockers may have a decreased, but not absent, chance of rehospitalization as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.	769143811	Genotype GG is associated with decreased cardiac rehospitalization of acute coronary syndrome patients discharged on beta-blockers (at 1 year) as compared to genotypes CC + CG.	18855529	1	Beta Blocking Agents	Coronary Disease		
655384790	rs12248560	CYP2C19 (PA124)	2A	Dosage	655384793; 655384792; 655384791	CC:Adult patients with the CC genotype who are treated with omeprazole may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration. May not be applicable to pediatric patients.; CT:Patients with this genotype were not studied.; TT:Adult patients with the TT genotype who are treated with omeprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration. May not be applicable to pediatric patients.	655387717; 655387758; 655387718; 655387742	Allele T is associated with CYP2C19*17.; Allele T is not associated with increased metabolism of omeprazole as compared to allele C.; Genotype TT is associated with increased metabolism of omeprazole in people with no disease as compared to genotype CC.; Genotype TT is associated with decreased AUC of omeprazole in people with no disease as compared to genotype CC.	16413245; 20223877; 16413245; 18294333	4	omeprazole		White	
655384794	rs1799722	BDKRB2 (PA80)	3	Toxicity/ADR	655384798; 655384797; 655384796	CC:Patients with the CC genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.; CT:Patients with the CT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.; TT:Patients with the TT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.	655388464; 655388472; 655388481; 655388475	Allele T is associated with increased risk of Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele C.; Allele T is not associated with increased risk of Cough when treated with Ace Inhibitors, Plain in people with Diabetes Mellitus, Type 2 as compared to allele C.; Allele T is not associated with Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele C.; Genotypes TT + CT are associated with increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to genotype CC.	10904024; 11699055; 19744011; 12522467	4	Ace Inhibitors, Plain	Cough	Asian	
655384799	rs1800629	TNF (PA435)	3	Efficacy	655384801; 655384802; 655384803	AA:Patients with the AA genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anti-TNF therapy.; AG:Patients with the AG genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype or may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-TNF therapy.; GG:Patients with the GG genotype and rheumatoid arthritis who are treated with anti-TNF therapies may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-TNF therapy.	699638591; 769169846	Allele A is associated with decreased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to allele G.; Allele A is associated with risk of poorer response to anti-TNF therapy in people with Arthritis, Rheumatoid as compared to allele G.	19365401; 16909270	2	adalimumab;etanercept;infliximab	Arthritis, Rheumatoid		
655384804	rs2781659	ARG1 (PA24947),MED23 (PA162395499)	3	Efficacy	655384806; 655384807; 655384808	AA:Patients with the AA genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.; AG:Patients with the AG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype or may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.; GG:Patients with the GG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.	769146107	Allele A is associated with increased response to selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele G.	18617639	1	selective beta-2-adrenoreceptor agonists	Asthma	White	
655384809	rs622342	SLC22A1 (PA329)	3	Efficacy	655384812; 655384811; 655384810	AA:Patients with the AA genotype and the GG genotype at rs2289669 who have diabetes may have a better response to metformin, as measured by a larger reduction in HbA1c levels, as compared to patients with the CC genotype and the GG genotype at rs2289669. This association is not significant when compared to patients with the CC genotype and the AG or AA genotype at rs2289699. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment.; AC:Patients with the AC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype. Although contradictory information exists for this association, and may be dependent on the absence of an A allele at rs2289669. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment.; CC:Patients with the CC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype and the GG genotype at rs2289669. This association is no longer significant in patients with the CC genotype and the AG or AA genotype at rs2289669. Other genetic and clinical factors may also influence a patient's response to metformin treatment.	769169367; 769169370; 608178461; 769169373	Genotype AA is not associated with response to metformin in people with genetic variation at rs2289669.; Genotype AC is associated with response to metformin in people with genetic variation at rs2289669.; Allele C is associated with decreased reduction in HbA1c levels when treated with metformin in people with Diabetes Mellitus.; Genotype CC is associated with response to metformin in people with genetic variation at rs2289669.	19898263; 19898263; 19381165; 19898263	4	metformin	Diabetes Mellitus	White	
655384813	rs1801253	ADRB1 (PA38)	4	Toxicity/ADR	655384816; 655384815; 655384814	CC:Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.; CG:Patients with the CG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.; GG:Patients with the GG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype but the results were not statistically significant. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.	608178465	Genotype GG is associated with increased risk of edema when treated with muraglitazar in people with Diabetes Mellitus as compared to genotype CC.	18794727	1	muraglitazar	Diabetes Mellitus;Edema;Hyperlipidemias		
655384817	rs5370	EDN1 (PA27614)	3	Toxicity/ADR	655384820; 655384819; 655384818	GG:Patients with the GG genotype and type 2 diabetes who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.; GT:No conclusive results were found for patients with the GT genotype. But patients with the TT genotype and type 2 diabetes who are treated with muarglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.; TT:Patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.	608178470	Genotype GG is associated with decreased risk of edema when treated with muraglitazar in people with Diabetes Mellitus as compared to genotype TT.	18794727	1	muraglitazar	Diabetes Mellitus;Edema;Hyperlipidemias		
655384821	rs2306283	SLCO1B1 (PA134865839)	3	Other	655384824; 655384823; 655384822	AA:Patients with the AA genotype may have higher plasma concentrations of repaglinide in people with no health problems compared to GG genotype. Other genetic and clinical factors may also influence a patient's response.; AG:While the GG genotype is associated with reduced plasma concentrations of repaglinide, no results are shown for the GA genotype.; GG:Patients with the GG genotype may have reduced plasma concentrations of repaglinide and higher blood glucose concentrations after repaglinide intake in people with no health problems compared to AA genotype. Other genetic and clinical factors may also influence a patient's response.	827831546	Genotype GG is associated with decreased repaglinide plasma concentration (AUC) and Cmax when exposed to repaglinide in healthy individuals as compared to genotype AA.	18854776	1	repaglinide		White	
655384830	rs4987161	CYP3A (PA27114),CYP3A4 (PA130)	4	Other	655384831; 655384832; 655384833	AA:In vitro, the construct expressing the wild type allelic protein has average nifedipine metabolism.; AG:Expression study did not included heterozygous genotype.; GG:In vitro, the recombinant CYP3A4*17 allelic protein exhibits significantly decreased catalytic activity for nifedipine oxidation by 98 to 99% compared to wild-type construct at high concentration of nifedipine.	608431726	Allele G is associated with decreased metabolism of nifedipine as compared to allele A.	15634941	1	nifedipine			
655384834	rs11572080	CYP2C8 (PA125)	4	Other	655384837; 655384836; 655384835	CC:Patients with the CC genotype may have increased clearance of paclitaxel as compared to patients with the CT or TT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.; CT:Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.; TT:Patients with the TT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.	608431735; 655388190	Allele T is associated with decreased metabolism of paclitaxel as compared to allele C.; Allele T is not associated with metabolism of paclitaxel in people with Neoplasms as compared to allele C.	11668219; 16299241	2	paclitaxel			
655384838	rs10509681	CYP2C8 (PA125)	4	Other	655384839; 655384840; 655384841	CC:Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.; CT:Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.; TT:Patients with the TT genotype may have increased metabolism of paclitaxel as compared to patients with the CT or CC genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.	608431745	Allele C is associated with decreased metabolism of paclitaxel as compared to allele T.	11668219	1	paclitaxel			
655384842	rs11572080	CYP2C8 (PA125)	3	Toxicity/ADR	655384845; 655384844; 655384843	CC:Patients with the CC genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.; CT:Patients with the CT genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype or may be at increased risk of neurotoxicity when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.; TT:Patients with the TT genotype may be at increased risk of neurotoxicity when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.	608431006	Genotype TT is associated with increased risk of neurotoxicity when treated with paclitaxel in people with Neoplasms as compared to genotype CC.	20212519	1	paclitaxel	Drug Toxicity;Neurotoxicity Syndromes	White	
655384846	rs1045642	ABCB1 (PA267)	3	Toxicity/ADR	655384847; 655384848; 655384849	AA:Patients with the AA genotype and depression who are treated with nortriptyline may have a higher likelihood to develop postural hypotension as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.; AG:Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.; GG:Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.	608178486	Genotype AA is associated with increased likelihood of postural hypotension when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotypes GG + GA.	12082591	1	nortriptyline	Depression;Depressive Disorder;Depressive Disorder, Major;Hypotension		
655384850	rs1045642	ABCB1 (PA267)	3	Other	655384851; 655384852; 655384853	AA:Patients with the AA genotype who are also CYP2C19 extensive metabolizers and are receiving tacrolimus 1) may have increased clearance of (R)-lansoprazole after renal transplantation 2) have a similar likelihood of gastroesophageal complications as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence lansoprazole clearance.; AG:Patients with the AG genotype who are also CYP2C19 extensive metabolizers and are receiving tacrolimus 1) may have decreased clearance of (R)-lansoprazole after renal transplantation 2) have a similar likelihood of gastroesophageal complications as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.; GG:Patients with the GG genotype who are also CYP2C19 extensive metabolizers and are receiving tacrolimus 1) may have decreased clearance of (R)-lansoprazole after renal transplantation 2) have a similar likelihood of gastroesophageal complications as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.	608178490	Allele G is associated with increased metabolism of lansoprazole in people with CYP2C19 extensive metabolizers status after renal transplantation as compared to genotype AA.	17190370	1	lansoprazole;tacrolimus	Gastroesophageal Reflux;Transplantation	Asian	
655384854	rs2740574	CYP3A4 (PA130)	3	Other	655384855; 655384856; 655384857	CC:Patients with the CC genotype and HIV infection may have decreased metabolism of indinavir compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence indinavir metabolism.; CT:Patients with the CT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism.; TT:Patients with the TT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism.	608178494	Genotype CC is associated with decreased metabolism of indinavir in people with HIV as compared to genotypes TT + TC.	19440701	1	indinavir	HIV Infections		
655384862	rs10042486	HTR1A (PA192)	3	Efficacy	655384863; 655384864; 655384865	CC:Patients with the CC genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have a better response to treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.; CT:Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.	608178504	Genotype CC is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes CT + TT.	18484082	1	fluvoxamine;milnacipran;paroxetine	Depressive Disorder, Major	Asian	
655384866	rs909706	DTNBP1 (PA27512)	4	Efficacy	655384869; 655384868; 655384867	CC:Patients with the CC genotype and Schizophrenia may have a reduced response to haloperidol as compared to patients with the CT genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patient's response to haloperidol.; CT:Patients with the CT genotype and Schizophrenia may have a better response to haloperidol as compared to patients with the the CC genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patient's response to haloperidol.; TT:Patients with the TT genotype and Schizophrenia may have a better response to haloperidol as compared to patients with the the CC genotype. Please note, while the CT genotype was associated with suggestively better response to haloperidol in unrelated schizophrenic inpatients, no results were shown for the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.	608178665	Genotype TC is associated with increased response to haloperidol in people with Schizophrenia as compared to genotype CC.	19369910	1	haloperidol	Schizophrenia	Black or African American	
655384878	rs4933824	NRG3 (PA31778)	3	Toxicity/ADR	655384879; 655384880; 655384881	GG:Patients with the GG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence a patient's response.; GT:Patients with the GT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.	608431051	Genotype GG is associated with the highest mean increased QT when treated with iloperidone in people with Schizophrenia as compared to genotypes TT + GT.	18521091	1	iloperidone	Acquired Long QT Syndrome (aLQTS)		
655384882	rs7142881	NUBPL (PA134907818)	3	Toxicity/ADR	655384885; 655384884; 655384883	AA:Patients with the AA genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.; AG:Patients with the AG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.; GG:Patients with the GG genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.	608431055	Genotype GG is associated with the lowest mean increased QT when treated with iloperidone in people with Schizophrenia as compared to genotypes AA + AG.	18521091	1	iloperidone	Acquired Long QT Syndrome (aLQTS)		
655384886	rs4799915	CELF4 (PA25428)	3	Toxicity/ADR	655384889; 655384888; 655384887	CC:Patients with the CC genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.; CT:Patients with the CT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.	608431059	Genotype CC is associated with the lowest mean increased QT when treated with iloperidone in people with Schizophrenia.	18521091	1	iloperidone	Acquired Long QT Syndrome (aLQTS)		
655384890	rs993648	CERKL (PA134984780)	3	Toxicity/ADR	655384893; 655384892; 655384891	CC:Patients with the CC genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.; CT:Patients with the CT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with either the CC or the TT genotype. It is unclear at this time why the heterozygous genotype would confer a different phenotype than either homozygous genotype.; TT:Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.	608431067	Genotype CT is associated with the lowest mean increased QT when treated with iloperidone in people with Schizophrenia as compared to genotype CC.	18521091	1	iloperidone	Acquired Long QT Syndrome (aLQTS)		
655384894	rs10918594	NOS1AP (PA142671259)	4	Toxicity/ADR	655384897; 655384896; 655384895	CC:Patients with the CC genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.; CG:While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype, it was not shown conclusively if heterzygous (GC) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.; GG:Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.	608178672	Genotype GG is associated with increased risk of QTc prolongation when treated with verapamil.	19247217	1	verapamil	Acquired Long QT Syndrome (aLQTS)	White	
655384898	rs10494366	NOS1AP (PA142671259)	3	Toxicity/ADR	655384899; 655384900; 655384901	GG:Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.; GT:While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype, it was not shown conclusively if heterzygous (GT) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.; TT:Patients with the TT genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.	608178676	Genotype GG is associated with increased risk of QTc prolongation when treated with verapamil as compared to genotype TT.	19247217	1	verapamil	Acquired Long QT Syndrome (aLQTS)	White	
655384902	rs762551	CYP1A2 (PA27093)	3	Toxicity/ADR	655384905; 655384904; 655384903	AA:Patients with the AA genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.; AC:Patients with the AC genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.; CC:Patients with the CC genotype and rheumatoid arthritis who are treated with leflunomide may have an increased risk of toxicity as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.	769235406; 608431071	Allele A is not associated with metabolism of leflunomide in people with Arthritis as compared to genotype CC.; Genotype CC is associated with increased risk of toxicity when treated with leflunomide in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.	19581389; 18496682	2	leflunomide	Arthritis, Rheumatoid	White	
655384906	rs3213422	ATP5A1P3 (PA25121),DHODH (PA27327),PKD1L3 (PA134907578)	4	Efficacy	655384909; 655384908; 655384907	AA:Patients with the AA genotype who are treated with leflunomide may be less likely to respond compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.; AC:It is not clear how patients with the AC genotype who are treated with leflunomide respond as compared to patients with the AA or the CC genotype.; CC:Patients with the CC genotype who are treated with leflunomide may be more likely to respond compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.	608431010	Genotype CC is associated with increased frequency of remission when treated with leflunomide in people with Arthritis, Rheumatoid as compared to genotype AA.	19207032	1	leflunomide	Arthritis, Rheumatoid	White	
655384910	rs4646	CYP19A1 (PA27091)	3	Efficacy	655384911; 655384912; 655384913	AA:Patients with the AA genotype who are treated with letrozole may have improved treatment efficacy compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.; AC:Patients with the AC genotype who are treated with letrozole may have improved treatment efficacy compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.; CC:Patients with the CC genotype who are treated with letrozole may have decreased treatment efficacy compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response.	608431153	Allele A is associated with increased treatment efficacy when treated with letrozole in people with Breast Neoplasms as compared to allele C.	18245543	1	letrozole	Breast Neoplasms		
655384914	rs3775291	TLR3 (PA36551)	3	Efficacy	655384915; 655384916; 655384917	CC:Children with the CC genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.; CT:Children with the CT genotype may have a decreased response to measles vaccination as compared to patients with the CC and TT genotype. Other genetic and clinical factors may also influence response to measles vaccination.; TT:Children with the TT genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.	608431157	Genotype TC is associated with decreased response to Measles vaccines as compared to genotype CC.	18325643	1	Measles vaccines		White	
655384918	rs2076369	PICK1 (PA33760)	3	Toxicity/ADR	655384921; 655384920; 655384919	GG:Patients with the GG genotype who are methamphetamine abusers may have a decreased, but not absent, risk for spontaneous relapse of psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for spontaneous relapse of psychosis with methamphetamine abuse.; GT:Patients with this genotype were not studied.; TT:Patients with the TT genotype who are methamphetamine abusers may have an increased risk for spontaneous relapse of psychosis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for spontaneous relapse of psychosis with methamphetamine abuse.	608431161	Allele T is associated with increased likelihood of relapse of psychosis when exposed to methamphetamine.	17606663	1	methamphetamine	Psychotic Disorders;Substance-Related Disorders	Asian	
655384922	rs3213207	DTNBP1 (PA27512)	3	Toxicity/ADR	655384923; 655384924; 655384925	CC:Patients with this genotype were not studied.; CT:Patients with the CT genotype who are exposed to methamphetamine may have an increased risk for psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for psychosis with methamphetamine exposure.; TT:Patients with the TT genotype who are exposed to methamphetamine may have a decreased, but not absent, risk for psychosis as compared to patients with the TC genotype. Other genetic and clinical factors may also influence a patient's risk for psychosis with methamphetamine exposure.	608431166	Allele C is associated with increased risk of psychosis when exposed to methamphetamine.	17555717	1	methamphetamine	Psychotic Disorders	Asian	
655384926	rs2619538	DTNBP1 (PA27512)	4	Toxicity/ADR	655384927; 655384928; 655384929	AA:Patients with the AA genotype may have an increased risk for methamphetamine psychosis compared to patients with the TT genotype. Please note that in the study reporting this association there were no subjects with the AA genotype, but the A allele was found to be associated with increased risk. Please note the associated did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis.; AT:Patients with the AT genotype may have an increased risk for methamphetamine psychosis compared to patients with the TT genotype. Please note this associated did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis.; TT:Patients with the TT genotype may have a decreased risk for methamphetamine psychosis compared to patients with the AT genotype. Please note this association did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis.	608431170	Allele A is associated with increased risk of psychosis when exposed to methamphetamine.	17555717	1	methamphetamine	Psychotic Disorders	Asian	
655384930	rs2115819	ALOX5 (PA46)	3	Efficacy	655384931; 655384932; 655384933	AA:Patients with the AA genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.; AG:Patients with the AG genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.; GG:Patients with the GG genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.	608431175	Genotype GG is associated with increased FEV1 response when treated with montelukast in people with Asthma as compared to genotypes AA + GA.	16293801	1	montelukast	Asthma	White	
655384934	rs2660845	LTA4H (PA24345)	3	Efficacy	655384937; 655384936; 655384935	AA:Patients with the AA genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.; AG:Patients with the AG genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.; GG:Patients with the GG genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.	608431182	Allele G is associated with increased risk of asthma exacerbations when treated with montelukast in people with Asthma as compared to allele A.	16293801	1	montelukast	Asthma	White	
655384938	rs730012	LTC4S (PA235),MGAT4B (PA30783)	3	Efficacy	655384941; 655384940; 655384939	AA:Patients with the AA genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.; AC:Patients with the AC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.; CC:Patients with the CC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. However, this difference was not statistically significant. This may be related to the relatively low frequency of CC homozygotes (11%) in the study. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.	608431188	Allele C is associated with decreased risk of asthma exacerbation when treated with montelukast in people with Asthma as compared to genotype AA.	16293801	1	montelukast	Asthma	White	
655384942	rs5443	GNB3 (PA176)	3	Toxicity/ADR	655384945; 655384944; 655384943	CC:Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.; CT:Patients with the CT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.; TT:Patients with the TT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.	608431206	Allele T is associated with increased risk of weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype CC.	19193342	1	olanzapine	Schizophrenia;Weight gain	Asian	
655384946	rs6313	HTR2A (PA193)	3	Toxicity/ADR	655384947; 655384948; 655384949	AA:Patients with the AA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.; AG:Patients with the GA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.; GG:Patients with the GG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.	608431210	Genotype GG is associated with decreased risk of weight gain when treated with olanzapine in people with Schizophrenia as compared to genotypes AA + GA.	19193342	1	olanzapine	Schizophrenia;Weight gain	Asian	
655384950	rs6313	HTR2A (PA193)	3	Efficacy	655384951; 655384952; 655384953	AA:Patients with the AA genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.; AG:Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.; GG:Patients with the GG genotype and Alzheimer disease may have decreased but not non-existent risk for treatment-resistance to olanzapine or risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.	608431018	Allele A is associated with increased risk of treatment-resistance when treated with olanzapine and risperidone in people with Alzheimer Disease as compared to allele G.	19494443	1	olanzapine;risperidone	Alzheimer Disease	White	
655384954	rs6318	HTR2C (PA194)	4	Toxicity/ADR	655384955; 655384956; 655384957	CC:Patients with the CC genotype and schizophrenia, treated with olanzapine, may have an increased (but not statistically significant) likelihood for tendency of olanzapine-induced weight as compared to patients the genotype GG. Other genetic and clinical factors may also influence a patient's risk for olanzapine-induced weight gain.; CG:Patients with the CG genotype and schizophrenia, treated with olanzapine, may have an increased (but not statistically significant) likelihood for tendency of olanzapine-induced weight as compared to patients the genotype GG. Other genetic and clinical factors may also influence a patient's risk for olanzapine-induced weight gain.; GG:Patients with the GG genotype and schizophrenia, treated with olanzapine, may have decreased (but not statistically significant) likelihood for tendency of olanzapine-induced weight as compared to patients the genotype GG. Other genetic and clinical factors may also influence a patient's risk for olanzapine-induced weight gain.	608431214	Allele C is associated with tendency of olanzapine-induced weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype GG.	19193342	1	olanzapine	Schizophrenia;Weight gain	Asian	
655384958	rs4994	ADRB3 (PA24598)	3	Toxicity/ADR	655384961; 655384960; 655384959	AA:Patients with the AA genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.; AG:Patients with the AG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.; GG:Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.	608431218	Genotype GG is associated with increased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotypes AA + GA.	19193342	1	olanzapine	Schizophrenia;Weight gain	Asian	
655384962	rs6280	DRD3 (PA27479)	3	Efficacy	655384963; 655384964; 655384965	CC:Patients with the CC genotype and schizophrenia who are treated with olanzapine may have greater positive symptom improvement and positive symptom remission as compared to patients with the TT and CT genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.; CT:Patients with the CT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.; TT:Patients with the TT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.	608431224	Genotype CC is associated with greater positive symptom improvement and positive symptom remission when treated with olanzapine in people with Schizophrenia as compared to genotypes TT + CT.	18320559	1	olanzapine	Schizophrenia		
655384966	rs518147	HTR2C (PA194)	2B	Toxicity/ADR	655384968; 655384969; 655384970	CC:Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine treatment.; CG:Patients with the CG genotype and schizophrenia who are treated with olanzapine were not studied.; GG:Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine treatment.	769181734; 769261685	Allele C is associated with decreased risk of >or=10% increase in body mass index when treated with olanzapine in people with Schizophrenia as compared to allele G.; Allele G is associated with increased likelihood of weight gain when treated with clozapine, haloperidol, olanzapine and risperidone in people with Schizophrenia as compared to allele C.	19434072; 21121776	2	olanzapine	Schizophrenia;Weight gain	White	
655384971	rs3813929	HTR2C (PA194)	2B	Toxicity/ADR	655384974; 655384973; 655384972	CC:Patients with the CC genotype and psychiatric disorders or schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.; CT:Patients with the CT genotype and psychiatric disorders or schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.; TT:Patients with the TT genotype and psychiatric disorders or schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.	608431026; 608431038; 608431041; 827811981	Allele T is associated with decreased risk of short-term weight gain when treated with olanzapine in people with psychiatric disorders as compared to allele C.; Allele T is associated with decreased risk of lower incidence of weight gain when treated with olanzapine in people with Schizophrenia as compared to allele C.; Allele T is associated with decreased risk of >or=10% increase in body mass index when treated with olanzapine in people with Schizophrenia as compared to allele C.; Allele T is associated with decreased likelihood of Obesity when treated with antipsychotics as compared to allele C.	19636338; 15666332; 19434072; 21510767	4	olanzapine	Schizophrenia;Weight gain	White	
655384975	rs2842030	RGS4 (PA34375)	3	Efficacy	655384978; 655384977; 655384976	GG:Patients with the GG genotype and schizophrenia may be less likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.; GT:Patients with the GT genotype and schizophrenia may be less likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.; TT:Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.	608431246	Genotype TT is associated with increased response to olanzapine and perphenazine in people with Schizophrenia as compared to genotypes GG + GT.	17588543	1	olanzapine;perphenazine	Schizophrenia	Black or African American	
655384979	rs2842030	RGS4 (PA34375)	4	Efficacy	655384982; 655384981; 655384980	GG:Patients with the GG genotype is associated with better response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response.; GT:Patients with the GT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.	608431255	Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes TT + GT.	17588543	1	risperidone	Schizophrenia	White	
655384983	rs4731426	LEP (PA228)	3	Toxicity/ADR	655384984; 655384985; 655384986	CC:Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.; CG:Patients with the CG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.; GG:Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of extreme weight gain as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.	608431299	Genotype GG is associated with increased risk of extreme weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype CC.	18681781	1	olanzapine	Schizophrenia	Asian	
655384987	rs1123617	SLC14A2 (PA35811)	3	Efficacy	655384988; 655384989; 655384990	AA:Patients with the AA genotype who are treated with nifedipine may have larger changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.; AG:Patients with the GA genotype who are treated with nifedepine may have larger changes in systolic and diastolic blood pressures compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.; GG:Patients with the GG genotype who are treated with nifediping may have smaller changes in systolic and diastolic blood pressure as compared to patients with the GA and AA genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.	608431315; 608431318	Genotype AA is associated with larger mean changes in systolic and diastolic blood pressure when treated with nifedipine as compared to genotype GG.; Genotype GA is associated with larger mean changes in systolic and diastolic blood pressure when treated with nifedipine as compared to genotype GG.	17344938; 17344938	2	nifedipine	Hypertension	Asian	
655384991	rs3745009	SLC14A2 (PA35811)	3	Efficacy	655384992; 655384993; 655384994	AA:Patients with the AA genotype who are treated with nifedipine may have smaller mean changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.; AG:Patients with the GA genotype who are treated with nifedipine may have smaller mean changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.; GG:Patients with the GG genotype who are treated with nifedipine may have larger mean changes in systolic and diastolic blood pressure as compared to patients with the GA and AA genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.	608431322; 608431327	Genotype AA is associated with smaller mean changes in systolic and diastolic blood pressure when treated with nifedipine as compared to genotype GG.; Genotype GA is associated with smaller mean changes in systolic and diastolic blood pressure when treated with nifedipine as compared to genotype GG.	17344938; 17344938	2	nifedipine	Hypertension	Asian	
655384995	rs2284017	CACNG2 (PA26016)	3	Efficacy	655384996; 655384997; 655384998	CC:Patients with the CC genotype and bipolar disorder who are treated with lithium may be more likely to have a reduction in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.; CT:Patients with the CT genotype and bipolar disorder who are treated with lithium may be more likely to have a reduction in symptoms as compared to patients with the TT genotype or may be less likely to have a reduction in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.; TT:Patients with the TT genotype and bipolar disorder who are treated with lithium may be less likely to have a reduction in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.	608431344; 699639151	Allele C is associated with increased response to lithium in people with Bipolar Disorder as compared to allele T.; Genotype CC is associated with increased response to lithium in people with Bipolar Disorder.	18408563; 21047205	2	Lithium	Bipolar Disorder	White	
655385004	rs61750900	UGT2B10 (PA37186)	4		655385007; 655385006; 655385005	GG:The GG genotype is not associated with changes in nicotine metabolism/clearance in human liver microsomes from subjects with GG genotype and HEK293 over expressing UGT2B10.; GT:The GT genotype is significantly associated with a decrease in nicotine metabolism/clearance in human liver microsomes from subjects with GT genotype compared to GG genotype.; TT:The TT genotype is significant associated with a decrease in nicotine metabolism/clearance in human liver microsomes from subjects with TT genotype compared to GG genotype and HEK293 over expressing UGT2B10.	608431753; 769169917	Allele T is associated with decreased metabolism of nicotine as compared to allele G.; Allele T is associated with decreased clearance of nicotine.	17909004; 18300939	2	nicotine			
655385012	rs9923231	VKORC1 (PA133787052)	1A	Dosage	655385015; 655385014; 655385013	CC:Patients with the CC genotype may require an increased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the dose of warfarin.; CT:Patients with the CT genotype may require a lower dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the dose of warfarin.; TT:Patients with the TT genotype may require the lowest dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the dose of warfarin.	608431774; 637879838; 637880237; 637880240; 637880249; 637880256; 827864542; 827864552; 827814719; 827823796; 827826043; 978614455; 827567282; 827567361; 827601694; 827602484; 827603022; 827603306; 827664180; 827783301; 827925119	Allele T is associated with decreased dose of warfarin.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with decreased dose of warfarin.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Genotype TT is associated with decreased dose of phenprocoumon and warfarin as compared to genotype CC.; Genotypes TT + CT are associated with decreased dose of warfarin as compared to genotype CC.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with dose of warfarin.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with decreased transcription of VKORC1.; Allele T is associated with decreased dose of warfarin.; Allele T is associated with decreased expression of VKORC1.; Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.; Genotype TT is associated with decreased dose of warfarin in people with Atrial Fibrillation.; Genotype CT is associated with increased dose of warfarin in people with Thromboembolism as compared to genotype TT.	19794411; 20203262; 19300499; 19300499; 19228618; 18535201; 20833980; 21228733; 21148049; 21110192; 21747589; 22676192; 15883587; 15888487; 18305455; 15888487; 15930419; 15930419; 16580898; 22040439; 22528326	21	warfarin			
655385016	rs10871454	STX4 (PA36236)	3	Dosage	655385019; 655385018; 655385017	CC:Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype.; CT:Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype.; TT:Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype.	608431827	Allele T is associated with decreased dose of warfarin.	18535201	1	warfarin		White	
655385024	rs2359612	PRSS53 (PA165450635),VKORC1 (PA133787052)	3	Dosage	655385025; 655385026; 655385027	AA:Patients with the AA genotype who are treated with warfarin may require the lowest dose as compared to patients with the AG or GG genotype.; AG:Patients with the AG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype.; GG:Patients with the GG genotype who are treated with warfarin may require a higher dose as compared to patients with the AG or AA genotype.	613977249	Allele A is associated with decreased dose of warfarin.	16270629	1	warfarin			
655385028	rs8050894	PRSS53 (PA165450635),VKORC1 (PA133787052)	3	Dosage	655385032; 655385031; 655385030	CC:Patients with the CC genotype who are treated with warfarin may require a higher dose as compared to patients with the CG or GG genotype.; CG:Patients with the CG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype.; GG:Patients with the GG genotype who are treated with warfarin may require the lowest dose as compared to patients with the CG or CC genotype.	769160740	Allele G is associated with decreased dose of warfarin.	16270629	1	warfarin			
655385033	rs1136201	ERBB2 (PA27844)	3	Toxicity/ADR	655385036; 655385035; 655385034	AA:Patients with the AA genotype may have decreased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.; AG:Patients with the AG genotype may have increased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.; GG:Cardiotox was not not found in GG group in this small study. The GG genotype (Val form) is more sensitive to trastuzamab in vitro. There was no link between tumor response or survival and HER2 genotype in clinical study.	613977311	Allele G is associated with response to trastuzumab.	17693647	1	trastuzumab	Breast Neoplasms;Drug Toxicity	White	
655385037	rs6280	DRD3 (PA27479)	3	Efficacy	655385040; 655385039; 655385038	CC:Patients with the CC genotype may have decreased response to pramipexole in Chinese patients with Parkinson's disease compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.; CT:Patients with the CT genotype may have lower response rate to pramipexole in Chinese patients with Parkinson's disease than TT allele carriers. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype may have better therapeutic efficacy (response rate = 60%)of pramipexole in Chinese patients with Parkinson's disease compared to patiens carrying the C allele (response rate =13%). Other genetic and clinical factors may also influence a patient's response.	613977365	Allele T is associated with increased response to pramipexole.	19396436	1	pramipexole	Parkinson Disease	Asian	
655385041	rs2306283	SLCO1B1 (PA134865839)	3	Efficacy	655385044; 655385043; 655385042	AA:Patients with the AA genotype may have increased plasma AUC of pravastatin as compared to patients with the AG or GG genotype.; AG:Patients with the AG genotype may have decreased plasma AUC of pravastatin as compared to patients with the AA genotype.; GG:Patients with the GG genotype may have decreased plasma AUC of pravastatin as compared to patients with the AA genotype.	613977375	Allele G is associated with decreased plasma AUC of pravastatin.	15116054	1	pravastatin		White	
655385045	rs2472677	NR1I2 (PA378)	4	Other	655385049; 655385048; 655385047	CC:Genotype CC is associated with higher CYP3A4 acitvity induced by rifampin compared to genotype CT or TT in liver samples.; CT:Genotype CT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects.; TT:Genotype TT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects.	699638854	Allele T is associated with decreased CYP3A4 acitvity when exposed to rifampin.	17925385	1	rifampin		White	
655385050	rs2661319	RGS4 (PA34375)	3	Efficacy	655385051; 655385052; 655385053	CC:Patients with the CC genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.; CT:Patients with the CT genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the CC genotype or may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.; TT:Patients with the TT genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.	613979204	Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele T.	18204343	1	risperidone	Schizophrenia	Asian	
655385054	rs1800497	ANKK1 (PA134872551)	3	Efficacy	655385055; 655385056; 655385057	AA:Patients with the AA genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.; AG:Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype or may have less improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.; GG:Patients with the GG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.	613979290; 769168986	Allele A is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.; Allele A is not associated with response to antipsychotics in people with Schizophrenia as compared to allele G.	18855532; 20194480	2	risperidone	Schizophrenia	Asian	
655385062	rs2494732	AKT1 (PA24684)	3	Efficacy	655385066; 655385065; 655385064	CC:Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.; CT:Patients with the CT genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.; TT:Patients with the TT genotype and schizophrenia who are treated with risperidone may be more likely to have an improvement in symptoms as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.	699638857	Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT.	18855532	1	risperidone	Schizophrenia	Asian	
655385067	rs3803300	AKT1 (PA24684)	4	Efficacy	655385070; 655385069; 655385071	CC:Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the CT or GG genotype. Please note this did not reach statistical significance. Other genetic and clinical factors may also influence a patient's response to risperidone.; CT:Patients with the CT genotype and schizophrenia who are treated with risperidone may be more likely to have an improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.; TT:Patients with the TT genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.	699638861	Genotype CT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype TT.	18855532	1	risperidone	Schizophrenia	Asian	
655385072	rs165599	COMT (PA117)	3	Efficacy	655385074; 655385075; 655385076	AA:Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.; AG:Patients with the AG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.; GG:Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.	699638917	Allele G is associated with increased response to risperidone in people with Schizophrenia.	19451915	1	risperidone	Schizophrenia		
655385077	rs724226	GRM3 (PA28992)	3	Efficacy	655385079; 655385080; 655385081	AA:Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.; AG:Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.; GG:Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.	699638922	Allele G is associated with increased response to risperidone in people with Schizophrenia.	19451915	1	risperidone	Schizophrenia		
655385082	rs2854117	APOA4 (PA24887),APOC3 (PA53)	3	Toxicity/ADR	655385084; 655385085; 655385086	CC:Patients with the CC genotype and HIV who are treated with ritonavir may have lower triglyceride levels (lower risk of Hypertriglyceridemia) as compared to patients with the TC or TT genotype. Patients with the CC genotype may still be at risk for toxicity when taking ritonavir. Other genetic and clinical factors may also influence a patient's triglyceride levels.; CT:Patients with the TC genotype and HIV who are treated with ritonavir may have higher triglyceride (increased risk of Hypertriglyceridemia) levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype and HIV who are treated with ritonavir may have higher triglyceride levels (increased risk of Hypertriglyceridemia) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	655385847	Allele T is associated with increased risk of Hypertriglyceridemia when treated with ritonavir in people with HIV as compared to allele C.	15809899	1	ritonavir	HIV;HIV Infections;Hyperlipidemias		
655385087	rs2854116	APOA4 (PA24887),APOC3 (PA53)	3	Toxicity/ADR	655385089; 655385090; 655385091	CC:Patients with the CC genotype and HIV who are treated with ritonavir may have decreased severity of triglyceride elevation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.; CT:Patients with the CT genotype and HIV who are treated with ritonavir may have decreased severity of triglyceride elevation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.; TT:Patients with the TT genotype and HIV who are treated with ritonavir may have increased severity of triglyceride elevation as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.	769180706	Genotypes CC + CT are associated with decreased severity of triglyceride elevation when treated with protease inhibitors.	16417409	1	ritonavir	HIV;HIV Infections;Hyperlipidemias		
655385092	rs5128	APOC3 (PA53)	3	Toxicity/ADR	655385096; 655385095; 655385094	CC:Patients with the CC genotype and HIV who are treated with ritonavir may have an increased risk of triglyceride elevation as compared to patients with the CG or GG genotype.; CG:Patients with the CG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation.; GG:Patients with the GG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation.	769180711	Genotypes GG + CG are associated with decreased triglyceride elevation when treated with protease inhibitors.	16417409	1	ritonavir	HIV;HIV Infections;Hyperlipidemias	White	
655385097	rs10192566	LPIN1 (PA30436)	3	Efficacy	655385101; 655385100; 655385099	CC:Patients with the CC genotype and type 2 diabetes who are treated with rosiglitazone may have the smallest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.; CG:Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.; GG:Patients with the GG genotype and type 2 diabetes who are treated with rosiglitazone may have the largest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.	699639130	Allele G is associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to allele C.	18693052	1	rosiglitazone	Diabetes Mellitus, Type 2	Asian	
655385102	rs1042713	ADRB2 (PA39)	3		655385103; 655385104; 655385105	AA:no conclusive result regarding the association between this variant and albuterol response.; AG:no conclusive result regarding the association between this variant and albuterol response.; GG:no conclusive result regarding the association between this variant and albuterol response.	699639135; 769170806; 827828657	Genotype AA is associated with decreased response to salmeterol in people with Asthma as compared to genotype GG.; Genotype GG is associated with increased morning peak expiratory flow rate during treatment with regularly scheduled albuterol compared with placebo when treated with salbutamol in people with Asthma as compared to genotype AA.; Allele A is not associated with differences in improvement in morning peak expiratory flow (PEF) when treated with corticosteroids and salmeterol in people with Asthma as compared to allele G.	16322642; 15500895; 19932356	3	salbutamol	Asthma		
655385110	rs2267715	CRHR2 (PA26875)	3	Efficacy	655385114; 655385113; 655385112	AA:Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. No conclusive results regarding the association between this variant and bronchodilator response.; AG:Patients with the AG genotype may have decreased response to salbutamol in people with Asthma as compare to patients with the AA genotype. However, contradictory finding has been reported. No conclusive results regarding the association between this variant and bronchodilator response.; GG:Patients with the GG genotype may have decreased response to salbutamol in people with Asthma as compare to patients with the AA genotype. However, contradictory finding has been reported. No conclusive results regarding the association between this variant and bronchodilator response.	699639165; 699639154	Allele G is not associated with decreased response to salbutamol in people with Asthma.; Genotype GG is associated with decreased response to salbutamol in people with Asthma.	18408560; 18408560	2	salbutamol;selective beta-2-adrenoreceptor agonists	Asthma	White	
655385115	rs2284220	CRHR2 (PA26875)	3	Efficacy	655385119; 655385118; 655385117	AA:No conclusive results regarding the association between this variant and bronchodilator response.; AG:No conclusive results regarding the association between this variant and bronchodilator response.; GG:No conclusive results regarding the association between this variant and bronchodilator response.	699639185; 699639192	Genotype GG is associated with decreased response to salbutamol in people with Asthma.; Genotype GG is not associated with decreased response to salbutamol in people with Asthma.	18408560; 18408560	2	salbutamol;selective beta-2-adrenoreceptor agonists	Asthma	White	
655385120	rs255100	CRHR2 (PA26875)	3	Efficacy	655385122; 655385123; 655385124	AA:No conclusive results regarding the association between this variant and bronchodilator response.; AT:No conclusive results regarding the association between this variant and bronchodilator response.; TT:No conclusive results regarding the association between this variant and bronchodilator response.	699639201; 699639212	Genotype AA is associated with decreased response to salbutamol in people with Asthma.; Genotype AA is not associated with decreased response to salbutamol in people with Asthma.	18408560; 18408560	2	salbutamol;selective beta-2-adrenoreceptor agonists	Asthma	White	
655385125	rs5443	GNB3 (PA176)	2B	Efficacy	655385128; 655385127; 655385126	CC:Patients with the CC genotype and erectile dysfunction who are treated with sildenafilthan may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.; CT:Patients with the CT genotype and erectile dysfunction who are treated with sildenafilthan may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.; TT:Patients with the TT genotype and erectile dysfunction who are treated with sildenafilthan may be more likely to have positive erectile response as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.	699639234	Genotype TT is associated with increased response to sildenafil in people with Erectile Dysfunction as compared to genotypes CC + CT.	12576843	1	sildenafil	Erectile Dysfunction	White	
655385129	rs3846662	HMGCR (PA189)	4	Other	655385131; 655385132; 655385133	AA:This intronic variant is associated with differential induction, upon simvastatin exposure, of expression of full-length HMGCR transcript versus alternatively spliced transcript lacking exon 13 (HMGCRv_1). In immortalized lymphocytes, A/A homozygotes exhibit 40% greater induction of full-length transcripts and 20% less alternatively spliced HMGCRv_1 transcript relative to A/G or G/G subjects. These differences may have implications for simvastatin efficacy, since increased induction of the alternatively spliced transcript is correlated with reduced percent response to simvastatin.; AG:The AG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript as compared to AA genotype.; GG:The GG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript as compared to AA genotype.	699639387	Genotype AA is associated with decreased HMGCRv_1 expression and an increase in the expression of the full-length transcript as compared to genotypes GG + AG.	18559695	1	simvastatin	Cardiovascular Diseases		
655385134	rs12255372	TCF7L2 (PA36394)	3	Efficacy	655385138; 655385137; 655385136	GG:Patients with the GG genotype and type II diabetes who are treated with sulfonylureas may be more likely to achieve a HbA1c level of <7% as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response.; GT:Patients with the GT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.	699639389	Genotype TT is associated with decreased response to sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	17519421	1	sulfonamides, urea derivatives	Diabetes Mellitus, Type 2	White	
655385139	rs5219	ABCC8 (PA24395),KCNJ11 (PA217)	3	Efficacy	655385141; 655385142; 655385143	CC:Patients with the CC genotype are less likely to respond to repaglinide than patients with the CT or TT genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.; CT:Patients with the CT genotype are more likely to respond to repaglinide than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype are more likely to respond to repaglinide than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.	655385756	Allele T is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	20054294	1	repaglinide	Diabetes Mellitus, Type 2	Asian	
655385144	rs2273697	ABCC2 (PA116)	3		655385146; 655385147; 655385148	AA:People with the AA genotype may have increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol as compared to people with GG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.; AG:People with the AG genotype may have increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol as compared to people with the GG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.; GG:People with the GG genotype may have higher bioavailablilty of orally administered talinolol as compared to people with the AA or AG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.	699639419	Allele A is associated with increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol as compared to allele G.	18334920	1	talinolol		White	
655385149	rs4986938	ESR2 (PA27886)	3	Toxicity/ADR	655385151; 655385152; 655385153	CC:Patients with the CC genotype may have higher tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the TT or CT genotype. Other genetic and clinical factors may influence the response to tamoxifen.; CT:Patients with the CT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.; TT:Patients with the TT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.	699639424	Genotype CC is associated with tamoxifen-induced increase in triglycerides in postmenopausal woman..	17713466	1	tamoxifen			
655385154	rs9340799	ESR1 (PA156)	3	Toxicity/ADR	655385158; 655385157; 655385156	AA:The AA genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and tamoxifen-induced decrease in triglycerides and increase in high density lipoprotein in premenopausal women compared to GG genotype carriers; AG:The AG genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and intermediate tamoxifen-induced increase in triglycerides and decrease in high density lipoprotein in premenopausal women compared to GG genotype carriers.; GG:The GG genotype carriers had larger tamoxifen-induced decrease in total cholesterol in postmenopausal woman compared to GA/AA genotypes (P=0.03; GG vs GA/AA) and tamoxifen-induced increase in triglycerides (P=0.002; gene-dose effect) and decrease in high density lipoprotein (P=0.004; gene-dose effect) in premenopausal women.	699639427	Genotype GG is associated with tamoxifen-induced decrease in total cholesterol in postmenopausal woman (P=0.03; GG vs GA/AA) and tamoxifen-induced increase in triglycerides (P=0.002; gene-dose effect) and decrease in high density lipoprotein (P=0.004; gene-dose effect) in premenopausal women..	17713466	1	tamoxifen			
655385159	rs1751034	ABCC4 (PA397)	2B		655385161; 655385162; 655385163	CC:The CC genotype carriers had lower tenofovir renal clearance, and higher AUC than TT genotype.; CT:The TC genotype carriers had lower tenofovir renal clearance, and higher AUC than TT genotype.; TT:The TT genotype is associated with higher tenofovir renal clearance, and lower AUC compared to TC and CC cariers.	699642168; 699642165	Genotype C is associated with increased intracellular tenofovir diphosphate (TFV-DP) concentrations in people with HIV.; Allele TT is associated with increased tenofovir renal clearance, and lower AUC as compared to genotypes CC + CT.	18398970; 17597712	2	tenofovir	HIV;HIV Infections	White	
655385164	rs1138272	GSTP1 (PA29028)	3		655385167; 655385166; 655385165	CC:Patients with the CC genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype.; CT:Patients with the CT genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype.; TT:Patients with the TT genotype may have increased clearance of thiotepa as compared to patients with the CT or TT genotype.	699642171	Allele T is associated with increased non-inducible thiotepa clearance by 52% [95% confidence interval (CI) 41, 64, P < 0.001] and decreased tepa clearance by 32% (95% CI 29, 35, P < 0.001).	19076156	1	thiotepa	Neoplasms	White	
655385168	rs1487278	TPH2 (PA128747823)	3	Efficacy	655385172; 655385171; 655385170	CC:Patients with the CC genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant. (The frequency for CC allele is very low, homozygous minor allele carriers were pooled together with the heterozygous samples and compared with the homozygous major allele (T) carrier.); CT:Patients with the CT genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant.; TT:Patients with the TT genotype may be less likely to respond to antidepressant treatments as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant.	699642174	Allele C is associated with increased response to mirtazapine and venlafaxine in people with Depression as compared to genotype TT.	18496129	1	mirtazapine;venlafaxine	Depression	White	
655385178	rs119774	ABCC1 (PA244)	3	Efficacy	655385181; 655385180; 655385182	CC:Patients with the CC genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.; CT:Patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.; TT:Patients with the TT genotype were not studied. But patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.	699642198	Genotype CT is associated with higher percentagechanges in % predicted FEV1 change when treated with montelukast in people with Asthma as compared to genotype CC.	16293801	1	montelukast	Asthma	White	
655385195	rs12422149	SLCO2B1 (PA35845)	3	Efficacy	655385197; 655385198; 655385199	AA:No AA genotype carrier was found in the study. But patients with the AG genotype and Asthma treated with montelukast may have significantly reduced plasma concentration of montelukast and poorer response to montelukast compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.; AG:Patients with the AG genotype and Asthma treated with montelukast may have significantly reduced plasma concentration of montelukast and poorer response to montelukast compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.; GG:Patients with the GG genotype and Asthma treated with montelukast may have higher plasma concentration of montelukast and better response to montelukast compared to patients with the GA genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.	699642204	Genotype AG is associated with decreased response to montelukast in people with Asthma as compared to genotype GG.	19151602	1	montelukast	Asthma		
655385200	rs1799971	OPRM1 (PA31945)	2B	Dosage;Efficacy	655385204; 655385203; 655385202	AA:Patients with the AA genotype who are treated with morphine: 1) may require a lower dose as compared to patients with the AG or GG genotype 2) may be more likely to have an increased pain relief as compared to patients with the AG or GG genotype and neoplasms. Other genetic and clinical factors may also influence a patient's response when treated with morphine.; AG:Patients with the AG genotype who are treated with morphine: 1) may require a higher dose as compared to patients with the AA genotype 2) may be less likely to have an increased pain relief as compared to patients the AA genotype and neoplasms. Other genetic and clinical factors may also influence a patient's response when treated with morphine.; GG:Patients with the GG genotype who are treated with morphine: 1) may require the highest dose as compared to patients with the AG and AA genotype 2) may be less likely to have an increased pain relief as compared to patients the AA genotype and neoplasms. Other genetic and clinical factors may also influence a patient's response when treated with morphine.	731462495; 827807525	Genotypes GG + AG are associated with increased dose of morphine as compared to genotype AA.; Genotype AA is associated with increased reduction in pain when treated with morphine in people with Neoplasms as compared to genotypes AG + GG.	17156920; 17898703	2	morphine	Pain	White	
655385205	rs4680	COMT (PA117)	3	Dosage	655385209; 655385208; 655385207	AA:Patients with the AA genotype who are treated with morphine may require the lowest dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response when treated with morphine.; AG:Patients with the AG genotype who are treated with morphine may require a higher dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with morphine.; GG:Patients with the GG genotype who are treated with morphine may require the highest dose as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with morphine.	731493498	Genotypes GG + AG are associated with increased dose of morphine as compared to genotype AA.	17156920	1	morphine	Pain	White	
655385210	rs2368564	REN (PA297)	3	Toxicity/ADR	655385214; 655385213; 655385212	CC:Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.; CT:No conclusive results were found for patients with the CT genotype. But patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.; TT:Patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.	731577503	Genotype TT is associated with decreased risk of edema when treated with muraglitazar in people with Diabetes Mellitus as compared to genotype CC.	18794727	1	muraglitazar	Diabetes Mellitus;Edema;Hyperlipidemias		
655385223	rs2278293	IMPDH1 (PA29862)	3	Toxicity/ADR	655385227; 655385226; 655385225	CC:Patients with the CC genotype may have an increased risk for acute rejection after kidney transplantation as compared to patients with the CT or TT genotypes but the CC genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.; CT:Patients with the CT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype but the CT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.; TT:Patients with the TT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype but the TT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.	769262708; 731672567	Allele T is not associated with increased risk of adverse drug reactions and risk of biopsy-proven acute rejection when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.; Genotypes TT + CT are associated with decreased risk of biopsy-proven acute rejection when treated with mycophenolate mofetil in people with Transplantation as compared to genotype CC.	21142914; 17851563	2	mycophenolate mofetil			
655385241	rs1799971	OPRM1 (PA31945)	2B	Efficacy	655385244; 655385243; 655385242	AA:Patients with the AA genotype who are treated with naloxone may have lower cortisol response as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence the response to naloxone.; AG:Patients with the AG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype.; GG:Patients with the GG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to naloxone.	747714537; 747435525; 747661534	Allele G is associated with increased cortisol response when treated with naloxone as compared to genotype AA.; Genotypes GG + AG are associated with increased cortisol response when treated with naloxone as compared to genotype AA.; Genotypes GG + AG are associated with increased peak cortisol response when treated with naloxone as compared to genotype AA.	11751037; 18004207; 12627468	3	naloxone			
655385253	rs4149056	SLCO1B1 (PA134865839)	4		655385254; 655385255; 655385256	CC:This genotype has no significant effect on the PK or PD of nateglinide.; CT:This genotype has no significant effect on the PK or PD of nateglinide.; TT:This genotype has no significant effect on the PK or PD of nateglinide.	747884257	Allele C is not associated with PK of nateglinide as compared to genotype TT.	18187595	1	nateglinide		White	
655385257	rs28364006	ABCC1 (PA244)	3	Efficacy	655385261; 655385260; 655385259	AA:Patients with the AA genotype were not studied, and so conclusions cannot be made in regard to response to methotrexate. However, patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; AG:Patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; GG:Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.	747926545	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG.	18256692	1	methotrexate	Psoriasis		
655385262	rs2238476	ABCC1 (PA244)	3	Efficacy;Toxicity/ADR	655385266; 655385265; 655385264	AA:Patients with the AA genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.; AG:Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.; GG:Patients with the GG genotype and psoriasis who are treated with methotrexate: 1) may be more likely to have a reduction in psoriasis area or disease severity 2) may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.	747943548; 748020560	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to allele A.; Genotype GG is associated with increased risk of toxicity when treated with methotrexate in people with Psoriasis as compared to genotypes AA + AG.	18256692; 18256692	2	methotrexate	Psoriasis		
655385267	rs35592	ABCC1 (PA244)	3	Efficacy	655385271; 655385270; 655385269	CC:Patients with the CC genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; CT:Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; TT:Patients with the TT genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.	747980551	Genotype TT is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CC + CT.	18256692	1	methotrexate	Psoriasis		
655385272	rs17731538	ABCG2 (PA390)	3	Efficacy	655385276; 655385275; 655385274	AA:Patients with the AA genotype were not studied. However, patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; AG:Patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; GG:Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area or severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.	747991835	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG.	18256692	1	methotrexate	Psoriasis		
655385277	rs246240	ABCC1 (PA244)	3	Toxicity/ADR	655385279; 655385280; 655385281	AA:Patients with the AA genotype and psoriasis who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.; AG:Patients with the AG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.; GG:Patients with the GG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.	748006197	Genotypes GG + AG are associated with decreased risk of onset of  toxicity when treated with methotrexate in people with Psoriasis as compared to genotype AA.	18256692	1	methotrexate	Drug Toxicity;Psoriasis		
655385286	rs13120400	ABCG2 (PA390)	3	Efficacy	655385288; 655385289; 655385290	CC:Patients with the CC genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; CT:Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; TT:Patients with the TT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.	748042563	Genotype CC is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes TT + CT.	18256692	1	methotrexate	Psoriasis		
655385295	rs1801253	ADRB1 (PA38)	3	Efficacy	655385296; 655385297; 655385298	CC:Patients with the CC (Arg389) genotype may have a stronger DBP response to metoprolol with a significantly greater reduction in 24-hour and daytime DBP than was found in carriers of a G(Gly389) allele. Other genetic and clinical factors may also influence the patient's response to metoprolol.; CG:Patients with the CG genotype may have weaker response to metoprolol compared to CC genotype carriers. Other genetic and clinical factors may also influence the patient's response to metoprolol.; GG:Patients with the GG genotype may have weaker response to metoprolol compared to CC genotype carriers. Other genetic and clinical factors may also influence the patient's response to metoprolol.	748396572	Allele C is associated with increased response to metoprolol in people with Hypertension as compared to allele G.	12844134	1	metoprolol	Hypertension		
655385299	rs2372536	ATIC (PA25094)	3	Efficacy	655385302; 655385301; 655385300	CC:Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have symptom improvement as compared to patients with the GG genotype.; CG:Patients with the CG genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have symptom improvement as compared to patients with the GG genotype.; GG:Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have symptom improvement as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.	769160719	Genotype GG is associated with decreased disease activity as assessed by the physician when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.	15457444	1	methotrexate	Arthritis, Rheumatoid		
655385303	rs1801133	MTHFR (PA245)	3	Toxicity/ADR	655385304; 655385305; 655385306	AA:Patients with the AA genotype were not studied. However, patients with the AG genotype and Rheumatoid Arthritis may be more at risk of alopecia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of alopecia.; AG:Patients with the AG genotype and Rheumatoid Arthritis may be more at risk of alopecia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of alopecia.; GG:Patients with the GG genotype and Rheumatoid Arthritis may be less less at risk of alopecia when treated with methotrexate as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk of alopecia.	748441277	Genotype AG is associated with increased risk of Alopecia when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	18381794	1	methotrexate	Alopecia;Arthritis, Rheumatoid;Drug Toxicity	Black or African American	
655385307	rs1801133	MTHFR (PA245)	3	Toxicity/ADR	655385308; 655385309; 655385310	AA:Patients with the AA genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.; AG:Patients with the AG genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse events as compared to patients with the AA genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.; GG:Patients with the GG genotype and Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of adverse events and toxicity as compared to patients with the AA genotype (though this association has not been found in all studies). There does not seem to be an association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.	827829138; 608431516; 751539632; 769170688; 769170776; 769171242; 769173669; 769170642; 769170659; 769171291; 748441277; 827774210; 827774221	Genotype AA is associated with increased risk of hepatotoxicity and hematological toxicity when treated with methotrexate as compared to genotype GG.; Allele A is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.; Allele A is associated with increased risk of methotrexate treatment discontinuation due to adverse events , mostly as a result of increased risk of elevated levels of liver enzyme alanine aminotransferase in people with Arthritis, Rheumatoid as compared to genotype GG.; Allele A is not associated with toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.; Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.; Allele A is not associated with response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid.; Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.; Genotype AA is associated with increased risk of Toxic liver disease when treated with in people with Arthritis, Psoriatic as compared to genotypes GG + AG.; Genotype AA is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Juvenile Rheumatoid as compared to genotype GG.; Genotype AA is associated with increased red blood cell folate when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.; Genotype AG is associated with increased risk of Alopecia when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.; Allele A is not associated with efficacy when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.; Allele A is not associated with Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	22143415; 20863444; 11710708; 20514079; 19827168; 18322994; 19193698; 20472929; 20595278; 20386493; 18381794; 21931346; 21931346	13	methotrexate	Arthritis, Juvenile Rheumatoid;Arthritis, Psoriatic;Arthritis, Rheumatoid;Drug Toxicity		
655385311	rs1801133	MTHFR (PA245)	3	Toxicity/ADR	655385312; 655385313; 655385314	AA:Patients with the AA genotype and non-Hodgkin lymphoma who are treated with methotrexate may have an increased risk of mucositis, thrombocytopenia and hepatic toxicity as compared to patients with the GG genotype. This association was not found in pediatric patients with non-Hodgkin lymphoma who were treated with methotrexate. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity.; AG:Patients with the AG genotype and non-Hodgkin lymphoma who are treated with methotrexate may have a decreased, but not absent, risk of mucositis, thrombocytopenia and hepatic toxicity as compared to patients with the AA genotype. This association was not found in pediatric patients with non-Hodgkin lymphoma who were treated with methotrexate. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity.; GG:Patients with the GG genotype and non-Hodgkin lymphoma who are treated with methotrexate may have a decreased, but not absent, risk of mucositis, thrombocytopenia and hepatic toxicity as compared to patients with the AA genotype. This association was not found in pediatric patients with non-Hodgkin lymphoma who were treated with methotrexate. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity.	827829042; 827829138; 769170766; 637879722; 637879736; 637879739	Genotype AA is associated with increased risk of overall toxicity (measured as more than two adverse effects) when treated with as compared to genotype GG.; Genotype AA is associated with increased risk of hepatotoxicity and hematological toxicity when treated with methotrexate as compared to genotype GG.; Allele A is not associated with response to methotrexate in people with Lymphoma, Non-Hodgkin as compared to allele G.; Genotype AA is associated with increased risk of severe mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes GG + GA.; Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes GG + GA.; Genotype AA is associated with increased risk of Thrombocytopenia when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes GG + GA.	22143415; 22143415; 16463153; 17488658; 17488658; 17488658	6	methotrexate	Drug Toxicity;Lymphoma, Non-Hodgkin;Thrombocytopenia;Toxic liver disease	White	
655385315	rs1801133	MTHFR (PA245)	1B	Toxicity/ADR	655385316; 655385317; 655385318	AA:Patients with the AA genotype with Leukemia or Lymphoma who are treated with methotrexate regimens may have an increased risk and increased severity of mucositis, as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's risk of oral mucositis.; AG:Patients with the AG genotype with Leukemia or Lymphoma who are treated with methotrexate regimens may have a decreased risk and decreased severity of mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of oral mucositis.; GG:Patients with the GG genotype with Leukemia or Lymphoma who are treated with methotrexate regimens may have a decreased risk and decreased severity of mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of oral mucositis.	637879722; 637879773; 769146371; 769146398	Genotype AA is associated with increased risk of severe mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes GG + GA.; Genotype AA is associated with increased risk of oral mucositis when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes GG + GA.; Genotype AA is associated with increased severity of oral mucositis when treated with methotrexate in people with hematopoietic-cell-transplantation as compared to genotype GG.; Genotype AA is associated with increased risk of oral mucositis when treated with busulfan, cyclophosphamide and methotrexate in people with hematopoietic cell transplants for chronic myelogenous leukemia as compared to genotype GG.	17488658; 11418485; 16501586; 15051775	4	methotrexate	Drug Toxicity;Leukemia;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Transplantation		
655385323	rs45445694	C18orf56 (PA134956204),TYMS (PA359)	3	Efficacy	655385325; 655385326; 655385327	(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2:Patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 may have increased response to methotrexate in people with Rheumatoid Arthritis as compared to patients who were carriers of the a third 28-bp repeat (for TSER*3/*3,TSER*2/*3). Other genetic and clinical factors may also influence a patient's response to methotrexate.; (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3:Patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2. Other genetic and clinical factors may also influence a patient's response to methotrexate.; (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3:Patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2. Other genetic and clinical factors may also influence a patient's response to methotrexate.	769181620	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype 3.	15457444	1	methotrexate	Arthritis, Rheumatoid		
655385328	rs9345389		3	Toxicity/ADR	655385332; 655385331; 655385330	AA:Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of end-of-induction minimal residual disease (MRD).; AG:Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.; GG:Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.	751755636	Allele G is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance. as compared to allele A.	19176441	1	methotrexate	Neoplasm, Residual;Precursor Cell Lymphoblastic Leukemia-Lymphoma		
655385333	rs4888024		3	Toxicity/ADR	655385337; 655385336; 655385335	AA:Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for MRD.; AG:Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.; GG:Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.	751776639	Allele G is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance..	19176441	1	methotrexate	Neoplasm, Residual;Precursor Cell Lymphoblastic Leukemia-Lymphoma		
655385338	rs5030655	CYP2D6 (PA128)	3	Efficacy	655385339; 655385340; 655385341	A/del:Patients with the A/del genotype who are treated with metoprolol may have average reponse to metoprolol (check other variants for PM phenotype) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.; AA:Patients with the AA genotype who are treated with metoprolol may have average reponse to metoprolol (check other variants for PM phenotype) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.; del/del:Patients with the del/del genotype who are treated with metoprolol may have an greater reduction in heart rate, diastolic blood pressure, and mean arterial pressure as compared to patients with the A/del or A/A genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.	751884916; 751923645	Genotype DELDEL is associated with increased response to metoprolol.; Genotype DELDEL is associated with higher plasma concentrations of metoprolol.	19037197; 19037197	2	metoprolol		White	
655385352	rs3892097	CYP2D6 (PA128)	3	Efficacy	655385355; 655385354; 655385353	CC:Patients with CC genotype may have lower plasma concentrations of metoprolol and have smaller reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.; CT:Patients with CT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.; TT:Patients with TT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.	769181593	Allele T is associated with increased higher plasma concentrations of metoprolol and greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs. of metoprolol as compared to allele C.	19037197	1	metoprolol		White	
655385361	rs1044396	CHRNA4 (PA26490)	3	Other	655385362; 655385363; 655385364	AA:The AA genotype was found less often in smokers as compared to the GG genotype but the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.; AG:The AG genotype was found more often in smokers as compared to the AA genotype (smoker OR = 1.13) but the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.; GG:The GG genotype was found more often in smokers as compared to the AA genotype (smoker OR = 1.28) but the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.	613977160	Allele G is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A.	19290018	1	nicotine	Tobacco Use Disorder	White	
655385369	rs1367117	APOB (PA50)	3	Efficacy	655385371; 655385372; 655385373	AA:Patients with the AA genotype who are treated with irbesartan may be less likely to respond than patients with the AG or the GG genotype. Other genetic and clinical factors may also influence a patient's response.; AG:Patients with the AG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.; GG:Patients with the GG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.	655387073; 655387074	Genotype AG is associated with response to irbesartan in people with Hypertension.; Genotype GG is associated with response to irbesartan in people with Hypertension.	15453913; 15453913	2	irbesartan	Hypertension	White	
981238348	rs1979277	SHMT1 (PA35753)	3	Other	981481611; 981481612; 981481613	AA:Patients with the AA genotype and with Rheumatoid Arthritis who are treated with methotrexate may have increased red blood cell folate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; AG:Patients with the AG genotype and with Rheumatoid Arthritis who are treated with methotrexate may have increased red blood cell folate as compared to patients with the GG genotype or may have decreased red blood cell folate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; GG:Patients with the GG genotype and with Rheumatoid Arthritis who are treated with methotrexate may have decreased red blood cell folate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.	769171254; 769171300; 827863356	Allele A is not associated with response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid.; Genotype AA is associated with increased red blood cell folate when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.; Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid.	18322994; 20386493; 22450926	3	methotrexate	Arthritis, Rheumatoid	White	
981238459	rs1057910	CYP2C9 (PA126)	3	Efficacy	981238460; 981238461; 981238462	AA:Subjects with the AA genotype who are treated with losartan may have increased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.; AC:Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.; CC:Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.	769169612; 769169634	Allele C is associated with decreased clearance of losartan.; Allele C is associated with decreased metabolism of losartan in people with no disease as compared to allele A.	11408373; 11823761	2	losartan		White	
981237695	rs17222723	ABCC2 (PA116)	3	Toxicity/ADR	981237696; 981237697; 981237698	AA:Patients with the AA genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.; AT:Patients with the AT genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.; TT:Patients with the TT genotype and HIV who are treated with tenofovir may have an increased risk of renal proximal tubulopathy as compared to patients with the AT and AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.	827828664; 827828804	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV as compared to allele T.; Allele A is associated with decreased risk of renal proximal tubulopathy due to tenofovir in people with HIV as compared to allele T.	19400747; 17083032	2	tenofovir	HIV		
981344897	rs4149056	SLCO1B1 (PA134865839)	2A	Toxicity/ADR	981344898; 981344899; 981344900	CC:Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.; CT:Patients with the CT genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.; TT:Patients with the TT genotype may have a lower risk of cerivastatin-related rhabdomyolysis as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.	769180358	Genotype CC is associated with a four-fold higher risk of rhabdomyolysis when treated with cerivastatin as compared to genotype TT.	21386754	1	cerivastatin	Rhabdomyolysis		
981237922	rs1128503	ABCB1 (PA267)	3	Other	981237923; 981237924; 981237925	AA:Patients with the AA genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.; AG:Patients with the AG genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.; GG:Patients with the GG genotype who receive phenytoin may have decreased plasma drug levels of phenytoin as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.	769250001	Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG.	16220110	1	phenytoin		Black or African American	
981238471	rs1057910	CYP2C9 (PA126)	3	Toxicity/ADR	981238472; 981238473; 981238474	AA:Patients with the AA genotype and with Epilepsy who are treated with valproic acid may have decreased mean plasma drug concentrations of valproic acid as compared to patients with the AC genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.; AC:Patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.; CC:Patients with the CC genotype were not studied. However, patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.	827691648; 827691666	Genotype AC is associated with increased mean plasma drug concentrations of valproic acid in people with Epilepsy as compared to genotype AA.; Allele C is associated with decreased enzyme activity of CYP2C9 when assayed with valproic acid in human liver microsomes.	20089352; 14597963	2	valproic acid	Epilepsy	Asian	
981237950	rs1695	GSTP1 (PA29028)	3	Efficacy	981237951; 981237952; 981237953	AA:Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.; AG:Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.; GG:Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.	655386344; 827824994	Genotype AA is associated with increased progression free survival when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes GG + AG.; Genotype AA is not associated with increased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes AG + GG.	19786980; 22188361	2	cisplatin;cyclophosphamide	Ovarian Neoplasms		
981204890	rs1800497	ANKK1 (PA134872551)	2B	Toxicity/ADR	981204891; 981204892; 981204893	AA:Patients with AA genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.; AG:Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.; GG:Patients with GG genotype may have a decreased, but not absent, risk for Alcoholism when exposed to ethanol as compared to patients with the AG and AA genotype. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.	769173001; 769173005	Allele A is associated with increased risk of Alcoholism when exposed to ethanol.; Allele A is associated with increased risk of Alcoholism when exposed to ethanol.	1969501; 17989061	2	ethanol	Alcoholism		
981352141	rs1050828	G6PD (PA28469)	1B	Toxicity/ADR	981481621; 981481622; 981481623	CC:Patients with the CC genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have 1) a decreased, but not absent, risk of hemolysis and severe/ unsafe hemoglobin decreases 2) decreased, but not absent, risk of requiring a blood transfusion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone.; CT:Patients with the CT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have an increased risk of requiring a blood transfusion as compared to patients with the CC genotype. This association was contradicted in another study showing no association of the CT genotype with increased risk of unsafe hemoglobin decreases or requirement for a blood transfusion when treated with artesunate, chlorproguanil and dapsone compared to to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone.; TT:Patients with the TT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have 1) an increased risk of hemolysis and severe/ unsafe hemoglobin decreases 2) an increased risk of requiring a blood transfusion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone.	769176539; 769165047; 769176533	Genotype CT is not associated with increased risk of unsafe hemoglobin decreases or requirement for a blood transfusion when treated with artesunate, chlorproguanil and dapsone in children with Malaria.; Genotypes CT + TT are associated with increased risk of requiring a blood transfusion when treated with artesunate, chlorproguanil and dapsone in children with Malaria as compared to genotype CC.; Genotype TT is associated with increased risk of severe/ unsafe hemoglobin decreases when treated with artesunate, chlorproguanil and dapsone in people with Malaria as compared to genotype CC.	19690618; 19112496; 19690618	3	chlorproguanil;dapsone	Malaria	Black or African American	
655384786	rs11188072	CYP2C19 (PA124)	2A	Dosage	655384789; 655384788; 655384787	CC:Adult patients, but not pediatric patients, with the CC genotype who are treated with omeprazole may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration. This might not be applicable to pediatric patients.; CT:Patients with this genotype were not studied.; TT:Adult patients, but not pediatric patients, with the TT genotype who are treated with omeprazole may require an increased dose as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration. This might not be applicable to pediatric patients.	605077264; 655387709; 655387711; 655387738	Allele T is not associated with increased metabolism of omeprazole as compared to allele C.; Allele T is associated with CYP2C19*17.; Genotype TT is associated with increased metabolism of omeprazole in people with no disease as compared to genotype CC.; Genotype TT is associated with decreased AUC of omeprazole in people with no disease as compared to genotype CC.	20223877; 16413245; 16413245; 18294333	4	omeprazole		White	
827847725	rs9981861	DSCAM (PA27491)	3	Efficacy	827847726; 827847727; 827847728	CC:Patients with the CC genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.; CT:Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.; TT:Patients with the TT genotype may have decreased survival when treated with carboplatin and paclitaxel as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence survival.	827827855	Genotype TT is associated with decreased survival when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.	21079520	1	carboplatin;paclitaxel	Carcinoma, Non-Small-Cell Lung;Neoplasms	Asian	
655387749	rs11188072	CYP2C19 (PA124)	3	Dosage	655387750; 655387751; 655387752	CC:Patients with the CC genotype who are treated with pantoprazole may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration; CT:Patients with the CT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; TT:Patients with the TT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.	604828714; 655387709	Allele T is associated with increased metabolism of pantoprazole.; Allele T is associated with CYP2C19*17.	20223877; 16413245	2	pantoprazole			
827830327	rs1127354	DDRGK1 (PA164718734),ITPA (PA29973)	3	Efficacy	827830328; 827830329; 827830330	AA:Patients with the AA genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.; AC:Patients with the AC genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.; CC:Patients with the CC genotype may experience a greater response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the AA or AC genotype. Patients with the CC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.	827784888	Genotype AC is associated with increased likelihood of non-response when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype CC.	21961091	1	azathioprine	Inflammatory Bowel Diseases		
827831435	rs2032582	ABCB1 (PA267)	3	Dosage	827831436; 827831437; 827831438	AA:Patients with the AA genotype may have higher blood trough concentrations of cyclosporine compared to patients with the CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.; AC:Patients with the AC genotype may have higher blood trough concentrations of cyclosporine compared to patients with the CC genotype, or may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.; CC:Patients with the CC genotype may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.	655388177; 827814005	Genotype AA is associated with increased trough blood concentration of cyclosporine in people with Myasthenia Gravis as compared to genotype CC.; Genotype AT is not associated with dose of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele C.	18717915; 21806386	2	cyclosporine		Asian	
827832280	rs1801253	ADRB1 (PA38)	3	Efficacy	827832281; 827832282; 827832283	CC:Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents.; CG:Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents.; GG:Patients with the GG genotype may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents.	613979015; 748396572; 827567343; 827567370; 827603889; 827782095; 827808186; 827816261; 827863984; 827863996; 827864008; 827864029	Allele C is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to allele G.; Allele C is associated with increased response to metoprolol in people with Hypertension as compared to allele G.; Genotype CC is associated with increased response to metoprolol in healthy individuals as compared to genotype GG.; Allele C is not associated with increased response to metoprolol in people with Heart Failure as compared to allele G.; Genotypes GG + CG are associated with increased likelihood of requiring more heart failure medication when treated with metoprolol in people with Heart Failure as compared to genotype CC.; Genotype CC is associated with increased reduction in blood pressure when treated with atenolol in healthy individuals as compared to genotype GG.; Allele G is not associated with the reduction in systolic blood pressure, diastolic blood pressure, pulse pressure, mean arterial pressure, or heart rate, or treatment differences between losartan and atenolol on these endpoints or risk of the primary composite endpoint or its components stroke, myocardial infarction, and cardiovascular death, or treatment differences between losartan and atenolol on these endpoints when treated with atenolol or losartan as compared to allele C.; Genotypes CG + GG are associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype CC.; Genotype CC is associated with increased response when treated with bucindolol in people with Heart Failure.; Genotype CC is associated with greater increase in LVEF (left ventricular ejection fraction), and a larger improvement in left ventricular(LV) remodeling when treated with Beta Blocking Agents and metoprolol in people with Heart Failure as compared to genotypes CG + GG.; Genotype CC is associated with significantly greater improvement in left ventricular ejection fraction (LVEF) when treated with Beta Blocking Agents and carvedilol in people with Heart Failure as compared to genotypes CG + GG.; Genotype CC is associated with greater improvement in left ventricular function (LVEF) when treated with carvedilol in people with Heart Failure as compared to genotype GG.	15861037; 12844134; 14534524; 12921807; 15735607; 12709726; 20065889; 22192668; 16844790; 15864115; 18075464; 14502278	12	atenolol;Beta Blocking Agents;bucindolol;carvedilol;metoprolol			
827836551	rs20417	PTGS2 (PA293)	3	Efficacy	827836552; 827836553; 827836554	CC:Patients with the CC genotype may have decreased pain relief to ibuprofen as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.; CG:Patients with the CG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.; GG:Patients with the GG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.	699638654	Genotypes GG + CG are associated with increased pain relief when treated with ibuprofen as compared to genotype CC.	16678543	1	ibuprofen			
827831123	rs712829	EGFR (PA7360)	3	Toxicity/ADR	827831124; 827831125; 827831126	GG:Patients with the GG genotype and cancer who are treated with erlotinib may have increased severity of Diarrhea compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.; GT:Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.; TT:Patients with the TT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.	827807448	Genotype GG is associated with increased severity of Diarrhea when treated with erlotinib in people with Neoplasms as compared to genotypes GT + TT.	18309947	1	erlotinib	Neoplasms		
827832264	rs1801252	ADRB1 (PA38)	4	Efficacy	827832265; 827832266; 827832267	AA:Patients with the AA genotype who are also carriers of rs1801253 allele C who have Coronary Artery Disease may have an increased risk for death when treated with verapamil as compared to patients with the GG genotype or rs1801253 G allele. Other genetic and clinical factors may also influence risk of death.; AG:Patients with the AG genotype who are also carriers of rs1801253 allele C who have Coronary Artery Disease may have an increased risk for death when treated with verapamil as compared to patients with the GG genotype or rs1801253 G allele. Other genetic and clinical factors may also influence risk of death.; GG:Patients with the GG genotype who have Coronary Artery Disease may have a decreased risk for death when treated with verapamil as compared to patients with the AA or AG genotype and the rs1801253 allele C. Other genetic and clinical factors may also influence risk of death.	655387953	Genotypes AA + AG are associated with increased risk of Death when treated with verapamil in people with Coronary Artery Disease as compared to genotype GG.	18615004	1	verapamil	Coronary Artery Disease;Death		
827831021	rs532545	CDA (PA98)	4	Toxicity/ADR	827831022; 827831023; 827831024	CC:Patients with the CC genotype who are treated with cytarabine may have an decreased risk of toxicity compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence cytarabine toxicity.; CT:Patients with the CT genotype who are treated with cytarabine may have an increased risk of toxicity compared to patients with the CC genotype. Other genetic and clinical factors may also influence cytarabine toxicity.; TT:Patients with the TT genotype who are treated with cytarabine may have an increased risk of toxicity compared to patients with the CC genotype. Other genetic and clinical factors may also influence cytarabine toxicity.	827803655; 827829873	Genotypes CT + TT are associated with increased toxicity when exposed to cytarabine in healthy individuals as compared to genotype CC.; Genotype TT is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotype CC.	21521023; 22304580	2	cytarabine	Drug Toxicity	White	
827831417	rs3212986	CD3EAP (PA142672156),ERCC1 (PA155),PPP1R13L (PA34195)	3	Efficacy	827831418; 827831419; 827831420	AA:Patients with the AA genotype may have better overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.; AC:Patients with the AC genotype may have better overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.; CC:Patients with the CC genotype may have worse overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma as compared to patients with AA and AC genotypes. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.	769172559	Genotypes AA + AC are associated with better overall survival rate when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	19362955	1	Platinum compounds	Carcinoma, Non-Small-Cell Lung		
827848732	rs9344	CCND1 (PA75)	3	Efficacy;Toxicity/ADR	827848733; 827848734; 827848735	AA:Patients with the AA genotype may have 1) decreased but not absent risk for drug toxicity 2) decreased event free survival when treated with methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033.; AG:Patients with the AG genotype may have 1) increased risk for drug toxicity 2) increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033.; GG:Patients with the GG genotype may have 1) increased risk for drug toxicity 2) increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033.	769171028; 769171268	Genotype AA is associated with decreased severity of Drug Toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + AG.; Genotype AA is associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + AG.	16870553; 12972956	2	methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma	White	
827848776	rs9332131	CYP2C9 (PA126)	3	Other	827848777; 827848778; 827848779	A/del:Patients with the A/del genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of phenytoin.; AA:Patients with the AA genotype may have increased metabolism of phenytoin as compared to patients with the A/del or del/del genotype. Other genetic and clinical factors may also influence metabolism of phenytoin.; del/del:Patients with the del/del genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of phenytoin.	769249041	Genotype DEL is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype AA.	16220110	1	phenytoin		Black or African American	
827848785	rs9316233	HTR2A (PA193)	3	Efficacy	827848786; 827848787; 827848788	CC:Patients with the CC genotype may have increased antidepressant response to escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to escitalopram.; CG:Patients with the CG genotype may have increased antidepressant response to escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to escitalopram.; GG:Patients with the GG genotype may have decreased antidepressant response to escitalopram as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to escitalopram.	769245963	Allele C is associated with increased antidepressant response when treated with escitalopram in people with Depressive Disorder as compared to allele G.	19365399	1	escitalopram	Depressive Disorder	White	
827843617	rs3918290	DPYD (PA145)	1B	Toxicity/ADR	827843618; 827843619; 827843620	CC:Patients with the CC genotype may have decreased, but not non-existent, risk for drug toxicity when treated with fluoropyrimidine based chemotherapy as compared to patients with the CT or TT genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence a patients response to fluoropyrimidine based chemotherapy.; CT:Patients with the CT genotype may 1) have DPYD deficiency and 2) be at risk for severe or even fatal drug toxicity when treated with fluoropyrimidine based chemotherapy as compared to patients with the CC genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence a patients response to fluoropyrimidine based chemotherapy.; TT:Patients with the TT genotype may 1) have complete DPYD deficiency and 2) be at risk for severe or even fatal drug toxicity when treated with fluoropyrimidine based chemotherapy as compared to patients with the CC genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence a patients response to fluoropyrimidine based chemotherapy.	827827351; 769166460; 769171393; 769176388; 769271292; 827810882; 827810951; 827810976; 827814910; 827823452; 827824632; 827824695; 827825029; 827825042; 827825063; 827892647; 827892654; 827892773	Genotype TT is associated with Purine-Pyrimidine Metabolism, Inborn Errors.; Genotype CT is associated with increased severity of Drug Toxicity when treated with capecitabine and raltitrexed in people with Colorectal Neoplasms as compared to genotype CC.; Genotype CT is associated with mucositis and leukopenia drug toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.; Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.; Allele T is associated with increased risk of Drug Toxicity when treated with Pyrimidine analogues as compared to allele C.; Genotype CT is associated with increased likelihood of Drug Toxicity when treated with bevacizumab, capecitabine, cetuximab and oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.; Genotype CT is associated with increased severity of Diarrhea when treated with leucovorin and tegafur in people with Rectal Neoplasms as compared to genotype CC.; Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.; Genotype TT is associated with Death when treated with fluorouracil in people with Drug Toxicity as compared to genotype CC.; Genotype CT is not associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.; Genotype CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC.; Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.; Genotype CT is not associated with Death when treated with fluorouracil in people with Drug Toxicity as compared to genotype CC.; Genotype CT is associated with Death when treated with fluorouracil.; Genotype TT is associated with Purine-Pyrimidine Metabolism, Inborn Errors.; Genotype CT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.; Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.; Genotypes CT + TT are associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	10071185; 17203168; 18299612; 20819423; 10071185; 21498394; 21410976; 20809970; 11555601; 19530960; 18600527; 17700593; 17335544; 17165084; 16151913; 17064846; 17064846; 17121937	18	capecitabine;fluorouracil;Pyrimidine analogues;tegafur	Purine-Pyrimidine Metabolism, Inborn Errors		
827847788	rs1695	GSTP1 (PA29028)	2A	Efficacy	827847789; 827847790; 827847791	AA:Patients with the AA genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have poorer treatment outcome (reduced responsiveness, lower overall survival time, increased risk of death) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil and oxaliplatin treatment.; AG:Patients with the AG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have better treatment outcome as compared to patients with the AA genotype, or may have poorer treatment outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil and oxaliplatin treatment.; GG:Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil and oxaliplatin treatment.	637880107; 637880121; 769166391; 827793307; 827793320	Genotype AA is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype AA is associated with increased risk of disease progression when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype GG is associated with increased progression free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.; Genotypes AG + GG are associated with increased response to fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.; Genotypes AG + GG are associated with increased overall survival when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.	15213713; 15213713; 20078613; 21449681; 21449681	5	fluorouracil;oxaliplatin	Colorectal Neoplasms		
827847759	rs963468	DRD3 (PA27479)	3	Efficacy	827847760; 827847761; 827847762	AA:Patients with the AA genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.; AG:Patients with the AG genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.; GG:Patients with the GG genotype may have decreased response to duloxetine as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.	827820202	Genotype GG is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes AA + AG.	22249355	1	duloxetine	Anxiety Disorders	White	
827848325	rs1801133	MTHFR (PA245)	3	Efficacy	827848326; 827848327; 827848328	AA:Patients with the AA genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; AG:Patients with the AG genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; GG:Patients with the GG genotype with non-hodgkin lymphoma who are treated with methotrexate may be more likely to have event free survival at 5 years as compared to patients with the AA genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.	637879719; 769170766	Allele A is associated with decreased likelihood of event free survival when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotype GG.; Allele A is not associated with response to methotrexate in people with Lymphoma, Non-Hodgkin as compared to allele G.	17488658; 16463153	2	methotrexate	Lymphoma, Non-Hodgkin	White	
827848740	rs9340799	ESR1 (PA156)	3	Efficacy	827848741; 827848742; 827848743	AA:Patients with the AA genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.; AG:Patients with the AG genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.; GG:Patients with the GG genotype may experience decreased response to leflunomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.	827783461	Genotype AA is associated with increased response to leflunomide in women with Arthritis, Rheumatoid as compared to genotypes AG + GG.	21174621	1	leflunomide	Arthritis, Rheumatoid		
827848762	rs9332239	CYP2C9 (PA126)	4	Other	827848763; 827848764; 827848765	CC:Patients with the CC genotype may have increased metabolism of tolbutamide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence tolbutamide metabolism.; CT:Patients with the CT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.; TT:Patients with the TT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.	827788986	Allele T is associated with decreased catalytic activity of CYP2C9 when assayed with tolbutamide.	15284535	1	tolbutamide			
827848751	rs9340799	ESR1 (PA156)	3	Efficacy	827848752; 827848753; 827848754	AA:Patients with the AA genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.; AG:Patients with the AG genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.; GG:Patients with the GG genotype may experience 1) greater increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) smaller decreases in spine bone mineral density when untreated, as compared to patient with the AA genotype. Other genetic and clinical factors may also influence spine bone mineral density.	769164633	Genotype GG is associated with increased spine Bone Mineral Density when treated with conjugated estrogens and medroxyprogesterone as compared to genotype AA.	9860300	1	conjugated estrogens;medroxyprogesterone		White	
827848365	rs1801133	MTHFR (PA245)	3	Dosage;Efficacy;Toxicity/ADR	827848366; 827848367; 827848368	AA:Patients with the AA genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment.; AG:Patients with the AG genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype or may be at decreased risk of toxicity as compared to patients with the AA genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment.; GG:Patients with the GG genotype and Leukemia who are treated with methotrexate: 1) may have better response to treatment 2) may be at decreased risk of toxicity 3) may require a higher dose of methotrexate as compared to patients with the AA genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment.	827829042; 827829138; 608431574; 608431599; 751696635; 769170744; 769170968; 769171000; 769173703; 769174309; 637879745; 637879749; 637879769; 655387891; 769171101; 769170671; 769171025; 827698212; 827698220	Genotype AA is associated with increased risk of overall toxicity (measured as more than two adverse effects) when treated with as compared to genotype GG.; Genotype AA is associated with increased risk of hepatotoxicity and hematological toxicity when treated with methotrexate as compared to genotype GG.; Allele A is associated with decreased likelihood of event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; Allele A is associated with increased risk of relapse when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; Allele A is not associated with risk of MTX-induced toxicity (seizures or thrombosis) when treated with methotrexate in people with Leukemia.; Allele A is not associated with response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; Allele A is not associated with increased risk of Neoplasms, Second Primary when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; Allele A is not associated with Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Allele A is not associated with decreased IQ when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Allele A is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.; Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GA.; Genotype AA is associated with decreased mortality when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Leukemia as compared to genotype GA.; Genotype AA is associated with increased risk of hepatotoxicity, leukopenia and gastrointestinal toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; Genotype AA is associated with increased plasma drug concentrations when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + AG.; Genotypes AA + AG are associated with increased likelihood of treatment interruptions when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; Genotypes AA + AG are associated with decreased severity of Leukopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; Genotype GG is associated with increased dose of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.; Genotype GG is associated with increased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.	22143415; 22143415; 14647408; 15781665; 12915598; 16462575; 16019535; 17323057; 16013960; 15797993; 17512587; 17512587; 12453860; 19648163; 17180579; 18458567; 16870553; 21747412; 21747412	19	methotrexate	Leukemia;Precursor Cell Lymphoblastic Leukemia-Lymphoma		
827863928	rs1051375	CACNA1C (PA83)	3	Efficacy	827863929; 827863930; 827863931	AA:Patients with the AA genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with verapamil compared to treatment with atenolol. Other genetic and clinical factors may also influence a patient's response to treatment.; AG:Patients with the AG genotype, hypertension and stable coronary artery disease, may respond similarily to treatment with atenolol or verapamil. Other genetic and clinical factors may also influence a patient's response to treatment.; GG:Patients with the GG genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with atenolol compared to treatment with verapamil. Other genetic and clinical factors may also influence a patient's response to treatment.	769174175; 769174179; 769174182	Genotype AA is associated with decreased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.; Genotype AG is not associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.; Genotype GG is associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.	20031608; 20031608; 20031608	3	atenolol;verapamil	Coronary Artery Disease;Hypertension		
827864513	rs17098707	GRK5 (PA180)	4	Efficacy	827864514; 827864515; 827864516	AA:Patients with the AA genotype and heart failure may have an elevated risk for death as compared to patients with the TT genotype and may benefit more from beta blocker treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events.; AT:Patients with the AT genotype and heart failure may have lower, but not absent, risk for death as compared to patients with the AA genotype and may benefit more from beta blocker treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events.; TT:Patients with the TT genotype and heart failure may have lower, but not absent, risk for death as compared to patients with the AA genotype regardless of beta blocker. treatment. Other genetic and clinical factors may also influence a patient's risk for adverse cardiovascular events.	769169291; 827864486	Genotypes AT + TT are associated with decreased risk of Death in people not taking Beta Blocking Agents in people with Heart Failure as compared to genotype AA.; Genotypes AA + AT are associated with response to Beta Blocking Agents in people with Heart Failure as compared to genotype TT.	18425130; 18425130	2	Beta Blocking Agents	Heart Failure	Black or African American	
827847768	rs9597	BAIAP3 (PA25252),RPS20P2 (PA34809),UBE2I (PA37134)	3	Efficacy	827847769; 827847770; 827847771	CC:Patients with the CC genotype may have a decreased response to cisplatin and irinotecan as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.; CG:Patients with the CG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.; GG:Patients with the GG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype, although the GG genotype was not observed in the supporting study. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.	769164968	Genotype CG is associated with increased response to cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	19859084	1	cisplatin;irinotecan	Carcinoma, Non-Small-Cell Lung	Asian	
827847738	rs9895420	ABCC3 (PA376)	3	Efficacy;Toxicity/ADR	827847739; 827847740; 827847741	AA:Patients with the AA genotype may have 1) decreased event free survival 2) increased risk of central nervous system relapse 3) decreased risk of thrombocytopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; AT:Patients with the AT genotype may have 1) decreased event free survival 2) increased risk of central nervous system relapse 3) decreased risk of thrombocytopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; TT:Patients with the TT genotype may have 1) increased event free survival 2) decreased, but not non-existent, risk of central nervous system relapse 3) increased risk of thrombocytopenia when treated with methotrexate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate.	827573981; 827573986; 827573991; 827573996	Genotypes AA + AT are associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.; Genotypes AA + AT are associated with increased plasma levels of in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.; Genotypes AA + AT are associated with increased risk of relapse in the central nervous system when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.; Genotypes AA + AT are associated with decreased likelihood of Thrombocytopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	21606946; 21606946; 21606946; 21606946	4	methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma	White	
827847744	rs9679162	GALNT14 (PA134920089)	3	Efficacy	827847745; 827847746; 827847747	GG:Patients with the GG genotype may have decreased response, including decreased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; GT:Patients with the GT genotype may have decreased response, including decreased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; TT:Patients with the TT genotype may have increased response, including increased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patient's response to treatment.	827812110; 827812125; 827812137	Genotype TT is associated with increased response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.; Genotype TT is associated with increased likelihood of progression-free survival when treated with cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.; Genotype TT is associated with increased overall survival when treated with cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.	21635146; 21635146; 21635146	3	cisplatin;fluorouracil;mitoxantrone	Carcinoma, Hepatocellular;Neoplasms		
827848548	rs9561778	ABCC4 (PA397)	3	Toxicity/ADR	827848549; 827848550; 827848551	GG:Patients with the GG genotype may have a decreased but not absent risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs.; GT:Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs.; TT:Patients with the TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs.	655387580	Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.	19696793	1	cyclophosphamide;doxorubicin;fluorouracil	Breast Neoplasms;Neoplasms	Asian	
827848725	rs9349256	ABCC10 (PA24392)	3	Toxicity/ADR	827848726; 827848727; 827848728	AA:Patients with the AA genotype may have decreased but not absent risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse events.; AG:Patients with the AG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; GG:Patients with the GG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.	827815689	Allele G is associated with increased kidney tubular dysfunction when exposed to tenofovir as compared to allele A.	21628669	1	tenofovir			
827847751	rs9657182	IDO1 (PA29869)	3	Toxicity/ADR	827847752; 827847753; 827847754	CC:Patients with the CC genotype may have increased risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.; CT:Patients with the CT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.; TT:Patients with the TT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.	827815660; 827815673	Genotype CC is associated with increased moderate or severe depression in Caucasians when treated with interferon alfa-2a, recombinant or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes CT + TT.; Genotype CC is not associated with increased moderate or severe depression in African Americans when treated with interferon alfa-2a, recombinant or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	21691274; 21691274	2	interferon alfa-2a, recombinant;peginterferon alfa-2b	Hepatitis C, Chronic	White	
827849109	rs9272105	HLA-DQA1 (PA35066)	3	Efficacy	827849110; 827849111; 827849112	AA:Patients with the AA genotype may have decreased but not absent risk for developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to interferon-beta therapy.; AG:Patients with the AG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.; GG:Patients with the GG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.	769258178	Allele G is associated with increased anti-IFN-beta antibodies when treated with interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.	21502966	1	interferon beta-1a;interferon beta-1b		White	
827849115	rs9267445	MICB (PA30812),PPIAP9 (PA33601)	3	Toxicity/ADR	827849116; 827849117; 827849118	CC:Patients with the CC genotype may have decreased but not absent risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; CG:Patients with the CG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; GG:Patients with the GG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. This is a very rare allele and the GG homozygote was not observed in the supporting study. Other genetic and clinical factors may also influence risk for SJS/TEN.	827708582	Genotype CG is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol as compared to genotype CC.	21912425	1	allopurinol	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome	Asian	
827849127	rs9263800	CCHCR1 (PA134942738),POU5F1 (PA33545),TCF19 (PA36384)	3	Toxicity/ADR	827849128; 827849129; 827849130	AA:Patients with the AA genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; AG:Patients with the AG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; GG:Patients with the GG genotype may have decreased but not absent risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk for SJS/TEN.	827708662	Allele A is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol as compared to allele G.	21912425	1	allopurinol	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome	Asian	
827849180	rs9263781	CCHCR1 (PA134942738),TCF19 (PA36384)	3	Toxicity/ADR	827849181; 827849182; 827849183	CC:Patients with the CC genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; CT:Patients with the CT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; TT:Patients with the TT genotype may have decreased but not absent risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk for SJS/TEN.	827708624	Allele C is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol as compared to allele T.	21912425	1	allopurinol	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome	Asian	
827849189	rs9263745	CCHCR1 (PA134942738),PSORS1C2 (PA33920)	3	Toxicity/ADR	827849190; 827849191; 827849192	AA:Patients with the AA genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; AG:Patients with the AG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; GG:Patients with the GG genotype may have decreased but not absent risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk for SJS/TEN.	827708607	Allele A is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol as compared to allele G.	21912425	1	allopurinol	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome	Asian	
827849198	rs9263733	CCHCR1 (PA134942738),PSORS1C1 (PA33919),PSORS1C2 (PA33920)	3	Toxicity/ADR	827849199; 827849200; 827849201	CC:Patients with the CC genotype may have decreased but not absent risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; CT:Patients with the CT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; TT:Patients with the TT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.	827708601	Allele T is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol as compared to allele C.	21912425	1	allopurinol	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome	Asian	
827848563	rs943580	AGT (PA42)	3	Toxicity/ADR	827848564; 827848565; 827848566	AA:Patients with the AA genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.; AG:Patients with the AG genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.; GG:Patients with the GG genotype may have decreased but not non-existent risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.	827836674	Genotype GG is associated with decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotypes AA + AG.	20538124	1	Antiinflammatory agents, non-steroids	Acute coronary syndrome		
827849079	rs9282861	SULT1A1 (PA343),SULT1A2 (PA341)	3	Toxicity/ADR	827849080; 827849081; 827849082	CC:Patients with the CC genotype may have a decreased but not absent risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.; CT:Patients with the CT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.; TT:Patients with the TT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.	827639365	Genotypes TT + CT are associated with increased likelihood of Endometrial Neoplasms when treated with conjugated estrogens as compared to genotype CC.	16985250	1	conjugated estrogens	Endometrial Neoplasms		
827849165	rs9263785	CCHCR1 (PA134942738),TCF19 (PA36384)	3	Toxicity/ADR	827849166; 827849167; 827849168	GG:Patients with the GG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; GT:Patients with the GT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; TT:Patients with the TT genotype may have decreased but not absent risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also influence risk for SJS/TEN.	827708633	Allele G is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol as compared to allele T.	21912425	1	allopurinol	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome	Asian	
827849205	rs9263726	CCHCR1 (PA134942738),PSORS1C1 (PA33919),PSORS1C2 (PA33920)	3	Toxicity/ADR	827849206; 827849207; 827849208	AA:Patients with the AA genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. This is a very rare allele and the AA homozygote was not observed in the supporting study. This allele was in complete LD with HLA-B*5801 in the Japanese population. Evidence for the HLA-B*5801 allele and risk for SJS/TEN is stronger. Other genetic and clinical factors may also influence risk for SJS/TEN.; AG:Patients with the AG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the GG genotype. This allele was in complete LD with HLA-B*5801 in the Japanese population. Evidence for the HLA-B*5801 allele and risk for SJS/TEN is stronger. Other genetic and clinical factors may also influence risk for SJS/TEN.; GG:Patients with the GG genotype may have decreased but not absent risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the AA or AG genotype. This allele was in complete LD with HLA-B*5801 in the Japanese population. Evidence for the HLA-B*5801 allele and risk for SJS/TEN is stronger. Other genetic and clinical factors may also influence risk for SJS/TEN.	827708554	Genotype AG is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol as compared to genotype GG.	21912425	1	allopurinol	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome	Asian	
827849095	rs9274407	HLA-DQB1 (PA35068)	3	Toxicity/ADR	827849096; 827849097; 827849098	AA:Patients with the AA genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.; AT:Patients with the AT genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.; TT:Patients with the TT genotype may have decreased but not absent risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk for drug induced liver injury.	827826967	Allele A is associated with increased likelihood of drug induced liver injury when treated with amoxicillin and clavulanate in people with Drug Toxicity as compared to allele T.	21570397	1	amoxicillin;clavulanate	Drug Toxicity	White	
827862258	rs1057910	CYP2C9 (PA126)	2A	Dosage	827862261; 827862260; 827862259	AA:Patients with the AA genotype may require higher dose of celecoxib as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.; AC:Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.; CC:Patients with the CC genotype may have greatly reduced metabolism of celecoxib and may require dose reduction (50% of standard starting dose) when starting celecoxib therapy or alternative management in juvenile rheumatoid arthritis patients who carry this genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.	827826380; 827826398; 827826422; 827826446	Allele C is associated with decreased metabolism of celecoxib.; Allele C is associated with increased AUC of celecoxib when treated with celecoxib as compared to allele A.; Genotype CC is associated with decreased oral clearance of celecoxib (3-fold) and a 1.5-fold prolonged elimination half-life when exposed to celecoxib in healthy individuals as compared to genotype AA.; Genotype CC is associated with increased AUC of celecoxib (10 fold higher) when treated with celecoxib in children as compared to genotype AA.	11337938; 11337938; 12893985; 16153401	4	celecoxib		White	
827848555	rs9514091	SLC10A2 (PA318)	3	Toxicity/ADR	827848556; 827848557; 827848558	AA:Patients with the AA genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for cardiotoxicity.; AG:Patients with the AG genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for cardiotoxicity.; GG:Patients with the GG genotype may have an increased risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk for cardiotoxicity.	827805749	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.	21900104	1	anthracyclines and related substances	Neoplasms		
827849121	rs9263827	POU5F1 (PA33545),PSORS1C3 (PA33921)	3	Toxicity/ADR	827849122; 827849123; 827849124	CC:Patients with the CC genotype may have decreased but not absent risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for SJS/TEN.; CT:Patients with the CT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; TT:Patients with the TT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.	827708681	Allele T is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol as compared to allele C.	21912425	1	allopurinol	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome	Asian	
827849144	rs9263796	CCHCR1 (PA134942738),POU5F1 (PA33545),TCF19 (PA36384)	3	Toxicity/ADR	827849145; 827849146; 827849147	CC:Patients with the CC genotype may have decreased but not absent risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for SJS/TEN.; CT:Patients with the CT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; TT:Patients with the TT genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.	827708654	Allele T is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol as compared to allele C.	21912425	1	allopurinol	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome	Asian	
827849156	rs9263794	CCHCR1 (PA134942738),POU5F1 (PA33545),TCF19 (PA36384)	3	Toxicity/ADR	827849157; 827849158; 827849159	AA:Patients with the AA genotype may have decreased but not absent risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk for SJS/TEN.; AG:Patients with the AG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.; GG:Patients with the GG genotype may have increased risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for SJS/TEN.	827708639	Allele G is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol as compared to allele A.	21912425	1	allopurinol	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome	Asian	
981201549	rs2298383	ADORA2A (PA24584)	2B	Toxicity/ADR	981201550; 981201551; 981201552	CC:Patients with the CC genotype may have increased anxiety when exposed to caffeine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patients response to caffeine.; CT:Patients with the CT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.; TT:Patients with the TT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.	769278134; 827700157	Genotype CC is associated with increased anxiety when exposed to caffeine in people with no disease as compared to genotype TT.; Genotype CC is associated with increased anxiety when exposed to caffeine as compared to genotypes CT + TT.	18305461; 20520601	2	caffeine			
981201653	rs35350960	UGT1A1 (PA420),UGT1A10 (PA37174),UGT1A3 (PA37178),UGT1A4 (PA37179),UGT1A5 (PA37180),UGT1A6 (PA37181),UGT1A7 (PA37182),UGT1A8 (PA37183),UGT1A9 (PA419)	4	Other	981201655; 981201654; 981201656	AA:Patients with the AA, AC, or AT genotype may have decreased metabolism of SN-38 compared to patients with the CC genotype, as determined by in vitro assays. Other genetic and clinical factors may also influence metabolism of SN-38.; CC:Patients with the CC genotype may have increased metabolism of SN-38 compared to patients with the A or T allele at this position, as determined by in vitro assays. Other genetic and clinical factors may also influence metabolism of SN-38.; TT:Patients with the TT, CT or AT genotype may have decreased metabolism of SN-38 compared to patients with the CC genotype, as determined by in vitro assays. Other genetic and clinical factors may also influence metabolism of SN-38.	827666647; 827677344	Allele A is associated with decreased metabolism of SN-38 as compared to allele C.; Allele A is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.	15572581; 12181437	2	SN-38			
981201864	rs2046934	MED12L (PA134884590),P2RY12 (PA134971947)	3	Efficacy	981201865; 981201866; 981201867	AA:Genotype AA is not associated with response to clopidogrel as compared to genotypes GG + AG. Other genetic and clinical factors may influence a patient's response to clopidogrel.; AG:Genotypes GG + AG are not associated with response to clopidogrel as compared to genotype AA. Other genetic and clinical factors may influence a patient's response to clopidogrel.; GG:Genotypes GG + AG are not associated with response to clopidogrel as compared to genotype AA. Other genetic and clinical factors may influence a patient's response to clopidogrel.	699638721; 699638755; 699638765; 699638814; 769169225; 827892728; 699638805	Allele G is not associated with response to clopidogrel in people with good health as compared to allele A.; Allele G is not associated with response to clopidogrel.; Allele G is not associated with response to clopidogrel as compared to allele A.; Allele G is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele A.; Allele G is not associated with increased likelihood of Myocardial Infarction in people with Coronary Artery Disease as compared to allele A.; Allele G is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele A.; Genotypes GG + AG are not associated with response to clopidogrel as compared to genotype AA.	16961627; 16769602; 16581111; 15795539; 16405973; 17337040; 16181985	7	clopidogrel	Acute coronary syndrome;Angina Pectoris	White	
981201881	rs3093726	LST1 (PA37856),LTB (PA30475),TNF (PA435)	4	Toxicity/ADR	981201882; 981201883; 981201884	CC:Patients with the CC genotype may have decreased but not absent risk of hypersensitivity when treated with abacavir as compared to patients with the CT or TT genotypes. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.; CT:Patients with the CT genotype may have increased risk of hypersensitivity when treated with abacavir as compared to patients with the CC genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.; TT:Patients with the TT genotype may have increased risk of hypersensitivity when treated with abacavir as compared to patients with the CC genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.	769179106	Allele T is associated with increased risk of hypersensitivity when treated with abacavir.	11888582	1	abacavir	Drug Hypersensitivity		
981202562	rs4244285	CYP2C19 (PA124)	4	Toxicity/ADR	981202563; 981202564; 981202565	AA:Female patients with the AA genotype and Systemic Lupus Erythematosus who are treated with a high cumulative dose of cyclophosphamide (= or >23.75 g) may have a decreased risk of ovarian toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced ovarian toxicity.; AG:Female patients with the AG genotype and Systemic Lupus Erythematosus who are treated with a high cumulative dose of cyclophosphamide (= or >23.75 g) may have a decreased risk of ovarian toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced ovarian toxicity.; GG:Female patients with the GG genotype and Systemic Lupus Erythematosus who are treated with a high cumulative dose of cyclophosphamide (= or >23.75 g) may have an increased risk of ovarian toxicity as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced ovarian toxicity.	827828575	Genotype GG is associated with increased risk of ovarian toxicity when patients receiving a higher cumulative dose of cyclophosphamide (>23.75 g) when treated with cyclophosphamide in women with Lupus Erythematosus, Systemic as compared to genotypes AA + AG.	20358205	1	cyclophosphamide	Lupus Erythematosus, Systemic	Asian	
981202520	rs4149601	NEDD4L (PA31534)	3	Efficacy	981202521; 981202522; 981202523	AA:Patients with the AA genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.; AG:Patients with the AG genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.; GG:Patients with the GG genotype and Hypertension who are treated with hydrochlorothiazide may have a poorer response to treatment as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.	827784007; 827924775	Allele A is associated with increased pressure reduction when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.; Genotype AA is associated with decreased reduction in SBP when treated with hydrochlorothiazide in people with Hypertension.	19635985; 18591455	2	hydrochlorothiazide	Hypertension	Asian	
981201888	rs2069514	CYP1A2 (PA27093)	3	Toxicity/ADR	981201889; 981201890; 981201891	AA:Schizophrenia patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AA is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.; AG:Schizophrenia patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.; GG:Schizophrenia patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the AA or AG genotype. Genotype GG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype AA. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.	769246515; 827704013	Allele A is not associated with increased QT interval when treated with antipsychotics in people with Schizophrenia as compared to allele G.; Allele A is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele G.	17611010; 15505641	2	antipsychotics	Schizophrenia	Asian	
981201981	rs1801265	DPYD (PA145)	3	Toxicity/ADR	981201982; 981201983; 981201984	AA:Genotypes AA is not associated with Drug Toxicity in white cancer patients treated with fluorouracil as compared to genotypes AG and GG. Other genetic and clinical factors may influence a patient's risk of fluorouracil-related toxicity.; AG:Genotypes AG is not associated with Drug Toxicity in white cancer patients treated with fluorouracil as compared to genotype AA. Other genetic and clinical factors may influence a patient's risk of fluorouracil-related toxicity.; GG:Genotypes GG is not associated with Drug Toxicity in white cancer patients treated with fluorouracil as compared to genotype AA. Other genetic and clinical factors may influence a patient's risk of fluorouracil-related toxicity.	827892677; 827892687; 827892796; 827892947	Genotypes AG + GG are not associated with Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.; Genotype AG is not associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	17064846; 17064846; 17121937; 14635116	4	fluorouracil	Colorectal Neoplasms;Neoplasms	White	
827923032	rs3745274	CYP2A7P1 (PA27103),CYP2B6 (PA123)	2A	Dosage	827923033; 827923034; 827923035	GG:Patients with the GG genotype may have decreased plasma concentration of efavirenz in people with HIV as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.; GT:Patients with the GT genotype may have decreased plasma concentration of efavirenz in people with HIV as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.; TT:Patients with the TT genotype may have increased plasma concentration of efavirenz in people with HIV as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.	769162981; 769162974; 769163086; 769163473; 769163522; 769163543; 827692937; 827695744; 827807674; 827811199; 827820044; 827922951	Genotypes GT + TT are associated with increased PBMC-associated drug concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; Genotype TT is associated with increased intracellular PBMC exposure of efavirenz in people with HIV Infections as compared to genotype GG.; Genotype TT is associated with increased plasma concentration (p<0.001) of efavirenz in people with HIV Infections as compared to genotypes GG + GT.; Genotype TT is associated with increased mid-dose plasma concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.; Genotype TT is associated with increased plasma exposure of nevirapine in people with HIV Infections as compared to genotype GG.; Genotype TT is associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotype GG.; Genotype TT is associated with increased minimum plasma concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; Genotype TT is associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotype GG.; Allele T is associated with increased plasma concentration of efavirenz in people with HIV as compared to allele G.; Genotype TT is associated with increased plasma concentration of efavirenz in people with HIV as compared to genotypes GG + GT.; Genotype TT is associated with decreased clearance of efavirenz in people with HIV as compared to genotypes GG + GT.; Allele T is associated with increased plasma efavirenz exposure (AUC) during the first 24 weeks of antiretroviral therapy when treated with efavirenz in people with HIV as compared to allele G.	20860463; 15864119; 19779319; 19371316; 15864119; 16267764; 20860463; 15864119; 18281305; 20723261; 22188122; 15622315	12	efavirenz	HIV		
981201642	rs34489327	ENOSF1 (PA134897613),TYMS (PA359)	3	Efficacy	981201645; 981201644; 981201643	TTAAAG/TTAAAG:Patients with the TTAAAG/TTAAAG genotype who are treated with methotrexate may have a lower response to treatment as compared to patients with the del/del genotype and the 3/3 genotype at rs34743033. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; TTAAAG/del:Patients with the TTAAAG/del genotype and the 3/3 genotype at rs34743033 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAG/TTAAAG genotype. Patients with the TTAAAG/del genotype may have a lower response to treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; del/del:Patients with the del/del genotype and the 3/3 genotype at rs34743033 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.	769171248; 769174430; 827863352	Genotype DEL is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele TTAAAG.; Allele TTAAAG is associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype DELDEL.; Genotype DEL is not associated with response to methotrexate in people with Arthritis, Rheumatoid.	18322994; 16130010; 22450926	3	methotrexate	Arthritis, Rheumatoid;Precursor Cell Lymphoblastic Leukemia-Lymphoma	White	
981201797	rs28399433	CYP2A6 (PA121)	4	Other	981201798; 981201799; 981201800	AA:Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.; AC:Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.; CC:Patients with the CC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.	827641958; 827641986; 827698774	Allele C is associated with decreased expression of enzyme contributing to the metabolism of coumarin and nicotine.; Allele C is associated with decreased metabolism of nicotine.; Genotypes AC + CC are associated with decreased expression of CYP2A6 in human liver samples.	11394901; 12844137; 21521021	3	nicotine			
827923042	rs3745274	CYP2A7P1 (PA27103),CYP2B6 (PA123)	2A	Toxicity/ADR	827923043; 827923044; 827923045	GG:Patients with the GG genotype may have a decreased, but not absent risk of efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GT:Patients with the GT genotype may have an increased risk of efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype may have an increased risk for efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.	827695756; 827695768; 827811208; 827922492; 827922504; 827922962	Genotype TT is associated with increased likelihood of Sleep Disorders when treated with efavirenz in people with HIV Infections as compared to genotypes GG + GT.; Genotype TT is associated with increased likelihood of Fatigue when treated with efavirenz in people with HIV Infections as compared to genotypes GG + GT.; Genotype TT is associated with increased likelihood of side effects when treated with efavirenz, lamivudine and stavudine in people with HIV as compared to genotypes GG + GT.; Genotype TT is associated with increased risk of drug induced liver injury (DILI) when treated with efavirenz and rifampin as compared to genotype GG.; Genotype TT is associated with early (< 3 months) termination of efavirenz therapy when treated with efavirenz as compared to genotypes GG + GT.; Allele T is associated with increased risk of central nervous system symptoms at week 1 when treated with efavirenz in people with HIV as compared to allele G.	15864119; 15864119; 20723261; 22162992; 21715435; 15622315	6	efavirenz	HIV		
981188329	rs34743033	C18orf56 (PA134956204),TYMS (PA359)	3	Efficacy;Toxicity/ADR	981188330; 981188331; 981188332	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2:Patients with the 2R/2R genotype may have an increased risk for toxicity and increased response to fluoropyrimidine chemotherapy regimens as compared to patients with the 3R/3R genotype. However, patients with the 2R2R genotype may have a decreased response to fluorouracil radiochemotherapy compared to patients with the 3R3R genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response.; (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3:Patients with the 2R/3R genotype may have an increased risk for toxicity and increased response with fluoropyrimidine chemotherapy regimens as compared to patients with the 3R/3R genotype. However, patients with the 2R3R genotype may have a decreased response to fluorouracil radiochemotherapy compared to patients with the 3R3R genotype. In addition a SNP within the third repeat (no rs#) may modify the actions of the 3R allele. Other genetic and clinical factors may also influence a patient's risk for toxicity and response.; (CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3:Patients with the 3R/3R genotype may have a decreased but not absent risk for toxicity and decreased response to with fluoropyrimidine chemotherapy regimens as compared to patients with the 2R/2R genotype. However, patients with the 3R3R genotype may have an increased response to fluorouracil radiochemotherapy compared to patients with the 2R2R genotype. In addition a SNP within the third repeat (no rs#) may modify the actions of the 3R allele. Other genetic and clinical factors may also influence a patient's risk for toxicity and response.	827811344; 827811361; 827813447; 827820320; 827823429; 827825053; 769165161; 769169683; 769169688; 769245532; 769245656; 769169069; 769169072; 769169082; 769176378; 769245499; 769245561; 769261466; 769165179; 769166457; 769169063; 769169085; 769169205; 769169217; 769245498	Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with survival when treated with fluorouracil in people with Colorectal Neoplasms.; Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms.; Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with response to fluorouracil in people with Colonic Neoplasms as compared to allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)3.; Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3 is associated with increased response rate (pathological complete remission and microfoci residual tumor) when treated with fluorouracil in people with Rectal Neoplasms as compared to genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3.; Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3 is associated with Hyperammonemia when treated with fluorouracil in people with Neoplasms.; Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3 is associated with increased survival when treated with cisplatin and fluorouracil in people with Stomach Neoplasms.; Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with increased dose of fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype 33.; Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with increased risk of grade 3 to 4 neutropenia and diarrhea when treated with fluorouracil and leucovorin in people with Adenocarcinoma as compared to genotype 33.; Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with increased likelihood of experiencing severe toxicity when treated with fluorouracil in people with Adenocarcinoma as compared to genotype 33.; Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with likelihood of grade 3 hand-foot syndrome when treated with capecitabine in people with Neoplasms as compared to genotype 3.; Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to genotype 3.; Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with increased survival when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype 33.; Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with decreased expression of TYMS.; Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with increased response to fluorouracil in people with Colorectal Neoplasms as compared to genotypes 33 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)23.; Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.; Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with increased response to fluorouracil as compared to genotypes 33 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)23.; Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with likelihood of tumor downstaging when treated with fluorouracil in people with Rectal Neoplasms.; Genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)23 are associated with increased progression free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype 33.; Genotype 3 is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2.; Genotype 33 is associated with decreased response to capecitabine and raltitrexed in people with Colorectal Neoplasms as compared to genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2.; Genotype 33 is associated with increased expression of TYMS when treated with tegafur cancer tissues.; Genotype 33 is associated with decreased severity of side effects when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2.; Genotype 33 is associated with increased expression of TYMS when treated with fluorouracil in colonic mucosa of colorectal cancer patients.; Genotype 33 is associated with decreased response to fluorouracil in people with in established cell lines of human solid tumors as compared to genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2.; Genotype 33 is associated with increased expression of TYMS when treated with fluorouracil pancreatic cell lines.	19384296; 19384296; 20665215; 20165956; 20714149; 16249645; 21273624; 16818689; 16818689; 21325291; 20638924; 14522928; 14522928; 11913730; 20819423; 21362378; 20932673; 20385995; 21167658; 17203168; 10652619; 11913730; 16182121; 15918040; 21362378	25	capecitabine;fluorouracil;Pyrimidine analogues;tegafur	Colorectal Neoplasms;Neoplasms;Pancreatic Neoplasms;Rectal Neoplasms		
981188353	rs2070959	UGT1A10 (PA37174),UGT1A6 (PA37181),UGT1A7 (PA37182),UGT1A8 (PA37183),UGT1A9 (PA419)	3	Dosage	981188354; 981188355; 981188356	AA:Patients with the AA genotype may require a decreased dose of valproic acid compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patients dose requirements.; AG:Patients with the AG genotype may require an increased dose of valproic acid compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients dose requirements.; GG:Patients with the GG genotype may require an increased dose of valproic acid compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patients dose requirements.	769164791; 827812626; 827812675	Allele G is associated with increased glucuronidation of valproic acid.; Genotype GG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AG.; Genotype AG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype AA.	15761113; 21806385; 21806385	3	valproic acid	Epilepsy	Asian	
981202646	rs4680	COMT (PA117)	3	Toxicity/ADR	981202647; 981202648; 981202649	AA:Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.; AG:Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.; GG:Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have an increased risk of tardive dyskinesia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.	699638567	Genotypes AA + AG are associated with decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotype GG.	18180754	1	antipsychotics	tardive dyskinesia		
981201455	rs2284017	CACNG2 (PA26016)	3	Efficacy	981201456; 981201457; 981201458	CC:Patients with the CC genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; CT:Patients with the CT genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; TT:Patients with the TT genotype may have decreased response to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.	608431344; 699639151	Allele C is associated with increased response to lithium in people with Bipolar Disorder as compared to allele T.; Genotype CC is associated with increased response to lithium in people with Bipolar Disorder.	18408563; 21047205	2	lithium	Bipolar Disorder	White	
981201805	rs28399433	CYP2A6 (PA121)	4	Other	981201806; 981201807; 981201808	AA:Patients with the AA genotype may have increased metabolism of coumarin as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.; AC:Patients with the AC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.; CC:Patients with the CC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.	827641958; 827642007; 827698774	Allele C is associated with decreased expression of enzyme contributing to the metabolism of coumarin and nicotine.; Allele C is associated with decreased metabolism of coumarin.; Genotypes AC + CC are associated with decreased expression of CYP2A6 in human liver samples.	11394901; 16041240; 21521021	3	coumarin			
981202103	rs7297610	YEATS4 (PA134992686)	2B	Efficacy	981202104; 981202105; 981202106	CC:Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.; CT:Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.; TT:Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.	827843599; 827843607; 827843612; 827924796	Genotype CC is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotypes CT + TT.; Genotype CC is associated with increased expression of YEATS4 in whole blood RNA.; Genotype CC is associated with decreased expression of YEATS4 when treated with hydrochlorothiazide in whole blood RNA.; Allele C is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to allele T.	22350108; 22350108; 22350108; 18591461	4	hydrochlorothiazide	Essential hypertension;Hypertension	Black or African American	
981202261	rs3740066	ABCC2 (PA116)	3	Efficacy	981202262; 981202263; 981202264	CC:Patients with the CC genotype and Epilepsy who are treated with antiepileptics may have a decreased risk of drug resistance as compared to patients with the CT or TT genotype. This association was not found in all studies. Other genetic and clinical factors may also influence a patient's response to antiepileptics.; CT:Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. This association was not found in all studies. Other genetic and clinical factors may also influence a patient's response to antiepileptics.; TT:Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. This association was not found in all studies. Other genetic and clinical factors may also influence a patient's response to antiepileptics.	827824467; 827824547; 827845000; 827921753	Genotypes CT + TT are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.; Allele T is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele C.; Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.; Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.	22256867; 22256867; 21449672; 22630058	4	antiepileptics	Epilepsy		
981201571	rs3215400	CDA (PA98)	4	Toxicity/ADR	981201572; 981201573; 981201574	C/del:Patients with the C/del genotype who are treated with cytarabine may have an increased risk of drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; CC:Patients with the CC genotype who are treated with cytarabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; del/del:Patients with the del/del genotype who are treated with cytarabine may have an increased risk of drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.	827803673; 827829888; 827922327	Genotypes C/DEL + DEL/DEL are associated with increased toxicity when treated with cytarabine as compared to genotype CC.; Genotype DEL/DEL is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotypes C/DEL + CC.; Genotype DEL/DEL is associated with increased risk of Drug Toxicity when treated with cytarabine in children with Lymphoma, T-Cell.	21521023; 22304580; 22379997	3	cytarabine			
981201844	rs28399499	CYP2B6 (PA123)	2A	Other	981201845; 981201846; 981201847	CC:Patients with the CC genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.; CT:Patients with the CT genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.; TT:Patients with the TT genotype may have decreased plasma drug exposure when treated with efavirenz as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.	769170849; 769170861; 769170863; 769162986; 769163091; 769163497; 827807683	Allele C is associated with decreased expression of CYP2B6.; Allele C is associated with decreased expression of CYP2B6.; Allele C is associated with decreased metabolism of efavirenz in people with HIV.; Genotype CT is associated with increased minimum plasma concentrations of efavirenz in people with HIV Infections as compared to genotype TT.; Genotype CT is not associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype TT.; Genotype CT is not associated with increased mid-dose plasma concentrations of efavirenz in people with HIV Infections as compared to genotype TT.; Allele C is associated with increased plasma concentration of efavirenz in people with HIV as compared to allele T.	16272958; 16495778; 16495778; 20860463; 19779319; 19371316; 18281305	7	efavirenz	HIV		
981201946	rs1801158	DPYD (PA145)	3	Toxicity/ADR	981201947; 981201948; 981201949	CC:Patients with the CC genotype may have decreased risk of fluorouracil-related toxicity in cancer patients as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of fluorouracil-related toxicity.; CT:Patients with the CT genotype may have an increased risk of fluorouracil-related toxicity in cancer patients as compared to patients with the CC genotype. Genotype CT is also associated with decreased DPYD activity. Other genetic and clinical factors may also influence a patient's risk of fluorouracil-related toxicity.; TT:Patients with the TT genotype may have an increased risk of fluorouracil-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of fluorouracil-related toxicity.	827825116; 827892811; 827892923	Genotype CT is associated with severity of Drug Toxicity when treated with fluorouracil and leucovorin.; Genotype CT is associated with decreased DPYD activity in people with Neoplasms as compared to genotype CC.; Genotype CT is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	15591715; 10803677; 14635116	3	fluorouracil	Neoplasms		
981201994	rs1801265	DPYD (PA145)	3	Toxicity/ADR	981201995; 981201996; 981201997	AA:Patients with the AA genotype may have decreased likelihood of middle-severe nausea and vomiting in Asian cancer patients treated with fluorouracil as as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient's risk for fluorouracil-related toxicity.; AG:Patients with the AG genotype may have increased likelihood of middle-severe nausea and vomiting in Asian cancer patients treated with fluorouracil as as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk for fluorouracil-related toxicity.; GG:Patients with the GG genotype may have increased likelihood of middle-severe nausea and vomiting in Asian cancer patients treated with fluorouracil as as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk for fluorouracil-related toxicity.	769169883; 827824640	Genotype AG is associated with increased likelihood of middle-severe nausea and vomiting when treated with fluorouracil in people with Neoplasms as compared to genotype AA.; Allele G is not associated with decreased catalytic activity of DPYD in peripheral blood.	17848752; 18452418	2	fluorouracil	Neoplasms	Asian	
981202230	rs34489327	TYMS (PA359)	3	Efficacy	981202231; 981202232; 981202233	TTAAAG/TTAAAG:Patients with the TTAAAG/TTAAAG genotype and Colorectal Cancer who are treated with the drug combination fluorouracil, leucovorin and irinotecan may have an increased risk of disease progression as compared to patients with the TTAAAG/del or del/del genotypes. Other genetic and clinical factors may also influence a patient's response to treatment.; TTAAAG/del:Patients with the TTAAAG/del genotype and Colorectal Cancer who are treated with the drug combination fluorouracil, leucovorin and irinotecan may have a decreased risk of disease progression as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; del/del:Patients with the del/del genotype and Colorectal Cancer who are treated with the drug combination fluorouracil, leucovorin and irinotecan may have a decreased risk of disease progression as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.	769166443	Genotype TTAAAGTTAAAG is associated with increased risk of progression when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes DELDEL + TTAAAGDEL.	17549067	1	fluorouracil;irinotecan;leucovorin	Colorectal Neoplasms	White	
981202356	rs3745274	CYP2B6 (PA123)	3	Dosage	981202357; 981202358; 981202359	GG:Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose requirements.; GT:Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.; TT:Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.	827811269	Allele T is associated with decreased likelihood of dose reduction when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele G.	20179710	1	cyclophosphamide;doxorubicin	Breast Neoplasms		
981201399	rs2273697	ABCC2 (PA116)	3	Toxicity/ADR	981201400; 981201401; 981201402	AA:Patients with the AA genotype may have increased risk of renal proximal tubulopathy when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; AG:Patients with the AG genotype may have increased risk of renal proximal tubulopathy when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; GG:Patients with the GG genotype may have decreased but not absent risk of renal proximal tubulopathy when treated with tenofovir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.	827828651; 827828798	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV as compared to allele G.; Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV as compared to allele G.	19400747; 17083032	2	tenofovir	HIV;Kidney Diseases		
981201684	rs4124874	UGT1A1 (PA420),UGT1A10 (PA37174),UGT1A3 (PA37178),UGT1A4 (PA37179),UGT1A5 (PA37180),UGT1A6 (PA37181),UGT1A7 (PA37182),UGT1A8 (PA37183),UGT1A9 (PA419)	3	Toxicity/ADR	981201685; 981201686; 981201687	GG:Patients with the GG genotype and Cancer who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; GT:Patients with the GT genotype and Cancer who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype, or may have a decreased risk of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; TT:Patients with the TT genotype and Cancer who are treated with irinotecan may have a decreased risk of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.	827552123	Allele G is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to allele T.	15007088	1	irinotecan	Lymphoma;Neoplasms		
981201827	rs28399468	CYP2A6 (PA121)	4	Other	981201828; 981201829; 981201830	AA:Patients with the AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.; AC:Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.; CC:Patients with the CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.	769278040; 827551899	Allele A is associated with decreased metabolism of nicotine as compared to allele C.; Allele A is associated with decreased metabolism of nicotine as compared to allele C.	12445030; 11779172	2	nicotine			
981201895	rs1045642	ABCB1 (PA267)	3	Efficacy	981201896; 981201897; 981201898	AA:Genotype AA may be associated with increased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype GG. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. There's also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patient's response to antiepileptics.; AG:Genotype AG may be associated with increased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype GG. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. There's also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patient's response to antiepileptics.; GG:Genotype GG genotype may be associated with decreased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype AA. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. There's also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patient's response to antiepileptics.	769257594; 769257607; 769257735; 769257755; 769257621; 769257569; 769257578; 769257624; 827804313; 827921768	Allele A is not associated with response to antiepileptics in people with Epilepsy as compared to allele G.; Allele A is not associated with response to antiepileptics in people with Epilepsy as compared to allele G.; Allele A is not associated with likelihood of drug resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.; Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.; Genotype AA is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy.; Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.; Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.; Genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy as compared to genotype AA.; Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.; Allele A is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele G.	16542858; 16386926; 15452306; 17125969; 17521963; 17306068; 15857428; 12686700; 21391884; 22630058	10	antiepileptics	Epilepsy		
981201962	rs1801159	DPYD (PA145)	3	Toxicity/ADR	981201963; 981201964; 981201965	CC:Patients with the CC genotype may have increased likelihood of middle-severe nausea, vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the TT genotype. Genotype CC is also associated with decreased clearance of fluorouracil. Other genetic and clinical factors may also influence a patient's risk of fluorouracil related adverse events.; CT:Patients with the CT genotype may have increased likelihood of middle-severe nausea, vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of fluorouracil related adverse events.; TT:Patients with the TT genotype may have decreased likelihood of middle-severe nausea, vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of fluorouracil related adverse events.	769169847; 769169854; 769169871; 827824648; 827892939	Genotype CC is associated with increased likelihood of middle-severe nausea and vomiting when treated with fluorouracil in people with Neoplasms as compared to genotype TT.; Genotype CC is associated with increased incidence of middle-severe white blood cell decreases when treated with fluorouracil in people with Neoplasms as compared to genotype TT.; Genotype CC is associated with decreased clearance of fluorouracil.; Allele C is not associated with decreased catalytic activity of DPYD in peripheral blood.; Genotype CT is not associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	17848752; 17848752; 17848752; 18452418; 14635116	5	fluorouracil	Neoplasms	Asian	
981202618	rs4680	COMT (PA117)	2A	Efficacy	981202619; 981202620; 981202621	AA:Patients with the AA genotype who are treated with nicotine replacement therapy may have an increased likelihood of smoking cessation and decreased risk of relapse as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.; AG:Patients with the AG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.; GG:Patients with the GG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.	655386671; 655386691; 655386700	Genotype AA is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotypes GG + AG.; Genotype AG is associated with increased likelihood of relapse when treated with nicotine.; Genotype GG is associated with increased likelihood of relapse when treated with nicotine.	17548664; 18192898; 18192898	3	nicotine	Tobacco Use Disorder	White	
981201387	rs2236225	MTHFD1 (PA31236)	3	Efficacy	981201388; 981201389; 981201390	AA:Patients with the AA genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for response to therapy.; AG:Patients with the AG genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for response to therapy.; GG:Patients with the GG genotype may have increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for response to therapy.	608431578; 769174305	Allele A is associated with decreased likelihood of event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; Allele A is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.	14647408; 15797993	2	methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma	White	
981201443	rs2070744	NOS3 (PA254)	3	Efficacy	981201444; 981201445; 981201446	CC:Patients with the CC genotype may have increased risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.; CT:Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.; TT:Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.	699638662	Genotype CC is associated with increased risk of resistant hypertension when treated with Antihypertensives and diuretics in people with Hypertension as compared to genotypes TT + CT.	19650939	1	Antihypertensives;Antihypertensives And Diuretics In Combination;diuretics	Hypertension	White	
981202609	rs4673993	ATIC (PA25094)	2B	Efficacy	981202610; 981202611; 981202612	CC:Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; CT:Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype or may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; TT:Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.	769153041; 769173673	Allele C is associated with decreased risk of Disease Activity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.; Allele C is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	20847201; 19193698	2	methotrexate	Arthritis, Rheumatoid		
981188379	rs2072671	CDA (PA98)	3	Toxicity/ADR	981188380; 981188381; 981188382	AA:Patients with the AA genotype who are treated with gemcitabine may have an increased risk of hematological toxicity and decreased risk of gastrointestinal toxicity as compared to patients with the the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; AC:Patients with the AC genotype who are treated with gemcitabine may have an increased risk of hematological toxicity as compared to patients with the the CC genotype and an increased risk of gastrointestinal toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; CC:Patients with the CC genotype who are treated with gemcitabine may have an increased risk of gastrointestinal toxicity and decreased risk of hematological toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.	655386820; 769245523; 827641523; 827803765; 827815544; 827817256	Allele C is not associated with decreased metabolism of gemcitabine in people with Neoplasms as compared to allele A.; Allele C is not associated with expression of CDA in CEPH cell lines.; Genotypes AA + AC are associated with increased severity of Drug Toxicity when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.; Genotype CC is associated with increased expression of CDA in PBMCs.; Allele C is associated with increased frequency of nausea/vomiting grade>=2 events when treated with gemcitabine and Platinum compounds in people with Mesothelioma as compared to allele A.; Genotypes AC + CC are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.	17194903; 21325291; 21625252; 21521023; 22134350; 22026922	6	gemcitabine	Mesothelioma;Pancreatic Neoplasms		
981201333	rs2227983	EGFR (PA7360)	3	Toxicity/ADR	981201336; 981201335; 981201334	AA:Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AG:Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype may have an increased risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.	637880031; 769170841; 827812838	Allele A is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele G.; Allele A is associated with cytotoxicity of egfr inhibitors.; Genotype GG is associated with increased likelihood of Exanthema when treated with egfr inhibitors in people with Neoplasms as compared to genotypes AA + AG.	16788380; 18006781; 22158333	3	cetuximab;egfr inhibitors;erlotinib	Carcinoma, Non-Small-Cell Lung;Colorectal Neoplasms;Neoplasms;Pancreatic Neoplasms		
981201424	rs2278294	IMPDH1 (PA29862)	3	Toxicity/ADR	981201425; 981201426; 981201427	CC:Patients with the CC genotype may have decreased but not absent risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; CT:Patients with the CT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; TT:Patients with the TT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.	769262707; 827808010	Allele T is not associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.; Allele T is associated with increased risk of leucopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	21142914; 20679962	2	mycophenolate mofetil	Leukopenia		
981201535	rs2297595	DPYD (PA145)	2A	Toxicity/ADR	981201536; 981201537; 981201538	CC:Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.; CT:Patients with the CT genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.; TT:Patients with the TT genotype may have decreased but not absent risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.	769169640; 827810914; 827892931	Allele C is associated with increased risk of toxicity of fluoropyrimidine-based chemotherapy when treated with capecitabine and fluorouracil in people with Breast Neoplasms as compared to allele T.; Genotypes CC + CT are associated with increased severity of Drug Toxicity when treated with bevacizumab, capecitabine, cetuximab and oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT.; Genotype CT is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	19104657; 21498394; 14635116	3	capecitabine;fluorouracil	Breast Neoplasms;Colorectal Neoplasms;Drug Toxicity;Neoplasms;Pancreatic Neoplasms	White	
981201584	rs3215400	CDA (PA98)	3	Toxicity/ADR	981201585; 981201586; 981201587	C/del:Patients with the C/del genotype and cancer who are treated with capecitabine may have a decreased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the del/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.; CC:Patients with the C/C genotype and cancer who are treated with capecitabine may have a decreased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the del/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.; del/del:Patients with the del/del genotype and cancer who are treated with capecitabine may have an increased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the CC or C/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.	769245524; 827824412	Genotypes CC + CDEL are associated with decreased likelihood of grade 3 hand-foot syndrome when treated with capecitabine in people with Neoplasms as compared to genotype DELDEL.; Genotypes C/DEL + CC are associated with increased likelihood of grade III hand foot syndrome when treated with capecitabine in people with Neoplasms as compared to genotype DEL/DEL.	21325291; 18473752	2	capecitabine	Neoplasms;Palmar-plantar erythrodysaesthesia syndrome		
981201674	rs3909184	FLOT1 (PA28175)	1B	Toxicity/ADR	981201675; 981201676; 981201677	CC:Patients with the CC genotype (non-carriers of the HLA-B*1502 allele) who are treated with carbamazapine may have a decreased risk of Stevens-Johnson Syndrome as compared to patients with the GG or CG genotype (patients who carry the HLA-B*1502 allele). Please note, this SNP is used as a tagging SNP for the HLA-B*1502 allele, and the genotyping method used to determine the HLA-B*1502 allele was not described. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions when treated with carbamazapine.; CG:Patients with the CG genotype (carriers of the HLA-B*1502 allele) who are treated with carbamazapine may have an increased risk of Stevens-Johnson Syndrome as compared to patients with the CC genotype (non-carriers of the HLA-B*1502 allele). Please note, this SNP is used as a tagging SNP for the HLA-B*1502 allele, and the genotyping method used to determine the HLA-B*1502 allele was not described. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions when treated with carbamazapine.; GG:Patients with the GG genotype (carriers of the HLA-B*1502 allele) who are treated with carbamazapine may have an increased risk of Stevens Johnson-Syndrome as compared to patients with the CC genotype (non-carriers of the HLA-B*1502 allele). Please note, this SNP is used as a tagging SNP for the HLA-B*1502 allele, and the genotyping method used to determine the HLA-B*1502 allele was not described. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions when treated with carbamazapine.	769251028; 769251037	Allele G is associated with increased risk of Stevens Johnson Syndrome when treated with carbamazepine in people with Epilepsy.; Allele G is associated with increased risk of Stevens Johnson Syndrome when treated with carbamazepine.	18637831; 15057820	2	carbamazepine	Epilepsy;Stevens-Johnson Syndrome	Asian	
981201713	rs4148323	UGT1A1 (PA420),UGT1A10 (PA37174),UGT1A3 (PA37178),UGT1A4 (PA37179),UGT1A5 (PA37180),UGT1A6 (PA37181),UGT1A7 (PA37182),UGT1A8 (PA37183),UGT1A9 (PA419)	3	Other	981201714; 981201715; 981201716	AA:Patients with the AA genotype and Cancer may have decreased inactivation of irinotecan metabolite SN38, as compared to patients with the GG genotype. This variant is not associated with risk of severe toxicities. Other genetic and clinical factors may also influence metabolism of irinotecan.; AG:Patients with the AG genotype and Cancer may have decreased inactivation of irinotecan metabolite SN38 as compared to patients with the GG genotype, or may have increased inactivation of irinotecan metabolite SN38 as compared to patients with the AA genotype. This variant is not associated with risk of severe toxicities. Other genetic and clinical factors may also influence metabolism of irinotecan.; GG:Patients with the GG genotype and Cancer may have increased inactivation of irinotecan metabolite SN38 as compared to patients with the AA genotype. This variant is not associated with risk of severe toxicities. Other genetic and clinical factors may also influence metabolism of irinotecan.	827552273; 827639062; 827675836	Allele A is associated with decreased metabolism of irinotecan in people with Neoplasms as compared to allele G.; Allele A is not associated with increased likelihood of severe toxicities when treated with irinotecan in people with Neoplasms as compared to allele G.; Allele A is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.	15179405; 11156391; 12181437	3	irinotecan	Neoplasms	Asian	
981201770	rs4149117	SLCO1B3 (PA35844)	4	Dosage;Toxicity/ADR	981201771; 981201772; 981201773	GG:Patients with the GG genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.; GT:Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.; TT:Patients with the TT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.	655387664; 769262706	Allele G is associated with decreased in mycophenolic acid dn Cmax and dn AUC0to12 h when treated with mycophenolate mofetil in people with kidney transplants as compared to allele T.; Allele G is associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.	19890249; 21142914	2	mycophenolate mofetil	Kidney Transplantation		
981201875	rs2844682	MUC21 (PA162396305)	3	Toxicity/ADR	981201876; 981201877; 981201878	AA:Patients with the AA genotype may have decreased but not absent risk of Stevens-Johnson syndrome when treated with carbamazepine as compared to patients with the AG or GG genotypes. This variant is a tagging SNP for HLA-B*1502, for which there is greater evidence of association with carbamazepine associated Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Other genetic and clinical factors may also influence a patient's risk for adverse events.; AG:Patients with the AG genotype may have increased risk of Stevens-Johnson syndrome when treated with carbamazepine as compared to patients with the AA genotype. This variant is a tagging SNP for HLA-B*1502, for which there is greater evidence of association with carbamazepine associated Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Other genetic and clinical factors may also influence a patient's risk for adverse events.; GG:Patients with the GG genotype may have increased risk of Stevens-Johnson syndrome when treated with carbamazepine as compared to patients with the AA genotype. This variant is a tagging SNP for HLA-B*1502, for which there is greater evidence of association with carbamazepine associated Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Other genetic and clinical factors may also influence a patient's risk for adverse events.	769251031; 769251040	Allele G is associated with increased risk of Stevens Johnson Syndrome when treated with carbamazepine in people with Epilepsy.; Allele G is associated with increased risk of Stevens Johnson Syndrome when treated with carbamazepine.	18637831; 15057820	2	carbamazepine	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome	Asian	
981201937	rs12714145	GGCX (PA28660)	3	Dosage	981201938; 981201939; 981201940	CC:Genotype CC may be associated with decreased dose of warfarin as compared to genotype TT. However, contradictory findings (no association) have been reported. Other genetic and clinical factors may influence a patient's dose of warfain.; CT:Genotype CT may be associated with decreased dose of warfarin as compared to genotype TT. However, contradictory findings (no association) have been reported. Other genetic and clinical factors may influence a patient's dose of warfain.; TT:Genotype TT may be associated with increased dose of warfarin as compared to genotype GG. However, contradictory findings (no association) have been reported. Other genetic and clinical factors may influence a patient's dose of warfain.	608431741; 769168963; 827567352	Allele T is not associated with dose of warfarin.; Allele T is not associated with dose of warfarin.; Allele C is associated with decreased dose of warfarin as compared to allele T.	19794411; 20694283; 15883587	3	warfarin			
981201972	rs1801159	DPYD (PA145)	3		981201973; 981201974; 981201975	CC:CC genotype is not associated with response to fluorouracil in white colon cancer patients as compared to TT genotype. Other genetic and clinical factors may influence a patient's response to fluorouracil.; CT:CT genotype is not associated with response to fluorouracil in white colon cancer patients as compared to TT genotype. Other genetic and clinical factors may influence a patient's response to fluorouracil.; TT:TT genotype is not associated with response to fluorouracil in white colon cancer patients as compared to CC genotype. Other genetic and clinical factors may influence a patient's response to fluorouracil.	827813451	Allele C is not associated with response to fluorouracil in people with Colonic Neoplasms as compared to allele T.	20665215	1	fluorouracil	Colonic Neoplasms	White	
981202046	rs5031016	CYP2A6 (PA121)	4	Other	981202047; 981202048; 981202049	AA:Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the GG or AG genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. Other genetic and clinical factors may also influence metabolism of nicotine.; AG:Patients with the AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. Other genetic and clinical factors may also influence metabolism of nicotine.; GG:Patients with the GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. Other genetic and clinical factors may also influence metabolism of nicotine.	769278041; 769278059	Allele G is associated with decreased metabolism of nicotine as compared to allele A.; Allele G is associated with decreased metabolism of nicotine as compared to allele A.	12445030; 11779172	2	nicotine		Asian	
981202068	rs662	PON1 (PA33529)	3	Efficacy	981202069; 981202070; 981202071	CC:Patients with the CC genotype who are treated with clopidogrel 1) may have higher levels of active metabolite, resulting in increased platelet inhibition and better response 2) may have a decreased, but not absent, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CT or TT genotype. This association has not been found in more studies than the number of studies the association was shown. Other genetic and clinical factors may also influence a patient's response to clopidogrel.; CT:Patients with the CT genotype who are treated with clopidogrel 1) may have lower levels of active metabolite, resulting in decreased platelet inhibition and decreased response 2) may have an increased risk for stent thrombosis, target vessel revascularization, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CC genotype. This association has not been found in more studies than the number of studies the association was shown. Other genetic and clinical factors may also influence a patient's response to clopidogrel.; TT:Patients with the TT genotype who are treated with clopidogrel 1) may have lower levels of active metabolite, resulting in decreased platelet inhibition and decreased response 2) may have an increased risk for stent thrombosis, target vessel revascularization, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CC genotype. This association has not been found in more studies than the number of studies the association was shown. Other genetic and clinical factors may also influence a patient's response to clopidogrel.	769258865; 769164682; 827714744; 827783951; 827783972; 827784037; 827784078; 827814062; 827814135; 827919665	Allele T is not associated with increased risk of stent thrombosis when treated with in people with Coronary Artery Disease as compared to allele C.; Genotype TT is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.; Allele T is not associated with increased risk of in-hospital ischemic events and major cardiovascular events at 1 year when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.; Allele C is not associated with ADP-stimulated, pre-clopidogrel  platelet aggregation when treated with as compared to allele T.; Allele C is not associated with cardiovascular events as compared to allele T.; Allele C is not associated with ADP-stimulated platelet aggregation when treated with clopidogrel as compared to allele T.; Allele C is not associated with High Platelet Reactivity (HPR) when treated with clopidogrel as compared to allele T.; Allele C is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele T.; Genotype CC is associated with lower on-clopidogrel platelet reactivity (PR) at 1 month and at 6 months after percutaneous coronary intervention (PCI) when treated with clopidogrel in people with Myocardial Ischemia as compared to genotypes CT + TT.; Genotype CC is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to genotype TT.	21527445; 21170047; 21918510; 21881565; 21881565; 21881565; 21881565; 21806387; 21819538; 22462746	10	clopidogrel	Angina Pectoris;Coronary Artery Disease;Myocardial Infarction;Myocardial Ischemia;Thrombosis		
981202294	rs3745274	CYP2B6 (PA123)	2A	Other	981202295; 981202296; 981202297	GG:Patients with the GG genotype and HIV infection may have increased clearance of and decreased exposure to nevirapine as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug.; GT:Patients with the GT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug.; TT:Patients with the TT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug.	769163522; 827807692; 827823670; 827848013; 827848806; 827848956; 827848963; 827849230; 827861835; 827861846; 827784211	Genotype TT is associated with increased plasma exposure of nevirapine in people with HIV Infections as compared to genotype GG.; Allele T is associated with increased plasma concentration of nevirapine in people with HIV as compared to allele G.; Genotypes GT + TT are associated with decreased clearance of nevirapine in people with HIV as compared to genotype GG.; Allele T is associated with decreased clearance of nevirapine in people with HIV as compared to allele G.; Allele T is not associated with increased risk of toxicity when treated with nevirapine in people with HIV as compared to allele G.; Genotype GT is associated with decreased clearance of nevirapine in people with HIV as compared to genotype GG.; Genotype TT is associated with decreased clearance of nevirapine in people with HIV as compared to genotype GG.; Genotype TT is associated with decreased clearance of nevirapine in children with HIV as compared to genotypes GG + GT.; Genotype TT is associated with decreased clearance of nevirapine in people with HIV as compared to genotype GG.; Genotype GT is associated with decreased clearance of nevirapine in people with HIV as compared to genotype GG.; Allele T is associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele G.	15864119; 18281305; 22111602; 22354160; 21824325; 19228205; 19228205; 21393201; 21441248; 21441248; 21860339	11	nevirapine	HIV Infections		
981202334	rs3745274	CYP2B6 (PA123)	3	Toxicity/ADR	981202335; 981202336; 981202337	GG:Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GG genotype may have an increased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.; GT:Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.; TT:Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the TT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.	699642251	Genotypes TT + GT are associated with decreased risk of venoocclusive disease of the liver when treated with cyclophosphamide in people with HLA-identical hematopoietic stem cell transplantation as compared to genotype GG.	19005482	1	cyclophosphamide	Hepatic Veno-Occlusive Disease;Transplantation		
981202366	rs3758149	GGH (PA432)	3	Efficacy	981202367; 981202368; 981202369	AA:Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have decreased conversion of the drug to active polyglutamates 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.; AG:Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have increased conversion of the drug to active polyglutamates as compared to the AA genotype 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.; GG:Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have increased conversion of the drug to active polyglutamates 2) may have increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.	655387656; 769170797	Genotype AA is associated with decreased methotrexate polyglutamate (MTXPG3-5) levels when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + AG.; Genotypes AA + AG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	15564880; 19827168	2	methotrexate	Arthritis, Rheumatoid		
981202598	rs4444903	EGF (PA27664)	2B	Efficacy	981202599; 981202600; 981202601	AA:Patients with the AA genotype who are treated with cetuximab may have a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.; AG:Patients with the AG genotype who are treated with cetuximab may have a poorer response as compared to patients with the GG genotype or may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.; GG:Patients with the GG genotype who are treated with cetuximab may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.	637880035; 637880058; 827697915	Genotype AA is associated with increased survival when treated with cetuximab in people with Colorectal Neoplasms as compared to genotypes GG + AG.; Genotype AA is associated with decreased overall survival when treated with cetuximab in people with colorectal neoplasms as compared to genotype GG.; Genotype GG is associated with increased likelihood of complete pathologic response when treated with cetuximab in people with Rectal Neoplasms as compared to genotype AA.	16788380; 18349392; 21673069	3	cetuximab	Colorectal Neoplasms;Rectal Neoplasms	White	
981202393	rs1801394	MTRR (PA31277)	2B	Toxicity/ADR	981478307; 981478308; 981478309	AA:Pediatric ALL patients with AA genotypes may have decreased likelihood of methotrexate induced toxicity (oral mucositis) and decreased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the GG and AG genotype. Other genetic and clinical factors may also influence response to methotrexate.; AG:Pediatric ALL patients with AG genotypes may have increased likelihood of methotrexate induced toxicity (oral mucositis), increased speed of platelet recovery and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.; GG:Pediatric ALL patients with GG genotypes may have increased likelihood of methotrexate induced toxicity (oral mucositis) and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.	981202405; 769170712; 769173709; 769174311	Genotypes AG + GG are associated with increased likelihood of MTX induced toxicity (oral mucositis) when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotype AG is associated with increased speed of platelet recovery when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + GG.; Allele G is not associated with decreased IQ when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotypes GG + AG are associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.	18368069; 18368069; 16013960; 15797993	4	methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma		
981202674	rs4680	COMT (PA117)	4	Other	981202675; 981202676; 981202677	AA:Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype. Metabolic syndrome was also associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AA genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.; AG:Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype or decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AG genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.; GG:Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. Patients with the GG genotype who are treated with antipsychotics and have metabolic syndrome may have similar levels of methylation at sites within the COMT gene promoter to those seen in patients with the AA genotype without metabolic syndrome. Other genetic and clinical factors may also influence methylation of the COMT gene promoter. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.	827849062	Allele A is associated with increased methylation at sites 1 and 2 in the COMT promoter when treated with antipsychotics in people with Schizophrenia as compared to allele G.	22391769	1	antipsychotics	Schizophrenia		
981201637	rs34489327	TYMS (PA359)	3	Toxicity/ADR	981201640; 981201639; 981201638	TTAAAG/TTAAAG:Patients with the TTAAAG/TTAAAG genotype who are treated with methotrexate may have a decreased, but not absent, risk of hepatotoxicity and may develop less severe oral mucositis as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity.; TTAAAG/del:Patients with the TTAAAG/del genotype who are treated with methotrexate may have a decreased, but not absent, risk of hepatotoxicity and may develop less severe oral mucositis as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity.; del/del:Patients with the del/del genotype who are treated with methotrexate may have an increased risk of hepatotoxicity and may develop more severe oral mucositis as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity.	655385907; 769146377	Genotype DEL is associated with increased risk of hepatotoxicity when exposed to methotrexate in people with Psoriasis.; Genotype DELDEL is associated with increased severity of oral mucositis when treated with methotrexate in people with hematopoietic-cell-transplantation as compared to genotype TTAAAGTTAAAG.	17410198; 16501586	2	methotrexate	Drug Toxicity;Toxic liver disease		
981201788	rs2740574	CYP3A (PA27114),CYP3A4 (PA130)	3	Other	981201789; 981201790; 981201791	CC:Patients with the CC genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.; CT:Patients with the CT genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.; TT:Patients with the TT genotype may have decreased plasma drug exposure when treated with efavirenz as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.	827922971; 827695641	Allele C is associated with increased plasma efavirenz exposure when treated with efavirenz in people with HIV as compared to allele T.; Genotypes CC + CT are not associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotype TT.	15622315; 16267764	2	efavirenz	HIV		
981201854	rs28399499	CYP2A7P1 (PA27103),CYP2B6 (PA123)	2A	Other	981201855; 981201856; 981201857	CC:Patients with the CC genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.; CT:Patients with the CT genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.; TT:Patients with the TT genotype may have decreased plasma drug exposure when treated with nevirapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.	769170849; 769170861; 827807701; 827848035; 827848949; 827861853	Allele C is associated with decreased expression of CYP2B6.; Allele C is associated with decreased expression of CYP2B6.; Genotype CT is associated with increased plasma concentration of nevirapine in people with HIV as compared to genotype TT.; Genotypes CC + CT are not associated with decreased clearance of nevirapine in people with HIV as compared to genotype TT.; Genotype CC is not associated with decreased clearance of nevirapine in people with HIV as compared to genotypes CT + TT.; Genotype CT is associated with decreased clearance of nevirapine in people with HIV as compared to genotype TT.	16272958; 16495778; 18281305; 22354160; 19228205; 21441248	6	nevirapine	HIV		
981201408	rs2278294	IMPDH1 (PA29862)	2B	Efficacy	981201409; 981201410; 981201411	CC:Patients with the CC genotype may have increased risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; CT:Patients with the CT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; TT:Patients with the TT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.	769262707; 731714509; 827807997; 827808010	Allele T is not associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.; Genotypes TT + CT are associated with decreased risk of biopsy-proven acute rejection when treated with mycophenolate mofetil in people with kidney transplant as compared to genotype CC.; Allele T is associated with decreased risk of acute rejection when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.; Allele T is associated with increased risk of leucopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	21142914; 17851563; 20679962; 20679962	4	mycophenolate mofetil	Kidney Transplantation;Organ Transplantation		
981202240	rs34489327	TYMS (PA359)	3	Efficacy	981202241; 981202242; 981202243	TTAAAG/TTAAAG:Patients with the TTAAAG/TTAAAG genotype and Colorectal Cancer who are treated with fluorouracil-based adjuvant therapy may have a better response as compared to patients with the TTAAAG/del or del/del genotype who also have rs45445694 genotype 2R/2R. Other genetic and clinical factors may also influence a patient's response to treatment.; TTAAAG/del:Patients with the TTAAAG/del genotype who also have rs45445694 genotype 2R/2R and Colorectal Cancer who are treated with fluorouracil may have a decreased response as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; del/del:Patients with the del/del genotype who also have rs45445694 genotype 2R/2R and Colorectal Cancer who are treated with fluorouracil may have a decreased response as compared to patients with the TTAAAG/TTAAAG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.	827811348; 827811365; 827813357; 769166443	Allele TTAAAG is not associated with survival when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms.; Allele TTAAAG is not associated with Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms.; Genotypes TTAAAG/DEL + DEL/DEL are associated with decreased response to fluorouracil in people with Colorectal Neoplasms.; Genotype TTAAAGTTAAAG is associated with increased risk of progression when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes DELDEL + TTAAAGDEL.	19384296; 19384296; 21919605; 17549067	4	fluorouracil	Colorectal Neoplasms		
981202551	rs4244285	CYP2C19 (PA124)	4	Efficacy	981202552; 981202553; 981202554	AA:Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; AG:Patients with the AG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; GG:Patients with the AG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.	827811311	Genotype AA is associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes AG + GG.	20179710	1	cyclophosphamide;doxorubicin	Breast Neoplasms		
981201817	rs28399454	CYP2A6 (PA121)	4	Other	981201818; 981201819; 981201820	CC:Patients with the CC genotype may have decreased plasma drug concentration when treated with efavirenz as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.; CT:Patients with the CT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.; TT:Patients with the TT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.	769163300; 769163503; 769163136	Genotype CT is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to genotype CC.; Genotype TT is not associated with increased mid-dose plasma concentrations of efavirenz in people with HIV Infections.; Genotypes TT + CT are not associated with increased plasma concentration (p=0.509) of efavirenz in people with HIV Infections as compared to genotype CC.	20860463; 19371316; 19779319	3	efavirenz	HIV		
978608464	rs1801133	MTHFR (PA245)	3	Efficacy	978608465; 978608466; 978608467	AA:Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.; AG:Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.; GG:Patients with the GG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have an increased risk of Graft vs Host disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.	699642245; 769146358	Allele A is associated with graft vs host disease in people with recipients of HLA-identical hematopoietic stem cell transplantation.; Genotype AA is associated with decreased risk of Graft vs Host Disease when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.	19005482; 16920564	2	methotrexate	Graft vs Host Disease;Leukemia;Leukemia, Myelogenous, Chronic, BCR-ABL Positive		
981202090	rs71647871	CES1 (PA107)	3	Dosage	981202091; 981202092; 981202093	CC:Patients with the CC genotype and Attention Deficit Disorder may require an increased dose of methylphenidate as compared to patients with the CC genotype. This was not associated with response. Other genetic and clinical factors may also influence methylphenidate dose and response.; CT:Patients with the CT genotype and Attention Deficit Disorder may require a decreased dose of methylphenidate as compared to patients with the CC genotype. This was not associated with response. Other genetic and clinical factors may also influence methylphenidate dose and response.; TT:Patients with the TT genotype were not studied, however patients with the CT genotype and Attention Deficit Disorder may require a decreased dose of methylphenidate as compared to patients with the CC genotype. This was not associated with response. Other genetic and clinical factors may also influence methylphenidate dose and response.	827923804; 827923820; 827923830	Allele T is associated with decreased catalytic activity of CES1 when assayed with methylphenidate.; Genotype CT is associated with decreased dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.; Genotype CT is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	18485328; 19733552; 19733552	3	methylphenidate	Attention Deficit Disorder with Hyperactivity	White	
981202714	rs4961	ADD1 (PA31)	3	Efficacy	981202715; 981202716; 981202717	GG:Patients with the GG genotype may have a poorer response to hydrochlorothiazide treatment as compared to patients with the TT or GT genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.; GT:Patients with the GT genotype may have a better response to hydrochlorothiazide treatment as compared to patients with the GG genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.; TT:Patients with the TT genotype may have a better response to hydrochlorothiazide treatment as compared to patients with the GG genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.	769170910; 827921263; 827923882; 827923903; 827923924; 827924535; 827924748	Allele T is associated with the largest mean blood pressure decrease in combination with the I allele of ACE:I/D variant when treated with hydrochlorothiazide in people with Hypertension as compared to allele G.; Allele T is not associated with response to hydrochlorothiazide in people with Essential hypertension as compared to allele G.; Genotype GT is associated with increased reduction in mean arterial pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotype GG.; Genotypes GT + TT are associated with increased reduction in mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.; Genotypes GT + TT are associated with increased reduction in mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.; Allele T is associated with decreased reduction in ambulatory SBP when treated with hydrochlorothiazide in men with Hypertension as compared to allele G.; Genotypes GT + TT are associated with increased reduction in blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.	12623934; 14553962; 9149697; 10523341; 11882573; 19057513; 18591455	7	hydrochlorothiazide	Essential hypertension;Hypertension		
981188336	rs34743033	C18orf56 (PA134956204),TYMS (PA359)	3	Efficacy;Toxicity/ADR	981188337; 981188338; 981188339	(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2:Patients with the 2R/2R genotype may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R/3R genotype. Other genetic and clinical factors may also influence response to methotrexate. The relevance of this genotype for toxicity or for efficacy of methotrexate in inflammatory disease is not clear.; (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3:Patients with the 2R/3R genotype may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R/3R genotype. Other genetic and clinical factors may also influence response to methotrexate. The relevance of this genotype for toxicity or for efficacy of methotrexate in inflammatory disease is not clear.; (CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3:Patients with the 3R/3R genotype may have decreased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 2R/2R genotype. Other genetic and clinical factors may also influence response to methotrexate. The relevance of this genotype for toxicity or for efficacy of methotrexate in inflammatory disease is not clear.	978639836; 769170720; 769169072; 608431580; 655385912; 769171237; 769171288; 769174317; 769174406; 769166457; 769170736; 769171001; 769171263; 769171272; 769171359; 769174427; 827699118; 827863348	Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with decreased expression of TYMS.; Genotype 3 is associated with decreased likelihood of event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotype 3 is associated with increased risk of adverse event when exposed to methotrexate in people with Psoriasis.; Genotype 3 is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2.; Genotype 3 is not associated with response to methotrexate in people with Arthritis, Rheumatoid.; Genotype 3 is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.; Genotype 3 is not associated with response to cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2.; Genotype 33 is associated with decreased response to capecitabine and raltitrexed in people with Colorectal Neoplasms as compared to genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2.; Genotype 33 is associated with increased risk of CNS relapse when treated with asparaginase, cytarabine, daunorubicin, dexamethasone, etoposide, mercaptopurine, methotrexate and vincristine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)23.; Genotype 33 is not associated with Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotype 33 is associated with decreased progression free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)23.; Genotype 33 is associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotype 33 is not associated with increased risk of relapse when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)23.; Genotype 33 is associated with decreased event free survuval when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)23.; Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with response to carboplatin and pemetrexed in people with Mesothelioma as compared to allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)3.; Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)3 is not associated with response to methotrexate in people with Arthritis, Rheumatoid.	22838948; 18368069; 14522928; 14647408; 17410198; 18322994; 20386493; 15797993; 19159907; 17203168; 15713801; 17323057; 11937185; 12972956; 12651279; 16130010; 21262916; 22450926	18	methotrexate;pemetrexed;raltitrexed	Arthritis, Rheumatoid;Colorectal Neoplasms;Neoplasms;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Psoriasis	White	
981202440	rs396991	FCGR3A (PA28065)	2B	Efficacy	981202441; 981202442; 981202443	AA:Patients with the AA genotype with Colorectal Cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to therapy.; AC:Patients with the AC genotype with Colorectal Cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype or may have poorer response and treatment outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to therapy.; CC:Patients with the CC genotype with Colorectal Cancer who are treated with cetuximab may have poorer response and treatment outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to therapy.	769171568; 827843556	Allele A is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to allele C.; Allele A is associated with increased overall survival and progression-free survival when treated with cetuximab in people with Colorectal Neoplasms as compared to allele C.	17704420; 22117530	2	cetuximab	Colorectal Neoplasms		
978639596	rs10509681	CYP2C8 (PA125)	3	Other	978639597; 978639598; 978639599	CC:Individuals with the CC genotype were not studied, however individuals with the CT (CYP2C8*3/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide and blood glucose levels.; CT:Individuals with the CT (CYP2C8*3/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide.; TT:Individuals with the TT (CYP2C8*1/*1) genotype may have decreased metabolism of repaglinide compared to patients with the CT genotype (CYP2C8*3/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide.	655387159	Allele C is associated with increased metabolism of repaglinide in people with no disease as compared to allele T.	14534525	1	repaglinide		White	
981201917	rs4986893	CYP2C19 (PA124)	1A	Efficacy;Toxicity/ADR	981201918; 981201919; 981201920	AA:Patients with the AA genotype 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.; AG:Patients with the AG genotype 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.; GG:Patients with the GG genotype 1) may have increased metabolism of clopidogrel and formation of active drug metabolite, resulting in increased response 2) may have a decreased, but not absent, risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.	655386901; 769255162; 827919808	Allele A is associated with increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.; Genotype AA is associated with decreased response to clopidogrel.; Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.	20801494; 21178986; 22462746	3	clopidogrel	Acute coronary syndrome;Coronary Artery Disease		
981419266	HLA-B *15:02:01	HLA-B (PA35056)	1A	Toxicity/ADR	981419398	*15:02:01:Patients with one or two copies of the HLA-B*15:02:01 allele have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with phenytoin as compared to patients with no HLA-B*15:02:01 alleles or negative for the HLA-B*15:02:01 test.	981349390; 981349397	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.; HLA-B *15:02:01 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine or phenytoin in people with Epilepsy.	18637831; 18637831	2	phenytoin	Epidermal Necrolysis, Toxic;Stevens-Johnson Syndrome	Asian	
981204695	rs1799971	OPRM1 (PA31945)	3	Efficacy;Toxicity/ADR	981204696; 981204697; 981204698	AA:Patients with the AA genotype who are treated with naltrexone may have a decreased 1) response to naltrexone, 2) blunting of alcohol craving, 3) severity of intoxication when exposed to ethanol and naltrexone as compared to patients with the AG or GG genotype. The association with naltrexone response has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to naltrexone.; AG:Patients with the AG genotype who are treated with naltrexone may have an increased 1) response to naltrexone, 2) blunting of alcohol craving, 3) severity of intoxication when exposed to ethanol and naltrexone as compared to patients with the AA genotype. The association with naltrexone response has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to naltrexone.; GG:Patients with the GG genotype who are treated with naltrexone may have an increased 1) response to naltrexone, 2) blunting of alcohol craving, 3) severity of intoxication when exposed to ethanol and naltrexone as compared to patients with the AA genotype. The association with naltrexone response has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to naltrexone.	769171526; 827785851; 827805932; 827806034	Genotypes GG + AG are associated with increased response to naltrexone in people with Alcoholism as compared to genotype AA.; Allele G is not associated with treatment success on any of the outcome measures when treated with naltrexone in people with Alcoholism as compared to allele A.; Genotypes AG + GG are associated with increased blunting of alcohol craving when treated with naltrexone in healthy individuals as compared to genotype AA.; Genotypes AG + GG are associated with increased severity of intoxication when exposed to ethanol and naltrexone in healthy individuals as compared to genotype AA.	18250251; 21946895; 21900886; 21900886	4	naltrexone	Alcoholism		
981237907	rs1127354	ITPA (PA29973)	2B	Dosage;Toxicity/ADR	981237908; 981237909; 981237910	AA:Patients with the AA genotype and Hepatitis C, Chronic may have a decreased, but not absent, risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.; AC:Patients with the AC genotype and Hepatitis C, Chronic may have a decreased, but not absent, risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.; CC:Patients with the CC genotype and Hepatitis C, Chronic may have an increased risk of 1) dose reduction of ribavirin, 2) rapid decrease in hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin or interferon alfa-2b, recombinant and ribavirin, and telaprevir as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.	827814638; 827815086; 827815123; 827815133	Genotype CC is associated with requirement for earlier dose reduction of ribavirin when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis as compared to genotypes AA + AC.; Genotype CC is associated with rapid decrease in hemoglobin levels during the initial 4 weeks when treated with interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.; Genotype CC is associated with cumulative reduction of ribavirin when treated with interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.; Genotype CC is associated with decreased frequency of patients who received at least the recommended 80% of scheduled ribavirin when treated with interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	21628662; 21503919; 21503919; 21503919	4	interferon alfa-2b, recombinant;ribavirin	Hepatitis C, Chronic	Asian	
981238370	rs1979277	SHMT1 (PA35753)	3	Toxicity/ADR	981481601; 981481602; 981481603	AA:Pediatric patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased catalytic activity of TYMS as compared to pediatric patients with the AG and GG genotype. Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.; AG:Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Toxic liver disease as compared to patients with the AA and GG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.; GG:Pediatric patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.	769174314; 769170716; 978639846	Genotype AA is associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.; Genotype AG is associated with decreased likelihood of Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + GG.; Allele A is not associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	15797993; 18368069; 22838948	3	methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma		
981237900	rs11212617	C11orf65 (PA144596484)	2B	Efficacy	981237901; 981237902; 981237903	AA:Patients with the AA genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.; AC:Patients with the AC genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype or may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.; CC:Patients with the CC genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.	978614975; 827864536	Allele C is not associated with increased response to metformin in people with impaired glucose tolerance as compared to allele A.; Allele C is associated with treatment success, achieving an HbA1c below 7% when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	22751958; 21186350	2	metformin	Diabetes Mellitus, Type 2		
981238025	rs2032582	ABCB1 (PA267)	3	Efficacy	981238028; 981238027; 981238026	CC:Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.; CT:Patients with the CT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.; TT:Patients with the TT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.	827811288	Genotypes CT + TT are associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes AC + CC.	20179710	1	cyclophosphamide;doxorubicin	Breast Neoplasms		
981240029	rs5219	KCNJ11 (PA217)	3	Efficacy	981240032; 981240031; 981240030	CC:Patients with CC genotype may have poorer response (higher decrease in HbA1c) to 6-month treatment of sulfonylureas in people with Type 2 diabetes as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.; CT:Patients with CT genotype may have better response (higher decrease in HbA1c) to 6-month treatment of sulfonylureas in people with Type 2 diabetes as compared to patients with genotype CC. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.; TT:Patients with TT genotype may have better response (higher decrease in HbA1c) to 6-month treatment of sulfonylureas in people with Type 2 diabetes as compared to patients with genotype CC. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.	981240002; 981240017; 827641446	Genotypes CT + TT are associated with higher decrease in HbA1c after 6-month treatment when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; Genotypes CT + TT are associated with higher decrease in HbA1c when treated with gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; Allele T is not associated with decreased response to sulfonamides, urea derivatives.	22385882; 22385882; 11318841	3	gliclazide;sulfonamides, urea derivatives	Diabetes Mellitus, Type 2	White	
981239544	rs104894540	VKORC1 (PA133787052)	4	Dosage	981239545; 981239546; 981239547	AA:Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence warfarin dose.; AG:Patients with the AG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.; GG:Patients with the GG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.	981239480; 981239514	Allele G is associated with increased dose of warfarin as compared to allele A.; Allele G is associated with increased dose of warfarin as compared to allele A.	14765194; 18234403	2	warfarin			
981475838	rs121434568	EGFR (PA7360)	1B	Efficacy;Toxicity/ADR	981476128; 981476129; 981476130	GG:GG is associated with increased response rate (RR), increased progression-free survival (PFS), increased overall survival (OS) time and decreased serious adverse events when treated with erlotinib in advanced non-small-cell lung cancer patients as compared to TT. The association of increased RR and PFS time with GG genotype well replicated. The results of manuscripts were presented according to EGFR mutation status. In this annotation, the rs121434568 (L858R), exon 19 deletion, and other activating somatic mutations were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having somatic mutation.; GT:GT is associated with increased response rate (RR), increased progression-free survival (PFS), increased overall survival (OS) time and decreased serious adverse events when treated with erlotinib in advanced non-small-cell lung cancer patients as compared to TT. The association of increased RR and PFS time with GT genotype well replicated. The results of manuscripts were presented according to EGFR mutation status. In this annotation, the rs121434568 (L858R), exon 19 deletion, and other activating somatic mutations were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having somatic mutation.; TT:TT is associated with decreased response rate (RR), decreased progression-free survival (PFS), decreased overall survival (OS) time and increased serious adverse events when treated with erlotinib in advanced non-small-cell lung cancer patients as compared to GT or GG. The association of decreased RR and PFS time with TT vs. GT or GG genotype well replicated. The results of manuscripts were presented according to EGFR mutation status. In this annotation, the rs121434568 (L858R), exon 19 deletion, and other activating somatic mutations were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having somatic mutation.	981417597; 981417607; 981417616; 981417625; 981419202; 981419226; 981419236; 981419373; 981419400; 981419498; 981419523; 981419813; 981475368; 827921493	Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased Overall survival (OS) time when treated with erlotinib in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased response rate when treated with erlotinib in people with lung adenocarcinoma as compared to allele T.; Allele G is associated with increased response rate when treated with erlotinib in people with lung adenocarcinoma as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when exposed to erlotinib in people with advanced non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased overall survival (OS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with carboplatin, erlotinib and paclitaxel in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased overall survival time when treated with carboplatin, erlotinib and paclitaxel in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased response rate when treated with erlotinib in bronchioloalveolar carcinoma and adenocarcinoma patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib in bronchioloalveolar carcinoma and adenocarcinoma patients as compared to allele T.; Allele G is associated with increased response rate when treated with erlotinib or gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.; Genotypes GT + TT are associated with decreased response to erlotinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	22982650; 22982650; 22740981; 22740981; 21969500; 22760226; 22760226; 16043828; 16043828; 18349398; 18349398; 17285735; 22215752; 19692684	14	erlotinib	Carcinoma, Non-Small-Cell Lung		
981475871	rs121434568	EGFR (PA7360)	2A	Efficacy	981477437; 981477438; 981477439	GG:Patients with GG genotype included in this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients. Patients with GG genotype had increased response rate (RR) and increased progression-free survival time when treated with gefitinib vs paclitaxel plus carboplatin. There is no genotype comparison in this annotation.The somatic EGFR mutations [rs121434568 (L858R), exon 19 deletion, and other activating mutations] were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity (GT) or homozygocity (GG), it is worded as having somatic mutation.; GT:Patients with GT genotype included in this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients. Patients with GT genotype had increased response rate (RR) and increased progression-free survival time when treated with gefitinib vs paclitaxel plus carboplatin. There is no genotype comparison in this annotation. The somatic EGFR mutations [rs121434568 (L858R), exon 19 deletion, and other activating mutations] were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity (GT) or homozygocity (GG), it is worded as having somatic mutation.; TT:Patients with TT genotype were NOT included in these studies where this annotation is derived from. in this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients who have somatic mutation. There is no genotype comparison in this annotation.	981417228; 981417247; 981417256; 981417279; 981417296; 981417305; 981419215; 981477324; 981477332; 981477365; 981477373; 981477381	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with increased longer median progression-free survival time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with increased response rate when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele T is associated with decreased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation negative non-small-cell lung cancer.; Allele G is associated with increased physical and life well-being quality of life (QoL) scales when treated with gefitinib in people with EGFR mutation positive advanced non-small-cell lung cancer.; Allele G is not associated with overall survival (OS) time when treated with gefitinib in people with EGFR mutation negative non-small-cell lung cancer.; Allele T is not associated with overall survival (OS) time when treated with gefitinib in people with EGFR mutation negative non-small-cell lung cancer.; Allele G is associated with increased response rate (RR) when treated with gefitinib in lung adenocarcinoma patients as compared to allele T.; Allele G is not associated with progression-free survival (PFS) time when treated with gefitinib in lung adenocarcinoma patients as compared to allele T.; Allele G is not associated with overall survival (OS) time when treated with gefitinib in lung adenocarcinoma patients as compared to allele T.	20573926; 20573926; 20573926; 21900837; 19692680; 19692680; 22581822; 19692680; 19692680; 22370314; 22370314; 22370314	12	carboplatin;gefitinib;paclitaxel	Carcinoma, Non-Small-Cell Lung		
981475880	rs121434568	EGFR (PA7360)	2A	Efficacy;Toxicity/ADR	981476112; 981476113; 981476114	GG:Patients with GG genotype included in this annotation and effects of gefitinib vs standard chemotherapy [i) paclitaxel plus carboplatin, ii) cisplatin plus gemcitabine or docetaxel] were compared in non-small-cell lung cancer patients. Patients with GG genotype had increased progression-free survival (PFS) time, decreased toxic effects and decreased serious adverse events when treated with gefitinib vs standard chemotherapy. There is no genotype comparison in this annotation. The somatic EGFR mutations [rs121434568 (L858R), exon 19 deletion, and other activating mutations] were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity (GT) or homozygocity (GG), it is worded as having somatic mutation.; GT:Patients with GT genotype included in this annotation and effects of gefitinib vs standard chemotherapy [i) paclitaxel plus carboplatin, ii) cisplatin plus gemcitabine or docetaxel] were compared in non-small-cell lung cancer patients. Patients with GT genotype had increased progression-free survival (PFS) time, decreased toxic effects and decreased serious adverse events when treated with gefitinib vs standard chemotherapy. There is no genotype comparison in this annotation. The somatic EGFR mutations [rs121434568 (L858R), exon 19 deletion, and other activating mutations] were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity (GT) or homozygocity (GG), it is worded as having somatic mutation.; TT:Patients with TT genotype were NOT included in these studies where this annotation is derived from. In this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients who have somatic mutation. There is no genotype comparison in this annotation.	981417078; 981417107; 981417122; 981417145	Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with decreased grade 3 or 4 toxic effects when treated with erlotinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with decreased serious adverse events when treated with erlotinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib in people with EGFR mutation positive non-small-cell lung cancer.	21783417; 21783417; 21783417; 22285168	4	carboplatin;docetaxel;erlotinib;gemcitabine;paclitaxel	Carcinoma, Non-Small-Cell Lung		
981475986	rs11568315	EGFR (PA7360)	2B	Efficacy	981476100; 981476101; 981476102	(CA)16/(CA)16:Patients with genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with better clinical response (increased response rate (RR), increased progression-free survival (PFS) and increased survival time) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17. NOTE:The rs11568315 is (CA)n repeat in intron 1 of EGFR. 16 or fewer CA repeats were considered short, were combined together and named as (CA)16, and; 17 or more CA repeats were considered long, were combined together and named as (CA)17.; (CA)16/(CA)17:Patients with genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with better clinical response (increased response rate (RR), increased progression-free survival (PFS) and increased survival time) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17. NOTE:The rs11568315 is (CA)n repeat in intron 1 of EGFR. 16 or fewer CA repeats were considered short, were combined together and named as (CA)16, and; 17 or more CA repeats were considered long, were combined together and named as (CA)17.; (CA)17/(CA)17:Patients with genotypes (CA)17/(CA)17 are associated with worse clinical response (decreased response rate (RR), decreased progression-free survival (PFS) and decreased survival time) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)16/(CA)16 + (CA)16/(CA)17. NOTE:The rs11568315 is (CA)n repeat in intron 1 of EGFR. 16 or fewer CA repeats were considered short, were combined together and named as (CA)16, and; 17 or more CA repeats were considered long, were combined together and named as (CA)17.	981475086; 981475152; 981475175; 981475181; 981475186	Genotype (CA)16/(CA)16 is associated with increased progression-free survival (PFS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotypes (CA)16/(CA)17 + (CA)17/(CA)17.; Genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with increased response rate (RR) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17.; Genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with increased median survival time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17.; Genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with increased survival time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17.; Genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with increased better clinical response when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17.	17375033; 19201048; 19473722; 17597605; 17597605	5	gefitinib	Carcinoma, Non-Small-Cell Lung		
981204560	rs1801131	MTHFR (PA245)	2A	Efficacy;Toxicity/ADR	981204561; 981204562; 981204563	GG:Patients with the GG genotype may have 1) increased response, 2) increased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with TT genotype. Other genetic and clinical factors may influence a patient's response to these drugs.; GT:Patients with the GT genotype may have 1) increased response, 2) increased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with TT genotype. Other genetic and clinical factors may influence a patient's response to these drugs.; TT:Patients with the TT genotype may have 1) decreased response, 2) decreased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with GG or GT genotype. Other genetic and clinical factors may influence a patient's response to these drugs.	769166385; 769176381; 769261454	Allele G is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele T.; Genotype GG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.; Genotypes GG + GT are associated with increased response to oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT.	20078613; 20819423; 20385995	3	capecitabine;fluorouracil;leucovorin;oxaliplatin	Colorectal Neoplasms	White	
981204345	rs1045642	ABCB1 (PA267)	4	Dosage;Efficacy	981204346; 981204347; 981204348	AA:Patient with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine.; AG:Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine.; GG:Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine...	613978577; 769146005; 769257715; 769257724; 827824114	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.; Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.; Allele A is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele G.; Allele A is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to allele G.; Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.	15805193; 20417680; 16753003; 16753003; 22188362	5	carbamazepine	Epilepsy	Asian	
981204433	rs1045642	ABCB1 (PA267)	3	Efficacy	981204436; 981204435; 981204434	AA:Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.; AG:Patients with the AG genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.; GG:Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.	769169480	Genotype GG is associated with decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype AA.	18408561	1	dexamethasone;doxorubicin;vincristine	Multiple Myeloma		
981204444	rs1045642	ABCB1 (PA267)	4	Other	981204447; 981204446; 981204445	AA:Genotype AA may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported.; AG:Genotype AG may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported.; GG:Genotype GG may be associated with increased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes AA + AG. However, contradictory finding has been reported.	655386370; 655388038	Allele A is not associated with difference in efflux of rhodamine 123 as compared to allele G.; Genotype GG is associated with increased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes AA + AG.	12914549; 11434506	2	rhodamine 123		White	
981238288	rs2032582	ABCB1 (PA267)	3	Efficacy	981238289; 981238290; 981238291	AA:Patients with the AA genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.; AC:Patients with the AC genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.; CC:Patients with the CC genotype may have increased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the AA genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz	769163063; 827695494; 827695550	Genotype AA is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections.; Allele A is associated with decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to allele C.; Genotypes AT + CT are not associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotypes CC + CT.	20860463; 16267764; 16267764	3	efavirenz	HIV		
981475450	rs121434569	EGFR (PA7360)	2A	Efficacy	981477548; 981477549; 981477550	CC:CC is associated with decreased acquired resistance and increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to CT or TT. In these studies, patients who have EGFR activating mutations [e.g. rs121434568 (L858R) or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having T790M mutation.; CT:CT is associated with increased acquired resistance and decreased progression-free survival (PFS) time when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to CC. In these studies, patients who have EGFR activating mutations [e.g. rs121434568 (L858R) or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having T790M mutation. ; TT:TT is associated with increased acquired resistance and decreased progression-free survival (PFS) time when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to CC. In these studies, patients who have EGFR activating mutations [e.g. rs121434568 (L858R) or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having T790M mutation. 	981417754; 981417766; 981475217; 981475231; 981475241; 981475253; 981475265; 981475276; 981475286; 981475298; 981475309; 981475337; 981475352; 981475378; 981475801; 981477537	Allele T is associated with decreased progression-free survival (PFS) time when exposed to erlotinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.; Allele T is associated with decreased progression-free survival (PFS) time when treated with erlotinib or gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.; Genotype CT is associated with increased resistance when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype CC.; Allele T is associated with decreased response rate (RR) when treated with gefitinib in non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with gefitinib in non-small cell lung cancer as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with decreased progression free survival (PFS) time when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients.; Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in lung adenocarcinoma patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitor when treated with gefitinib in non-small cell lung cancer patients as compared to allele C.	21233402; 18596266; 18992959; 16912157; 18093943; 17085664; 17020982; 18981003; 20129249; 19381876; 19589612; 21430269; 22215752; 21248300; 21921847; 16258541	16	erlotinib;gefitinib	Carcinoma, Non-Small-Cell Lung		
981204026	rs9977268	SLC19A1 (PA327)	4	Efficacy	981204027; 981204028; 981204029	CC:Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; CT:Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being ineffective as compared to patients with the CC genotype or may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; TT:Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have increased likelihood of treatment being ineffective as compared to patients with the CC genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.	827863237	Allele T is associated with increased likelihood of treatment inefficacy when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	22450926	1	methotrexate	Arthritis, Rheumatoid	White	
981204044	rs9923231	VKORC1 (PA133787052)	3	Dosage	981204047; 981204046; 981204045	CC:Patients with the CC genotype who are treated with acenocoumarol may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's acenocoumarol dose requirement.; CT:Patients with the CT genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the CC genotype or may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's acenocoumarol dose requirement.; TT:Patients with the TT genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's acenocoumarol dose requirement.	827814729	Allele T is associated with decreased dose of acenocoumarol as compared to allele C.	21148049	1	acenocoumarol		Asian	
981203554	rs6275	DRD2 (PA27478)	3	Dosage	981203555; 981203556; 981203557	AA:Patients with the AA genotype and Heroin Dependence may require an increased dose of methadone as compared to patients with the GG genotype. This was seen in White patients - the opposite association was seen in a different study with Asian patients. Other genetic and clinical factors may also influence a patient's dose requirements.; AG:Patients with the AG genotype and Heroin Dependence may require an increased dose of methadone as compared to patients with the GG genotype. This was seen in White patients - the opposite association was seen in a different study with Asian patients. Other genetic and clinical factors may also influence a patient's dose requirements.; GG:Patients with the GG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the AA genotype. This was seen in White patients - the opposite association was seen in a different study with Asian patients. Other genetic and clinical factors may also influence a patient's dose requirements.	769169148; 827816268	Genotypes AA + AG are associated with increased dose of methadone in people with treatment for heroin addiction as compared to genotype GG.; Genotype AA is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG.	19373123; 21902500	2	methadone	Heroin Dependence	White	
981203627	rs67376798	DPYD (PA145)	3	Toxicity/ADR	981203628; 981203629; 981203630	AA:Patients with the AA genotype were not reported, however patients with the AT genotype and Cancer who are treated with regimens containing leucovorin may have increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; AT:Patients with the AT genotype and Cancer who are treated with regimens containing leucovorin may have increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; TT:Patients with the TT genotype and Cancer who are treated with regimens containing leucovorin may have decreased severity of drug toxicity as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.	827810959; 827892669	Genotype AT is associated with increased severity of Diarrhea when treated with leucovorin and tegafur in people with Rectal Neoplasms as compared to genotype TT.; Genotype AT is associated with increased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype TT.	21410976; 17064846	2	leucovorin	Colorectal Neoplasms;Rectal Neoplasms		
981203886	rs776746	CYP3A5 (PA131)	3	Other	981203887; 981203888; 981203889	CC:Patients with the CC genotype and HIV infection who are treated with nevirapine may have increased clearance of the drug as compared to patients with the CT and TT genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.; CT:Patients with the CT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.; TT:Patients with the TT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.	827823764; 827848827; 827848927; 655386238	Genotype CC is associated with increased clearance of nevirapine in people with HIV as compared to genotypes CT + TT.; Allele C is not associated with increased risk of toxicity when treated with nevirapine in people with HIV as compared to allele T.; Genotype CC is not associated with decreased clearance of nevirapine in people with HIV as compared to genotypes CT + TT.; Genotype TT is associated with differences in alanine aminotransferase levels when treated with nevirapine in people with HIV as compared to genotypes CC + CT.	22111602; 21824325; 19228205; 20017669	4	nevirapine	HIV;HIV Infections	Black or African American	
981204116	rs2032582	ABCB1 (PA267)	3	Efficacy	981204117; 981204118; 981204119	AA:Patients with AA genotype may have higher success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to patients with CC or AC genotype. Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C. Other genetic or clinical factors may influence response and dose of tacrolimus.; AC:Patients with AC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to patients with the AA genotype. Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C. Other genetic or clinical factors may influence response and dose of tacrolimus.; CC:Patients with CC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to patients with the AA genotype. Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C. Other genetic or clinical factors may influence response and dose of tacrolimus.	769172714; 769180585; 769179457; 827813827; 827813837; 827814005	Allele A is not associated with trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C.; Genotype AA is associated with higher success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to genotypes CC + AC.; Genotype AT is not associated with stable dose of tacrolimus in people with Transplantation as compared to allele C.; Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.; Allele T is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.; Genotype AT is not associated with dose of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele C.	15521904; 21289623; 21047202; 21770725; 21770725; 21806386	6	tacrolimus	Colitis, Ulcerative;Kidney Transplantation		
981204055	rs9923231	PRSS53 (PA165450635),VKORC1 (PA133787052)	3	Dosage	981204056; 981204057; 981204058	CC:Children with the CC genotype who are treated with vitamin K antagonists may require a higher dose as compared to children with the TT genotype. Other genetic and clinical factors may also influence warfarin and phenprocoumon dose requirement in children.; CT:This genotype was not reported, however children with the CT genotype who are treated with vitamin K antagonists may require a higher dose as compared to children with the TT genotype or may require a lower dose as compared to children with the CC genotype. Other genetic and clinical factors may also influence warfarin and phenprocoumon dose requirement in children.; TT:Children with the TT genotype who are treated with vitamin K antagonists may require a lower dose as compared to children with the CC genotype. Other genetic and clinical factors may also influence warfarin and phenprocoumon dose requirement in children.	827864542	Genotype TT is associated with decreased dose of phenprocoumon and warfarin as compared to genotype CC.	20833980	1	phenprocoumon;warfarin		White	
981203602	rs66554220	HLA-G (PA35083)	3	Efficacy	981203603; 981203604; 981203605	ATTTGTTCATGCCT/ATTTGTTCATGCCT:Patients with the ATTTGTTCATGCCT/ATTTGTTCATGCCT genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a poorer response as compared to patients with the del/del genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; ATTTGTTCATGCCT/del:Patients with the ATTTGTTCATGCCT/del genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a poorer response as compared to patients with the del/del genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; del/del:Patients with the del/del genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a better response as compared to patients with the ATTTGTTCATGCCT/del and ATTTGTTCATGCCT/ATTTGTTCATGCCT genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.	769174292; 769174296	Genotype DELDEL is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes ATTTGTTCATGCCTATTTGTTCATGCCT + ATTTGTTCATGCCTDEL.; Genotype DELDEL is not associated with response to methotrexate in people with Arthritis, Rheumatoid.	16906016; 19088262	2	methotrexate	Arthritis, Rheumatoid		
981203689	rs717620	ABCC2 (PA116)	3	Toxicity/ADR	981203690; 981203691; 981203692	CC:Patients with the CC genotype and HIV infection who are treated with tenofovir may have an increased risk of kidney tubular dysfunction as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.; CT:Patients with the CT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.; TT:Patients with the TT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.	827828625; 827828787	Genotype CC is associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV as compared to genotypes CT + TT.; Genotype CC is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV as compared to genotypes CT + TT.	19400747; 17083032	2	tenofovir	HIV		
981204912	rs1801133	MTHFR (PA245)	2A	Toxicity/ADR	981204913; 981204914; 981204915	AA:Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. However, conflicting finding of no-association for this genotype has also been reported. Other genetic and clinical factors may also influence a patient's risk of toxicity to fluorouracil.; AG:Patients with the AG genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to fluorouracil.; GG:Patients with the GG genotype may have decreased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to fluorouracil.	827811335; 769245648; 769176384; 769176385	Genotype GG is associated with decreased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.; Allele A is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele G.; Genotype AA is not associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.; Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.	19384296; 20638924; 20819423; 20819423	4	fluorouracil	Neoplasms		
981238057	rs2032582	ABCB1 (PA267)	3	Other	981238058; 981238059; 981238060	AA:Patients with the AA genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.; AC:Patients with the AC genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.; CC:Patients with the CC genotype may have increased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of doxorubicin.	769250973	Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype CC.	18377430	1	doxorubicin	Breast Neoplasms	Asian	
981204466	rs1045642	ABCB1 (PA267)	3	Toxicity/ADR	981204469; 981204468; 981204467	AA:Patients with AA genotype may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype GG. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.; AG:Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.; GG:Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.	769262755; 827817217	Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.	21142915; 22026922	2	capecitabine	Neoplasms	White	
981237713	rs1805087	MTR (PA31272)	3	Toxicity/ADR	981237714; 981237715; 981237716	AA:Patients with the AA genotype may have decreased likelihood of Drug Toxicity when treated with cisplatin in people with Osteosarcoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk for toxicity to cisplatin.; AG:Patients with the AG genotype may have decreased likelihood of Drug Toxicity when treated with cisplatin in people with Osteosarcoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk for toxicity to cisplatin.; GG:Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cisplatin in people with Osteosarcoma as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patient's risk for toxicity to cisplatin.	769174400; 827807299	Genotype GG is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to genotypes AA + AG.; Genotype AA is not associated with increased likelihood of response to chemotherapy when treated with carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel and vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	19159907; 21605004	2	cisplatin			
981238041	rs2032582	ABCB1 (PA267)	3	Efficacy	981238042; 981238043; 981238044	AA:Patients with the AA genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.; AC:Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.; CC:Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.	769169476	Genotypes AA + AC are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma.	18408561	1	dexamethasone;doxorubicin;vincristine	Multiple Myeloma		
981238092	rs2032582	ABCB1 (PA267)	3	Dosage;Efficacy	981238093; 981238094; 981238095	AA:Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.; AC:Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.; CC:Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.	769257727; 769146001; 769257721; 827824085; 827824096	Genotype AA is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to genotype CC.; Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.; Allele C is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele A.; Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.; Allele T is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.	16753003; 20417680; 16753003; 22188362; 22188362	5	antiepileptics;carbamazepine	Epilepsy	Asian	
981238910	rs5219	KCNJ11 (PA217)	3	Efficacy	981238913; 981238912; 981238911	CC:Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.; CT:Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.; TT:Patients with the TT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.	827641446; 827892722	Allele T is not associated with decreased response to sulfonamides, urea derivatives.; Allele T is associated with increased likelihood of treatment failure when treated with metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele C.	11318841; 16595597	2	metformin;sulfonamides, urea derivatives	Diabetes Mellitus, Type 2	White	
981202790	rs4961	ADD1 (PA31)	3	Efficacy	981202791; 981202792; 981202793	GG:Patients with the GG genotype and Hypertension who are treated with diuretics may have an increased likelihood of Myocardial Infarction as compared to patients with the GT or TT genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.; GT:Patients with the GT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.; TT:Patients with the TT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.	827923960; 827924164	Genotypes GT + TT are associated with decreased likelihood of Myocardial Infarction when treated with diuretics in people with Hypertension.; Allele G is not associated with risk of Myocardial Infarction when treated with diuretics in people with Hypertension as compared to allele T.	11926892; 17189961	2	diuretics	Hypertension;Myocardial Infarction		
981203697	rs717620	ABCC2 (PA116)	3	Efficacy	981203698; 981203699; 981203700	CC:Patients with the CC genotype and Epilepsy who are treated with antiepileptics may be less likely to be resistant to treatment as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.; CT:Patients with the CT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.; TT:Patients with the TT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.	827824453; 827824530; 827921746	Genotypes CT + TT are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.; Allele T is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele C.; Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.	22256867; 22256867; 22630058	3	antiepileptics	Epilepsy	Asian	
981203854	rs776746	CYP3A5 (PA131)	3	Toxicity/ADR	981203855; 981203856; 981203857	CC:Patients with the CC genotype and recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of developing hyperlipidemia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.; CT:Patients with the CT genotype and recipients of Kidney Transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.; TT:Patients with the TT genotype and recipients of Kidney Transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.	769166534	Genotype CC is associated with increased risk of developing hyperlipidemia 6 months post renal transplantation when treated with tacrolimus as compared to genotypes TT + CT.	21047202	1	tacrolimus	Hyperlipidemias;Kidney Transplantation		
981203954	rs7439366	UGT2B7 (PA361)	3	Other	981203955; 981203956; 981203957	CC:Patients with the CC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.; CT:Patients with the CT genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.; TT:Patients with the TT genotype and HIV infection who are treated with efavirenz may have lower plasma concentrations of the drug as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.	769163066; 769163146	Allele C is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to allele T.; Genotypes CC + CT are associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype TT.	20860463; 19779319	2	efavirenz	HIV Infections	Black or African American	
981204258	rs1045642	ABCB1 (PA267)	3	Toxicity/ADR	981204259; 981204260; 981204261	AA:Patients with the AA genotype may have increased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype GG. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.; AG:Patients with the AG genotype may have increased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype GG. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.; GG:Patients with the GG genotype may have decreased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.	769169025; 769169021	Genotype AA is associated with increased risk of Neutropenia when treated with paclitaxel in people with Neoplasms as compared to genotype GG.; Genotype GG is associated with decreased risk of Neurotoxicity Syndromes when treated with paclitaxel in people with Neoplasms as compared to allele A.	16950614; 16950614	2	paclitaxel	Neoplasms;Neurotoxicity Syndromes;Neutropenia		
981202806	rs4961	ADD1 (PA31)	2B	Efficacy	981202807; 981202808; 981202809	GG:Patients with the GG genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be more likely to respond to diuretic treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.; GT:Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.; TT:Patients with the TT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.	978639529	Genotypes GT + TT are associated with increased likelihood of diuretic unresponsiveness when treated with furosemide and spironolactone in people with Liver Cirrhosis as compared to genotype GG.	21692745	1	furosemide;spironolactone	Liver Cirrhosis	Asian	
981203790	rs776746	CYP3A5 (PA131)	2A	Toxicity/ADR	981203791; 981203792; 981203793	CC:Patients with the CC (*3/*3) genotype and are recipients of Kidney Transplant who are treated with tacrolimus may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.; CT:Patients with the CT genotype (*1/*3) and are recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of nephrotoxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.; TT:Patients with the TT (*1/*1) genotype and are recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of nephrotoxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.	769179627; 827699004	Allele T is associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.; Genotype CT is associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	17495880; 20526235	2	tacrolimus	Kidney Transplantation		
981203936	rs776746	CYP3A5 (PA131)	2A	Dosage	981203937; 981203938; 981203939	CC:Patients with the CC genotype (*3/*3) and who are recipients of transplants may have decreased metabolism of sirolimus and require a lower dose as compared to patients with the CT and TT genotype (*1/*3 and *3*/3). Other genetic and clinical factors may also influence a patient's sirolimus dose requirements.; CT:Patients with the CT genotype (*1/*3) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's sirolimus dose requirements.; TT:Patients with the TT genotype (*1/*1) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's sirolimus dose requirements.	769250136; 769250129	Genotype CC is associated with decreased metabolism of sirolimus in people with Transplantation as compared to genotypes TT + CT.; Genotypes CT + TT are associated with increased dose of sirolimus in people with Transplantation as compared to genotype CC.	16815317; 15707415	2	sirolimus	Transplantation		
981204272	rs1045642	ABCB1 (PA267)	3	Efficacy	981204273; 981204274; 981204275	AA:Genotype AA may be associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype GG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.; AG:Genotype AG may be associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype GG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.; GG:Genotype GG may be associated with increased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype AG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.	655387906; 827778808; 827922851	Genotype AG is associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in people with metastatic breast cancer as compared to genotype GG.; Allele A is not associated with overall survival when treated with dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to allele G.; Genotypes AA + AG are not associated with increased response to paclitaxel in women with Breast Neoplasms as compared to genotype GG.	18836089; 19504558; 22527101	3	paclitaxel	Breast Neoplasms		
981204317	rs1045642	ABCB1 (PA267)	3	Dosage	981204318; 981204319; 981204320	AA:Patients with genotype AA may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.; AG:Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.; GG:Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.	613978575; 769250004	Allele A is not associated with increased dose of phenytoin in people with Epilepsy as compared to allele G.; Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG.	15805193; 16220110	2	phenytoin			
981220481	rs1801133	CLCN6 (PA26551),MTHFR (PA245)	2A	Efficacy	981220482; 981220483; 981220484	AA:Patients with AA genotype may have 1) increased likelihood of response 2) increased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient's response to carboplatin.; AG:Patients with AG genotype may have 1) decreased likelihood of response 2) decreased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to carboplatin.; GG:Patients with GG genotype may have 1) decreased likelihood of response 2) decreased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to carboplatin.	827807290; 769166424	Genotype AA is associated with increased likelihood of response to chemotherapy when treated with carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel and vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.; Genotype AA is associated with increased progression free survival when treated with carboplatin and pemetrexed in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GG + AG.	21605004; 19307503	2	carboplatin	Carcinoma, Non-Small-Cell Lung	Asian	
981203709	rs7412	APOE (PA55)	4	Toxicity/ADR	981203710; 981203711; 981203712	CC:Patients with the CC genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.; CT:Patients with the CT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype or may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.; TT:Patients with the TT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.	699642389; 699642392	Allele T is associated with increased triglycerides when treated with Antivirals for treatment of HIV infections, combinations and ritonavir in people with HIV as compared to allele C.; Allele T is associated with increased triglycerides when treated with Antivirals for treatment of HIV infections, combinations in people with HIV as compared to allele C.	15809899; 17700364	2	Antivirals for treatment of HIV infections, combinations;ritonavir	HIV Infections;Hypertriglyceridemia		
981204107	rs20417	PTGS2 (PA293)	3	Efficacy	981204108; 981204109; 981204110	CC:Patients with the CC genotype may have increased risk of Coronary Disease when treated with aspirin as compared to patients with the GG or CG genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.; CG:Patients with the CG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.; GG:Patients with the GG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.	827690365; 827690372	Allele G is associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C.; Allele G is associated with decreased risk of Coronary Disease when treated with aspirin as compared to allele C.	17495879; 17495879	2	aspirin	Coronary Artery Disease	White	
981204137	rs2032582	ABCB1 (PA267)	4	Efficacy	981204138; 981204139; 981204140	AA:Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.; AC:Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.; CC:Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.	769257752; 769257727; 769257609; 827804302	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele C.; Genotype AA is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to genotype CC.; Allele C is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.; Allele C is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.	17125969; 16753003; 16386926; 21391884	4	antiepileptics	Epilepsy		
981204929	rs1801133	MTHFR (PA245)	2A	Toxicity/ADR	981204930; 981204931; 981204932	AA:Patients with the AA genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to cyclophosphamide.; AG:Patients with the AG genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to cyclophosphamide.; GG:Patients with the GG genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to cyclophosphamide.	769245648; 769146398; 769174403	Allele A is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele G.; Genotype AA is associated with increased risk of oral mucositis when treated with busulfan, cyclophosphamide and methotrexate in people with hematopoietic cell transplants for chronic myelogenous leukemia as compared to genotype GG.; Genotype AA is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to genotypes GG + AG.	20638924; 15051775; 19159907	3	cyclophosphamide			
981345293	rs4149056	SLCO1B1 (PA134865839)	2A	Other	981345294; 981345295; 981345296	CC:Patients with the CC genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype, although this does not appear to influence risk for statin-related myopathy. Other genetic and clinical factors may also influence a patient's metabolism and response to pravastatin.; CT:Patients with the CT genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype, although this does not appear to influence risk for statin-related myopathy. Other genetic and clinical factors may also influence a patient's metabolism and response to pravastatin.; TT:Patients with the TT genotype may have decreased plasma concentrations of pravastatin as compared to patients with the CC or CT genotype, although this does not appear to influence risk for statin-related myopathy. Other genetic and clinical factors may also influence a patient's metabolism and response to pravastatin.	827827131; 827827144; 827827157; 827827440; 769169405; 769170865; 827811014; 827826991	Allele C is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin as compared to allele T.; Allele C is not associated with the lipid-lowering efficacy of pravastatin when exposed to pravastatin in healthy individuals.; Genotype CC is associated with increased mean peak concentration in plasma and area under the plasma concentration when exposed to pravastatin in men as compared to genotypes CT + TT.; Genotype CT is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to genotype TT.; Allele C is associated with increased risk of composite adverse events when treated with atorvastatin, hmg coa reductase inhibitors and simvastatin in people with Hypercholesterolemia as compared to allele T.; Allele C is associated with decreased metabolism of pravastatin in people with no disease as compared to allele T.; Genotypes CT + TT are not associated with the response of total cholesterol, LDL, HDL, triglycerides or CRP to pravastatin when treated with pravastatin in men with as compared to genotype CC.; Allele C is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to allele T.	16678544; 16678544; 17015053; 17622941; 19833260; 12811365; 21851379; 15116054	8	pravastatin		White	
981203518	rs5751876	ADORA2A (PA24584)	3	Dosage;Toxicity/ADR	981203519; 981203520; 981203521	CC:Individuals with the CC genotype 1) may be less sensitive to caffeine and less likely to experience anxiety 2) may consume more caffeine as compared to individuals with the TT genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individual's response to caffeine.; CT:Individuals with the CT genotype 1) may be less sensitive to caffeine and less likely to experience anxiety 2) may consume more caffeine as compared to individuals with the TT genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individual's response to caffeine.; TT:Individuals with the TT genotype 1) may be more sensitive to caffeine and more likely to experience anxiety 2) may consume less caffeine as compared to individuals with the CC genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individual's response to caffeine.	769278094; 769278098; 769278090; 769278113; 769278124; 827783588; 827783690	Genotype CC is associated with increased likelihood of being sensitive to caffeine when exposed to caffeine as compared to genotype TT.; Genotype CC is associated with increased likelihood of insomnia when exposed to caffeine as compared to genotype TT.; Genotype TT is associated with increased anxiety when exposed to caffeine.; Genotype TT is associated with decreased habitual consumption of caffeine as compared to genotypes CC + CT.; Genotype TT is associated with increased anxiety when exposed to caffeine in people with no disease as compared to genotype CC.; Genotype TT is associated with increased anxiety when exposed to caffeine in healthy individuals as compared to genotypes CC + CT.; Genotype TT is not associated with anxiety when exposed to caffeine in healthy individuals as compared to genotypes CC + CT.	17329997; 17329997; 20520601; 17616786; 18305461; 12825092; 22012471	7	caffeine			
981203532	rs602950	CDA (PA98)	4	Toxicity/ADR	981203533; 981203534; 981203535	AA:Patients with the AA genotype who are treated with cytarabine may have lower levels of toxicity as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.; AG:Patients with the AG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.; GG:Patients with the GG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.	827803666; 827829878	Genotypes AG + GG are associated with increased toxicity when treated with cytarabine as compared to genotype AA.; Genotype GG is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotype AA.	21521023; 22304580	2	cytarabine			
981203545	rs6275	DRD2 (PA27478)	3	Dosage	981203546; 981203547; 981203548	AA:Patients with the AA genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype. This was seen in Asian patients - the opposite association was seen in a different study with White patients. Other genetic and clinical factors may also influence a patient's dose requirements.; AG:Patients with the AG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype or may require an increased dose of methadone as compared to patients with the AA genotype. This was seen in Asian patients - the opposite association was seen in a different study with White patients. Other genetic and clinical factors may also influence a patient's dose requirements.; GG:Patients with the GG genotype and Heroin Dependence may require an increased dose of methadone as compared to patients with the AA genotype. This was seen in Asian patients - the opposite association was seen in a different study with White patients. Other genetic and clinical factors may also influence a patient's dose requirements.	769169148; 827816268	Genotypes AA + AG are associated with increased dose of methadone in people with treatment for heroin addiction as compared to genotype GG.; Genotype AA is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG.	19373123; 21902500	2	methadone	Heroin Dependence	Asian	
981203641	rs6759892	UGT1A10 (PA37174),UGT1A6 (PA37181),UGT1A7 (PA37182),UGT1A8 (PA37183),UGT1A9 (PA419)	3	Dosage	981203642; 981203643; 981203644	GG:Patients with the GG genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT and GT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.; GT:Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.; TT:Patients with the TT genotype and Epilepsy who are treated with valproic acid may require a lower dose as compared to patients with the GG and GT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.	769164789; 827812612; 827812655	Allele G is associated with increased glucuronidation of valproic acid.; Genotype GG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes GT + TT.; Genotype GT is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype TT.	15761113; 21806385; 21806385	3	valproic acid	Epilepsy		
981203719	rs776746	CYP3A5 (PA131)	1B	Dosage	981203720; 981203721; 981203722	CC:Patients with the CC genotype who are treated with tacrolimus may have decreased metabolism of tacrolimus resulting in increased exposure, and may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's tacrolimus dose requirement.; CT:Patients with the CT genotype who are treated with tacrolimus may have increased clearance of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's tacrolimus dose requirement.; TT:Patients with the TT genotype who are treated with tacrolimus may have increased clearance of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's tacrolimus dose requirement.	827812467; 827813802; 827813909; 827815552; 769172716; 769179621; 769174170; 769166505; 769166529; 827698515; 827698530; 827698608; 827698642; 827698684; 827699040; 827783378; 827784291; 827785547; 827830139	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; Allele C is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to allele T.; Allele C is associated with increased tacrolimus concentration to dose ratio (C/D ratio) when treated with tacrolimus as compared to allele T.; Allele C is not associated with trough concentrations of tacrolimus in people with Kidney Transplantation.; Allele C is associated with increased dose-corrected exposure of tacrolimus in people with Kidney Transplantation as compared to allele T.; Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes TT + CT.; Genotype TT is associated with higher stable dose levels of tacrolimus in people with Transplantation as compared to genotypes CC + CT.; Genotype TT is associated with risk of being underdosed, with lower blood concentrations than target range of tacrolimus in people with Transplantation as compared to genotype CC.; Genotypes CT + TT are associated with decreased trough concentrations when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.; Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; Genotypes CT + TT are associated with decreased trough levels (drug level before a dose) when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.; Genotypes CT + TT are associated with decreased estimated glomeruler filtration rates when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.; Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; Genotype CT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; Genotype CC is associated with decreased mean stable tacrolimus dose when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; Genotypes CT + TT are associated with increased dose of tacrolimus in people with Organ Transplantation as compared to genotype CC.; Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.; Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	21635144; 21770725; 21806386; 22108237; 15521904; 17495880; 19865079; 21047202; 21047202; 21206424; 21206424; 21076384; 21076384; 20818834; 19258929; 21331500; 21886016; 20818295; 12966368	19	tacrolimus	Transplantation		
981203918	rs776746	CYP3A5 (PA131)	3	Other	981203919; 981203920; 981203921	CC:Patients with the CC genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.; CT:Patients with the CT genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype or may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.; TT:Patients with the TT genotype and HIV infection who are treated with efavirenz may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.	827922979; 827692959; 827695657	Allele C is associated with decreased plasma efavirenz exposure when treated with efavirenz in people with HIV as compared to allele T.; Allele C is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to allele T.; Genotypes CC + CT are not associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotype TT.	15622315; 20860463; 16267764	3	efavirenz	HIV Infections		
981203970	rs7439366	UGT2B7 (PA361)	3	Efficacy	981203971; 981203972; 981203973	CC:Healthy individuals with the CC genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype. Other genetic and clinical factors may also influence an individual's response to valproic acid and lorazepam treatment.; CT:Healthy individuals with the CT genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype or may have better responses in psychocognitive function tests as compared to patients with the CC genotype. Other genetic and clinical factors may also influence an individual's response to valproic acid and lorazepam treatment.; TT:Healthy individuals with the TT genotype who are treated with valproic acid and lorazepam may have better responses in psychocognitive function tests as compared to those with the CC genotype. Other genetic and clinical factors may also influence an individual's response to valproic acid and lorazepam treatment.	769164776	Allele T is associated with increased response to lorazepam and valproic acid in people with no disease as compared to allele C.	17687269	1	lorazepam;valproic acid		Asian	
981204090	rs9024	CBR1 (PA26121)	3	Toxicity/ADR	981204091; 981204092; 981204093	AA:Patients with the AA genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.; AG:Patients with the AG genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.; GG:Patients with the GG genotype and Cancer who are treated with anthracyclines and related substances may have an increased risk of developing Cardiomyopathies as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.	827807610; 827808476	Genotypes AA + AG are not associated with increased risk of Cardiomyopathies when treated with anthracyclines and related substances in people with Neoplasms.; Genotype GG is associated with increased risk of Cardiomyopathies when treated with anthracyclines and related substances in people with Neoplasms as compared to genotypes AA + AG.	22124095; 22124095	2	anthracyclines and related substances	Cardiomyopathies;Neoplasms		
981204286	rs1045642	ABCB1 (PA267)	3	Dosage;Efficacy	981204287; 981204288; 981204289	AA:Patients with genotype AA may have increased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.; AG:Patients with genotype AG may have increased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.; GG:Patients with genotype GG may have decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.	699638645; 827807645; 827814015; 827830252	Allele A is not associated with resistance when treated with cyclosporine in people with Colitis, Ulcerative as compared to allele G.; Genotype GG is associated with decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to genotypes AA + AG.; Allele A is not associated with dose of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.; Allele G is not associated with increased dose of cyclosporine in people with Kidney Transplantation as compared to allele A.	17206635; 18334915; 21806386; 12966368	4	cyclosporine	Transplantation		
981204372	rs1045642	ABCB1 (PA267)	2A	Other	981204373; 981204374; 981204375	AA:Patients with AA genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.; AG:Patients with AG genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.; GG:Patients with GG genotype may have increased metabolism and decreased serum concentration of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.	769170859; 827807733; 827925284	Genotype AA is associated with decreased metabolism of digoxin as compared to genotype GG.; Allele A is associated with increased serum concentrations of digoxin as compared to allele G.; Genotype GG is associated with increased metabolism of digoxin as compared to genotype AA.	10716719; 18334914; 12189368	3	digoxin			
981204403	rs1045642	ABCB1 (PA267)	3	Efficacy	981204404; 981204405; 981204406	AA:Patients with the AA genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.; AG:Patients with the AG genotype may have better response (decreased risk of lymph node metastases and increased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.; GG:Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.	827892730; 827892734; 827892732	Genotypes AA + AG are associated with decreased risk of lymph node metastases when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotype GG.; Genotype GG is associated with decreased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotypes AA + AG.; Allele G is not associated with response to cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to allele A.	21332314; 21332314; 21332314	3	cisplatin;fluorouracil	Esophageal Neoplasms		
981204414	rs1045642	ABCB1 (PA267)	3	Toxicity/ADR	981204417; 981204416; 981204415	AA:Patients with AA genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.; AG:Patients with AG genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.; GG:Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.	769245657; 769262752	Allele G is not associated with likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele A.; Genotype GG is associated with decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.	20638924; 21142915	2	fluorouracil	Colorectal Neoplasms		
981204455	rs1045642	ABCB1 (PA267)	3	Other	981204458; 981204457; 981204456	AA:Genotype AA may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.; AG:Genotype AG may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.; GG:Genotype GG may be associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.	655385617; 827923082	Allele A is not associated with pharmacokinetics of dicloxacillin.; Genotype GG is associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG.	15778422; 18576903	2	dicloxacillin			
981204746	rs1801131	MTHFR (PA245)	3	Toxicity/ADR	981204747; 981204748; 981204749	GG:Patients with the GG genotype may have decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.; GT:Patients with the GT genotype may have decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.; TT:Patients with the TT genotype may have increased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.	827783261	Genotype TT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Rectal Neoplasms as compared to genotypes GG + GT.	22045187	1	fluorouracil	Rectal Neoplasms		
981204864	rs1801131	MTHFR (PA245)	2A	Toxicity/ADR	981204865; 981204866; 981204867	GG:Patients with the GG genotype may have increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to capecitabine.; GT:Patients with the GT genotype may have increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to capecitabine.; TT:Patients with the TT genotype may have decreased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence a patient's risk of toxicity to capecitabine.	769176381; 827811371	Genotype GG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.; Genotype TT is associated with decreased Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotypes GG + GT.	20819423; 18245544	2	capecitabine	Colorectal Neoplasms		
981203578	rs6280	DRD3 (PA27479)	3	Efficacy	981203579; 981203580; 981203581	CC:Patients with the CC genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.; CT:Patients with the CT genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.; TT:Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a better response to treatment as compared to patients with the CC or CT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.	608431045; 827793137	Allele T is not associated with response to clozapine in people with Schizophrenia as compared to allele C.; Genotype TT is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes CC + CT.	20029384; 21332319	2	clozapine	Schizophrenia	White	
981204080	rs9461684	HLA-C (PA35057)	3	Toxicity/ADR	981204081; 981204082; 981204083	CC:Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.; CT:Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.; TT:Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.	827849283	Allele T is associated with increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to allele C.	21810746	1	nevirapine	HIV;HIV Infections	Asian	
981204306	rs1045642	ABCB1 (PA267)	3	Efficacy	981204309; 981204308; 981204307	AA:Patients with genotype AA may have decreased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype GG. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patient's response to phenytoin.; AG:Patients with genotype AG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patient's response to phenytoin.; GG:Patients with genotype GG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians. Other genetic or clinical factors may influence a patient's response to phenytoin.	769146005; 769250209	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.; Allele G is associated with increased likelihood of drug resistance when treated with phenytoin in people with Epilepsy as compared to allele A.	20417680; 17529887	2	phenytoin	Epilepsy	Black or African American	
981420042	rs121434568	EGFR (PA7360)	1B	Efficacy	981477428; 981477429; 981477430	GG:GG is associated with increased response rate (RR), increased progression-free survival (PFS) and increased overall survival (OS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to TT. The association of increased RR and PFS time with GG genotype well replicated. The results of manuscripts were presented according to EGFR mutation status. In this annotation, the rs121434568 (L858R), exon 19 deletion, and other activating somatic mutations were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having somatic mutation.; GT:GT is associated with increased response rate (RR), increased progression-free survival (PFS) and increased overall survival (OS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to TT. The association of increased RR and PFS time with GT genotype well replicated. The results of manuscripts were presented according to EGFR mutation status. In this annotation, the rs121434568 (L858R), exon 19 deletion, and other activating somatic mutations were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having somatic mutation.; TT:TT is associated with decreased response rate (RR), decreased progression-free survival (PFS) and decreased overall survival (OS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to GT or GG. The association of decreased RR and PFS time with GT or GG genotype well replicated. The results of manuscripts were presented according to EGFR mutation status. In this annotation, the rs121434568 (L858R), exon 19 deletion, and other activating somatic mutations were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having somatic mutation.	981419226; 981419236; 981419322; 981419331; 981419441; 981419460; 981419469; 981419477; 981419589; 981419598; 981419607; 981419616; 981419624; 981419634; 981419643; 981419653; 981419668; 981419710; 981419719; 981419727; 981419736; 981419746; 981419755; 981419803; 981419813; 981475192; 981475201; 981475368; 981477340; 981477349; 981477357; 827926134	Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased overall survival (OS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rates when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased median survial time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased median survival time (MST) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in chemorefractory advanced non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with erlotinib or gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased overall survival (OS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate (RR) when treated with gefitinib in lung adenocarcinoma patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in lung adenocarcinoma patients as compared to allele T.; Allele G is not associated with Overall survival (OS) time when treated with gefitinib in lung adenocarcinoma patients as compared to allele T.; Genotype GT is associated with increased response to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	22760226; 22760226; 20038723; 20038723; 16204011; 17047654; 17047654; 17473659; 17106442; 17106442; 16956694; 16956694; 16956694; 15897572; 15897572; 16203769; 17317677; 17387341; 17387341; 17192902; 17192902; 16865253; 16865253; 16115929; 17285735; 17429313; 17429313; 22215752; 22370314; 22370314; 22370314; 15118073	32	gefitinib	Carcinoma, Non-Small-Cell Lung		
981204361	rs1045642	ABCB1 (PA267)	2A	Toxicity/ADR	981204362; 981204363; 981204364	AA:People with AA genotype may have increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG or AG.Genotype AA is also associated with decreased peak plasma concentration (Cmax) and the total area under the plasma concentration-time curve (AUC) of clopidogrel and its active metabolite. Other genetic and clinical factors may also impact the response to clopidogrel.; AG:People with AG genotype may have increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG. Other genetic and clinical factors may also impact the response to clopidogrel.; GG:People with GG genotype may have decreased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Other genetic and clinical factors may also impact the response to clopidogrel.	655386894; 655388271; 769169793; 827814073	Genotype AA is associated with increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes GG + AG.; Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.; Genotype AA is associated with decreased peak plasma concentration (Cmax) and the total area under the plasma concentration-time curve (AUC) of clopidogrel and its active metabolite after a single oral loading dose of 300 or 600 mg of clopidogrel in people with Coronary Artery Disease as compared to genotypes GG + AG.; Allele A is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele G.	20801494; 19106083; 17112805; 21806387	4	clopidogrel	Acute coronary syndrome;Myocardial Infarction	White	
981204965	rs1801133	MTHFR (PA245)	3	Toxicity/ADR	981204966; 981204967; 981204968	AA:Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with leucovorin, oxaliplatin as compared to patients with the GG genotype. However, conflicting finding of no-association for this genotype has also been reported. Other genetic and clinical factors may also influence a patient's risk of toxicity to leucovorin.; AG:Patients with the AG genotype may have increased risk of Drug Toxicity in cancer patients treated with leucovorin, oxaliplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to leucovorin.; GG:Patients with the GG genotype may have decreased risk of Drug Toxicity in cancer patients treated with leucovorin, oxaliplatin as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to leucovorin.	827811335; 769176384; 769176385	Genotype GG is associated with decreased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.; Genotype AA is not associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.; Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.	19384296; 20819423; 20819423	3	leucovorin;oxaliplatin	Colorectal Neoplasms	White	
981204985	rs1801133	MTHFR (PA245)	3	Efficacy;Toxicity/ADR	981204986; 981204987; 981204988	AA:Patients with the AA genotype may have: 1) increased likelihood of response to chemotherapy, 2) increased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotypes AG or GG. Other genetic and clinical factors may also influence a patient's response to cisplatin.; AG:Patients with the AG genotype may have: 1) decreased likelihood of response to chemotherapy, 2) decreased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to cisplatin.; GG:Patients with the GG genotype may have: 1) decreased likelihood of response to chemotherapy, 2) decreased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to cisplatin.	827807290; 769174403	Genotype AA is associated with increased likelihood of response to chemotherapy when treated with carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel and vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.; Genotype AA is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to genotypes GG + AG.	21605004; 19159907	2	cisplatin		Asian	
981237704	rs1805087	MTR (PA31272)	3	Efficacy;Toxicity/ADR	981237705; 981237706; 981237707	AA:Patients with the AA genotype may have: 1) decreased likelihood of Drug Toxicity, 2) increased response when treated with methotrexate as compared to patients with genotypes GG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patient's response to methotrexate.; AG:Patients with the AG genotype may have: 1) decreased likelihood of Drug Toxicity, 2) increased response when treated with methotrexate as compared to patients with genotypes GG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patient's response to methotrexate.; GG:Patients with the GG genotype may have: 1) increased likelihood of Drug Toxicity, 2) decreased response when treated with methotrexate as compared to patients with genotypes AA or AG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patient's response to methotrexate.	769171236; 769173710; 769174400; 769174419; 769174421; 978639863	Allele A is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele G.; Allele G is not associated with decreased IQ when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotype GG is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to genotypes AA + AG.; Genotype GG is associated with increased risk of Brain Diseases when treated with methotrexate.; Genotype GG is associated with increased likelihood of methotrexate-induced nodulosis when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.; Allele G is not associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	18322994; 16013960; 19159907; 17855192; 17611986; 22838948	6	methotrexate			
981238341	CYP2C9 *1, CYP2C9 *2, CYP2C9 *3	CYP2C9 (PA126)	1A	Dosage	981238343; 981238342; 981238344	*1/*1:CYP2C9*1/*1 is considered a fully functional genotype. Patients with CYP2C9*1/*1 may require increased dose of warfarin as compared to patients with decreased (or loss of) function CYP2C9 alleles. Other genetic and clinical factors may also influence the dose of warfarin.; *2/*2:Patients with CYP2C9*2/*2 may require reduced dose of warfarin as compared to patients with CYP2C9*1/*1. Other genetic and clinical factors may also influence the dose of warfarin.; *2/*3:Patients with CYP2C9*2/*3 may require reduced dose of warfarin as compared to patients with CYP2C9*1/*1. Other genetic and clinical factors may also influence the dose of warfarin.	827863698; 827919910; 827783312; 827783868; 827783863; 827783860; 978614428	CYP2C9 *2 is associated with decreased clearance of warfarin as compared to CYP2C9 *1.; CYP2C9 *2 is associated with decreased dose of warfarin.; CYP2C9 *3/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*25.; CYP2C9 *3/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.; CYP2C9 *2/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.; CYP2C9 *2/*2 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.; CYP2C9 *2 is associated with dose of warfarin.	21692828; 22594507; 22040439; 21174619; 21174619; 21174619; 22676192	7	warfarin			
981345277	rs25487	XRCC1 (PA369)	3	Efficacy	981345278; 981345279; 981345280	CC:Patients with the CC genotype may have increased response to fluorouracil-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.; CT:Patients with the CT genotype may have decreased response to fluorouracil-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.; TT:Patients with the TT genotype may have decreased response to fluorouracil-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.	769165182; 827641636; 827784173; 827784178	Genotype CC is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype CT.; Allele T is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele C.; Genotype CC is associated with increased overall survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.; Genotype CC is associated with increased progression-free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.	21167658; 16875718; 21057378; 21057378	4	fluorouracil	Colorectal Neoplasms;Neoplasms;Rectal Neoplasms;Uterine Cervical Neoplasms	Asian	
981345311	rs4149056	SLCO1B1 (PA134865839)	3	Other	981345312; 981345313; 981345314	CC:Patients with the CC genotype may have increased plasma concentrations of atorvastatin as compared to patients with the TT genotype. Patients with the CC genotype may have smaller increases in plasma atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.; CT:Patients with the CT genotype may have increased plasma concentrations of atorvastatin as compared to patients with the TT genotype. Patients with the CT genotype may have smaller increases in plasma atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.; TT:Patients with the TT genotype may have decreased plasma concentrations of atorvastatin as compared to patients with the CC or CT genotype. However, patients with the TT genotype may have greater increases in plasma atorvastatin when treated concomitantly with rifampin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.	827827481; 769164520; 769169405; 769171454; 827810986	Genotype CC is associated with increased AUC when exposed to atorvastatin in healthy individuals as compared to genotype TT.; Allele C is not associated with risk of Muscular Diseases when treated with atorvastatin in people with Hyperlipidemias as compared to allele T.; Allele C is associated with increased risk of composite adverse events when treated with atorvastatin, hmg coa reductase inhibitors and simvastatin in people with Hypercholesterolemia as compared to allele T.; Genotype TT is associated with a nearly tripled increased percentage of atorvastatin AUC(0 - 48) values after a single oral dose of rifampicin when exposed to atorvastatin and rifampin in people with no disease as compared to genotype CC.; Genotypes CC + CT are not associated with increased risk of myalgia or abnormal CK values when treated with atorvastatin in people with Hyperlipoproteinemia Type II as compared to genotype TT.	17473846; 21243006; 19833260; 19374892; 21928084	5	atorvastatin;rifampin			
981345382	rs4149056	SLCO1B1 (PA134865839)	2A	Toxicity/ADR	981345383; 981345384; 981345385	CC:Patients with the CC genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient's metabolism and response to statins.; CT:Patients with the CT genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient's metabolism and response to statins.; TT:Patients with the TT genotype may have decreased plasma drug concentrations of particular statins as compared to patients with the CC or CT genotype. For some statins this is associated with decreased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient's metabolism and response to statins.	827827131; 827827157; 827827170; 827827440; 827827481; 827827497; 769162953; 769164520; 769169405; 769170865; 655386684; 655386692; 769180358; 769164512; 655386696; 827810986; 827811024; 827826991	Allele C is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin as compared to allele T.; Genotype CC is associated with increased mean peak concentration in plasma and area under the plasma concentration when exposed to pravastatin in men as compared to genotypes CT + TT.; Genotype CC is not associated with increased mean peak concentration in plasma and area under the plasma concentration when exposed to fluvastatin in men as compared to genotypes CT + TT.; Genotype CT is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to genotype TT.; Genotype CC is associated with increased AUC when exposed to atorvastatin in healthy individuals as compared to genotype TT.; Genotype CC is associated with increased AUC (p=0.002) and Cmax (p=0.003) when exposed to rosuvastatin in healthy individuals as compared to genotype TT.; Allele C is associated with general intolerance to statins in a logistic regression model accounting for age, both the genotypes, statin adherence, study duration, maximum dose, and concomitant prescriptions for other lipid-regulating drugs and CYP3A4 inhibiting drugs when treated with hmg coa reductase inhibitors in people with Diabetes Mellitus, Type 2 as compared to allele T.; Allele C is not associated with risk of Muscular Diseases when treated with atorvastatin in people with Hyperlipidemias as compared to allele T.; Allele C is associated with increased risk of composite adverse events when treated with atorvastatin, hmg coa reductase inhibitors and simvastatin in people with Hypercholesterolemia as compared to allele T.; Allele C is associated with decreased metabolism of pravastatin in people with no disease as compared to allele T.; Genotype CC is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Myocardial Infarction as compared to genotype TT.; Genotype CC is associated with increased risk of Muscular Diseases when treated with simvastatin as compared to genotype CT.; Genotype CC is associated with a four-fold higher risk of rhabdomyolysis when treated with cerivastatin as compared to genotype TT.; Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin in people with Hyperlipidemias as compared to genotype TT.; Genotype CT is associated with increased risk of Muscular Diseases when treated with simvastatin as compared to genotype TT.; Genotypes CC + CT are not associated with increased risk of myalgia or abnormal CK values when treated with atorvastatin in people with Hyperlipoproteinemia Type II as compared to genotype TT.; Genotype CC is associated with increased plasma concentrations of simvastatin when exposed to simvastatin in healthy individuals as compared to genotypes CT + TT.; Allele C is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to allele T.	16678544; 17015053; 17015053; 17622941; 17473846; 17473846; 21178985; 21243006; 19833260; 12811365; 18650507; 18650507; 21386754; 21243006; 18650507; 21928084; 17108811; 15116054	18	hmg coa reductase inhibitors	Muscular Diseases;Rhabdomyolysis		
981203808	rs776746	CYP3A5 (PA131)	3	Efficacy	981203809; 981203810; 981203811	CC:Patients with the CC (*3/*3) genotype and recipients of Kidney Transplant who are treated with tacrolimus may have a decreased, but not absent, risk of transplant rejection as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.; CT:Patients with the CT genotype (*1/*3) and recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.; TT:Patients with the TT (*1/*1) genotype and recipients of Kidney Transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.	827698623	Genotypes CT + TT are associated with increased likelihood of T-cell mediated rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	21076384	1	tacrolimus	Kidney Transplantation	Asian	
981345285	rs25487	XRCC1 (PA369)	3	Efficacy;Toxicity/ADR	981345286; 981345287; 981345288	CC:Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.; CT:Patients with the CT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.; TT:Patients with the TT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.	655386624; 827828058; 827828072; 827828226	Genotype CC is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes TT + CT.; Genotypes CC + CT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.; Genotypes CT + TT are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Genotypes CT + TT are associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	19786980; 22188361; 22188361; 22188361	4	cyclophosphamide	Neoplasms;Ovarian Neoplasms	White	
981238108	rs2032582	ABCB1 (PA267)	3	Other	981238111; 981238110; 981238109	AA:Patients with genotype AA may have decreased metabolism of digoxin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of digoxin.; AC:Patients with genotype AC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.; CC:Patients with genotype CC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.	827807741; 827925294	Allele A is associated with increased serum concentrations digoxin as compared to allele C.; Genotype CC is associated with increased metabolism of digoxin as compared to genotype AA.	18334914; 12189368	2	digoxin			
981204975	rs1801133	MTHFR (PA245)	3	Toxicity/ADR	981204976; 981204977; 981204978	AA:Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.; AG:Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.; GG:Patients with the GG genotype may have decreased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype AA or AG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.	978639856; 769171000; 769170674	Allele A is not associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; Allele A is not associated with Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotypes AA + AG are associated with increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	22838948; 17323057; 18458567	3	mercaptopurine	Precursor Cell Lymphoblastic Leukemia-Lymphoma		
981203618	rs67376798	DPYD (PA145)	2A	Toxicity/ADR	981203619; 981203620; 981203621	AA:Patients with the AA genotype were not reported, however, patients with the AT genotype and Cancer who are treated with fluorouracil-containing regimens 1) may have decreased clearance of the drug 2) may have an increased risk and severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for fluorouracil-induced toxicity.; AT:Patients with the AT genotype and Cancer who are treated with fluorouracil-containing regimens 1) may have decreased clearance of the drug 2) may have an increased risk and severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for fluorouracil-induced toxicity.; TT:Patients with the TT genotype and Cancer who are treated with fluorouracil-containing regimens 1) may have increased clearance of the drug 2) may have a decreased risk and reduced severity of drug toxicity as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's risk for fluorouracil-induced toxicity.	827823460; 827824687; 827892661; 827892669; 827892780	Allele A is not associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to allele T.; Genotype AT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.; Genotype AT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.; Genotype AT is associated with increased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype TT.; Genotype AT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	19530960; 17700593; 17064846; 17064846; 17121937	5	fluorouracil	Colorectal Neoplasms;Neoplasms	White	
981204525	rs1801131	MTHFR (PA245)	3	Efficacy	981204526; 981204527; 981204528	GG:Genotype GG may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.; GT:Genotype GT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.; TT:Genotype TT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.	769166427; 769258433; 827825848	Genotype GG is associated with decreased progression free survival when treated with carboplatin and pemetrexed in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes TT + GT.; Genotypes GG + GT are associated with decreased overall survival when treated with cisplatin and pemetrexed in people with Stomach Neoplasms as compared to genotype TT.; Genotypes GG + GT are associated with increased overall survival when treated with bevacizumab, cyanocobalamin, folic acid and pemetrexed in people with Head and Neck Neoplasms as compared to genotype TT.	19307503; 20634689; 21343546	3	bevacizumab;carboplatin;cisplatin;cyanocobalamin;folic acid;pemetrexed	Neoplasms		
981345350	rs4149056	SLCO1B1 (PA134865839)	3	Other	981345351; 981345352; 981345353	CC:Patients with the CC genotype may have increased plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.; CT:Patients with the CT genotype may have increased plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.; TT:Patients with the TT genotype may have decreased plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.	827827497	Genotype CC is associated with increased AUC (p=0.002) and Cmax (p=0.003) when exposed to rosuvastatin in healthy individuals as compared to genotype TT.	17473846	1	rosuvastatin			
981238323	rs1695	GSTP1 (PA29028)	2A	Efficacy;Toxicity/ADR	981238324; 981238325; 981238326	AA:Patients with the AA genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patient's response to cyclophosphamide, epirubicin and fluorouracil.; AG:Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patient's response to cyclophosphamide, epirubicin and fluorouracil.; GG:Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patient's response to cyclophosphamide, epirubicin and fluorouracil.	827704813; 827704840; 827704848	Allele A is associated with increased response to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.; Genotypes AA + AG are associated with increased response to cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG.; Genotypes AA + AG are associated with decreased severity of toxicity when treated with cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG.	20568049; 21362365; 21362365	3	cyclophosphamide;epirubicin	Breast Neoplasms		
981419540	rs6535454	COQ2 (PA142672084)	3	Toxicity/ADR	981419541; 981419542; 981419543	AA:Patients with the AA genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.; AG:Patients with the AG genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.; GG:Patients with the GG genotype may have decreased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.	981419504	Allele A is associated with increased risk of statin intolerance, defined primarily through muscle symptomatology when treated with hmg coa reductase inhibitors as compared to allele G.	17376224	1	atorvastatin;hmg coa reductase inhibitors;rosuvastatin	Muscular Diseases	White	
981237683	rs1799853	CYP2C9 (PA126)	3	Efficacy	981237684; 981237685; 981237686	CC:Patients with the CC genotype who are treated with celecoxib may have an increased metabolism of celecoxib and as compared to patients with the CT and TT genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.; CT:Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.; TT:Patients with the TT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.	827826389; 827826410; 827826431; 827826458	Allele T is associated with decreased metabolism of celecoxib.; Allele T is not associated with increased AUC of celecoxib when treated with celecoxib.; Allele T is not associated with celecoxib AUC or total clearance when exposed to celecoxib in healthy individuals as compared to allele C.; Genotype CT is associated with higher plasma concentrations of celecoxib when exposed to celecoxib in healthy individuals as compared to genotype CC.	11337938; 11337938; 12893985; 16401468	4	celecoxib			
981238397	rs1695	GSTP1 (PA29028)	3	Toxicity/ADR	981238398; 981238399; 981238400	AA:Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Drug Toxicity as compared to patients with the GG genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.; AG:Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Drug Toxicity as compared to patients with the GG genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.; GG:Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.	769171104; 769171080	Allele G is not associated with toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotype GG is associated with increased likelihood of Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.	17180579; 17264302	2	methotrexate	Precursor Cell Lymphoblastic Leukemia-Lymphoma		
827864250	rs1876828	CRHR1 (PA26874)	2B	Efficacy	827864251; 827864252; 827864253	CC:Patients with the CC genotype may have 1) decreased short term response to inhaled corticosteroids (as measured by FEV after 6 weeks of treatment) and 2) increased endogenous cortisol compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's hypothalamic pituitary adrenal axis and response to corticosteroids.; CT:Patients with the CT genotype may have decreased short term response to inhaled corticosteroids (as measured by FEV after 6 weeks of treatment). Other genetic and clinical factors may also influence a patient's hypothalamic pituitary adrenal axis and response to corticosteroids.; TT:Patients with the TT genotype may have 1) increased short term response to inhaled corticosteroids (as measured by FEV after 6 weeks of treatment) and 2) altered hypothalamic pituitary adrenal axis and decreased endogenous cortisol compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's hypothalamic pituitary adrenal axis and response to corticosteroids.	827863788; 827863814; 827863822; 827863834; 827863877; 827921704	Genotype TT is associated with increased percent change in FEV when treated with corticosteroids in people with Asthma as compared to genotypes CC + CT.; Genotype TT is associated with delayed cortisol response to stress when treated with budesonide or fluticasone propionate in children with Asthma as compared to genotype CT.; Genotype TT is associated with decreased baseline cortisol levels in children with Asthma as compared to genotype CC.; Genotypes CT + TT are not associated with mean annual change in FEV when treated with beclomethasone, budesonide or fluticasone propionate in people with Asthma as compared to genotype CC.; Genotype TT is not associated with mean change in FEV when treated with fluticasone/salmeterol in people with Pulmonary Disease, Chronic Obstructive as compared to genotype CC.; Allele T is associated with increased response to glucocorticoids in people with Asthma as compared to allele C.	15128701; 22248724; 22248724; 18539200; 19210659; 22641026	6	budesonide;corticosteroids;fluticasone propionate;fluticasone/salmeterol;triamcinolone	Asthma		
827864301	rs11739136	KCNIP1 (PA30041),KCNMB1 (PA221)	3	Efficacy	827864302; 827864303; 827864304	CC:Patients with the CC genotype: 1) may have increased blood pressure, 2) increased risk for hypertension and 3) slower control of blood pressure when treated with verapamil as compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.; CT:Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.; TT:Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.	827783397; 827864262; 827864280	Genotypes CT + TT are associated with earlier achievement of blood pressure control when treated with verapamil in people with Hypertension as compared to genotype CC.; Genotypes CT + TT are associated with decreased blood pressure in men as compared to genotype CC.; Genotypes CT + TT are associated with decreased risk of Hypertension as compared to genotype CC.	17700361; 18854753; 18496125	3	verapamil	Hypertension		
827864179	rs1801272	CYP2A6 (PA121)	4	Other	827864180; 827864181; 827864182	AA:Patients with the AA genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.; AT:Patients with the AT genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.; TT:Patients with the TT genotype may have minimal 7-hydroxylation of coumarin compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of coumarin.	769278048; 769278055	Genotype TT is associated with decreased metabolism of coumarin as compared to genotype AT.; Genotype TT is associated with decreased metabolism of coumarin as compared to genotypes AA + AT.	9409631; 9827545	2	coumarin			
827864159	rs1024323	GRK4 (PA28941)	3	Efficacy	827864160; 827864161; 827864162	CC:In male patients with the rs1024323 CC genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.; CT:In male patients with the rs1024323 CT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype TT, or better response compared to those with rs1024323 genotype CC, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CC and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.; TT:In male patients with the rs1024323 TT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a better response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.	827864047; 827864069	Genotype CC is associated with decreased response to metoprolol in men with Hypertensive Nephrosclerosis as compared to genotype TT.; Genotype CC is not associated with decreased response to metoprolol in women with Hypertensive Nephrosclerosis as compared to genotype TT.	19119263; 19119263	2	metoprolol	Hypertension;Kidney Diseases;Nephrosclerosis	Black or African American	
827863843	rs37973	GLCCI1 (PA38657)	3	Efficacy	827863844; 827863845; 827863846	AA:Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to glucocorticoids.; AG:Patients with the AG genotype may have intermediate increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with heterozygous AG genotype has an intermediate GLCC1 expression value.; GG:Patients with the GG genotype may have increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with homozygous GG genotype has the lowest GLCC1 expression value compared to AA or AG.	827777782	Genotype GG is associated with increased risk of poor response when treated with glucocorticoids in people with Asthma as compared to genotype AA.	21991891	1	budesonide;flunisolide;fluticasone propionate;glucocorticoids;nedocromil;triamcinolone	Asthma		
827862764	rs12979860	IL28B (PA134952671)	1A	Efficacy	827862765; 827862766; 827862767	CC:Patients with the CC genotype may have increased response (about 2 fold increase in SVR (sustained virological response) rate) to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CT or TT genotype. Patients with the CC genotype may also have higher spontaneous clearance in acute HCV infections than patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon.; CT:Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon.; TT:Patients with the TT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the TT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon.	981240111; 769251002; 827789030; 827813726; 827820480; 827864105	Genotype CC is associated with significantly greater chance of an SVR when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.; Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.; Genotype CC is associated with increased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.; Genotype CC is associated with increased sustained virological response rate (SVR) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CT.; Genotype CC is associated with increased increased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.; Genotype CC is associated with increased treatment response (SVR rate) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	22863269; 19684573; 21993426; 21726252; 21254158; 21951981	6	peginterferon alfa-2a;peginterferon alfa-2b;ribavirin	Hepatitis C		
